'thrombolytique (traitement)'
(id=16878897 ; fe=thrombolytique (traitement) ; type=1 ; niveau=200 ; luminosité=25 ; somme entrante=4472 creation date=2021-07-25 touchdate=2025-11-02 11:01:10.000)

≈ 3966 relations sortantes thrombolytique (traitement) -- r_associated #0: 81 / 1 -> chirurgie n1=thrombolytique (traitement) | n2=chirurgie | rel=r_associated | relid=0 | w=81 thrombolytique (traitement) -- r_associated #0: 69 / 0.852 -> thrombopénie n1=thrombolytique (traitement) | n2=thrombopénie | rel=r_associated | relid=0 | w=69 thrombolytique (traitement) -- r_associated #0: 66 / 0.815 -> thrombophlébite n1=thrombolytique (traitement) | n2=thrombophlébite | rel=r_associated | relid=0 | w=66 thrombolytique (traitement) -- r_associated #0: 50 / 0.617 -> médecine n1=thrombolytique (traitement) | n2=médecine | rel=r_associated | relid=0 | w=50 thrombolytique (traitement) -- r_associated #0: 48 / 0.593 -> thrombopénie induite par l'héparine dite spontanée n1=thrombolytique (traitement) | n2=thrombopénie induite par l'héparine dite spontanée | rel=r_associated | relid=0 | w=48 thrombolytique (traitement) -- r_associated #0: 47 / 0.58 -> processus pathologique n1=thrombolytique (traitement) | n2=processus pathologique | rel=r_associated | relid=0 | w=47 thrombolytique (traitement) -- r_associated #0: 45 / 0.556 -> thrombopathie n1=thrombolytique (traitement) | n2=thrombopathie | rel=r_associated | relid=0 | w=45 thrombolytique (traitement) -- r_associated #0: 44 / 0.543 -> maladies n1=thrombolytique (traitement) | n2=maladies | rel=r_associated | relid=0 | w=44 thrombolytique (traitement) -- r_associated #0: 44 / 0.543 -> pathologie n1=thrombolytique (traitement) | n2=pathologie | rel=r_associated | relid=0 | w=44 thrombolytique (traitement) -- r_associated #0: 44 / 0.543 -> thrombophlébite de la grossesse n1=thrombolytique (traitement) | n2=thrombophlébite de la grossesse | rel=r_associated | relid=0 | w=44 thrombolytique (traitement) -- r_associated #0: 43 / 0.531 -> thrombolytique n1=thrombolytique (traitement) | n2=thrombolytique | rel=r_associated | relid=0 | w=43 thrombolytique (traitement) -- r_associated #0: 43 / 0.531 -> thrombomoduline n1=thrombolytique (traitement) | n2=thrombomoduline | rel=r_associated | relid=0 | w=43 thrombolytique (traitement) -- r_associated #0: 43 / 0.531 -> thrombophilie n1=thrombolytique (traitement) | n2=thrombophilie | rel=r_associated | relid=0 | w=43 thrombolytique (traitement) -- r_associated #0: 43 / 0.531 -> traitement n1=thrombolytique (traitement) | n2=traitement | rel=r_associated | relid=0 | w=43 thrombolytique (traitement) -- r_associated #0: 42 / 0.519 -> thrombophlébite migrante n1=thrombolytique (traitement) | n2=thrombophlébite migrante | rel=r_associated | relid=0 | w=42 thrombolytique (traitement) -- r_associated #0: 40 / 0.494 -> anticoagulant n1=thrombolytique (traitement) | n2=anticoagulant | rel=r_associated | relid=0 | w=40 thrombolytique (traitement) -- r_associated #0: 40 / 0.494 -> thrombose artérielle des membres n1=thrombolytique (traitement) | n2=thrombose artérielle des membres | rel=r_associated | relid=0 | w=40 thrombolytique (traitement) -- r_associated #0: 39 / 0.481 -> thrombophlébite infectieuse n1=thrombolytique (traitement) | n2=thrombophlébite infectieuse | rel=r_associated | relid=0 | w=39 thrombolytique (traitement) -- r_associated #0: 38 / 0.469 -> thrombophlébite nodulaire migratrice n1=thrombolytique (traitement) | n2=thrombophlébite nodulaire migratrice | rel=r_associated | relid=0 | w=38 thrombolytique (traitement) -- r_associated #0: 37 / 0.457 -> en:thrombolysis n1=thrombolytique (traitement) | n2=en:thrombolysis | rel=r_associated | relid=0 | w=37 thrombolytique (traitement) -- r_associated #0: 37 / 0.457 -> thrombopénie immune n1=thrombolytique (traitement) | n2=thrombopénie immune | rel=r_associated | relid=0 | w=37 thrombolytique (traitement) -- r_associated #0: 36 / 0.444 -> thrombopénie de Paris-Trousseau n1=thrombolytique (traitement) | n2=thrombopénie de Paris-Trousseau | rel=r_associated | relid=0 | w=36 thrombolytique (traitement) -- r_associated #0: 36 / 0.444 -> thrombopénie induite par l'héparine n1=thrombolytique (traitement) | n2=thrombopénie induite par l'héparine | rel=r_associated | relid=0 | w=36 thrombolytique (traitement) -- r_associated #0: 35 / 0.432 -> en:thrombopenia n1=thrombolytique (traitement) | n2=en:thrombopenia | rel=r_associated | relid=0 | w=35 thrombolytique (traitement) -- r_associated #0: 35 / 0.432 -> en:thrombophilia n1=thrombolytique (traitement) | n2=en:thrombophilia | rel=r_associated | relid=0 | w=35 thrombolytique (traitement) -- r_associated #0: 34 / 0.42 -> en:noueuse n1=thrombolytique (traitement) | n2=en:noueuse | rel=r_associated | relid=0 | w=34 thrombolytique (traitement) -- r_associated #0: 34 / 0.42 -> maladie n1=thrombolytique (traitement) | n2=maladie | rel=r_associated | relid=0 | w=34 thrombolytique (traitement) -- r_associated #0: 33 / 0.407 -> thrombophlébite cérébrale puerpérale n1=thrombolytique (traitement) | n2=thrombophlébite cérébrale puerpérale | rel=r_associated | relid=0 | w=33 thrombolytique (traitement) -- r_associated #0: 32 / 0.395 -> en:puerpueral cerebral thrombophlebitis n1=thrombolytique (traitement) | n2=en:puerpueral cerebral thrombophlebitis | rel=r_associated | relid=0 | w=32 thrombolytique (traitement) -- r_associated #0: 31 / 0.383 -> en:heparin-induced thrombocytopenia n1=thrombolytique (traitement) | n2=en:heparin-induced thrombocytopenia | rel=r_associated | relid=0 | w=31 thrombolytique (traitement) -- r_associated #0: 31 / 0.383 -> en:HIT n1=thrombolytique (traitement) | n2=en:HIT | rel=r_associated | relid=0 | w=31 thrombolytique (traitement) -- r_associated #0: 31 / 0.383 -> en:infectious thrombophlebitis n1=thrombolytique (traitement) | n2=en:infectious thrombophlebitis | rel=r_associated | relid=0 | w=31 thrombolytique (traitement) -- r_associated #0: 31 / 0.383 -> en:thrombomodulin n1=thrombolytique (traitement) | n2=en:thrombomodulin | rel=r_associated | relid=0 | w=31 thrombolytique (traitement) -- r_associated #0: 31 / 0.383 -> thrombolyse n1=thrombolytique (traitement) | n2=thrombolyse | rel=r_associated | relid=0 | w=31 thrombolytique (traitement) -- r_associated #0: 30 / 0.37 -> sang n1=thrombolytique (traitement) | n2=sang | rel=r_associated | relid=0 | w=30 thrombolytique (traitement) -- r_associated #0: 29 / 0.358 -> hypercoagulabilité sanguine n1=thrombolytique (traitement) | n2=hypercoagulabilité sanguine | rel=r_associated | relid=0 | w=29 thrombolytique (traitement) -- r_associated #0: 28 / 0.346 -> en:heparin induced thrombocytopenia n1=thrombolytique (traitement) | n2=en:heparin induced thrombocytopenia | rel=r_associated | relid=0 | w=28 thrombolytique (traitement) -- r_associated #0: 28 / 0.346 -> en:thrombophlebitis of pregnancy n1=thrombolytique (traitement) | n2=en:thrombophlebitis of pregnancy | rel=r_associated | relid=0 | w=28 thrombolytique (traitement) -- r_associated #0: 27 / 0.333 -> en:immune thrombocytopenia n1=thrombolytique (traitement) | n2=en:immune thrombocytopenia | rel=r_associated | relid=0 | w=27 thrombolytique (traitement) -- r_associated #0: 27 / 0.333 -> en:thrombophlebitis n1=thrombolytique (traitement) | n2=en:thrombophlebitis | rel=r_associated | relid=0 | w=27 thrombolytique (traitement) -- r_associated #0: 26 / 0.321 -> en:thrombocytopathy n1=thrombolytique (traitement) | n2=en:thrombocytopathy | rel=r_associated | relid=0 | w=26 thrombolytique (traitement) -- r_associated #0: 26 / 0.321 -> héparine n1=thrombolytique (traitement) | n2=héparine | rel=r_associated | relid=0 | w=26 thrombolytique (traitement) -- r_associated #0: 26 / 0.321 -> spécialités médicales n1=thrombolytique (traitement) | n2=spécialités médicales | rel=r_associated | relid=0 | w=26 thrombolytique (traitement) -- r_associated #0: 26 / 0.321 -> thrombopénie liée à l'X n1=thrombolytique (traitement) | n2=thrombopénie liée à l'X | rel=r_associated | relid=0 | w=26 thrombolytique (traitement) -- r_associated #0: 25 / 0.309 -> caillot n1=thrombolytique (traitement) | n2=caillot | rel=r_associated | relid=0 | w=25 thrombolytique (traitement) -- r_associated #0: 25 / 0.309 -> dissolution n1=thrombolytique (traitement) | n2=dissolution | rel=r_associated | relid=0 | w=25 thrombolytique (traitement) -- r_associated #0: 25 / 0.309 -> en:blood platelet disorders n1=thrombolytique (traitement) | n2=en:blood platelet disorders | rel=r_associated | relid=0 | w=25 thrombolytique (traitement) -- r_associated #0: 25 / 0.309 -> en:thrombosis n1=thrombolytique (traitement) | n2=en:thrombosis | rel=r_associated | relid=0 | w=25 thrombolytique (traitement) -- r_associated #0: 25 / 0.309 -> induite n1=thrombolytique (traitement) | n2=induite | rel=r_associated | relid=0 | w=25 thrombolytique (traitement) -- r_associated #0: 25 / 0.309 -> médecine (science) n1=thrombolytique (traitement) | n2=médecine (science) | rel=r_associated | relid=0 | w=25 thrombolytique (traitement) -- r_associated #0: 25 / 0.309 -> physiologie n1=thrombolytique (traitement) | n2=physiologie | rel=r_associated | relid=0 | w=25 thrombolytique (traitement) -- r_associated #0: 24 / 0.296 -> embolie cruorique n1=thrombolytique (traitement) | n2=embolie cruorique | rel=r_associated | relid=0 | w=24 thrombolytique (traitement) -- r_associated #0: 24 / 0.296 -> infarctus du myocarde n1=thrombolytique (traitement) | n2=infarctus du myocarde | rel=r_associated | relid=0 | w=24 thrombolytique (traitement) -- r_associated #0: 24 / 0.296 -> urokinase n1=thrombolytique (traitement) | n2=urokinase | rel=r_associated | relid=0 | w=24 thrombolytique (traitement) -- r_associated #0: 23 / 0.284 -> phlébite n1=thrombolytique (traitement) | n2=phlébite | rel=r_associated | relid=0 | w=23 thrombolytique (traitement) -- r_associated #0: 23 / 0.284 -> plaquettes n1=thrombolytique (traitement) | n2=plaquettes | rel=r_associated | relid=0 | w=23 thrombolytique (traitement) -- r_associated #0: 23 / 0.284 -> thrombophlébite cérébrale n1=thrombolytique (traitement) | n2=thrombophlébite cérébrale | rel=r_associated | relid=0 | w=23 thrombolytique (traitement) -- r_associated #0: 22 / 0.272 -> état hypercoagulable n1=thrombolytique (traitement) | n2=état hypercoagulable | rel=r_associated | relid=0 | w=22 thrombolytique (traitement) -- r_associated #0: 22 / 0.272 -> hématologie n1=thrombolytique (traitement) | n2=hématologie | rel=r_associated | relid=0 | w=22 thrombolytique (traitement) -- r_associated #0: 22 / 0.272 -> médecine spécialisée n1=thrombolytique (traitement) | n2=médecine spécialisée | rel=r_associated | relid=0 | w=22 thrombolytique (traitement) -- r_associated #0: 21 / 0.259 -> embolie artérielle périphérique n1=thrombolytique (traitement) | n2=embolie artérielle périphérique | rel=r_associated | relid=0 | w=21 thrombolytique (traitement) -- r_associated #0: 21 / 0.259 -> plaquette n1=thrombolytique (traitement) | n2=plaquette | rel=r_associated | relid=0 | w=21 thrombolytique (traitement) -- r_associated #0: 20 / 0.247 -> en:arterial thrombosis of the limbs n1=thrombolytique (traitement) | n2=en:arterial thrombosis of the limbs | rel=r_associated | relid=0 | w=20 thrombolytique (traitement) -- r_associated #0: 20 / 0.247 -> en:hypercoagulable state n1=thrombolytique (traitement) | n2=en:hypercoagulable state | rel=r_associated | relid=0 | w=20 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:a disintegrin and metalloproteinase with thrombospondin type 1 motif 13 deficiency (adamts13) n1=thrombolytique (traitement) | n2=en:a disintegrin and metalloproteinase with thrombospondin type 1 motif 13 deficiency (adamts13) | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:abnormal clotting factor n1=thrombolytique (traitement) | n2=en:abnormal clotting factor | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:abnormal platelet n1=thrombolytique (traitement) | n2=en:abnormal platelet | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:abnormality of coagulation n1=thrombolytique (traitement) | n2=en:abnormality of coagulation | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:abnormality of prothrombin n1=thrombolytique (traitement) | n2=en:abnormality of prothrombin | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:abnormality of the common coagulation pathway n1=thrombolytique (traitement) | n2=en:abnormality of the common coagulation pathway | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:abnormality of the extrinsic pathway n1=thrombolytique (traitement) | n2=en:abnormality of the extrinsic pathway | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:abnormality of the intrinsic pathway n1=thrombolytique (traitement) | n2=en:abnormality of the intrinsic pathway | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:abnormality of von willebrand factor n1=thrombolytique (traitement) | n2=en:abnormality of von willebrand factor | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:acquired coagulation disorder n1=thrombolytique (traitement) | n2=en:acquired coagulation disorder | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:acquired coagulation factor deficiency n1=thrombolytique (traitement) | n2=en:acquired coagulation factor deficiency | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:acquired dysfibrinogenaemia n1=thrombolytique (traitement) | n2=en:acquired dysfibrinogenaemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:acute coagulopathy n1=thrombolytique (traitement) | n2=en:acute coagulopathy | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:afibrinogenemia n1=thrombolytique (traitement) | n2=en:afibrinogenemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:anaphylactoid syndrome in pregnancy n1=thrombolytique (traitement) | n2=en:anaphylactoid syndrome in pregnancy | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:anemia n1=thrombolytique (traitement) | n2=en:anemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:anticoagulant disorders n1=thrombolytique (traitement) | n2=en:anticoagulant disorders | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:antiphospholipid syndrome n1=thrombolytique (traitement) | n2=en:antiphospholipid syndrome | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:antithrombin iii deficiency n1=thrombolytique (traitement) | n2=en:antithrombin iii deficiency | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:aspects of mortality statistics n1=thrombolytique (traitement) | n2=en:aspects of mortality statistics | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:aspects of radionuclide imaging n1=thrombolytique (traitement) | n2=en:aspects of radionuclide imaging | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:bleeding diathesis n1=thrombolytique (traitement) | n2=en:bleeding diathesis | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:bleeding time abnormal n1=thrombolytique (traitement) | n2=en:bleeding time abnormal | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:blood coagulation n1=thrombolytique (traitement) | n2=en:blood coagulation | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:blood coagulation disorder complicating childbirth n1=thrombolytique (traitement) | n2=en:blood coagulation disorder complicating childbirth | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:blood coagulation disorder complicating pregnancy n1=thrombolytique (traitement) | n2=en:blood coagulation disorder complicating pregnancy | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:blood coagulation disorder, categorized by value of screening test n1=thrombolytique (traitement) | n2=en:blood coagulation disorder, categorized by value of screening test | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:blood coagulation disorders, inherited n1=thrombolytique (traitement) | n2=en:blood coagulation disorders, inherited | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:chemically induced n1=thrombolytique (traitement) | n2=en:chemically induced | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:clot retraction abnormal n1=thrombolytique (traitement) | n2=en:clot retraction abnormal | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:clotting decreased n1=thrombolytique (traitement) | n2=en:clotting decreased | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:coagulation disorder n1=thrombolytique (traitement) | n2=en:coagulation disorder | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:coagulation disorder related to liver dysfunction n1=thrombolytique (traitement) | n2=en:coagulation disorder related to liver dysfunction | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:coagulation disorders, general and nec n1=thrombolytique (traitement) | n2=en:coagulation disorders, general and nec | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:coagulation factor deficiencies and excesses n1=thrombolytique (traitement) | n2=en:coagulation factor deficiencies and excesses | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:coagulation factor deficiency n1=thrombolytique (traitement) | n2=en:coagulation factor deficiency | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:coagulation factor mutation n1=thrombolytique (traitement) | n2=en:coagulation factor mutation | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:coagulation protein disorders n1=thrombolytique (traitement) | n2=en:coagulation protein disorders | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:coagulation time abnormal n1=thrombolytique (traitement) | n2=en:coagulation time abnormal | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:complication aspects n1=thrombolytique (traitement) | n2=en:complication aspects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:congenital bleeding disorder n1=thrombolytique (traitement) | n2=en:congenital bleeding disorder | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:congenital coagulopathy n1=thrombolytique (traitement) | n2=en:congenital coagulopathy | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:congenital deficiency of other clotting factors n1=thrombolytique (traitement) | n2=en:congenital deficiency of other clotting factors | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:congenital hypercoagulation n1=thrombolytique (traitement) | n2=en:congenital hypercoagulation | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:congenital mesh qualifier n1=thrombolytique (traitement) | n2=en:congenital mesh qualifier | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:contact factor deficiency n1=thrombolytique (traitement) | n2=en:contact factor deficiency | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:decreased platelet count n1=thrombolytique (traitement) | n2=en:decreased platelet count | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:deficiency of naturally occurring coagulation factor inhibitor n1=thrombolytique (traitement) | n2=en:deficiency of naturally occurring coagulation factor inhibitor | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:diagnosis aspect n1=thrombolytique (traitement) | n2=en:diagnosis aspect | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:dilutional coagulopathy n1=thrombolytique (traitement) | n2=en:dilutional coagulopathy | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:disorder involving the fibrinolytic system n1=thrombolytique (traitement) | n2=en:disorder involving the fibrinolytic system | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:disseminated intravascular coagulation n1=thrombolytique (traitement) | n2=en:disseminated intravascular coagulation | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:disseminated intravascular coagulation in newborn n1=thrombolytique (traitement) | n2=en:disseminated intravascular coagulation in newborn | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:dysfibrinogenemia, congenital n1=thrombolytique (traitement) | n2=en:dysfibrinogenemia, congenital | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:ecchymosis n1=thrombolytique (traitement) | n2=en:ecchymosis | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:embryologic n1=thrombolytique (traitement) | n2=en:embryologic | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:endothelial protein c receptor polymorphism n1=thrombolytique (traitement) | n2=en:endothelial protein c receptor polymorphism | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:enzymology n1=thrombolytique (traitement) | n2=en:enzymology | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:epidemiologic n1=thrombolytique (traitement) | n2=en:epidemiologic | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:essential thrombocythemia n1=thrombolytique (traitement) | n2=en:essential thrombocythemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:ethnologic n1=thrombolytique (traitement) | n2=en:ethnologic | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:etiology aspects n1=thrombolytique (traitement) | n2=en:etiology aspects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:exposure as collected domain n1=thrombolytique (traitement) | n2=en:exposure as collected domain | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:extramedullary hematopoiesis n1=thrombolytique (traitement) | n2=en:extramedullary hematopoiesis | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:factor ii inhibition n1=thrombolytique (traitement) | n2=en:factor ii inhibition | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:factor ii mutation n1=thrombolytique (traitement) | n2=en:factor ii mutation | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:factor ix inhibition n1=thrombolytique (traitement) | n2=en:factor ix inhibition | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:factor v inhibition n1=thrombolytique (traitement) | n2=en:factor v inhibition | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:factor v leiden n1=thrombolytique (traitement) | n2=en:factor v leiden | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:factor vii inhibition n1=thrombolytique (traitement) | n2=en:factor vii inhibition | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:factor viii inhibition n1=thrombolytique (traitement) | n2=en:factor viii inhibition | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:factor x inhibition n1=thrombolytique (traitement) | n2=en:factor x inhibition | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:factor xiii inhibition n1=thrombolytique (traitement) | n2=en:factor xiii inhibition | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:familial hemorrhagic diathesis n1=thrombolytique (traitement) | n2=en:familial hemorrhagic diathesis | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:fibrinogen abnormality n1=thrombolytique (traitement) | n2=en:fibrinogen abnormality | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:genetic aspects n1=thrombolytique (traitement) | n2=en:genetic aspects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hematologic and lymphocytic disorder n1=thrombolytique (traitement) | n2=en:hematologic and lymphocytic disorder | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hematology n1=thrombolytique (traitement) | n2=en:hematology | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hemolytic uremic syndrome n1=thrombolytique (traitement) | n2=en:hemolytic uremic syndrome | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hemophilia a n1=thrombolytique (traitement) | n2=en:hemophilia a | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hemophilia b n1=thrombolytique (traitement) | n2=en:hemophilia b | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hemorrhage n1=thrombolytique (traitement) | n2=en:hemorrhage | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hemorrhagic disorder due to circulating anticoagulants n1=thrombolytique (traitement) | n2=en:hemorrhagic disorder due to circulating anticoagulants | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors n1=thrombolytique (traitement) | n2=en:hemorrhagic disorder due to intrinsic circulating anticoagulants, antibodies, or inhibitors | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hemorrhagic disorders n1=thrombolytique (traitement) | n2=en:hemorrhagic disorders | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:heparin resistance n1=thrombolytique (traitement) | n2=en:heparin resistance | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hereditary coagulopathy n1=thrombolytique (traitement) | n2=en:hereditary coagulopathy | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hereditary factor xi deficiency disease n1=thrombolytique (traitement) | n2=en:hereditary factor xi deficiency disease | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:high molecular weight kininogen deficiency n1=thrombolytique (traitement) | n2=en:high molecular weight kininogen deficiency | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:historical aspects qualifier n1=thrombolytique (traitement) | n2=en:historical aspects qualifier | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hyperfibrinogenemia n1=thrombolytique (traitement) | n2=en:hyperfibrinogenemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hyperfibrinolysis n1=thrombolytique (traitement) | n2=en:hyperfibrinolysis | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hypergammaglobulinemia n1=thrombolytique (traitement) | n2=en:hypergammaglobulinemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hyperheparinemia n1=thrombolytique (traitement) | n2=en:hyperheparinemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hyperhomocysteinemia n1=thrombolytique (traitement) | n2=en:hyperhomocysteinemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hyperlipidemia n1=thrombolytique (traitement) | n2=en:hyperlipidemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hyperprothrombinemia n1=thrombolytique (traitement) | n2=en:hyperprothrombinemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hyperthrombinaemia n1=thrombolytique (traitement) | n2=en:hyperthrombinaemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hypocellular bone marrow n1=thrombolytique (traitement) | n2=en:hypocellular bone marrow | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:hypocoagulable state n1=thrombolytique (traitement) | n2=en:hypocoagulable state | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:immunology aspects n1=thrombolytique (traitement) | n2=en:immunology aspects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:in blood n1=thrombolytique (traitement) | n2=en:in blood | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:in cerebrospinal fluid n1=thrombolytique (traitement) | n2=en:in cerebrospinal fluid | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:in urine n1=thrombolytique (traitement) | n2=en:in urine | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:inherited factor ii deficiency n1=thrombolytique (traitement) | n2=en:inherited factor ii deficiency | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:iron-deficiency anemia n1=thrombolytique (traitement) | n2=en:iron-deficiency anemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:leukopenia n1=thrombolytique (traitement) | n2=en:leukopenia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:lupus anticoagulant disorder n1=thrombolytique (traitement) | n2=en:lupus anticoagulant disorder | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:metabolic aspects n1=thrombolytique (traitement) | n2=en:metabolic aspects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:methemoglobinemia n1=thrombolytique (traitement) | n2=en:methemoglobinemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:methylenetetrahydrofolate reductase deficiency n1=thrombolytique (traitement) | n2=en:methylenetetrahydrofolate reductase deficiency | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:methylenetetrahydrofolate reductase polymorphism n1=thrombolytique (traitement) | n2=en:methylenetetrahydrofolate reductase polymorphism | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:microbiological n1=thrombolytique (traitement) | n2=en:microbiological | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:multiple organ failure n1=thrombolytique (traitement) | n2=en:multiple organ failure | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:myelodysplastic syndrome n1=thrombolytique (traitement) | n2=en:myelodysplastic syndrome | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:neonatal coagulation disorder n1=thrombolytique (traitement) | n2=en:neonatal coagulation disorder | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:neonatal research network terminology n1=thrombolytique (traitement) | n2=en:neonatal research network terminology | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:nursing therapy n1=thrombolytique (traitement) | n2=en:nursing therapy | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:nutritional management n1=thrombolytique (traitement) | n2=en:nutritional management | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:other coagulation defects n1=thrombolytique (traitement) | n2=en:other coagulation defects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:pancytopenia n1=thrombolytique (traitement) | n2=en:pancytopenia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:parasitology n1=thrombolytique (traitement) | n2=en:parasitology | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:pathological aspects n1=thrombolytique (traitement) | n2=en:pathological aspects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:pediatric adverse events terminology n1=thrombolytique (traitement) | n2=en:pediatric adverse events terminology | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:pediatric terminology n1=thrombolytique (traitement) | n2=en:pediatric terminology | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:pharmacotherapeutic n1=thrombolytique (traitement) | n2=en:pharmacotherapeutic | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:physiopathological n1=thrombolytique (traitement) | n2=en:physiopathological | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:plasminogen activator inhibitor polymorphism n1=thrombolytique (traitement) | n2=en:plasminogen activator inhibitor polymorphism | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:platelet storage pool deficiency n1=thrombolytique (traitement) | n2=en:platelet storage pool deficiency | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:polycythemia n1=thrombolytique (traitement) | n2=en:polycythemia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:postpartum coagulation defects n1=thrombolytique (traitement) | n2=en:postpartum coagulation defects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:postpartum coagulation defects, delivered, with mention of postpartum complication n1=thrombolytique (traitement) | n2=en:postpartum coagulation defects, delivered, with mention of postpartum complication | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:postpartum coagulation defects, unspecified as to episode of care or not applicable n1=thrombolytique (traitement) | n2=en:postpartum coagulation defects, unspecified as to episode of care or not applicable | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:prolonged partial thromboplastin time n1=thrombolytique (traitement) | n2=en:prolonged partial thromboplastin time | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:prolonged whole-blood clotting time n1=thrombolytique (traitement) | n2=en:prolonged whole-blood clotting time | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:protein c deficiency disease n1=thrombolytique (traitement) | n2=en:protein c deficiency disease | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:protein s deficiency disease n1=thrombolytique (traitement) | n2=en:protein s deficiency disease | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:prothrombin complex deficiency n1=thrombolytique (traitement) | n2=en:prothrombin complex deficiency | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:psychology qualifier n1=thrombolytique (traitement) | n2=en:psychology qualifier | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:purpura n1=thrombolytique (traitement) | n2=en:purpura | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:purpura and other haemorrhagic conditions n1=thrombolytique (traitement) | n2=en:purpura and other haemorrhagic conditions | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:purpura fulminans n1=thrombolytique (traitement) | n2=en:purpura fulminans | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:radiotherapeutic n1=thrombolytique (traitement) | n2=en:radiotherapeutic | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:rbc count low n1=thrombolytique (traitement) | n2=en:rbc count low | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:reduced protein s activity n1=thrombolytique (traitement) | n2=en:reduced protein s activity | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:rehabilitation aspects n1=thrombolytique (traitement) | n2=en:rehabilitation aspects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:resistance to activated protein c due to factor v leiden n1=thrombolytique (traitement) | n2=en:resistance to activated protein c due to factor v leiden | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:roentgenographic n1=thrombolytique (traitement) | n2=en:roentgenographic | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:serum complement decreased n1=thrombolytique (traitement) | n2=en:serum complement decreased | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:surgical aspects n1=thrombolytique (traitement) | n2=en:surgical aspects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:taxonomic n1=thrombolytique (traitement) | n2=en:taxonomic | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:therapeutic aspects n1=thrombolytique (traitement) | n2=en:therapeutic aspects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:thrombocytopenia n1=thrombolytique (traitement) | n2=en:thrombocytopenia | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:thrombocytopenic purpura | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:thrombotic microangiopathy n1=thrombolytique (traitement) | n2=en:thrombotic microangiopathy | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:thrombotic thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:thrombotic thrombocytopenic purpura | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:use of ultrasonography n1=thrombolytique (traitement) | n2=en:use of ultrasonography | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:vascular purpura n1=thrombolytique (traitement) | n2=en:vascular purpura | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:veterinary aspects n1=thrombolytique (traitement) | n2=en:veterinary aspects | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:viruses n1=thrombolytique (traitement) | n2=en:viruses | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:vitamin k deficiency n1=thrombolytique (traitement) | n2=en:vitamin k deficiency | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:von willebrand disease n1=thrombolytique (traitement) | n2=en:von willebrand disease | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:von willebrand disease, platelet type n1=thrombolytique (traitement) | n2=en:von willebrand disease, platelet type | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:von willebrand's factor inhibition n1=thrombolytique (traitement) | n2=en:von willebrand's factor inhibition | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> en:white blood cell abnormality n1=thrombolytique (traitement) | n2=en:white blood cell abnormality | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> état d'hypercoagulabilité n1=thrombolytique (traitement) | n2=état d'hypercoagulabilité | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> hypercoagulabilité n1=thrombolytique (traitement) | n2=hypercoagulabilité | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> Médecine n1=thrombolytique (traitement) | n2=Médecine | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> thrombolyse coronarienne n1=thrombolytique (traitement) | n2=thrombolyse coronarienne | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> thrombolyse intra-artérielle n1=thrombolytique (traitement) | n2=thrombolyse intra-artérielle | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 15 / 0.185 -> thrombose n1=thrombolytique (traitement) | n2=thrombose | rel=r_associated | relid=0 | w=15 thrombolytique (traitement) -- r_associated #0: 12 / 0.148 -> thrombo-phlébite n1=thrombolytique (traitement) | n2=thrombo-phlébite | rel=r_associated | relid=0 | w=12 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> anémie profonde n1=thrombolytique (traitement) | n2=anémie profonde | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> angiosarcome du foie n1=thrombolytique (traitement) | n2=angiosarcome du foie | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> anomalie des plaquettes n1=thrombolytique (traitement) | n2=anomalie des plaquettes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> anomalies des plaquettes n1=thrombolytique (traitement) | n2=anomalies des plaquettes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> anomalies plaquettaires n1=thrombolytique (traitement) | n2=anomalies plaquettaires | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> c-61 troubles des plaquettes n1=thrombolytique (traitement) | n2=c-61 troubles des plaquettes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> cérébrale n1=thrombolytique (traitement) | n2=cérébrale | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> chimie n1=thrombolytique (traitement) | n2=chimie | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> Chirurgie n1=thrombolytique (traitement) | n2=Chirurgie | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> d-dimère n1=thrombolytique (traitement) | n2=d-dimère | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> diminution n1=thrombolytique (traitement) | n2=diminution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> dite n1=thrombolytique (traitement) | n2=dite | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:'cloudy' or 'pink' blood (lipemia) n1=thrombolytique (traitement) | n2=en:'cloudy' or 'pink' blood (lipemia) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:'compensated hypothyroidism' with increased tsh and normal t4 n1=thrombolytique (traitement) | n2=en:'compensated hypothyroidism' with increased tsh and normal t4 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:'leukemoid' granulocytosis n1=thrombolytique (traitement) | n2=en:'leukemoid' granulocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:'rectilinear profiles' ultrastructurally in cells n1=thrombolytique (traitement) | n2=en:'rectilinear profiles' ultrastructurally in cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:{12 (methotrexate 2.5 mg oral tablet) } pack n1=thrombolytique (traitement) | n2=en:{12 (methotrexate 2.5 mg oral tablet) } pack | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:{16 (methotrexate 2.5 mg oral tablet) } pack n1=thrombolytique (traitement) | n2=en:{16 (methotrexate 2.5 mg oral tablet) } pack | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:{20 (methotrexate 2.5 mg oral tablet) } pack n1=thrombolytique (traitement) | n2=en:{20 (methotrexate 2.5 mg oral tablet) } pack | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.15 ml methotrexate 50 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.15 ml methotrexate 50 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.2 ml methotrexate 50 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.2 ml methotrexate 50 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.25 ml methotrexate 50 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.25 ml methotrexate 50 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.3 ml enoxaparin sodium 100 mg/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:0.3 ml enoxaparin sodium 100 mg/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.3 ml methotrexate 50 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.3 ml methotrexate 50 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.35 ml methotrexate 50 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.35 ml methotrexate 50 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.4 ml enoxaparin sodium 100 mg/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:0.4 ml enoxaparin sodium 100 mg/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.4 ml fondaparinux sodium 12.5 mg/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:0.4 ml fondaparinux sodium 12.5 mg/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.4 ml methotrexate 18.8 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.4 ml methotrexate 18.8 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.4 ml methotrexate 50 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.4 ml methotrexate 50 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.4 ml methotrexate 62.5 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.4 ml methotrexate 62.5 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.45 ml methotrexate 50 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.45 ml methotrexate 50 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.5 ml ardeparin sodium 10000 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:0.5 ml ardeparin sodium 10000 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.5 ml ardeparin sodium 20000 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:0.5 ml ardeparin sodium 20000 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.5 ml heparin sodium, porcine 10000 unt/ml cartridge n1=thrombolytique (traitement) | n2=en:0.5 ml heparin sodium, porcine 10000 unt/ml cartridge | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.5 ml methotrexate 50 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.5 ml methotrexate 50 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.55 ml methotrexate 50 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.55 ml methotrexate 50 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.6 ml enoxaparin sodium 100 mg/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:0.6 ml enoxaparin sodium 100 mg/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.6 ml fondaparinux sodium 12.5 mg/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:0.6 ml fondaparinux sodium 12.5 mg/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.6 ml methotrexate 50 mg/ml auto-injector n1=thrombolytique (traitement) | n2=en:0.6 ml methotrexate 50 mg/ml auto-injector | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.8 ml enoxaparin sodium 100 mg/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:0.8 ml enoxaparin sodium 100 mg/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:0.8 ml enoxaparin sodium 150 mg/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:0.8 ml enoxaparin sodium 150 mg/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:1 ml enoxaparin sodium 100 mg/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:1 ml enoxaparin sodium 100 mg/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:1 ml enoxaparin sodium 150 mg/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:1 ml enoxaparin sodium 150 mg/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:1 ml heparin sodium, porcine 10 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:1 ml heparin sodium, porcine 10 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:1 ml heparin sodium, porcine 100 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:1 ml heparin sodium, porcine 100 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:1 ml heparin sodium, porcine 1000 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:1 ml heparin sodium, porcine 1000 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:1 ml heparin sodium, porcine 5000 unt/ml injection n1=thrombolytique (traitement) | n2=en:1 ml heparin sodium, porcine 5000 unt/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:1 ml vinorelbine 10 mg/ml injection n1=thrombolytique (traitement) | n2=en:1 ml vinorelbine 10 mg/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:1,25-dihydroxyvitamin d was elevated in childhood but deficient in adulthood n1=thrombolytique (traitement) | n2=en:1,25-dihydroxyvitamin d was elevated in childhood but deficient in adulthood | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:1.61- and 1.76-mb microduplication of 3q29 n1=thrombolytique (traitement) | n2=en:1.61- and 1.76-mb microduplication of 3q29 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:10 ml heparin sodium, porcine 2500 unt/ml injection n1=thrombolytique (traitement) | n2=en:10 ml heparin sodium, porcine 2500 unt/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:10 ml methotrexate 25 mg/ml injection n1=thrombolytique (traitement) | n2=en:10 ml methotrexate 25 mg/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:2 ml heparin sodium, porcine 1000 unt/ml injection n1=thrombolytique (traitement) | n2=en:2 ml heparin sodium, porcine 1000 unt/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:2 ml methotrexate 25 mg/ml injection n1=thrombolytique (traitement) | n2=en:2 ml methotrexate 25 mg/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:2-aminoadipic aciduria n1=thrombolytique (traitement) | n2=en:2-aminoadipic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:2-oxoadipic aciduria n1=thrombolytique (traitement) | n2=en:2-oxoadipic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:2,8-dihydroxyadenine (dha) urinary stones n1=thrombolytique (traitement) | n2=en:2,8-dihydroxyadenine (dha) urinary stones | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:2.5 ml heparin sodium, porcine 10 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:2.5 ml heparin sodium, porcine 10 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:2.5 ml heparin sodium, porcine 100 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:2.5 ml heparin sodium, porcine 100 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:25 ml daunorubicin liposomal 2 mg/ml injection n1=thrombolytique (traitement) | n2=en:25 ml daunorubicin liposomal 2 mg/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:3 ml heparin sodium, porcine 10 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:3 ml heparin sodium, porcine 10 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:3 ml heparin sodium, porcine 100 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:3 ml heparin sodium, porcine 100 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:3 ml heparin sodium, porcine 2000 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:3 ml heparin sodium, porcine 2000 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:3-methylglutaconic aciduria n1=thrombolytique (traitement) | n2=en:3-methylglutaconic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:3-methylglutaconic aciduria (3-mgc) n1=thrombolytique (traitement) | n2=en:3-methylglutaconic aciduria (3-mgc) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:3-methylglutaric aciduria n1=thrombolytique (traitement) | n2=en:3-methylglutaric aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:3-methylglutaric aciduria (3-mga) n1=thrombolytique (traitement) | n2=en:3-methylglutaric aciduria (3-mga) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:4 ml daunorubicin 5 mg/ml injection n1=thrombolytique (traitement) | n2=en:4 ml daunorubicin 5 mg/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:4 ml methotrexate 25 mg/ml injection n1=thrombolytique (traitement) | n2=en:4 ml methotrexate 25 mg/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:4-hydroxycyclohexylacetic aciduria (adults) n1=thrombolytique (traitement) | n2=en:4-hydroxycyclohexylacetic aciduria (adults) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:4-hydroxyphenylacetic aciduria n1=thrombolytique (traitement) | n2=en:4-hydroxyphenylacetic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:4-hydroxyphenylactic aciduria n1=thrombolytique (traitement) | n2=en:4-hydroxyphenylactic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:4-hydroxyphenyllactic aciduria n1=thrombolytique (traitement) | n2=en:4-hydroxyphenyllactic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:4-hydroxyphenylpyruvic acid dioxygenase deficiency (hpd) n1=thrombolytique (traitement) | n2=en:4-hydroxyphenylpyruvic acid dioxygenase deficiency (hpd) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:4-hydroxyphenylpyruvic aciduria n1=thrombolytique (traitement) | n2=en:4-hydroxyphenylpyruvic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:5 ml abciximab 2 mg/ml injection n1=thrombolytique (traitement) | n2=en:5 ml abciximab 2 mg/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:5 ml fulvestrant 50 mg/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:5 ml fulvestrant 50 mg/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:5 ml heparin sodium, porcine 10 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:5 ml heparin sodium, porcine 10 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:5 ml heparin sodium, porcine 100 unt/ml prefilled syringe n1=thrombolytique (traitement) | n2=en:5 ml heparin sodium, porcine 100 unt/ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:5 ml heparin sodium, porcine 2000 unt/ml injection n1=thrombolytique (traitement) | n2=en:5 ml heparin sodium, porcine 2000 unt/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:5 ml vinorelbine 10 mg/ml injection n1=thrombolytique (traitement) | n2=en:5 ml vinorelbine 10 mg/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:5-alpha-reductase-2 enzyme deficiency n1=thrombolytique (traitement) | n2=en:5-alpha-reductase-2 enzyme deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:5-hiaa csf may be normal or decreased n1=thrombolytique (traitement) | n2=en:5-hiaa csf may be normal or decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:5-oxoprolinase deficiency n1=thrombolytique (traitement) | n2=en:5-oxoprolinase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:8 ml methotrexate 25 mg/ml injection n1=thrombolytique (traitement) | n2=en:8 ml methotrexate 25 mg/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:85-90% dgs patients have deletion of 22q11.2 n1=thrombolytique (traitement) | n2=en:85-90% dgs patients have deletion of 22q11.2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:a small minority of patients have translocations and inversions involving 16p13.3 n1=thrombolytique (traitement) | n2=en:a small minority of patients have translocations and inversions involving 16p13.3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:a subset of group b patients have absence of pc protein and mrna n1=thrombolytique (traitement) | n2=en:a subset of group b patients have absence of pc protein and mrna | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abacterial leukocyturia n1=thrombolytique (traitement) | n2=en:abacterial leukocyturia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abciximab n1=thrombolytique (traitement) | n2=en:abciximab | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aberrant gamma-interferon-mediated inflammation n1=thrombolytique (traitement) | n2=en:aberrant gamma-interferon-mediated inflammation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abetalipoproteinemia (lab finding) n1=thrombolytique (traitement) | n2=en:abetalipoproteinemia (lab finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal acylcarnitine profiles n1=thrombolytique (traitement) | n2=en:abnormal acylcarnitine profiles | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal blood coagulation studies (prolonged pt and ptt) n1=thrombolytique (traitement) | n2=en:abnormal blood coagulation studies (prolonged pt and ptt) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal bone marrow karyotype, t(8,21) n1=thrombolytique (traitement) | n2=en:abnormal bone marrow karyotype, t(8,21) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal cardiolipin subspecies composition n1=thrombolytique (traitement) | n2=en:abnormal cardiolipin subspecies composition | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal cartilage collagen on em n1=thrombolytique (traitement) | n2=en:abnormal cartilage collagen on em | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal cholesterol homeostasis n1=thrombolytique (traitement) | n2=en:abnormal cholesterol homeostasis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal columnization of chondrocytes n1=thrombolytique (traitement) | n2=en:abnormal columnization of chondrocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal dystrophin on muscle biopsy n1=thrombolytique (traitement) | n2=en:abnormal dystrophin on muscle biopsy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal eeg in 25% hospitalized patients n1=thrombolytique (traitement) | n2=en:abnormal eeg in 25% hospitalized patients | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal electrophoretic mobility of type ii collagen n1=thrombolytique (traitement) | n2=en:abnormal electrophoretic mobility of type ii collagen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal extrarenal response to ddavp (no increase in von willebrand factor or factor viii) n1=thrombolytique (traitement) | n2=en:abnormal extrarenal response to ddavp (no increase in von willebrand factor or factor viii) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal fecal fat n1=thrombolytique (traitement) | n2=en:abnormal fecal fat | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal glycosylation of serum transferrin, type 1 pattern n1=thrombolytique (traitement) | n2=en:abnormal glycosylation of serum transferrin, type 1 pattern | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal igfr1 function n1=thrombolytique (traitement) | n2=en:abnormal igfr1 function | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal isoelectric focusing of serum transferrin n1=thrombolytique (traitement) | n2=en:abnormal isoelectric focusing of serum transferrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal isoelectric focusing of serum transferrin (type 1 pattern without increase of asialotransferrin) n1=thrombolytique (traitement) | n2=en:abnormal isoelectric focusing of serum transferrin (type 1 pattern without increase of asialotransferrin) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal isoelectric focusing of serum transferrin (type 1 pattern) n1=thrombolytique (traitement) | n2=en:abnormal isoelectric focusing of serum transferrin (type 1 pattern) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal isoelectric focusing of serum transferrin (type 1 pattern) (in 1 patient) n1=thrombolytique (traitement) | n2=en:abnormal isoelectric focusing of serum transferrin (type 1 pattern) (in 1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal isoelectric focusing of serum transferrin (type 1 pattern) loss of complete n-glycans n1=thrombolytique (traitement) | n2=en:abnormal isoelectric focusing of serum transferrin (type 1 pattern) loss of complete n-glycans | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal isoelectric focusing of serum transferrin (type 2 pattern) n1=thrombolytique (traitement) | n2=en:abnormal isoelectric focusing of serum transferrin (type 2 pattern) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal karyotype in 3 patients involving distal 6p n1=thrombolytique (traitement) | n2=en:abnormal karyotype in 3 patients involving distal 6p | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal karyotype in single reported female patient 46, xx,r(18)(p14q23) n1=thrombolytique (traitement) | n2=en:abnormal karyotype in single reported female patient 46, xx,r(18)(p14q23) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal lipid profile n1=thrombolytique (traitement) | n2=en:abnormal lipid profile | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver enzymes (1 patient) n1=thrombolytique (traitement) | n2=en:abnormal liver enzymes (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver enzymes (in some patients) n1=thrombolytique (traitement) | n2=en:abnormal liver enzymes (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver enzymes (rare) n1=thrombolytique (traitement) | n2=en:abnormal liver enzymes (rare) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver enzymes during illness n1=thrombolytique (traitement) | n2=en:abnormal liver enzymes during illness | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver enzymes in those with hepatic cysts or fibrosis n1=thrombolytique (traitement) | n2=en:abnormal liver enzymes in those with hepatic cysts or fibrosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver enzymes, episodic n1=thrombolytique (traitement) | n2=en:abnormal liver enzymes, episodic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver enzymes, intermittent n1=thrombolytique (traitement) | n2=en:abnormal liver enzymes, intermittent | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver enzymes, intermittent (1 patient) n1=thrombolytique (traitement) | n2=en:abnormal liver enzymes, intermittent (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver function test n1=thrombolytique (traitement) | n2=en:abnormal liver function test | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver function tests (in some patients) n1=thrombolytique (traitement) | n2=en:abnormal liver function tests (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver function tests (less common) n1=thrombolytique (traitement) | n2=en:abnormal liver function tests (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver function tests (sgot, sgpt) n1=thrombolytique (traitement) | n2=en:abnormal liver function tests (sgot, sgpt) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal liver function tests during pregnancy, resolves postpartum n1=thrombolytique (traitement) | n2=en:abnormal liver function tests during pregnancy, resolves postpartum | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal myelination in sural nerve biopsies n1=thrombolytique (traitement) | n2=en:abnormal myelination in sural nerve biopsies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal n-glycosylation of transferrin n1=thrombolytique (traitement) | n2=en:abnormal n-glycosylation of transferrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal nasal potential difference n1=thrombolytique (traitement) | n2=en:abnormal nasal potential difference | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal nuclear morphology n1=thrombolytique (traitement) | n2=en:abnormal nuclear morphology | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal oral glucose tolerance n1=thrombolytique (traitement) | n2=en:abnormal oral glucose tolerance | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal phosphatidylglycerol profile (increased 34-to-1 and decreased 36-to-1 ratio) n1=thrombolytique (traitement) | n2=en:abnormal phosphatidylglycerol profile (increased 34-to-1 and decreased 36-to-1 ratio) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal phospholipid profile n1=thrombolytique (traitement) | n2=en:abnormal phospholipid profile | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal platelet maturation n1=thrombolytique (traitement) | n2=en:abnormal platelet maturation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal platelet morphology with paucity of granules (in some patients) n1=thrombolytique (traitement) | n2=en:abnormal platelet morphology with paucity of granules (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal platelets with giant morphology n1=thrombolytique (traitement) | n2=en:abnormal platelets with giant morphology | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal rbc morphology (anisocytosis, poikilocytes, acanthocytes) (in some patients) n1=thrombolytique (traitement) | n2=en:abnormal rbc morphology (anisocytosis, poikilocytes, acanthocytes) (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal response of 25-hydroxyvitamin d-1-alpha-hydroxylase activity (609506) to hypophosphatemia n1=thrombolytique (traitement) | n2=en:abnormal response of 25-hydroxyvitamin d-1-alpha-hydroxylase activity (609506) to hypophosphatemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal response to human chorionic gonadotropin indicates decreased testosterone n1=thrombolytique (traitement) | n2=en:abnormal response to human chorionic gonadotropin indicates decreased testosterone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal schilling test (not normalized by addition of intrinsic factor) n1=thrombolytique (traitement) | n2=en:abnormal schilling test (not normalized by addition of intrinsic factor) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal secretin test n1=thrombolytique (traitement) | n2=en:abnormal secretin test | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal serum glycoproteins n1=thrombolytique (traitement) | n2=en:abnormal serum glycoproteins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal serum lipoprotein levels (in 3 of 10 patients) n1=thrombolytique (traitement) | n2=en:abnormal serum lipoprotein levels (in 3 of 10 patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal serum liver enzyme levels n1=thrombolytique (traitement) | n2=en:abnormal serum liver enzyme levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal serum protein electrophoresis (elevated alpha-2 band) n1=thrombolytique (traitement) | n2=en:abnormal serum protein electrophoresis (elevated alpha-2 band) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal serum transferrin pattern (in some patients) n1=thrombolytique (traitement) | n2=en:abnormal serum transferrin pattern (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal serum transferrin pattern by isoelectric focusing (hyposialylation) n1=thrombolytique (traitement) | n2=en:abnormal serum transferrin pattern by isoelectric focusing (hyposialylation) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal spinocerebellar tracts, dorsal columns, pyramidal tracts, cerebellum and brainstem n1=thrombolytique (traitement) | n2=en:abnormal spinocerebellar tracts, dorsal columns, pyramidal tracts, cerebellum and brainstem | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal transaminases (1 patient) n1=thrombolytique (traitement) | n2=en:abnormal transaminases (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal transferrin isoelectric focusing (ief) n1=thrombolytique (traitement) | n2=en:abnormal transferrin isoelectric focusing (ief) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal urinary collagen-derived pyridinium crosslinks (absent glc-gal-pyd) n1=thrombolytique (traitement) | n2=en:abnormal urinary collagen-derived pyridinium crosslinks (absent glc-gal-pyd) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal urinary compounds n1=thrombolytique (traitement) | n2=en:abnormal urinary compounds | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal urinary mucopolysaccharides (elevated unsaturated nonsulfated disaccharides and decreased unsaturated 6-sulfated disaccharides) n1=thrombolytique (traitement) | n2=en:abnormal urinary mucopolysaccharides (elevated unsaturated nonsulfated disaccharides and decreased unsaturated 6-sulfated disaccharides) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal urinary oligosaccharides n1=thrombolytique (traitement) | n2=en:abnormal urinary oligosaccharides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormal urinary organic acids n1=thrombolytique (traitement) | n2=en:abnormal urinary organic acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormally low cerebrospinal fluid cystatin c n1=thrombolytique (traitement) | n2=en:abnormally low cerebrospinal fluid cystatin c | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:abnormally triglyceride-rich low and high density lipoproteins and beta-migrating very low density lipoproteins n1=thrombolytique (traitement) | n2=en:abnormally triglyceride-rich low and high density lipoproteins and beta-migrating very low density lipoproteins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absence of beta-ureidopropionase activity and protein in liver biopsy n1=thrombolytique (traitement) | n2=en:absence of beta-ureidopropionase activity and protein in liver biopsy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absence of cd59 expression on red cells n1=thrombolytique (traitement) | n2=en:absence of cd59 expression on red cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absence of chylomicrons in lymph and plasma n1=thrombolytique (traitement) | n2=en:absence of chylomicrons in lymph and plasma | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absence of cpt ii protein n1=thrombolytique (traitement) | n2=en:absence of cpt ii protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absence of emerin by immunohistochemistry on muscle biopsy n1=thrombolytique (traitement) | n2=en:absence of emerin by immunohistochemistry on muscle biopsy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absence of hb h inclusions in red blood cells n1=thrombolytique (traitement) | n2=en:absence of hb h inclusions in red blood cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absence of hepatic udp-glucuronyl-transferase n1=thrombolytique (traitement) | n2=en:absence of hepatic udp-glucuronyl-transferase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absence of lutheran antigen on red blood cells n1=thrombolytique (traitement) | n2=en:absence of lutheran antigen on red blood cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absence of outer dynein arms n1=thrombolytique (traitement) | n2=en:absence of outer dynein arms | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absence of peroxidase staining in neutrophils and monocytes n1=thrombolytique (traitement) | n2=en:absence of peroxidase staining in neutrophils and monocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absence of platelet dense bodies n1=thrombolytique (traitement) | n2=en:absence of platelet dense bodies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent 7-dehydrocholesterol n1=thrombolytique (traitement) | n2=en:absent 7-dehydrocholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent alkyl-dhap synthase activity n1=thrombolytique (traitement) | n2=en:absent alkyl-dhap synthase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent anti-insulin receptor antibodies n1=thrombolytique (traitement) | n2=en:absent anti-insulin receptor antibodies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent axonal flare response after intradermal histamine injection n1=thrombolytique (traitement) | n2=en:absent axonal flare response after intradermal histamine injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent axonal flare response to intradermal histamine injection n1=thrombolytique (traitement) | n2=en:absent axonal flare response to intradermal histamine injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent bone marrow myeloid elements n1=thrombolytique (traitement) | n2=en:absent bone marrow myeloid elements | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent ch50 activity in complete c4 deficiency n1=thrombolytique (traitement) | n2=en:absent ch50 activity in complete c4 deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent dense bodies in platelets n1=thrombolytique (traitement) | n2=en:absent dense bodies in platelets | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent dystrophin on muscle biopsy n1=thrombolytique (traitement) | n2=en:absent dystrophin on muscle biopsy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent enteric ganglia beginning at rectum and extending proximally by varying degrees n1=thrombolytique (traitement) | n2=en:absent enteric ganglia beginning at rectum and extending proximally by varying degrees | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent igg2 subclass n1=thrombolytique (traitement) | n2=en:absent igg2 subclass | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent neutrophil inclusions n1=thrombolytique (traitement) | n2=en:absent neutrophil inclusions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent or abnormal thyroglobulin n1=thrombolytique (traitement) | n2=en:absent or abnormal thyroglobulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent or hypoplastic megakaryocytes n1=thrombolytique (traitement) | n2=en:absent or hypoplastic megakaryocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent or severely reduced levels of serum immunoglobulins n1=thrombolytique (traitement) | n2=en:absent or severely reduced levels of serum immunoglobulins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent platelet agglutination in presence of ristocetin n1=thrombolytique (traitement) | n2=en:absent platelet agglutination in presence of ristocetin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent platelet aggregation response to epinephrine n1=thrombolytique (traitement) | n2=en:absent platelet aggregation response to epinephrine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent platelet delta granules n1=thrombolytique (traitement) | n2=en:absent platelet delta granules | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent pro alpha 2(i) chain synthesis (fibroblasts) n1=thrombolytique (traitement) | n2=en:absent pro alpha 2(i) chain synthesis (fibroblasts) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent tyrosinase activity n1=thrombolytique (traitement) | n2=en:absent tyrosinase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent-decreased prolyl 3-hydroxylation at collagen i alpha-1 pro986 n1=thrombolytique (traitement) | n2=en:absent-decreased prolyl 3-hydroxylation at collagen i alpha-1 pro986 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent/reduced free proteins and absent total protein s n1=thrombolytique (traitement) | n2=en:absent/reduced free proteins and absent total protein s | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:absent/reduced protein s and normal total proteins in heterozygote n1=thrombolytique (traitement) | n2=en:absent/reduced protein s and normal total proteins in heterozygote | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acanthocyte n1=thrombolytique (traitement) | n2=en:acanthocyte | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acanthocytosis n1=thrombolytique (traitement) | n2=en:acanthocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:accelerated phase chronic myelogenous leukemia, bcr-abl1 positive n1=thrombolytique (traitement) | n2=en:accelerated phase chronic myelogenous leukemia, bcr-abl1 positive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:accumulation of cholesterol esters in various tissues n1=thrombolytique (traitement) | n2=en:accumulation of cholesterol esters in various tissues | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:accumulation of guanidinoacetate in brain n1=thrombolytique (traitement) | n2=en:accumulation of guanidinoacetate in brain | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:accumulation of neutral lipids (triglycerides) in leukocytes, muscle cells, fibroblasts, and cardiomyocytes n1=thrombolytique (traitement) | n2=en:accumulation of neutral lipids (triglycerides) in leukocytes, muscle cells, fibroblasts, and cardiomyocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:accumulation of shortened dolichol-linked oligosaccharides in patient fibroblasts n1=thrombolytique (traitement) | n2=en:accumulation of shortened dolichol-linked oligosaccharides in patient fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:accumulation of sulfatides, glycosaminoglycans, sphingolipids, and steroid sulfates in tissues and body fluids n1=thrombolytique (traitement) | n2=en:accumulation of sulfatides, glycosaminoglycans, sphingolipids, and steroid sulfates in tissues and body fluids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:accumulation of unprocessed mt-trna intermediates in skeletal muscle cells and fibroblasts n1=thrombolytique (traitement) | n2=en:accumulation of unprocessed mt-trna intermediates in skeletal muscle cells and fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acetyl coa:alpha-glucosaminidase n-acetyltransferase deficiency in fibroblasts n1=thrombolytique (traitement) | n2=en:acetyl coa:alpha-glucosaminidase n-acetyltransferase deficiency in fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acetylcholinesterase staining reveals nerve trunk hypertrophy n1=thrombolytique (traitement) | n2=en:acetylcholinesterase staining reveals nerve trunk hypertrophy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acquired amegakaryocytic thrombocytopenia n1=thrombolytique (traitement) | n2=en:acquired amegakaryocytic thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acquired pancytopenia n1=thrombolytique (traitement) | n2=en:acquired pancytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acquired platelet disorder n1=thrombolytique (traitement) | n2=en:acquired platelet disorder | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acquired thrombocytopenia n1=thrombolytique (traitement) | n2=en:acquired thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acth normal n1=thrombolytique (traitement) | n2=en:acth normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute bilineal leukemia n1=thrombolytique (traitement) | n2=en:acute bilineal leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute biphenotypic leukemia n1=thrombolytique (traitement) | n2=en:acute biphenotypic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute hemolytic transfusion reaction when transfused with vel-positive blood n1=thrombolytique (traitement) | n2=en:acute hemolytic transfusion reaction when transfused with vel-positive blood | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute hyperammonemia n1=thrombolytique (traitement) | n2=en:acute hyperammonemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute idiopathic thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:acute idiopathic thrombocytopenic purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute leukemia of ambiguous lineage n1=thrombolytique (traitement) | n2=en:acute leukemia of ambiguous lineage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute megakaryoblastic leukemia n1=thrombolytique (traitement) | n2=en:acute megakaryoblastic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute myeloid leukemia arising from previous myelodysplastic syndrome n1=thrombolytique (traitement) | n2=en:acute myeloid leukemia arising from previous myelodysplastic syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute myeloid leukemia with minimal differentiation n1=thrombolytique (traitement) | n2=en:acute myeloid leukemia with minimal differentiation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute myeloid leukemia with multilineage dysplasia n1=thrombolytique (traitement) | n2=en:acute myeloid leukemia with multilineage dysplasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute myeloid leukemia with myelodysplasia-related changes n1=thrombolytique (traitement) | n2=en:acute myeloid leukemia with myelodysplasia-related changes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute myeloid leukemia without maturation n1=thrombolytique (traitement) | n2=en:acute myeloid leukemia without maturation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute myelomonocytic leukemia n1=thrombolytique (traitement) | n2=en:acute myelomonocytic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute myelomonocytic leukemia with abnormal eosinophils n1=thrombolytique (traitement) | n2=en:acute myelomonocytic leukemia with abnormal eosinophils | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute myelomonocytic leukemia without abnormal eosinophils n1=thrombolytique (traitement) | n2=en:acute myelomonocytic leukemia without abnormal eosinophils | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute undifferentiated leukemia n1=thrombolytique (traitement) | n2=en:acute undifferentiated leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acute-phase reactants during fever n1=thrombolytique (traitement) | n2=en:acute-phase reactants during fever | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acyl-coa dehydrogenase family, member 9, deficiency of n1=thrombolytique (traitement) | n2=en:acyl-coa dehydrogenase family, member 9, deficiency of | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acyl-coa:dihydroxyacetonephosphate acyltransferase deficiency n1=thrombolytique (traitement) | n2=en:acyl-coa:dihydroxyacetonephosphate acyltransferase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:acylglycinuria n1=thrombolytique (traitement) | n2=en:acylglycinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:adenylosuccinase deficiency (finding) n1=thrombolytique (traitement) | n2=en:adenylosuccinase deficiency (finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:adrenocorticotropic hormone, increased n1=thrombolytique (traitement) | n2=en:adrenocorticotropic hormone, increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:adult acute megakaryoblastic leukemia n1=thrombolytique (traitement) | n2=en:adult acute megakaryoblastic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:adult acute myeloid leukemia with minimal differentiation n1=thrombolytique (traitement) | n2=en:adult acute myeloid leukemia with minimal differentiation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:adult acute myeloid leukemia without maturation n1=thrombolytique (traitement) | n2=en:adult acute myeloid leukemia without maturation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:adult acute myelomonocytic leukemia n1=thrombolytique (traitement) | n2=en:adult acute myelomonocytic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:adult b acute lymphoblastic leukemia n1=thrombolytique (traitement) | n2=en:adult b acute lymphoblastic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:adult b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1 n1=thrombolytique (traitement) | n2=en:adult b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:affected mother has normal plasma zinc levels and is not zinc-deficient n1=thrombolytique (traitement) | n2=en:affected mother has normal plasma zinc levels and is not zinc-deficient | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:affected mother has reduced zinc levels in breast milk (may be up to 40% less than normal breast milk) n1=thrombolytique (traitement) | n2=en:affected mother has reduced zinc levels in breast milk (may be up to 40% less than normal breast milk) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:agammaglobulinemia n1=thrombolytique (traitement) | n2=en:agammaglobulinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aggressive nk-cell leukemia n1=thrombolytique (traitement) | n2=en:aggressive nk-cell leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alanine aminotransferase increased n1=thrombolytique (traitement) | n2=en:alanine aminotransferase increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:albuminuria n1=thrombolytique (traitement) | n2=en:albuminuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aldolase a deficiency n1=thrombolytique (traitement) | n2=en:aldolase a deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aldosterone concentration below normal n1=thrombolytique (traitement) | n2=en:aldosterone concentration below normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aldosterone level increased above normal n1=thrombolytique (traitement) | n2=en:aldosterone level increased above normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alkaline phosphatase decreased n1=thrombolytique (traitement) | n2=en:alkaline phosphatase decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alkaline phosphatase normal n1=thrombolytique (traitement) | n2=en:alkaline phosphatase normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alkaline phosphatase serum increased n1=thrombolytique (traitement) | n2=en:alkaline phosphatase serum increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alkylating agent-related acute myeloid leukemia n1=thrombolytique (traitement) | n2=en:alkylating agent-related acute myeloid leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alkylating agent-related acute myeloid leukemia and myelodysplastic syndrome n1=thrombolytique (traitement) | n2=en:alkylating agent-related acute myeloid leukemia and myelodysplastic syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alkylating agent-related myelodysplastic syndrome n1=thrombolytique (traitement) | n2=en:alkylating agent-related myelodysplastic syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:allelic loss on 16p13.3 in angiomyolipoma, cardiac rhabdomyoma, cortical tuber, and giant cell astrocytoma n1=thrombolytique (traitement) | n2=en:allelic loss on 16p13.3 in angiomyolipoma, cardiac rhabdomyoma, cortical tuber, and giant cell astrocytoma | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alloimmune platelet transfusion refractoriness n1=thrombolytique (traitement) | n2=en:alloimmune platelet transfusion refractoriness | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alloimmune thrombocytopenia n1=thrombolytique (traitement) | n2=en:alloimmune thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha 1 foetoprotein amniotic fluid increased n1=thrombolytique (traitement) | n2=en:alpha 1 foetoprotein amniotic fluid increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha fetoprotein increased n1=thrombolytique (traitement) | n2=en:alpha fetoprotein increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha ketoadipic aciduria n1=thrombolytique (traitement) | n2=en:alpha ketoadipic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha polypeptide hemoglobin chain n1=thrombolytique (traitement) | n2=en:alpha polypeptide hemoglobin chain | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha thalassemia n1=thrombolytique (traitement) | n2=en:alpha thalassemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha-fetoprotein low n1=thrombolytique (traitement) | n2=en:alpha-fetoprotein low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha-fetoprotein normal n1=thrombolytique (traitement) | n2=en:alpha-fetoprotein normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha-galactosidase a deficiency in plasma, leukocytes, or fibroblasts n1=thrombolytique (traitement) | n2=en:alpha-galactosidase a deficiency in plasma, leukocytes, or fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha-hydroxyadipic aciduria alpha-aminoadipic aciduria n1=thrombolytique (traitement) | n2=en:alpha-hydroxyadipic aciduria alpha-aminoadipic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha-thalassemia silent carrier (3 normal genes) n1=thrombolytique (traitement) | n2=en:alpha-thalassemia silent carrier (3 normal genes) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha-thalassemia with fatal hb bart's hydrops fetalis (no normal gene) n1=thrombolytique (traitement) | n2=en:alpha-thalassemia with fatal hb bart's hydrops fetalis (no normal gene) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha-thalassemia with microcytosis (2 normal genes) n1=thrombolytique (traitement) | n2=en:alpha-thalassemia with microcytosis (2 normal genes) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:alpha-thalassemia with microcytosis and hemolysis, hb h disease (1 normal gene) n1=thrombolytique (traitement) | n2=en:alpha-thalassemia with microcytosis and hemolysis, hb h disease (1 normal gene) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:altretamine n1=thrombolytique (traitement) | n2=en:altretamine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:altretamine 50mg capsule n1=thrombolytique (traitement) | n2=en:altretamine 50mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:amegakaryocytic thrombocytopenia n1=thrombolytique (traitement) | n2=en:amegakaryocytic thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:amegakaryocytic thrombocytopenia with congenital malformation n1=thrombolytique (traitement) | n2=en:amegakaryocytic thrombocytopenia with congenital malformation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:amelioration of ss disease (e.g. hb memphis 141800.0096) n1=thrombolytique (traitement) | n2=en:amelioration of ss disease (e.g. hb memphis 141800.0096) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:amemia n1=thrombolytique (traitement) | n2=en:amemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aminoaciduria n1=thrombolytique (traitement) | n2=en:aminoaciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aminoaciduria (1 patient) n1=thrombolytique (traitement) | n2=en:aminoaciduria (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aminoaciduria (in some patients) n1=thrombolytique (traitement) | n2=en:aminoaciduria (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aminoaciduria (less common) n1=thrombolytique (traitement) | n2=en:aminoaciduria (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aminoaciduria (rare) n1=thrombolytique (traitement) | n2=en:aminoaciduria (rare) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aminoaciduria, intermittent n1=thrombolytique (traitement) | n2=en:aminoaciduria, intermittent | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aminoaciduria, mild (in some patients) n1=thrombolytique (traitement) | n2=en:aminoaciduria, mild (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aminoadipic semialdehyde synthase (aass) deficiency n1=thrombolytique (traitement) | n2=en:aminoadipic semialdehyde synthase (aass) deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:amorphous hyaline substance (skin biopsy and visceral organs) n1=thrombolytique (traitement) | n2=en:amorphous hyaline substance (skin biopsy and visceral organs) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:amylo-1,6-glucosidase deficiency n1=thrombolytique (traitement) | n2=en:amylo-1,6-glucosidase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:amylo(1,4 - 1,6) transglucosidase deficiency (brancher enzyme) n1=thrombolytique (traitement) | n2=en:amylo(1,4 - 1,6) transglucosidase deficiency (brancher enzyme) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:amyloidosis, (iowa type 107680.0010, nonneuropathic 107680.0016) n1=thrombolytique (traitement) | n2=en:amyloidosis, (iowa type 107680.0010, nonneuropathic 107680.0016) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anaphase loss or nondisjunction with trisomies, tetrasomies, monosomies n1=thrombolytique (traitement) | n2=en:anaphase loss or nondisjunction with trisomies, tetrasomies, monosomies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:androgens increased n1=thrombolytique (traitement) | n2=en:androgens increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia (associated with mutation in the cox10 gene) n1=thrombolytique (traitement) | n2=en:anemia (associated with mutation in the cox10 gene) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia (in some patients) n1=thrombolytique (traitement) | n2=en:anemia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia (in some) n1=thrombolytique (traitement) | n2=en:anemia (in some) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia (less common) n1=thrombolytique (traitement) | n2=en:anemia (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia (not responsive to pyridoxine supplementation) n1=thrombolytique (traitement) | n2=en:anemia (not responsive to pyridoxine supplementation) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia (rare) n1=thrombolytique (traitement) | n2=en:anemia (rare) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia (with bone marrow involvement) n1=thrombolytique (traitement) | n2=en:anemia (with bone marrow involvement) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia due to poor nutrition n1=thrombolytique (traitement) | n2=en:anemia due to poor nutrition | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia may be exacerbated during infection or pregnancy n1=thrombolytique (traitement) | n2=en:anemia may be exacerbated during infection or pregnancy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia requiring transfusions n1=thrombolytique (traitement) | n2=en:anemia requiring transfusions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia, congenital hypoplastic, moderate-severe (normochromic, macrocytic) n1=thrombolytique (traitement) | n2=en:anemia, congenital hypoplastic, moderate-severe (normochromic, macrocytic) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia, corticosteroid-sensitive n1=thrombolytique (traitement) | n2=en:anemia, corticosteroid-sensitive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia, dyserythropoietic (in some patients) n1=thrombolytique (traitement) | n2=en:anemia, dyserythropoietic (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia, hemolytic, congenital nonspherocytic n1=thrombolytique (traitement) | n2=en:anemia, hemolytic, congenital nonspherocytic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia, mild (in some patients) n1=thrombolytique (traitement) | n2=en:anemia, mild (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia, severe n1=thrombolytique (traitement) | n2=en:anemia, severe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anemia, unresponsive to oral iron and only partially responsive to parenteral iron n1=thrombolytique (traitement) | n2=en:anemia, unresponsive to oral iron and only partially responsive to parenteral iron | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aneuploidy of the x chromosome n1=thrombolytique (traitement) | n2=en:aneuploidy of the x chromosome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aniso-poikilocytosis on blood smear n1=thrombolytique (traitement) | n2=en:aniso-poikilocytosis on blood smear | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anisocytosis n1=thrombolytique (traitement) | n2=en:anisocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anisopoikilocytosis n1=thrombolytique (traitement) | n2=en:anisopoikilocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anistreplase n1=thrombolytique (traitement) | n2=en:anistreplase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anistreplase 30unt/vial powder n1=thrombolytique (traitement) | n2=en:anistreplase 30unt/vial powder | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anomalies of cholesterol levels n1=thrombolytique (traitement) | n2=en:anomalies of cholesterol levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anti-ds dna antibody n1=thrombolytique (traitement) | n2=en:anti-ds dna antibody | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anti-factor viii positive n1=thrombolytique (traitement) | n2=en:anti-factor viii positive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anti-iga antibodies commonly present n1=thrombolytique (traitement) | n2=en:anti-iga antibodies commonly present | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anti-ssb positive n1=thrombolytique (traitement) | n2=en:anti-ssb positive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anti-tissue transglutaminase antibodies (anti-ttg) n1=thrombolytique (traitement) | n2=en:anti-tissue transglutaminase antibodies (anti-ttg) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:anticoagulant effect increased n1=thrombolytique (traitement) | n2=en:anticoagulant effect increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:antineutrophil antibody positivity n1=thrombolytique (traitement) | n2=en:antineutrophil antibody positivity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:antineutrophil cytoplasmic antibody n1=thrombolytique (traitement) | n2=en:antineutrophil cytoplasmic antibody | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:antiphospholipid antibody n1=thrombolytique (traitement) | n2=en:antiphospholipid antibody | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:antiphospholipid syndrome hemolytic anemia n1=thrombolytique (traitement) | n2=en:antiphospholipid syndrome hemolytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:antiribonuclear protein positive n1=thrombolytique (traitement) | n2=en:antiribonuclear protein positive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:antithrombin iii decreased n1=thrombolytique (traitement) | n2=en:antithrombin iii decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:antithrombin iii deficiency (in 1 patient) n1=thrombolytique (traitement) | n2=en:antithrombin iii deficiency (in 1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aplastic anemia n1=thrombolytique (traitement) | n2=en:aplastic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aplastic anemia (in some patients) n1=thrombolytique (traitement) | n2=en:aplastic anemia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:appropriately increased serum 1,25-dihydroxyvitamin d3 n1=thrombolytique (traitement) | n2=en:appropriately increased serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aprt deficiency measured in erythrocyte lysate n1=thrombolytique (traitement) | n2=en:aprt deficiency measured in erythrocyte lysate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ardeparin n1=thrombolytique (traitement) | n2=en:ardeparin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ardeparin sodium n1=thrombolytique (traitement) | n2=en:ardeparin sodium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:argininosuccinic aciduria n1=thrombolytique (traitement) | n2=en:argininosuccinic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:arterial bypass occlusion n1=thrombolytique (traitement) | n2=en:arterial bypass occlusion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:arylsulfatase b deficiency in fibroblasts and white blood cells n1=thrombolytique (traitement) | n2=en:arylsulfatase b deficiency in fibroblasts and white blood cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:aspartylglycosaminuria n1=thrombolytique (traitement) | n2=en:aspartylglycosaminuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:associated with iron deficiency anemia n1=thrombolytique (traitement) | n2=en:associated with iron deficiency anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:associated with serum anti-phospholipid antibodies in about 50% of patients n1=thrombolytique (traitement) | n2=en:associated with serum anti-phospholipid antibodies in about 50% of patients | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:asymptomatic (easy bruisability, postoperative hemorrhage) n1=thrombolytique (traitement) | n2=en:asymptomatic (easy bruisability, postoperative hemorrhage) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:asymptomatic bleeding tendencies (petechiae, epistaxis, mucosal bleeding) n1=thrombolytique (traitement) | n2=en:asymptomatic bleeding tendencies (petechiae, epistaxis, mucosal bleeding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:asymptomatic to mild bleeding episodes (epistaxis, postoperative hemorrhage) n1=thrombolytique (traitement) | n2=en:asymptomatic to mild bleeding episodes (epistaxis, postoperative hemorrhage) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:at least 2 complementation groups n1=thrombolytique (traitement) | n2=en:at least 2 complementation groups | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:atrial abnormalities on electrocardiogram n1=thrombolytique (traitement) | n2=en:atrial abnormalities on electrocardiogram | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:atypical chronic myeloid leukemia, bcr-abl1 negative n1=thrombolytique (traitement) | n2=en:atypical chronic myeloid leukemia, bcr-abl1 negative | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:atypical lymphocytosis n1=thrombolytique (traitement) | n2=en:atypical lymphocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:autoimmune cytopenia n1=thrombolytique (traitement) | n2=en:autoimmune cytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:autoimmune hemolytic anemia n1=thrombolytique (traitement) | n2=en:autoimmune hemolytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:autoimmune hemolytic anemia (in some patients) n1=thrombolytique (traitement) | n2=en:autoimmune hemolytic anemia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:autoimmune lymphoproliferative syndrome n1=thrombolytique (traitement) | n2=en:autoimmune lymphoproliferative syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:autoimmune neonatal thrombocytopenia n1=thrombolytique (traitement) | n2=en:autoimmune neonatal thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:autoimmune neutropenia n1=thrombolytique (traitement) | n2=en:autoimmune neutropenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:autoimmune pancytopenia n1=thrombolytique (traitement) | n2=en:autoimmune pancytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:autoimmune thrombotic thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:autoimmune thrombotic thrombocytopenic purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:axillary vein thrombosis n1=thrombolytique (traitement) | n2=en:axillary vein thrombosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:axonemes show normal structure n1=thrombolytique (traitement) | n2=en:axonemes show normal structure | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:azoospermia/oligospermia (present at diagnosis) n1=thrombolytique (traitement) | n2=en:azoospermia/oligospermia (present at diagnosis) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:azotemia n1=thrombolytique (traitement) | n2=en:azotemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:b acute lymphoblastic leukemia n1=thrombolytique (traitement) | n2=en:b acute lymphoblastic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:b acute lymphoblastic leukemia with t(1;19)(q23;p13.3); e2a-pbx1 (tcf3-pbx1) n1=thrombolytique (traitement) | n2=en:b acute lymphoblastic leukemia with t(1;19)(q23;p13.3); e2a-pbx1 (tcf3-pbx1) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:b acute lymphoblastic leukemia with t(12;21)(p13;q22); tel-aml1 (etv6-runx1) n1=thrombolytique (traitement) | n2=en:b acute lymphoblastic leukemia with t(12;21)(p13;q22); tel-aml1 (etv6-runx1) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:b acute lymphoblastic leukemia with t(5;14)(q31;q32); il3-igh n1=thrombolytique (traitement) | n2=en:b acute lymphoblastic leukemia with t(5;14)(q31;q32); il3-igh | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1 n1=thrombolytique (traitement) | n2=en:b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:b acute lymphoblastic leukemia with t(v;11q23); mll rearranged n1=thrombolytique (traitement) | n2=en:b acute lymphoblastic leukemia with t(v;11q23); mll rearranged | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:b acute lymphoblastic leukemia, philadelphia chromosome negative n1=thrombolytique (traitement) | n2=en:b acute lymphoblastic leukemia, philadelphia chromosome negative | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:b lymphocytopenia n1=thrombolytique (traitement) | n2=en:b lymphocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:b-cell prolymphocytic leukemia n1=thrombolytique (traitement) | n2=en:b-cell prolymphocytic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:balanced translocation carrier 46,xy,+(11:18)(p13:q21)mat n1=thrombolytique (traitement) | n2=en:balanced translocation carrier 46,xy,+(11:18)(p13:q21)mat | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:balanced/unbalanced chromosomal translocation t(2,13)(q36,q11) n1=thrombolytique (traitement) | n2=en:balanced/unbalanced chromosomal translocation t(2,13)(q36,q11) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ballooned neurons n1=thrombolytique (traitement) | n2=en:ballooned neurons | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:basophilic stippling n1=thrombolytique (traitement) | n2=en:basophilic stippling | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:below reference range n1=thrombolytique (traitement) | n2=en:below reference range | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:benign gestational thrombocytopenia n1=thrombolytique (traitement) | n2=en:benign gestational thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:benign neutropenia n1=thrombolytique (traitement) | n2=en:benign neutropenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bernard-soulier syndrome n1=thrombolytique (traitement) | n2=en:bernard-soulier syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:beta-galactosidase deficiency in fibroblasts and white blood cells n1=thrombolytique (traitement) | n2=en:beta-galactosidase deficiency in fibroblasts and white blood cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:beta-glucuronidase deficiency in fibroblasts and leukocytes n1=thrombolytique (traitement) | n2=en:beta-glucuronidase deficiency in fibroblasts and leukocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bi-cytopenia n1=thrombolytique (traitement) | n2=en:bi-cytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bicarbonaturia n1=thrombolytique (traitement) | n2=en:bicarbonaturia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bile contains cholesterol crystals n1=thrombolytique (traitement) | n2=en:bile contains cholesterol crystals | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bile shows increased cholesterol/phospholipid ratio n1=thrombolytique (traitement) | n2=en:bile shows increased cholesterol/phospholipid ratio | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bilirubin conjugated increased n1=thrombolytique (traitement) | n2=en:bilirubin conjugated increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bilirubin may or may not be increased n1=thrombolytique (traitement) | n2=en:bilirubin may or may not be increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:biotinidase deficiency n1=thrombolytique (traitement) | n2=en:biotinidase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding associated with peptic ulcer disease n1=thrombolytique (traitement) | n2=en:bleeding associated with peptic ulcer disease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding defect due to decreased plasminogen activator inhibitor-1 n1=thrombolytique (traitement) | n2=en:bleeding defect due to decreased plasminogen activator inhibitor-1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding disorder, platelet-type, 15 n1=thrombolytique (traitement) | n2=en:bleeding disorder, platelet-type, 15 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding due to vitamin k deficiency (1 patient) n1=thrombolytique (traitement) | n2=en:bleeding due to vitamin k deficiency (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding episodes n1=thrombolytique (traitement) | n2=en:bleeding episodes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding episodes (epistaxis, menorrhagia, ecchymosis) n1=thrombolytique (traitement) | n2=en:bleeding episodes (epistaxis, menorrhagia, ecchymosis) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding tendency (e.g., epistaxis) n1=thrombolytique (traitement) | n2=en:bleeding tendency (e.g., epistaxis) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding tendency due to defect in prothrombin and inability to form fibrin clot n1=thrombolytique (traitement) | n2=en:bleeding tendency due to defect in prothrombin and inability to form fibrin clot | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding tendency due to platelet defect n1=thrombolytique (traitement) | n2=en:bleeding tendency due to platelet defect | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding tendency, mild n1=thrombolytique (traitement) | n2=en:bleeding tendency, mild | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding tendency, mild, mucocutaneous n1=thrombolytique (traitement) | n2=en:bleeding tendency, mild, mucocutaneous | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding time normal n1=thrombolytique (traitement) | n2=en:bleeding time normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding time normal to mildly prolonged n1=thrombolytique (traitement) | n2=en:bleeding time normal to mildly prolonged | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bleeding, mild n1=thrombolytique (traitement) | n2=en:bleeding, mild | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:blood drug level low n1=thrombolytique (traitement) | n2=en:blood drug level low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:blood glucose normal n1=thrombolytique (traitement) | n2=en:blood glucose normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:blood pyruvic acid increased n1=thrombolytique (traitement) | n2=en:blood pyruvic acid increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:blood urea nitrogen increased n1=thrombolytique (traitement) | n2=en:blood urea nitrogen increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:blue rubber bleb nevus n1=thrombolytique (traitement) | n2=en:blue rubber bleb nevus | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:blunted cortisol response to adrenocorticotropic hormone (acth) n1=thrombolytique (traitement) | n2=en:blunted cortisol response to adrenocorticotropic hormone (acth) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bombay (hh) blood phenotype n1=thrombolytique (traitement) | n2=en:bombay (hh) blood phenotype | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow aspirate shows normal cellularity and reticular fibrosis n1=thrombolytique (traitement) | n2=en:bone marrow aspirate shows normal cellularity and reticular fibrosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow biopsy shows erythrocyte hypocellularity n1=thrombolytique (traitement) | n2=en:bone marrow biopsy shows erythrocyte hypocellularity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow biopsy shows erythroid hyperplasia n1=thrombolytique (traitement) | n2=en:bone marrow biopsy shows erythroid hyperplasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow biopsy shows increased eosinophils without myeloblasts n1=thrombolytique (traitement) | n2=en:bone marrow biopsy shows increased eosinophils without myeloblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow biopsy shows increased numbers of normal to small megakaryocytes n1=thrombolytique (traitement) | n2=en:bone marrow biopsy shows increased numbers of normal to small megakaryocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow biopsy shows megaloblastic erythroblasts n1=thrombolytique (traitement) | n2=en:bone marrow biopsy shows megaloblastic erythroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow biopsy shows megaloblastic erythroid hyperplasia n1=thrombolytique (traitement) | n2=en:bone marrow biopsy shows megaloblastic erythroid hyperplasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow contains lipid-laden macrophages n1=thrombolytique (traitement) | n2=en:bone marrow contains lipid-laden macrophages | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow failure n1=thrombolytique (traitement) | n2=en:bone marrow failure | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow failure (1 patient) n1=thrombolytique (traitement) | n2=en:bone marrow failure (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow failure (classic feature, nola3 patient) n1=thrombolytique (traitement) | n2=en:bone marrow failure (classic feature, nola3 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow failure (in some patients) n1=thrombolytique (traitement) | n2=en:bone marrow failure (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow failure syndrome 2 n1=thrombolytique (traitement) | n2=en:bone marrow failure syndrome 2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow fibrosis n1=thrombolytique (traitement) | n2=en:bone marrow fibrosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow foam cells (type ii) n1=thrombolytique (traitement) | n2=en:bone marrow foam cells (type ii) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow hypercellularity n1=thrombolytique (traitement) | n2=en:bone marrow hypercellularity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow hypocellularity n1=thrombolytique (traitement) | n2=en:bone marrow hypocellularity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow hypoplasia (in some patients) n1=thrombolytique (traitement) | n2=en:bone marrow hypoplasia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow involvement may cause pancytopenia n1=thrombolytique (traitement) | n2=en:bone marrow involvement may cause pancytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow may show hemophagocytosis n1=thrombolytique (traitement) | n2=en:bone marrow may show hemophagocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow megaloblastic (finding) n1=thrombolytique (traitement) | n2=en:bone marrow megaloblastic (finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow shows abnormal development of neutrophils n1=thrombolytique (traitement) | n2=en:bone marrow shows abnormal development of neutrophils | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow shows gaucher cells n1=thrombolytique (traitement) | n2=en:bone marrow shows gaucher cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow shows increased numbers of abnormal megakaryocytes n1=thrombolytique (traitement) | n2=en:bone marrow shows increased numbers of abnormal megakaryocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow smear shows erythroid hyperplasia n1=thrombolytique (traitement) | n2=en:bone marrow smear shows erythroid hyperplasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone marrow suppression n1=thrombolytique (traitement) | n2=en:bone marrow suppression | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bone-marrow foam cells n1=thrombolytique (traitement) | n2=en:bone-marrow foam cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:borderline elevated low-density lipoprotein n1=thrombolytique (traitement) | n2=en:borderline elevated low-density lipoprotein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:branched chain ketoaciduria (alpha-keto isocaproate, alpha-keto-beta methylisovalerate, alpha-keto isovalerate) n1=thrombolytique (traitement) | n2=en:branched chain ketoaciduria (alpha-keto isocaproate, alpha-keto-beta methylisovalerate, alpha-keto isovalerate) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:breastfed offspring have transient decrease of plasma zinc levels n1=thrombolytique (traitement) | n2=en:breastfed offspring have transient decrease of plasma zinc levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:broad tissue deposition of amylopectin-like material n1=thrombolytique (traitement) | n2=en:broad tissue deposition of amylopectin-like material | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:bromosulfophthalein test - secondary rise at 90 minutes n1=thrombolytique (traitement) | n2=en:bromosulfophthalein test - secondary rise at 90 minutes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:burr cell n1=thrombolytique (traitement) | n2=en:burr cell | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:c-band karyotype shows 'railroad track' appearance n1=thrombolytique (traitement) | n2=en:c-band karyotype shows 'railroad track' appearance | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:calcium normal n1=thrombolytique (traitement) | n2=en:calcium normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:calciuria n1=thrombolytique (traitement) | n2=en:calciuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:carbamazepine level low n1=thrombolytique (traitement) | n2=en:carbamazepine level low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:carmustine n1=thrombolytique (traitement) | n2=en:carmustine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:carmustine 100mg powder and solvent for infusion vial n1=thrombolytique (traitement) | n2=en:carmustine 100mg powder and solvent for infusion vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:carmustine 7.7mg wafer n1=thrombolytique (traitement) | n2=en:carmustine 7.7mg wafer | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:carnitine deficiency n1=thrombolytique (traitement) | n2=en:carnitine deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:carnitine palmitoyltransferase i deficiency (fibroblast, liver, leukocytes) n1=thrombolytique (traitement) | n2=en:carnitine palmitoyltransferase i deficiency (fibroblast, liver, leukocytes) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:carnitine palmitoyltransferase ii deficiency (25% of controls) n1=thrombolytique (traitement) | n2=en:carnitine palmitoyltransferase ii deficiency (25% of controls) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:carriers have balanced constitutional translocation - 46,xx(or xy), +(11:22)(q23:q11) n1=thrombolytique (traitement) | n2=en:carriers have balanced constitutional translocation - 46,xx(or xy), +(11:22)(q23:q11) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cd4/cd8 ratio decreased n1=thrombolytique (traitement) | n2=en:cd4/cd8 ratio decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cd4+/cd8+ ratio is reversed n1=thrombolytique (traitement) | n2=en:cd4+/cd8+ ratio is reversed | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cd4+/cd8+ ratio often reversed n1=thrombolytique (traitement) | n2=en:cd4+/cd8+ ratio often reversed | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cd43 (sialophorin) defectively expressed on surface of blood cells n1=thrombolytique (traitement) | n2=en:cd43 (sialophorin) defectively expressed on surface of blood cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cell studies show increased dna breakage n1=thrombolytique (traitement) | n2=en:cell studies show increased dna breakage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cells show defective transcription-coupled nucleotide excision repair (tc-ner) after uv irradiation n1=thrombolytique (traitement) | n2=en:cells show defective transcription-coupled nucleotide excision repair (tc-ner) after uv irradiation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cells show increased sensitivity to ionizing radiation n1=thrombolytique (traitement) | n2=en:cells show increased sensitivity to ionizing radiation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cellular arrest at g2 of the cell cycle n1=thrombolytique (traitement) | n2=en:cellular arrest at g2 of the cell cycle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cerebrospinal fluid lymphocytosis n1=thrombolytique (traitement) | n2=en:cerebrospinal fluid lymphocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cerebrospinal fluid oligoclonal bands n1=thrombolytique (traitement) | n2=en:cerebrospinal fluid oligoclonal bands | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ceruloplasmin decreased n1=thrombolytique (traitement) | n2=en:ceruloplasmin decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:characteristic spheroids can be found in peripheral tissue, such as skin and conjunctiva n1=thrombolytique (traitement) | n2=en:characteristic spheroids can be found in peripheral tissue, such as skin and conjunctiva | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:characteristic urinary coproporphyrin pattern (mostly isomer i (80%) instead of isomer iii) n1=thrombolytique (traitement) | n2=en:characteristic urinary coproporphyrin pattern (mostly isomer i (80%) instead of isomer iii) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chediak-higashi syndrome n1=thrombolytique (traitement) | n2=en:chediak-higashi syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chemical phlebitis n1=thrombolytique (traitement) | n2=en:chemical phlebitis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:childhood acute megakaryoblastic leukemia n1=thrombolytique (traitement) | n2=en:childhood acute megakaryoblastic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:childhood acute myeloid leukemia with minimal differentiation n1=thrombolytique (traitement) | n2=en:childhood acute myeloid leukemia with minimal differentiation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:childhood acute myeloid leukemia without maturation n1=thrombolytique (traitement) | n2=en:childhood acute myeloid leukemia without maturation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:childhood acute myelomonocytic leukemia n1=thrombolytique (traitement) | n2=en:childhood acute myelomonocytic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:childhood b acute lymphoblastic leukemia n1=thrombolytique (traitement) | n2=en:childhood b acute lymphoblastic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:childhood b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1 n1=thrombolytique (traitement) | n2=en:childhood b acute lymphoblastic leukemia with t(9;22)(q34;q11.2); bcr-abl1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cholesterol low n1=thrombolytique (traitement) | n2=en:cholesterol low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cholesterol normal n1=thrombolytique (traitement) | n2=en:cholesterol normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chondroitin 4-, 6-sulfate excretion in urine n1=thrombolytique (traitement) | n2=en:chondroitin 4-, 6-sulfate excretion in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chondroitin 6-sulfate excretion in urine n1=thrombolytique (traitement) | n2=en:chondroitin 6-sulfate excretion in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosomal breakage and abnormalities of the juxtacentromeric regions of chromosomes 1, 9, and 16 n1=thrombolytique (traitement) | n2=en:chromosomal breakage and abnormalities of the juxtacentromeric regions of chromosomes 1, 9, and 16 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosomal instability n1=thrombolytique (traitement) | n2=en:chromosomal instability | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosomal mosaicism in cultured cells n1=thrombolytique (traitement) | n2=en:chromosomal mosaicism in cultured cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosomal mosaicism in fibroblast and/or peripheral lymphocytes no consistent karyotypic finding n1=thrombolytique (traitement) | n2=en:chromosomal mosaicism in fibroblast and/or peripheral lymphocytes no consistent karyotypic finding | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosomal rearrangement n1=thrombolytique (traitement) | n2=en:chromosomal rearrangement | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin heavy chain (147100, 14q32) locus n1=thrombolytique (traitement) | n2=en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin heavy chain (147100, 14q32) locus | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin kappa light chain (147200, 2p12) locus n1=thrombolytique (traitement) | n2=en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin kappa light chain (147200, 2p12) locus | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin lambda light chain (147220, 22q11.2) locus n1=thrombolytique (traitement) | n2=en:chromosomal translocations involving c-myc (190080, 8q24) and the immunoglobin lambda light chain (147220, 22q11.2) locus | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosome 11q23.3 deletion n1=thrombolytique (traitement) | n2=en:chromosome 11q23.3 deletion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosome deletion extending from 8q24.11 to 8q24.13 n1=thrombolytique (traitement) | n2=en:chromosome deletion extending from 8q24.11 to 8q24.13 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosome instability (hypo-/hyperdiploidy, chromosomal breaks, premature centromere division) n1=thrombolytique (traitement) | n2=en:chromosome instability (hypo-/hyperdiploidy, chromosomal breaks, premature centromere division) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chromosome inversion - inv2(p12q14) in 2 patients n1=thrombolytique (traitement) | n2=en:chromosome inversion - inv2(p12q14) in 2 patients | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chronic anemia (in 1 patient) n1=thrombolytique (traitement) | n2=en:chronic anemia (in 1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chronic disseminated intravascular coagulation n1=thrombolytique (traitement) | n2=en:chronic disseminated intravascular coagulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chronic hemolytic anemia n1=thrombolytique (traitement) | n2=en:chronic hemolytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chronic hypercapnia n1=thrombolytique (traitement) | n2=en:chronic hypercapnia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chronic hypoxemia n1=thrombolytique (traitement) | n2=en:chronic hypoxemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chronic idiopathic thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:chronic idiopathic thrombocytopenic purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chronic lymphocytic leukemia n1=thrombolytique (traitement) | n2=en:chronic lymphocytic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chronic myelogenous leukemia, bcr-abl1 positive n1=thrombolytique (traitement) | n2=en:chronic myelogenous leukemia, bcr-abl1 positive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chronic thrombocytopenia n1=thrombolytique (traitement) | n2=en:chronic thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:chylomicronemia, refractory fasting n1=thrombolytique (traitement) | n2=en:chylomicronemia, refractory fasting | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cilia may also be static, with slow activity n1=thrombolytique (traitement) | n2=en:cilia may also be static, with slow activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cilia show inner and outer dynein arm defects n1=thrombolytique (traitement) | n2=en:cilia show inner and outer dynein arm defects | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cilia show nonflexible and hyperkinetic beating of axonemes n1=thrombolytique (traitement) | n2=en:cilia show nonflexible and hyperkinetic beating of axonemes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:circulating orthochromatic erythroblasts n1=thrombolytique (traitement) | n2=en:circulating orthochromatic erythroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cisplatin n1=thrombolytique (traitement) | n2=en:cisplatin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cisplatin 1 mg/ml injectable solution n1=thrombolytique (traitement) | n2=en:cisplatin 1 mg/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cisplatin 10mg/vial powder for injection n1=thrombolytique (traitement) | n2=en:cisplatin 10mg/vial powder for injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cisplatin 50 mg injection n1=thrombolytique (traitement) | n2=en:cisplatin 50 mg injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cisplatin 500micrograms/ml infusion concentrate 20ml vial n1=thrombolytique (traitement) | n2=en:cisplatin 500micrograms/ml infusion concentrate 20ml vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cisplatin pwdr n1=thrombolytique (traitement) | n2=en:cisplatin pwdr | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:citrullinemia n1=thrombolytique (traitement) | n2=en:citrullinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:coagulation defect due to decreased liver function n1=thrombolytique (traitement) | n2=en:coagulation defect due to decreased liver function | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:coagulation defects (1 patient) n1=thrombolytique (traitement) | n2=en:coagulation defects (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:coagulopathy (inr = 2.2 - 3.5) n1=thrombolytique (traitement) | n2=en:coagulopathy (inr = 2.2 - 3.5) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:coagulopathy due to hepatic failure n1=thrombolytique (traitement) | n2=en:coagulopathy due to hepatic failure | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:coagulopathy due to liver dysfunction n1=thrombolytique (traitement) | n2=en:coagulopathy due to liver dysfunction | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:coagulopathy in those with liver failure n1=thrombolytique (traitement) | n2=en:coagulopathy in those with liver failure | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:coagulopathy secondary to liver disease n1=thrombolytique (traitement) | n2=en:coagulopathy secondary to liver disease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:coagulopathy secondary to liver failure n1=thrombolytique (traitement) | n2=en:coagulopathy secondary to liver failure | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:coarse granulocyte chromatin n1=thrombolytique (traitement) | n2=en:coarse granulocyte chromatin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:coarse metachromatic granules in white blood cells n1=thrombolytique (traitement) | n2=en:coarse metachromatic granules in white blood cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:color index low n1=thrombolytique (traitement) | n2=en:color index low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:complement level below reference range n1=thrombolytique (traitement) | n2=en:complement level below reference range | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:complete mevalonate kinase deficiency n1=thrombolytique (traitement) | n2=en:complete mevalonate kinase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:complex organic aciduria n1=thrombolytique (traitement) | n2=en:complex organic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital amegakaryocytic thrombocytopenia n1=thrombolytique (traitement) | n2=en:congenital amegakaryocytic thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital bleeding diathesis n1=thrombolytique (traitement) | n2=en:congenital bleeding diathesis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital disorder of glycosylation type 1x n1=thrombolytique (traitement) | n2=en:congenital disorder of glycosylation type 1x | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital disorder of glycosylation, type iif n1=thrombolytique (traitement) | n2=en:congenital disorder of glycosylation, type iif | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital dysmegakaryopoietic thrombocytopenia, paris trousseau type n1=thrombolytique (traitement) | n2=en:congenital dysmegakaryopoietic thrombocytopenia, paris trousseau type | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital heinz body anemia (e.g. hb toyama 141800.0152) n1=thrombolytique (traitement) | n2=en:congenital heinz body anemia (e.g. hb toyama 141800.0152) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital hypoplastic anemia n1=thrombolytique (traitement) | n2=en:congenital hypoplastic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital idiopathic intestinal pseudoobstruction n1=thrombolytique (traitement) | n2=en:congenital idiopathic intestinal pseudoobstruction | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital neutropenia n1=thrombolytique (traitement) | n2=en:congenital neutropenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital thrombocytopenia n1=thrombolytique (traitement) | n2=en:congenital thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:congenital thrombocytopenic purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:congenital thrombotic thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:congenital thrombotic thrombocytopenic purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:contiguous gene deletion syndrome n1=thrombolytique (traitement) | n2=en:contiguous gene deletion syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:continuous urinary iodine loss n1=thrombolytique (traitement) | n2=en:continuous urinary iodine loss | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:coombs positive hemolytic anemia n1=thrombolytique (traitement) | n2=en:coombs positive hemolytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cortisol does not decrease on dexamethasone suppression test n1=thrombolytique (traitement) | n2=en:cortisol does not decrease on dexamethasone suppression test | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:creatine decreased n1=thrombolytique (traitement) | n2=en:creatine decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:creatine kinase levels may normalize with disease progression n1=thrombolytique (traitement) | n2=en:creatine kinase levels may normalize with disease progression | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:creatine kinase normal between episodes n1=thrombolytique (traitement) | n2=en:creatine kinase normal between episodes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:creatine phosphokinase increased n1=thrombolytique (traitement) | n2=en:creatine phosphokinase increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:creatine phosphokinase serum increased n1=thrombolytique (traitement) | n2=en:creatine phosphokinase serum increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:csf pleocytosis, particularly of lymphocytes n1=thrombolytique (traitement) | n2=en:csf pleocytosis, particularly of lymphocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:csf: chloride decreased n1=thrombolytique (traitement) | n2=en:csf: chloride decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ctcae grade 2 disseminated intravascular coagulation n1=thrombolytique (traitement) | n2=en:ctcae grade 2 disseminated intravascular coagulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ctcae grade 3 disseminated intravascular coagulation n1=thrombolytique (traitement) | n2=en:ctcae grade 3 disseminated intravascular coagulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ctcae grade 4 disseminated intravascular coagulation n1=thrombolytique (traitement) | n2=en:ctcae grade 4 disseminated intravascular coagulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ctcae grade 5 disseminated intravascular coagulation n1=thrombolytique (traitement) | n2=en:ctcae grade 5 disseminated intravascular coagulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ctrp terminology n1=thrombolytique (traitement) | n2=en:ctrp terminology | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:curvilinear intracellular accumulation of autofluorescent lipopigment storage material n1=thrombolytique (traitement) | n2=en:curvilinear intracellular accumulation of autofluorescent lipopigment storage material | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cutaneous anergy n1=thrombolytique (traitement) | n2=en:cutaneous anergy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cutaneovisceral angiomatosis with thrombocytopenia n1=thrombolytique (traitement) | n2=en:cutaneovisceral angiomatosis with thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cystathionine beta-synthase deficiency disease n1=thrombolytique (traitement) | n2=en:cystathionine beta-synthase deficiency disease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cystathioninemia n1=thrombolytique (traitement) | n2=en:cystathioninemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cystathioninuria (lab finding) n1=thrombolytique (traitement) | n2=en:cystathioninuria (lab finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cytochrome c oxidase deficiency in skeletal muscle and brain n1=thrombolytique (traitement) | n2=en:cytochrome c oxidase deficiency in skeletal muscle and brain | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cytogenetic breakpoints range from 10q23.3-q26.2 n1=thrombolytique (traitement) | n2=en:cytogenetic breakpoints range from 10q23.3-q26.2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cytogenetic deletion of chromosome 17p13.3 n1=thrombolytique (traitement) | n2=en:cytogenetic deletion of chromosome 17p13.3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cytogenetic deletion of chromosome 19q13 n1=thrombolytique (traitement) | n2=en:cytogenetic deletion of chromosome 19q13 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cytogenetic deletion of the terminal region of chromosome 10 (del(10)(q23.3-qter)) n1=thrombolytique (traitement) | n2=en:cytogenetic deletion of the terminal region of chromosome 10 (del(10)(q23.3-qter)) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cytogenetics - recombinant chromosome 8 characterized by duplication of 8q22.1-qter and deletion of 8pter-p23.1 n1=thrombolytique (traitement) | n2=en:cytogenetics - recombinant chromosome 8 characterized by duplication of 8q22.1-qter and deletion of 8pter-p23.1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cytopenia n1=thrombolytique (traitement) | n2=en:cytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cytoplasmic lamellar concentric inclusions n1=thrombolytique (traitement) | n2=en:cytoplasmic lamellar concentric inclusions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cytoplasmic lamellar inclusions consistent with neuronal ceroid lipofuscinosis (in some patients) n1=thrombolytique (traitement) | n2=en:cytoplasmic lamellar inclusions consistent with neuronal ceroid lipofuscinosis (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:cytosolic phosphoenolpyruvate carboxykinase deficiency n1=thrombolytique (traitement) | n2=en:cytosolic phosphoenolpyruvate carboxykinase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:d-2-hydroxyglutaric aciduria n1=thrombolytique (traitement) | n2=en:d-2-hydroxyglutaric aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin n1=thrombolytique (traitement) | n2=en:dalteparin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin sodium n1=thrombolytique (traitement) | n2=en:dalteparin sodium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin sodium 10,000iu/ml injection solution 1ml prefilled syringe n1=thrombolytique (traitement) | n2=en:dalteparin sodium 10,000iu/ml injection solution 1ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin sodium 10000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:dalteparin sodium 10000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin sodium 12500iu/ml injection solution 0.2ml prefilled syringe n1=thrombolytique (traitement) | n2=en:dalteparin sodium 12500iu/ml injection solution 0.2ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin sodium 25,000iu/ml injection solution 0.4ml prefilled syringe n1=thrombolytique (traitement) | n2=en:dalteparin sodium 25,000iu/ml injection solution 0.4ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin sodium 25,000iu/ml injection solution 0.5ml prefilled syringe n1=thrombolytique (traitement) | n2=en:dalteparin sodium 25,000iu/ml injection solution 0.5ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin sodium 25,000iu/ml injection solution 0.6ml prefilled syringe n1=thrombolytique (traitement) | n2=en:dalteparin sodium 25,000iu/ml injection solution 0.6ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin sodium 25,000iu/ml injection solution 0.72ml prefilled syringe n1=thrombolytique (traitement) | n2=en:dalteparin sodium 25,000iu/ml injection solution 0.72ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin sodium 25000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:dalteparin sodium 25000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin sodium 25000iu/ml injection solution 0.2ml prefilled syringe n1=thrombolytique (traitement) | n2=en:dalteparin sodium 25000iu/ml injection solution 0.2ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dalteparin sodium 7500iu/0.3ml prefilled syringe n1=thrombolytique (traitement) | n2=en:dalteparin sodium 7500iu/0.3ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:daunorubicin n1=thrombolytique (traitement) | n2=en:daunorubicin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:daunorubicin hcl 20mg/vil inj n1=thrombolytique (traitement) | n2=en:daunorubicin hcl 20mg/vil inj | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:daunorubicin hydrochloride n1=thrombolytique (traitement) | n2=en:daunorubicin hydrochloride | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decrease or absence of cathepsin d (ctsd) protein immunostaining n1=thrombolytique (traitement) | n2=en:decrease or absence of cathepsin d (ctsd) protein immunostaining | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decrease plasma serine (fasting) n1=thrombolytique (traitement) | n2=en:decrease plasma serine (fasting) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased 11-deoxy, 17-hydroxycorticosterone level n1=thrombolytique (traitement) | n2=en:decreased 11-deoxy, 17-hydroxycorticosterone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased 11-deoxycorticosterone level n1=thrombolytique (traitement) | n2=en:decreased 11-deoxycorticosterone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased 17-ketogenic steroids level n1=thrombolytique (traitement) | n2=en:decreased 17-ketogenic steroids level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased 3-beta-hydroxysteroid-delta-5-desaturase (sc5d) n1=thrombolytique (traitement) | n2=en:decreased 3-beta-hydroxysteroid-delta-5-desaturase (sc5d) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased 5-hydroxyindoleacetic acid (5-hiaa) in csf n1=thrombolytique (traitement) | n2=en:decreased 5-hydroxyindoleacetic acid (5-hiaa) in csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased acetyl-coa carboxylase activity n1=thrombolytique (traitement) | n2=en:decreased acetyl-coa carboxylase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased acid beta galactosidase protein and activity n1=thrombolytique (traitement) | n2=en:decreased acid beta galactosidase protein and activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased acid sphingomyelinase activity n1=thrombolytique (traitement) | n2=en:decreased acid sphingomyelinase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased acid sphingomyelinase activity (less than 5%) n1=thrombolytique (traitement) | n2=en:decreased acid sphingomyelinase activity (less than 5%) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activities of multiple sulfatases n1=thrombolytique (traitement) | n2=en:decreased activities of multiple sulfatases | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activities of the pyruvate dehydrogenase complex, the alpha-ketoglutarate dehydrogenase complex, and the branched-chain alpha-keto acid dehydrogenase complex n1=thrombolytique (traitement) | n2=en:decreased activities of the pyruvate dehydrogenase complex, the alpha-ketoglutarate dehydrogenase complex, and the branched-chain alpha-keto acid dehydrogenase complex | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of 2-methyl-3-hydroxybutyryl co-a dehydrogenase n1=thrombolytique (traitement) | n2=en:decreased activity of 2-methyl-3-hydroxybutyryl co-a dehydrogenase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of 2-oxoacid dehydrogenases n1=thrombolytique (traitement) | n2=en:decreased activity of 2-oxoacid dehydrogenases | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of 3-hydroxyacyl-coa dehydrogenase in various tissues (liver, muscle, fibroblasts) n1=thrombolytique (traitement) | n2=en:decreased activity of 3-hydroxyacyl-coa dehydrogenase in various tissues (liver, muscle, fibroblasts) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of 3-methylcrotonyl-coa carboxylase (less than 2%) n1=thrombolytique (traitement) | n2=en:decreased activity of 3-methylcrotonyl-coa carboxylase (less than 2%) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of 3-methylglutaconyl-coa hydratase n1=thrombolytique (traitement) | n2=en:decreased activity of 3-methylglutaconyl-coa hydratase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of ampd1 in skeletal muscle increased serum creatine kinase n1=thrombolytique (traitement) | n2=en:decreased activity of ampd1 in skeletal muscle increased serum creatine kinase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of aromatic l-amino acid decarboxylase (aadc) n1=thrombolytique (traitement) | n2=en:decreased activity of aromatic l-amino acid decarboxylase (aadc) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of coenzyme q10-dependent respiratory chain complexes n1=thrombolytique (traitement) | n2=en:decreased activity of coenzyme q10-dependent respiratory chain complexes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of complement factor d n1=thrombolytique (traitement) | n2=en:decreased activity of complement factor d | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of cytochrome c oxidase in muscle and fibroblasts n1=thrombolytique (traitement) | n2=en:decreased activity of cytochrome c oxidase in muscle and fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of cytosolic acetoacetyl-coa thiolase (acat2, 100678) n1=thrombolytique (traitement) | n2=en:decreased activity of cytosolic acetoacetyl-coa thiolase (acat2, 100678) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of dihydrofolate reductase n1=thrombolytique (traitement) | n2=en:decreased activity of dihydrofolate reductase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of galactocerebrosidase n1=thrombolytique (traitement) | n2=en:decreased activity of galactocerebrosidase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of glycosylceramidase, galactosylceramidase, ceramidase, and other lysosomal enzymes n1=thrombolytique (traitement) | n2=en:decreased activity of glycosylceramidase, galactosylceramidase, ceramidase, and other lysosomal enzymes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of long-chain 3-hydroxyacyl-coa dehydrogenase, long-chain 3-oxoacyl-coa thiolase, and long-chain 2-enoyl-coa hydratase n1=thrombolytique (traitement) | n2=en:decreased activity of long-chain 3-hydroxyacyl-coa dehydrogenase, long-chain 3-oxoacyl-coa thiolase, and long-chain 2-enoyl-coa hydratase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of mitochondrial complex i n1=thrombolytique (traitement) | n2=en:decreased activity of mitochondrial complex i | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of mitochondrial complex ii (succinate dehydrogenase) n1=thrombolytique (traitement) | n2=en:decreased activity of mitochondrial complex ii (succinate dehydrogenase) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of mitochondrial respiratory chain complex i n1=thrombolytique (traitement) | n2=en:decreased activity of mitochondrial respiratory chain complex i | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of mitochondrial respiratory complexes n1=thrombolytique (traitement) | n2=en:decreased activity of mitochondrial respiratory complexes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of mitochondrial respiratory complexes i, ii+iii, iv, and v n1=thrombolytique (traitement) | n2=en:decreased activity of mitochondrial respiratory complexes i, ii+iii, iv, and v | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of mitochondrial respiratory complexes i, iii, and iv n1=thrombolytique (traitement) | n2=en:decreased activity of mitochondrial respiratory complexes i, iii, and iv | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of nadph oxidase n1=thrombolytique (traitement) | n2=en:decreased activity of nadph oxidase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of phosphoglycerate kinase 1 n1=thrombolytique (traitement) | n2=en:decreased activity of phosphoglycerate kinase 1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of ppt1 n1=thrombolytique (traitement) | n2=en:decreased activity of ppt1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of pyruvate decarboxylase (e1 component) n1=thrombolytique (traitement) | n2=en:decreased activity of pyruvate decarboxylase (e1 component) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of pyruvate dehydrogenase complex n1=thrombolytique (traitement) | n2=en:decreased activity of pyruvate dehydrogenase complex | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of succinic semialdehyde dehydrogenase (ssadh, aldh5a1), less than 5% of control values n1=thrombolytique (traitement) | n2=en:decreased activity of succinic semialdehyde dehydrogenase (ssadh, aldh5a1), less than 5% of control values | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of the e2 subunit (lipoyl transacetylase, 608770) of the pdh n1=thrombolytique (traitement) | n2=en:decreased activity of the e2 subunit (lipoyl transacetylase, 608770) of the pdh | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of the pdh phosphatase n1=thrombolytique (traitement) | n2=en:decreased activity of the pdh phosphatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of the pyruvate dehydrogenase (pdh) complex n1=thrombolytique (traitement) | n2=en:decreased activity of the pyruvate dehydrogenase (pdh) complex | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of the pyruvate dehydrogenase complex (highly variable, 1-70% of controls) n1=thrombolytique (traitement) | n2=en:decreased activity of the pyruvate dehydrogenase complex (highly variable, 1-70% of controls) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of thiopurine s-methyltransferase n1=thrombolytique (traitement) | n2=en:decreased activity of thiopurine s-methyltransferase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of thymidine phosphorylase n1=thrombolytique (traitement) | n2=en:decreased activity of thymidine phosphorylase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of triosephosphate isomerase n1=thrombolytique (traitement) | n2=en:decreased activity of triosephosphate isomerase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased activity of tyrosine hydroxylase n1=thrombolytique (traitement) | n2=en:decreased activity of tyrosine hydroxylase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased adenosylcobalamin n1=thrombolytique (traitement) | n2=en:decreased adenosylcobalamin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased adenylic acid n1=thrombolytique (traitement) | n2=en:decreased adenylic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased adiponectin n1=thrombolytique (traitement) | n2=en:decreased adiponectin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased adrenal cortical hormone level n1=thrombolytique (traitement) | n2=en:decreased adrenal cortical hormone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased adrenocorticotropic hormone level n1=thrombolytique (traitement) | n2=en:decreased adrenocorticotropic hormone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased agt activity n1=thrombolytique (traitement) | n2=en:decreased agt activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased albumin n1=thrombolytique (traitement) | n2=en:decreased albumin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased alpha-n-acetylgalactosaminidase activity (less than 2% of control) n1=thrombolytique (traitement) | n2=en:decreased alpha-n-acetylgalactosaminidase activity (less than 2% of control) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased alpha-n-acetylgalactosaminidase protein n1=thrombolytique (traitement) | n2=en:decreased alpha-n-acetylgalactosaminidase protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased amino acid n1=thrombolytique (traitement) | n2=en:decreased amino acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased aminoacylase-1 activity n1=thrombolytique (traitement) | n2=en:decreased aminoacylase-1 activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased amount and activity of mitochondrial complexes i and iv n1=thrombolytique (traitement) | n2=en:decreased amount and activity of mitochondrial complexes i and iv | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased androgen level n1=thrombolytique (traitement) | n2=en:decreased androgen level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased angiotensin ii level n1=thrombolytique (traitement) | n2=en:decreased angiotensin ii level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased anti-diuretic hormone level n1=thrombolytique (traitement) | n2=en:decreased anti-diuretic hormone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased antithrombin iii (rare) n1=thrombolytique (traitement) | n2=en:decreased antithrombin iii (rare) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased apoa-i and apoa-ii n1=thrombolytique (traitement) | n2=en:decreased apoa-i and apoa-ii | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased arylsulfatase a (arsa) activity in urine, leukocytes, fibroblasts n1=thrombolytique (traitement) | n2=en:decreased arylsulfatase a (arsa) activity in urine, leukocytes, fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased asparagine levels (in some patients) n1=thrombolytique (traitement) | n2=en:decreased asparagine levels (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased atp synthase in muscle, heart, liver, and brain n1=thrombolytique (traitement) | n2=en:decreased atp synthase in muscle, heart, liver, and brain | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased axonal flare response after intradermal histamine injection n1=thrombolytique (traitement) | n2=en:decreased axonal flare response after intradermal histamine injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased b cells n1=thrombolytique (traitement) | n2=en:decreased b cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased beta-galactosidase activity n1=thrombolytique (traitement) | n2=en:decreased beta-galactosidase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased beta-glucocerebrosidase protein and activity n1=thrombolytique (traitement) | n2=en:decreased beta-glucocerebrosidase protein and activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased beta-glucosidase protein and activity n1=thrombolytique (traitement) | n2=en:decreased beta-glucosidase protein and activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased beta-mannosidase activity in plasma, fibroblasts, and leukocytes n1=thrombolytique (traitement) | n2=en:decreased beta-mannosidase activity in plasma, fibroblasts, and leukocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased beta-oxidation of pristanic acid n1=thrombolytique (traitement) | n2=en:decreased beta-oxidation of pristanic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased beta-thromboglobulin n1=thrombolytique (traitement) | n2=en:decreased beta-thromboglobulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased beta-tubulin in platelets n1=thrombolytique (traitement) | n2=en:decreased beta-tubulin in platelets | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased bilirubin level n1=thrombolytique (traitement) | n2=en:decreased bilirubin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased biotin n1=thrombolytique (traitement) | n2=en:decreased biotin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased blood eosinophil number (finding) n1=thrombolytique (traitement) | n2=en:decreased blood eosinophil number (finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased blood levels of cationic amino acids n1=thrombolytique (traitement) | n2=en:decreased blood levels of cationic amino acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased c3 activity n1=thrombolytique (traitement) | n2=en:decreased c3 activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased c3 antigen n1=thrombolytique (traitement) | n2=en:decreased c3 antigen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased carbohydrate n1=thrombolytique (traitement) | n2=en:decreased carbohydrate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased carboxyhemoglobin n1=thrombolytique (traitement) | n2=en:decreased carboxyhemoglobin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased carnitine in serum, muscle, heart, and liver n1=thrombolytique (traitement) | n2=en:decreased carnitine in serum, muscle, heart, and liver | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased carnitine palmitoyltransferase ii (cpt2) activity n1=thrombolytique (traitement) | n2=en:decreased carnitine palmitoyltransferase ii (cpt2) activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased carotene n1=thrombolytique (traitement) | n2=en:decreased carotene | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased cerebrospinal fluid folic acid n1=thrombolytique (traitement) | n2=en:decreased cerebrospinal fluid folic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased cholesterol (less common) n1=thrombolytique (traitement) | n2=en:decreased cholesterol (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased choline n1=thrombolytique (traitement) | n2=en:decreased choline | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased ciliary motility n1=thrombolytique (traitement) | n2=en:decreased ciliary motility | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased circulating aldosterone level n1=thrombolytique (traitement) | n2=en:decreased circulating aldosterone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased circulating cortisol level n1=thrombolytique (traitement) | n2=en:decreased circulating cortisol level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased circulating renin level n1=thrombolytique (traitement) | n2=en:decreased circulating renin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased clot retraction n1=thrombolytique (traitement) | n2=en:decreased clot retraction | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased coagulation factors ix, xi, xii n1=thrombolytique (traitement) | n2=en:decreased coagulation factors ix, xi, xii | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased cobalamin in liver, kidney, and cultured fibroblasts n1=thrombolytique (traitement) | n2=en:decreased cobalamin in liver, kidney, and cultured fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased complement factor d n1=thrombolytique (traitement) | n2=en:decreased complement factor d | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased conversion of beta-carotene to vitamin a (retinol) n1=thrombolytique (traitement) | n2=en:decreased conversion of beta-carotene to vitamin a (retinol) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased copper, iron, zinc n1=thrombolytique (traitement) | n2=en:decreased copper, iron, zinc | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased coproporphyrinogen oxidase activity (hcp, lymphocytes, 50% of normal) n1=thrombolytique (traitement) | n2=en:decreased coproporphyrinogen oxidase activity (hcp, lymphocytes, 50% of normal) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased coq10 levels in lymphoblasts or fibroblasts n1=thrombolytique (traitement) | n2=en:decreased coq10 levels in lymphoblasts or fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased corticosterone level n1=thrombolytique (traitement) | n2=en:decreased corticosterone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased corticotropin releasing factor level n1=thrombolytique (traitement) | n2=en:decreased corticotropin releasing factor level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased cortisol level n1=thrombolytique (traitement) | n2=en:decreased cortisol level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased cortisol-binding globulin n1=thrombolytique (traitement) | n2=en:decreased cortisol-binding globulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased cpt1 activity n1=thrombolytique (traitement) | n2=en:decreased cpt1 activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf 3-methoxy-4-hydroxyphenylethyleneglycol (mhpg) n1=thrombolytique (traitement) | n2=en:decreased csf 3-methoxy-4-hydroxyphenylethyleneglycol (mhpg) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf 5-hydroxyindoleacetic acid (5-hiaa) n1=thrombolytique (traitement) | n2=en:decreased csf 5-hydroxyindoleacetic acid (5-hiaa) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf 5-hydroxyindoleacetic acid (5hiaa) n1=thrombolytique (traitement) | n2=en:decreased csf 5-hydroxyindoleacetic acid (5hiaa) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf arginine n1=thrombolytique (traitement) | n2=en:decreased csf arginine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf ferritin despite normal serum ferritin levels n1=thrombolytique (traitement) | n2=en:decreased csf ferritin despite normal serum ferritin levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf folate n1=thrombolytique (traitement) | n2=en:decreased csf folate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf glycine n1=thrombolytique (traitement) | n2=en:decreased csf glycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf homovanillic acid (hva) n1=thrombolytique (traitement) | n2=en:decreased csf homovanillic acid (hva) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf hypocretin n1=thrombolytique (traitement) | n2=en:decreased csf hypocretin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf methyltetrahydrofolate (mthf) n1=thrombolytique (traitement) | n2=en:decreased csf methyltetrahydrofolate (mthf) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf pyridoxal n1=thrombolytique (traitement) | n2=en:decreased csf pyridoxal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf pyridoxal 5-prime-phosphate (plp) n1=thrombolytique (traitement) | n2=en:decreased csf pyridoxal 5-prime-phosphate (plp) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf serine n1=thrombolytique (traitement) | n2=en:decreased csf serine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased csf tetrahydrofolate and 5-methyltetrahydrofolate n1=thrombolytique (traitement) | n2=en:decreased csf tetrahydrofolate and 5-methyltetrahydrofolate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased cytochrome c oxidase activity in skin fibroblasts, liver, and skeletal muscle n1=thrombolytique (traitement) | n2=en:decreased cytochrome c oxidase activity in skin fibroblasts, liver, and skeletal muscle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased decr enzyme activity n1=thrombolytique (traitement) | n2=en:decreased decr enzyme activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased dermal hydroxylysine content n1=thrombolytique (traitement) | n2=en:decreased dermal hydroxylysine content | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased dihydroxyacetone phosphate acyltransferase (dhap-at) activity n1=thrombolytique (traitement) | n2=en:decreased dihydroxyacetone phosphate acyltransferase (dhap-at) activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased dihydroxyacetonephosphate acyltransferase (dhap-at) activity n1=thrombolytique (traitement) | n2=en:decreased dihydroxyacetonephosphate acyltransferase (dhap-at) activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased dna excision repair n1=thrombolytique (traitement) | n2=en:decreased dna excision repair | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased dna polymerase-gamma (polg, 174763) activity n1=thrombolytique (traitement) | n2=en:decreased dna polymerase-gamma (polg, 174763) activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased eno3 activity n1=thrombolytique (traitement) | n2=en:decreased eno3 activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased epinephrine level n1=thrombolytique (traitement) | n2=en:decreased epinephrine level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased erythrocyte 2,3-diphosphoglycerate (2,3-dpg) n1=thrombolytique (traitement) | n2=en:decreased erythrocyte 2,3-diphosphoglycerate (2,3-dpg) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased erythrocyte lactate clearance (transport), 40 to 50% of normal values n1=thrombolytique (traitement) | n2=en:decreased erythrocyte lactate clearance (transport), 40 to 50% of normal values | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased erythrocyte plasmalogen n1=thrombolytique (traitement) | n2=en:decreased erythrocyte plasmalogen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased erythropoietic response under hypoxic conditions n1=thrombolytique (traitement) | n2=en:decreased erythropoietic response under hypoxic conditions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased estradiol level n1=thrombolytique (traitement) | n2=en:decreased estradiol level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased estriol level n1=thrombolytique (traitement) | n2=en:decreased estriol level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased euglobin lysis time n1=thrombolytique (traitement) | n2=en:decreased euglobin lysis time | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased expression of cd44 and aqp1 on red cells n1=thrombolytique (traitement) | n2=en:decreased expression of cd44 and aqp1 on red cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased expression of glycosylphosphatidylinositol-anchored membrane proteins n1=thrombolytique (traitement) | n2=en:decreased expression of glycosylphosphatidylinositol-anchored membrane proteins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased expression of glycosylphosphatidylinositol-linked proteins (e.g., cd59 107271 and cd24 600274) on hematopoietic cells n1=thrombolytique (traitement) | n2=en:decreased expression of glycosylphosphatidylinositol-linked proteins (e.g., cd59 107271 and cd24 600274) on hematopoietic cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased expression of gpi-anchored proteins on blood cells n1=thrombolytique (traitement) | n2=en:decreased expression of gpi-anchored proteins on blood cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased f2 activity n1=thrombolytique (traitement) | n2=en:decreased f2 activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased f2 antigen levels (in some patients) n1=thrombolytique (traitement) | n2=en:decreased f2 antigen levels (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased factor xi n1=thrombolytique (traitement) | n2=en:decreased factor xi | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased fbp1 enzyme activity n1=thrombolytique (traitement) | n2=en:decreased fbp1 enzyme activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased fibrillin-1 immunostaining in the dermis n1=thrombolytique (traitement) | n2=en:decreased fibrillin-1 immunostaining in the dermis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased fibrinogen (in some patients) n1=thrombolytique (traitement) | n2=en:decreased fibrinogen (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased fibroblast alpha-mannosidase n1=thrombolytique (traitement) | n2=en:decreased fibroblast alpha-mannosidase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased fibroblast arylsulfatase a n1=thrombolytique (traitement) | n2=en:decreased fibroblast arylsulfatase a | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased fibroblast beta-hexosaminidase n1=thrombolytique (traitement) | n2=en:decreased fibroblast beta-hexosaminidase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased fibroblast iduronate sulfatase n1=thrombolytique (traitement) | n2=en:decreased fibroblast iduronate sulfatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased formation of complex (tri-, tetra-antennary) n-glycans n1=thrombolytique (traitement) | n2=en:decreased formation of complex (tri-, tetra-antennary) n-glycans | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased free t(3)/free t(4) n1=thrombolytique (traitement) | n2=en:decreased free t(3)/free t(4) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased fumarate hydratase activity n1=thrombolytique (traitement) | n2=en:decreased fumarate hydratase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased galactokinase activity n1=thrombolytique (traitement) | n2=en:decreased galactokinase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased globulin n1=thrombolytique (traitement) | n2=en:decreased globulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased glomerular filtration rate (gfr) n1=thrombolytique (traitement) | n2=en:decreased glomerular filtration rate (gfr) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased glucagon level n1=thrombolytique (traitement) | n2=en:decreased glucagon level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased glutamine in bodily fluids n1=thrombolytique (traitement) | n2=en:decreased glutamine in bodily fluids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased glycerol kinase activity n1=thrombolytique (traitement) | n2=en:decreased glycerol kinase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased grhpr activity n1=thrombolytique (traitement) | n2=en:decreased grhpr activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased gtp cyclohydrolase i activity (about 20% of normal) n1=thrombolytique (traitement) | n2=en:decreased gtp cyclohydrolase i activity (about 20% of normal) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased hdl cholesterol n1=thrombolytique (traitement) | n2=en:decreased hdl cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased heme-heme interaction (e.g. hb kanagawa 141800.0169) n1=thrombolytique (traitement) | n2=en:decreased heme-heme interaction (e.g. hb kanagawa 141800.0169) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased hemoglobin oxygen saturation n1=thrombolytique (traitement) | n2=en:decreased hemoglobin oxygen saturation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased hepatic gaba transaminase activity n1=thrombolytique (traitement) | n2=en:decreased hepatic gaba transaminase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased hepatic udp-glucuronyl-transferase activity n1=thrombolytique (traitement) | n2=en:decreased hepatic udp-glucuronyl-transferase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased hexokinase activity in red blood cells n1=thrombolytique (traitement) | n2=en:decreased hexokinase activity in red blood cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased high molecular weight plasma factor viii/ vwf multimers n1=thrombolytique (traitement) | n2=en:decreased high molecular weight plasma factor viii/ vwf multimers | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased homovanillic acid (hva) and 5-hydroxyindoleacetic acid (5hiaa) in csf n1=thrombolytique (traitement) | n2=en:decreased homovanillic acid (hva) and 5-hydroxyindoleacetic acid (5hiaa) in csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased human chorionic gonadotropin level n1=thrombolytique (traitement) | n2=en:decreased human chorionic gonadotropin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased human growth hormone level result n1=thrombolytique (traitement) | n2=en:decreased human growth hormone level result | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased iga, igg, igm n1=thrombolytique (traitement) | n2=en:decreased iga, igg, igm | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased immunoglobulin n1=thrombolytique (traitement) | n2=en:decreased immunoglobulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased insulin level n1=thrombolytique (traitement) | n2=en:decreased insulin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased insulin receptor binding n1=thrombolytique (traitement) | n2=en:decreased insulin receptor binding | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased intracellular fmr protein n1=thrombolytique (traitement) | n2=en:decreased intracellular fmr protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased ldl cholesterol n1=thrombolytique (traitement) | n2=en:decreased ldl cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased lecithin:cholesterol acyltransferase mass and activity n1=thrombolytique (traitement) | n2=en:decreased lecithin:cholesterol acyltransferase mass and activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased leptin n1=thrombolytique (traitement) | n2=en:decreased leptin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of cellular and mitochondrial fes-containing proteins n1=thrombolytique (traitement) | n2=en:decreased levels of cellular and mitochondrial fes-containing proteins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of certain coagulation factors n1=thrombolytique (traitement) | n2=en:decreased levels of certain coagulation factors | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of coenzyme q10 in skeletal muscle (5-35%) n1=thrombolytique (traitement) | n2=en:decreased levels of coenzyme q10 in skeletal muscle (5-35%) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of component x protein of the pdh complex n1=thrombolytique (traitement) | n2=en:decreased levels of component x protein of the pdh complex | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of cpt2 protein n1=thrombolytique (traitement) | n2=en:decreased levels of cpt2 protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of csf hypocretin (hcrt, 602358) n1=thrombolytique (traitement) | n2=en:decreased levels of csf hypocretin (hcrt, 602358) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of erythrocyte cytochrome b5 n1=thrombolytique (traitement) | n2=en:decreased levels of erythrocyte cytochrome b5 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of plasma factor viii n1=thrombolytique (traitement) | n2=en:decreased levels of plasma factor viii | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of plasma factor viii in patients with type 2n n1=thrombolytique (traitement) | n2=en:decreased levels of plasma factor viii in patients with type 2n | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of plasma vwf antigen n1=thrombolytique (traitement) | n2=en:decreased levels of plasma vwf antigen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of serum vitamin b12 n1=thrombolytique (traitement) | n2=en:decreased levels of serum vitamin b12 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased levels of the e2 subunit protein n1=thrombolytique (traitement) | n2=en:decreased levels of the e2 subunit protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased lipid n1=thrombolytique (traitement) | n2=en:decreased lipid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased lipid-linked oligosaccharides (llo) n1=thrombolytique (traitement) | n2=en:decreased lipid-linked oligosaccharides (llo) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased liver homogentisate 1,2-dioxygenase activity n1=thrombolytique (traitement) | n2=en:decreased liver homogentisate 1,2-dioxygenase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased long-chain fatty acid oxidation n1=thrombolytique (traitement) | n2=en:decreased long-chain fatty acid oxidation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased lysosomal alpha-mannosidase activity in plasma and leukocytes n1=thrombolytique (traitement) | n2=en:decreased lysosomal alpha-mannosidase activity in plasma and leukocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mean platelet volume (mpv) n1=thrombolytique (traitement) | n2=en:decreased mean platelet volume (mpv) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased melanocyte stimulating hormone level n1=thrombolytique (traitement) | n2=en:decreased melanocyte stimulating hormone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased metabolism of thiopurine drugs n1=thrombolytique (traitement) | n2=en:decreased metabolism of thiopurine drugs | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased methemoglobin n1=thrombolytique (traitement) | n2=en:decreased methemoglobin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased methionine synthase activity n1=thrombolytique (traitement) | n2=en:decreased methionine synthase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased methylcobalamin (mecbl) n1=thrombolytique (traitement) | n2=en:decreased methylcobalamin (mecbl) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased methylmalonyl-coa mutase activity n1=thrombolytique (traitement) | n2=en:decreased methylmalonyl-coa mutase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mitochondrial complex iii activity (in fibroblasts of 1 patient) n1=thrombolytique (traitement) | n2=en:decreased mitochondrial complex iii activity (in fibroblasts of 1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mitochondrial complex iii activity (in liver, muscle, and fibroblasts) n1=thrombolytique (traitement) | n2=en:decreased mitochondrial complex iii activity (in liver, muscle, and fibroblasts) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mitochondrial complex iii activity (skeletal muscle, fibroblasts) n1=thrombolytique (traitement) | n2=en:decreased mitochondrial complex iii activity (skeletal muscle, fibroblasts) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mitochondrial complex iii activity in liver and fibroblasts n1=thrombolytique (traitement) | n2=en:decreased mitochondrial complex iii activity in liver and fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mitochondrial complex iii activity in muscle n1=thrombolytique (traitement) | n2=en:decreased mitochondrial complex iii activity in muscle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mitochondrial complex iii activity seen in muscle n1=thrombolytique (traitement) | n2=en:decreased mitochondrial complex iii activity seen in muscle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mitochondrial complex v assembly n1=thrombolytique (traitement) | n2=en:decreased mitochondrial complex v assembly | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mitochondrial nadp(h) n1=thrombolytique (traitement) | n2=en:decreased mitochondrial nadp(h) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mitochondrial respiratory chain complex (2p21del) n1=thrombolytique (traitement) | n2=en:decreased mitochondrial respiratory chain complex (2p21del) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mitochondrial respiratory complexes i, iii, and iv in brain, heart, and skeletal muscle n1=thrombolytique (traitement) | n2=en:decreased mitochondrial respiratory complexes i, iii, and iv in brain, heart, and skeletal muscle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased monoamine oxidase a activity n1=thrombolytique (traitement) | n2=en:decreased monoamine oxidase a activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased mucosal alkaline phosphatase n1=thrombolytique (traitement) | n2=en:decreased mucosal alkaline phosphatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased multimerin n1=thrombolytique (traitement) | n2=en:decreased multimerin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased myeloperoxidase activity in neutrophils and monocytes n1=thrombolytique (traitement) | n2=en:decreased myeloperoxidase activity in neutrophils and monocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased n-acetylglucosamine-1-phosphotransferase (glcnac - phosphotransferase) using lysosomal enzymes n1=thrombolytique (traitement) | n2=en:decreased n-acetylglucosamine-1-phosphotransferase (glcnac - phosphotransferase) using lysosomal enzymes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased nasal nitric oxide n1=thrombolytique (traitement) | n2=en:decreased nasal nitric oxide | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased nasal nitric oxide (in some patients) n1=thrombolytique (traitement) | n2=en:decreased nasal nitric oxide (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased natural killer cells n1=thrombolytique (traitement) | n2=en:decreased natural killer cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased neopterin and biopterin in csf n1=thrombolytique (traitement) | n2=en:decreased neopterin and biopterin in csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased neopterin and biopterin in urine n1=thrombolytique (traitement) | n2=en:decreased neopterin and biopterin in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased nk cells (in some patients) n1=thrombolytique (traitement) | n2=en:decreased nk cells (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased norepinephrine level n1=thrombolytique (traitement) | n2=en:decreased norepinephrine level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased number of igf1 receptors (igf1r, 147370) on cell surface n1=thrombolytique (traitement) | n2=en:decreased number of igf1 receptors (igf1r, 147370) on cell surface | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased number of small megakaryocytes (1 patient) n1=thrombolytique (traitement) | n2=en:decreased number of small megakaryocytes (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased numbers of t regulatory cells n1=thrombolytique (traitement) | n2=en:decreased numbers of t regulatory cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent alpha-n-acetylgalactosaminidase activity n1=thrombolytique (traitement) | n2=en:decreased or absent alpha-n-acetylgalactosaminidase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent alpha-n-acetylgalactosaminidase protein n1=thrombolytique (traitement) | n2=en:decreased or absent alpha-n-acetylgalactosaminidase protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent apolipoprotein a-i n1=thrombolytique (traitement) | n2=en:decreased or absent apolipoprotein a-i | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent ciliary motility n1=thrombolytique (traitement) | n2=en:decreased or absent ciliary motility | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent d-bifunctional protein activity and protein n1=thrombolytique (traitement) | n2=en:decreased or absent d-bifunctional protein activity and protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent dihydropteridine reductase activity n1=thrombolytique (traitement) | n2=en:decreased or absent dihydropteridine reductase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent dihydropyrimidine dehydrogenase activity n1=thrombolytique (traitement) | n2=en:decreased or absent dihydropyrimidine dehydrogenase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent gch1 activity n1=thrombolytique (traitement) | n2=en:decreased or absent gch1 activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent glycogen branching enzyme activity n1=thrombolytique (traitement) | n2=en:decreased or absent glycogen branching enzyme activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent histidase activity n1=thrombolytique (traitement) | n2=en:decreased or absent histidase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent peroxisome acyl-coa oxidase activity and protein n1=thrombolytique (traitement) | n2=en:decreased or absent peroxisome acyl-coa oxidase activity and protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent pts activity n1=thrombolytique (traitement) | n2=en:decreased or absent pts activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent serum and urinary chenodeoxycholic acid and cholic acid n1=thrombolytique (traitement) | n2=en:decreased or absent serum and urinary chenodeoxycholic acid and cholic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent serum ceruloplasmin n1=thrombolytique (traitement) | n2=en:decreased or absent serum ceruloplasmin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent serum citrulline n1=thrombolytique (traitement) | n2=en:decreased or absent serum citrulline | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent steroid sulfatase activity n1=thrombolytique (traitement) | n2=en:decreased or absent steroid sulfatase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or absent udp-glucuronyl-transferase activity n1=thrombolytique (traitement) | n2=en:decreased or absent udp-glucuronyl-transferase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or increased serum testosterone n1=thrombolytique (traitement) | n2=en:decreased or increased serum testosterone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or low-normal serum parathyroid hormone (pth) n1=thrombolytique (traitement) | n2=en:decreased or low-normal serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or normal plasma insulin n1=thrombolytique (traitement) | n2=en:decreased or normal plasma insulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or normal serum c3 n1=thrombolytique (traitement) | n2=en:decreased or normal serum c3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or normal serum factor b n1=thrombolytique (traitement) | n2=en:decreased or normal serum factor b | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased or normal serum factor i n1=thrombolytique (traitement) | n2=en:decreased or normal serum factor i | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased orotic acid n1=thrombolytique (traitement) | n2=en:decreased orotic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased oxygen-binding capacity of hemoglobin n1=thrombolytique (traitement) | n2=en:decreased oxygen-binding capacity of hemoglobin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased oxytocin level n1=thrombolytique (traitement) | n2=en:decreased oxytocin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased palmitate oxidation n1=thrombolytique (traitement) | n2=en:decreased palmitate oxidation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased pantothenic acid n1=thrombolytique (traitement) | n2=en:decreased pantothenic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased peak expiratory flowrate n1=thrombolytique (traitement) | n2=en:decreased peak expiratory flowrate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased peroxisomal fatty acid beta-oxidation n1=thrombolytique (traitement) | n2=en:decreased peroxisomal fatty acid beta-oxidation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased phgdh activity (fibroblasts) n1=thrombolytique (traitement) | n2=en:decreased phgdh activity (fibroblasts) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased phk activity in liver n1=thrombolytique (traitement) | n2=en:decreased phk activity in liver | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased phosphoglucomutase 1 (pgm1) activity (less than 10% of normal values) n1=thrombolytique (traitement) | n2=en:decreased phosphoglucomutase 1 (pgm1) activity (less than 10% of normal values) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased phosphoglycerate mutase 1 (pgam2) activity (2 to 6% of normal values) n1=thrombolytique (traitement) | n2=en:decreased phosphoglycerate mutase 1 (pgam2) activity (2 to 6% of normal values) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased phytanic acid oxidase activity n1=thrombolytique (traitement) | n2=en:decreased phytanic acid oxidase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased pituitary follicle stimulating hormone n1=thrombolytique (traitement) | n2=en:decreased pituitary follicle stimulating hormone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased pituitary gonadotropin level n1=thrombolytique (traitement) | n2=en:decreased pituitary gonadotropin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased pituitary luteinizing hormone level n1=thrombolytique (traitement) | n2=en:decreased pituitary luteinizing hormone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma and urinary guanidinoacetate (gaa) n1=thrombolytique (traitement) | n2=en:decreased plasma and urinary guanidinoacetate (gaa) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma and urinary ornithine n1=thrombolytique (traitement) | n2=en:decreased plasma and urinary ornithine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma apolipoprotein b (apob, 107730) n1=thrombolytique (traitement) | n2=en:decreased plasma apolipoprotein b (apob, 107730) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma apolipoprotein c-ii n1=thrombolytique (traitement) | n2=en:decreased plasma apolipoprotein c-ii | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma arginine n1=thrombolytique (traitement) | n2=en:decreased plasma arginine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma esterified cholesterol n1=thrombolytique (traitement) | n2=en:decreased plasma esterified cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma free carnitine n1=thrombolytique (traitement) | n2=en:decreased plasma free carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma glycine n1=thrombolytique (traitement) | n2=en:decreased plasma glycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma gonadotrophin n1=thrombolytique (traitement) | n2=en:decreased plasma gonadotrophin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma hdl (<1/10 of normal levels) n1=thrombolytique (traitement) | n2=en:decreased plasma hdl (<1/10 of normal levels) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma lpl levels (in some patients) n1=thrombolytique (traitement) | n2=en:decreased plasma lpl levels (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma lysine, glutamic acid, and glutamine n1=thrombolytique (traitement) | n2=en:decreased plasma lysine, glutamic acid, and glutamine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma serine n1=thrombolytique (traitement) | n2=en:decreased plasma serine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma total and free carnitine n1=thrombolytique (traitement) | n2=en:decreased plasma total and free carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma total cholesterol n1=thrombolytique (traitement) | n2=en:decreased plasma total cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma triglycerides n1=thrombolytique (traitement) | n2=en:decreased plasma triglycerides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasma zinc levels n1=thrombolytique (traitement) | n2=en:decreased plasma zinc levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasmalogens n1=thrombolytique (traitement) | n2=en:decreased plasmalogens | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasminogen activity n1=thrombolytique (traitement) | n2=en:decreased plasminogen activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased plasminogen antigen n1=thrombolytique (traitement) | n2=en:decreased plasminogen antigen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased platelet derived growth factor n1=thrombolytique (traitement) | n2=en:decreased platelet derived growth factor | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased platelet expression of gp6 n1=thrombolytique (traitement) | n2=en:decreased platelet expression of gp6 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased platelet function n1=thrombolytique (traitement) | n2=en:decreased platelet function | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased platelet production (finding) n1=thrombolytique (traitement) | n2=en:decreased platelet production (finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased polypeptide hormone level n1=thrombolytique (traitement) | n2=en:decreased polypeptide hormone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased porphyrin n1=thrombolytique (traitement) | n2=en:decreased porphyrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased pregnanediol level n1=thrombolytique (traitement) | n2=en:decreased pregnanediol level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased pregnanetriol level n1=thrombolytique (traitement) | n2=en:decreased pregnanetriol level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased progesterone level n1=thrombolytique (traitement) | n2=en:decreased progesterone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased prolactin level n1=thrombolytique (traitement) | n2=en:decreased prolactin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased protein hormone level n1=thrombolytique (traitement) | n2=en:decreased protein hormone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased protein-bound iodine n1=thrombolytique (traitement) | n2=en:decreased protein-bound iodine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased prpp synthetase activity in erythrocytes and fibroblasts n1=thrombolytique (traitement) | n2=en:decreased prpp synthetase activity in erythrocytes and fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased pyruvate carboxylase (pc) activity (less than 5%) n1=thrombolytique (traitement) | n2=en:decreased pyruvate carboxylase (pc) activity (less than 5%) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased red cell pyruvate kinase activity n1=thrombolytique (traitement) | n2=en:decreased red cell pyruvate kinase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased renal calcium excretion n1=thrombolytique (traitement) | n2=en:decreased renal calcium excretion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased respiratory chain complex iii activity in multiple tissues n1=thrombolytique (traitement) | n2=en:decreased respiratory chain complex iii activity in multiple tissues | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased reversible oxygen-binding capacity (e.g. hb l (bombay) 141800.9999) n1=thrombolytique (traitement) | n2=en:decreased reversible oxygen-binding capacity (e.g. hb l (bombay) 141800.9999) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased s-ado:saicar ratio n1=thrombolytique (traitement) | n2=en:decreased s-ado:saicar ratio | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased scad activity n1=thrombolytique (traitement) | n2=en:decreased scad activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased secretin level n1=thrombolytique (traitement) | n2=en:decreased secretin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased secretion of igf1 in response to gh administration n1=thrombolytique (traitement) | n2=en:decreased secretion of igf1 in response to gh administration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serotonin level n1=thrombolytique (traitement) | n2=en:decreased serotonin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum 18-ohb n1=thrombolytique (traitement) | n2=en:decreased serum 18-ohb | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum 25-hydroxyvitamin d n1=thrombolytique (traitement) | n2=en:decreased serum 25-hydroxyvitamin d | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum acth n1=thrombolytique (traitement) | n2=en:decreased serum acth | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum alpha-2 macroglobulin levels n1=thrombolytique (traitement) | n2=en:decreased serum alpha-2 macroglobulin levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum and muscle coenzyme q n1=thrombolytique (traitement) | n2=en:decreased serum and muscle coenzyme q | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum and salivary lactoferrin has been described in 1 family n1=thrombolytique (traitement) | n2=en:decreased serum and salivary lactoferrin has been described in 1 family | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum androgens n1=thrombolytique (traitement) | n2=en:decreased serum androgens | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum b12 levels n1=thrombolytique (traitement) | n2=en:decreased serum b12 levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum bun n1=thrombolytique (traitement) | n2=en:decreased serum bun | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum c3 (atypical hus) n1=thrombolytique (traitement) | n2=en:decreased serum c3 (atypical hus) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum carnitine in acute stage n1=thrombolytique (traitement) | n2=en:decreased serum carnitine in acute stage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum ceruloplasmin n1=thrombolytique (traitement) | n2=en:decreased serum ceruloplasmin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum cholesterol (in some) n1=thrombolytique (traitement) | n2=en:decreased serum cholesterol (in some) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum cobalamin n1=thrombolytique (traitement) | n2=en:decreased serum cobalamin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum complement factor h n1=thrombolytique (traitement) | n2=en:decreased serum complement factor h | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum factor b (atypical hus) n1=thrombolytique (traitement) | n2=en:decreased serum factor b (atypical hus) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum factor h (atypical hus) n1=thrombolytique (traitement) | n2=en:decreased serum factor h (atypical hus) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum factor i (atypical hus) n1=thrombolytique (traitement) | n2=en:decreased serum factor i (atypical hus) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum ferritin n1=thrombolytique (traitement) | n2=en:decreased serum ferritin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum follicle-stimulating hormone (fsh) n1=thrombolytique (traitement) | n2=en:decreased serum follicle-stimulating hormone (fsh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum free thyroxine n1=thrombolytique (traitement) | n2=en:decreased serum free thyroxine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum glucosyltransferase (ggt) activity n1=thrombolytique (traitement) | n2=en:decreased serum glucosyltransferase (ggt) activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum haptoglobin n1=thrombolytique (traitement) | n2=en:decreased serum haptoglobin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum haptoglobin (in some patients) n1=thrombolytique (traitement) | n2=en:decreased serum haptoglobin (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum iga n1=thrombolytique (traitement) | n2=en:decreased serum iga | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum igm n1=thrombolytique (traitement) | n2=en:decreased serum igm | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum insulin-like growth factor-1 (igf1, 147440) n1=thrombolytique (traitement) | n2=en:decreased serum insulin-like growth factor-1 (igf1, 147440) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum insulin-like growth factor-1 (igf1) n1=thrombolytique (traitement) | n2=en:decreased serum insulin-like growth factor-1 (igf1) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum iron (in some patients) n1=thrombolytique (traitement) | n2=en:decreased serum iron (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum l-transferrin (heterozygous patient) n1=thrombolytique (traitement) | n2=en:decreased serum l-transferrin (heterozygous patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum leptin n1=thrombolytique (traitement) | n2=en:decreased serum leptin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum levels of maoa products n1=thrombolytique (traitement) | n2=en:decreased serum levels of maoa products | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum luteinizing hormone (lh) n1=thrombolytique (traitement) | n2=en:decreased serum luteinizing hormone (lh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum protein level n1=thrombolytique (traitement) | n2=en:decreased serum protein level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum rt3 n1=thrombolytique (traitement) | n2=en:decreased serum rt3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum thiamine pyrophosphate n1=thrombolytique (traitement) | n2=en:decreased serum thiamine pyrophosphate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum thromboxane b2 n1=thrombolytique (traitement) | n2=en:decreased serum thromboxane b2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum thyroid-stimulating hormone (tsh) n1=thrombolytique (traitement) | n2=en:decreased serum thyroid-stimulating hormone (tsh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum thyroxine (t4) n1=thrombolytique (traitement) | n2=en:decreased serum thyroxine (t4) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum trypsinogen n1=thrombolytique (traitement) | n2=en:decreased serum trypsinogen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased serum vitamin a n1=thrombolytique (traitement) | n2=en:decreased serum vitamin a | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased short/branched-chain acyl-coa dehydrogenase protein levels and enzyme activity n1=thrombolytique (traitement) | n2=en:decreased short/branched-chain acyl-coa dehydrogenase protein levels and enzyme activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased sulfhemoglobin n1=thrombolytique (traitement) | n2=en:decreased sulfhemoglobin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased sulfite oxidase activity n1=thrombolytique (traitement) | n2=en:decreased sulfite oxidase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased sulfite oxidase activity in fibroblasts n1=thrombolytique (traitement) | n2=en:decreased sulfite oxidase activity in fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased switched memory b cells n1=thrombolytique (traitement) | n2=en:decreased switched memory b cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased switched memory b cells (in some patients) n1=thrombolytique (traitement) | n2=en:decreased switched memory b cells (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased t cells n1=thrombolytique (traitement) | n2=en:decreased t cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased telomerase activity n1=thrombolytique (traitement) | n2=en:decreased telomerase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased telomere length in lymphocytes n1=thrombolytique (traitement) | n2=en:decreased telomere length in lymphocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased testosterone level n1=thrombolytique (traitement) | n2=en:decreased testosterone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased tetrahydrobiopterin (bh4) in csf n1=thrombolytique (traitement) | n2=en:decreased tetrahydrobiopterin (bh4) in csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased tetrasialo-transferrin n1=thrombolytique (traitement) | n2=en:decreased tetrasialo-transferrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased tetrasialotransferrin levels n1=thrombolytique (traitement) | n2=en:decreased tetrasialotransferrin levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased thrombospondin n1=thrombolytique (traitement) | n2=en:decreased thrombospondin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased thyroid hormone level n1=thrombolytique (traitement) | n2=en:decreased thyroid hormone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased thyroid stimulating hormone level n1=thrombolytique (traitement) | n2=en:decreased thyroid stimulating hormone level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased thyroxine level n1=thrombolytique (traitement) | n2=en:decreased thyroxine level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased tissue and serum alkaline phosphatase n1=thrombolytique (traitement) | n2=en:decreased tissue and serum alkaline phosphatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased tissue total and free carnitine n1=thrombolytique (traitement) | n2=en:decreased tissue total and free carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased transcobalamin i in saliva, serum, gastric juice, and cerebrospinal fluid n1=thrombolytique (traitement) | n2=en:decreased transcobalamin i in saliva, serum, gastric juice, and cerebrospinal fluid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased transferrin increased serum iron n1=thrombolytique (traitement) | n2=en:decreased transferrin increased serum iron | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased triiodothyronine level n1=thrombolytique (traitement) | n2=en:decreased triiodothyronine level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased ubiquinone-10 n1=thrombolytique (traitement) | n2=en:decreased ubiquinone-10 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased udp-glcnac n1=thrombolytique (traitement) | n2=en:decreased udp-glcnac | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased uric acid level n1=thrombolytique (traitement) | n2=en:decreased uric acid level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased urinary calcium and phosphate excretion n1=thrombolytique (traitement) | n2=en:decreased urinary calcium and phosphate excretion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased urinary excretion of uromodulin n1=thrombolytique (traitement) | n2=en:decreased urinary excretion of uromodulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased urinary hva, 5-hiaa, and vanillyl mandelic acid (vma) n1=thrombolytique (traitement) | n2=en:decreased urinary hva, 5-hiaa, and vanillyl mandelic acid (vma) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased urinary sulfate n1=thrombolytique (traitement) | n2=en:decreased urinary sulfate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased urobilin n1=thrombolytique (traitement) | n2=en:decreased urobilin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased urobilinogen level n1=thrombolytique (traitement) | n2=en:decreased urobilinogen level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased urocanic acid in blood, urine, and skin cells n1=thrombolytique (traitement) | n2=en:decreased urocanic acid in blood, urine, and skin cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased uros activity (1 patient) n1=thrombolytique (traitement) | n2=en:decreased uros activity (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased vanillylmandelic acid level n1=thrombolytique (traitement) | n2=en:decreased vanillylmandelic acid level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased very long-chain acyl-coa dehydrogenase protein and activity n1=thrombolytique (traitement) | n2=en:decreased very long-chain acyl-coa dehydrogenase protein and activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased vital capacity n1=thrombolytique (traitement) | n2=en:decreased vital capacity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased vitamin a n1=thrombolytique (traitement) | n2=en:decreased vitamin a | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased vitamin b n1=thrombolytique (traitement) | n2=en:decreased vitamin b | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased vitamin b>12< n1=thrombolytique (traitement) | n2=en:decreased vitamin b>12< | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased vitamin d n1=thrombolytique (traitement) | n2=en:decreased vitamin d | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased vitamin e n1=thrombolytique (traitement) | n2=en:decreased vitamin e | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased vitamin k n1=thrombolytique (traitement) | n2=en:decreased vitamin k | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased von willebrand factor n1=thrombolytique (traitement) | n2=en:decreased von willebrand factor | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased whole blood serotonin n1=thrombolytique (traitement) | n2=en:decreased whole blood serotonin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased xanthine n1=thrombolytique (traitement) | n2=en:decreased xanthine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased xanthine dehydrogenase activity n1=thrombolytique (traitement) | n2=en:decreased xanthine dehydrogenase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:decreased-absent intestinal mucosa lactase activity n1=thrombolytique (traitement) | n2=en:decreased-absent intestinal mucosa lactase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deep thrombophlebitis n1=thrombolytique (traitement) | n2=en:deep thrombophlebitis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deep vein thrombosis n1=thrombolytique (traitement) | n2=en:deep vein thrombosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deep venous thrombosis n1=thrombolytique (traitement) | n2=en:deep venous thrombosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defect in chylomicron secretion n1=thrombolytique (traitement) | n2=en:defect in chylomicron secretion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defect in dna repair n1=thrombolytique (traitement) | n2=en:defect in dna repair | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defect in double-stranded dna repair n1=thrombolytique (traitement) | n2=en:defect in double-stranded dna repair | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defect in mitochondrial and peroxisomal fission n1=thrombolytique (traitement) | n2=en:defect in mitochondrial and peroxisomal fission | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defect in n- and o-glycosylation n1=thrombolytique (traitement) | n2=en:defect in n- and o-glycosylation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defect in oxidative phosphorylation n1=thrombolytique (traitement) | n2=en:defect in oxidative phosphorylation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defect in retrograde intraflagellar transport in cilia n1=thrombolytique (traitement) | n2=en:defect in retrograde intraflagellar transport in cilia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective (ca2+) mobilization in t cells n1=thrombolytique (traitement) | n2=en:defective (ca2+) mobilization in t cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective bile acid metabolism n1=thrombolytique (traitement) | n2=en:defective bile acid metabolism | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective dna repair n1=thrombolytique (traitement) | n2=en:defective dna repair | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective dna repair after ultraviolet radiation damage n1=thrombolytique (traitement) | n2=en:defective dna repair after ultraviolet radiation damage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective glcnac-pi synthesis n1=thrombolytique (traitement) | n2=en:defective glcnac-pi synthesis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective mitochondrial respiratory enzyme activity n1=thrombolytique (traitement) | n2=en:defective mitochondrial respiratory enzyme activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective nk cell activity n1=thrombolytique (traitement) | n2=en:defective nk cell activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective nk cell degranulation n1=thrombolytique (traitement) | n2=en:defective nk cell degranulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective platelet activation and aggregation in response to collagen n1=thrombolytique (traitement) | n2=en:defective platelet activation and aggregation in response to collagen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective platelet adhesion with normal platelet count n1=thrombolytique (traitement) | n2=en:defective platelet adhesion with normal platelet count | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective platelet aggregation in response to adp n1=thrombolytique (traitement) | n2=en:defective platelet aggregation in response to adp | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective platelet aggregation in response to arachidonic acid n1=thrombolytique (traitement) | n2=en:defective platelet aggregation in response to arachidonic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective platelet binding to collagen n1=thrombolytique (traitement) | n2=en:defective platelet binding to collagen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective platelet calcium mobilization n1=thrombolytique (traitement) | n2=en:defective platelet calcium mobilization | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defective t-cell proliferative responses (in some patients) n1=thrombolytique (traitement) | n2=en:defective t-cell proliferative responses (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:defects in mitochondrial oxidative phosphorylation n1=thrombolytique (traitement) | n2=en:defects in mitochondrial oxidative phosphorylation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of alpha-1,4-glucosidase (acid maltase) n1=thrombolytique (traitement) | n2=en:deficiency of alpha-1,4-glucosidase (acid maltase) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of creatine phosphate in brain n1=thrombolytique (traitement) | n2=en:deficiency of creatine phosphate in brain | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of fat-soluble vitamins n1=thrombolytique (traitement) | n2=en:deficiency of fat-soluble vitamins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of fructokinase n1=thrombolytique (traitement) | n2=en:deficiency of fructokinase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of glycoprotein (gp)iib-iiia complex n1=thrombolytique (traitement) | n2=en:deficiency of glycoprotein (gp)iib-iiia complex | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of laminin alpha-2 chain of merosin (lama2, 156225) in muscle n1=thrombolytique (traitement) | n2=en:deficiency of laminin alpha-2 chain of merosin (lama2, 156225) in muscle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of laminin in basement membranes n1=thrombolytique (traitement) | n2=en:deficiency of laminin in basement membranes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of mitochondrial isovaleryl-coa dehydrogenase in fibroblasts n1=thrombolytique (traitement) | n2=en:deficiency of mitochondrial isovaleryl-coa dehydrogenase in fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of phosphatidylinositol (4,5) bisphosphate 5-phosphatase (ptdins(4,5)p(2) 5-phosphatase) in cultured fibroblasts n1=thrombolytique (traitement) | n2=en:deficiency of phosphatidylinositol (4,5) bisphosphate 5-phosphatase (ptdins(4,5)p(2) 5-phosphatase) in cultured fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of prolidase activity in erythrocytes, leukocytes, or fibroblasts n1=thrombolytique (traitement) | n2=en:deficiency of prolidase activity in erythrocytes, leukocytes, or fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of saposins a, b, c, and d n1=thrombolytique (traitement) | n2=en:deficiency of saposins a, b, c, and d | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency of serum properdin p factor n1=thrombolytique (traitement) | n2=en:deficiency of serum properdin p factor | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency or absence of cytochrome b(-245) n1=thrombolytique (traitement) | n2=en:deficiency or absence of cytochrome b(-245) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency or absence of p22-phox (608508) protein n1=thrombolytique (traitement) | n2=en:deficiency or absence of p22-phox (608508) protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency or absence of p22-phox protein n1=thrombolytique (traitement) | n2=en:deficiency or absence of p22-phox protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency or absence of p47-phox protein (type i) n1=thrombolytique (traitement) | n2=en:deficiency or absence of p47-phox protein (type i) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency or absence of p67-phox protein (type ii) n1=thrombolytique (traitement) | n2=en:deficiency or absence of p67-phox protein (type ii) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency or absence of p91-phox (300481) protein n1=thrombolytique (traitement) | n2=en:deficiency or absence of p91-phox (300481) protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficiency or absence of p91-phox protein n1=thrombolytique (traitement) | n2=en:deficiency or absence of p91-phox protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficient efflux of intracellular cholesterol n1=thrombolytique (traitement) | n2=en:deficient efflux of intracellular cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficient fibroblast aicar-tf activity n1=thrombolytique (traitement) | n2=en:deficient fibroblast aicar-tf activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficient hepatic 4-hydroxyphenylpyruvate dioxygenase n1=thrombolytique (traitement) | n2=en:deficient hepatic 4-hydroxyphenylpyruvate dioxygenase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficient plasma alpha-lecithin:cholesterol acyltransferase (high-density) activity n1=thrombolytique (traitement) | n2=en:deficient plasma alpha-lecithin:cholesterol acyltransferase (high-density) activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deficient ribose-s-phosphate isomerase (rpi) in fibroblasts n1=thrombolytique (traitement) | n2=en:deficient ribose-s-phosphate isomerase (rpi) in fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:degraded platelet alpha-granule proteins n1=thrombolytique (traitement) | n2=en:degraded platelet alpha-granule proteins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dehydration n1=thrombolytique (traitement) | n2=en:dehydration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dehydroepiandrosterone (dhea) at upper level of normal range n1=thrombolytique (traitement) | n2=en:dehydroepiandrosterone (dhea) at upper level of normal range | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:delayed plasma clearance of unconjugated bromsulphthalein, an anionic diagnostic dye n1=thrombolytique (traitement) | n2=en:delayed plasma clearance of unconjugated bromsulphthalein, an anionic diagnostic dye | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deletion (78kb to 1mb) of chromosome 8q24.3 including the scrib (607733) and puf60 (604819) genes n1=thrombolytique (traitement) | n2=en:deletion (78kb to 1mb) of chromosome 8q24.3 including the scrib (607733) and puf60 (604819) genes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:deletion of chromosome 18p11.2 n1=thrombolytique (traitement) | n2=en:deletion of chromosome 18p11.2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:delta-1-pyrroline-3-hydroxy-5-carboxylate levels increased in urine n1=thrombolytique (traitement) | n2=en:delta-1-pyrroline-3-hydroxy-5-carboxylate levels increased in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:delta-1-pyrroline-5-carboxylate (p5c) levels increased in plasma n1=thrombolytique (traitement) | n2=en:delta-1-pyrroline-5-carboxylate (p5c) levels increased in plasma | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:delta-1-pyrroline-5-carboxylate dehydrogenase activity decreased in fibroblasts or leukocytes n1=thrombolytique (traitement) | n2=en:delta-1-pyrroline-5-carboxylate dehydrogenase activity decreased in fibroblasts or leukocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:depletion of mtdna (skeletal muscle, fibroblasts) n1=thrombolytique (traitement) | n2=en:depletion of mtdna (skeletal muscle, fibroblasts) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dermatan and heparan sulfate excretion in urine n1=thrombolytique (traitement) | n2=en:dermatan and heparan sulfate excretion in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dermatan sulfate excretion in urine n1=thrombolytique (traitement) | n2=en:dermatan sulfate excretion in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:detection by rt-pcr and southern blot analysis for primary diagnosis and follow up for residual disease n1=thrombolytique (traitement) | n2=en:detection by rt-pcr and southern blot analysis for primary diagnosis and follow up for residual disease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:detection by rt-pcr, southern blot analysis, and fish for primary diagnosis and follow up for residual disease n1=thrombolytique (traitement) | n2=en:detection by rt-pcr, southern blot analysis, and fish for primary diagnosis and follow up for residual disease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dextran n1=thrombolytique (traitement) | n2=en:dextran | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dextran 1 n1=thrombolytique (traitement) | n2=en:dextran 1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dextran 1 150mg/ml injection solution ampule n1=thrombolytique (traitement) | n2=en:dextran 1 150mg/ml injection solution ampule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dextran 40 n1=thrombolytique (traitement) | n2=en:dextran 40 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dextran 70 n1=thrombolytique (traitement) | n2=en:dextran 70 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dextran 70 320 mg/ml injectable solution n1=thrombolytique (traitement) | n2=en:dextran 70 320 mg/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dextran 75 n1=thrombolytique (traitement) | n2=en:dextran 75 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dextran 75 60 mg/ml injectable solution n1=thrombolytique (traitement) | n2=en:dextran 75 60 mg/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dhea sulfotransferase below limit of detection n1=thrombolytique (traitement) | n2=en:dhea sulfotransferase below limit of detection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:di- and trihydroxycholestanoic acid accumulation n1=thrombolytique (traitement) | n2=en:di- and trihydroxycholestanoic acid accumulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:diagnosis by exposing muscle biopsy to caffeine and/or halothane n1=thrombolytique (traitement) | n2=en:diagnosis by exposing muscle biopsy to caffeine and/or halothane | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:diaminoaciduria (arginuria, lysinuria, cystinuria, ornithinuria) n1=thrombolytique (traitement) | n2=en:diaminoaciduria (arginuria, lysinuria, cystinuria, ornithinuria) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:diamond-blackfan anemia 1 n1=thrombolytique (traitement) | n2=en:diamond-blackfan anemia 1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dicarboxylic aciduria n1=thrombolytique (traitement) | n2=en:dicarboxylic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:diffuse deposition of calcium oxalate in various tissues n1=thrombolytique (traitement) | n2=en:diffuse deposition of calcium oxalate in various tissues | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:digoxin level low n1=thrombolytique (traitement) | n2=en:digoxin level low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dilated rough endoplasmic reticulum (rer) n1=thrombolytique (traitement) | n2=en:dilated rough endoplasmic reticulum (rer) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dilutional thrombocytopenia n1=thrombolytique (traitement) | n2=en:dilutional thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dimethylglycine dehydrogenase (dmgdh) deficiency n1=thrombolytique (traitement) | n2=en:dimethylglycine dehydrogenase (dmgdh) deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:diminished lymphocyte response to phytohemaglutinin n1=thrombolytique (traitement) | n2=en:diminished lymphocyte response to phytohemaglutinin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:direct coombs test negative n1=thrombolytique (traitement) | n2=en:direct coombs test negative | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:direct hyperbilirubinemia n1=thrombolytique (traitement) | n2=en:direct hyperbilirubinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:disorder of the circulatory system n1=thrombolytique (traitement) | n2=en:disorder of the circulatory system | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:disorganized growth plate cartilage n1=thrombolytique (traitement) | n2=en:disorganized growth plate cartilage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:disproportionate work-related increase in blood lactate and pyruvate n1=thrombolytique (traitement) | n2=en:disproportionate work-related increase in blood lactate and pyruvate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:disseminated intravascular coagulation adverse event n1=thrombolytique (traitement) | n2=en:disseminated intravascular coagulation adverse event | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:disseminated intravascular coagulation, episodic n1=thrombolytique (traitement) | n2=en:disseminated intravascular coagulation, episodic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:distal xp22.3 segmental monosomy n1=thrombolytique (traitement) | n2=en:distal xp22.3 segmental monosomy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:disturbed visual and brainstem auditory evoked responses indicative of cns demyelination n1=thrombolytique (traitement) | n2=en:disturbed visual and brainstem auditory evoked responses indicative of cns demyelination | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:diverse tissue cell types (vascular endothelial cells, adipocytes, schwann cells, leukocytes) have membrane-lined cytoplasmic vacuoles with amorphous and filamentous material n1=thrombolytique (traitement) | n2=en:diverse tissue cell types (vascular endothelial cells, adipocytes, schwann cells, leukocytes) have membrane-lined cytoplasmic vacuoles with amorphous and filamentous material | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dk phocomelia syndrome n1=thrombolytique (traitement) | n2=en:dk phocomelia syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:doan-wright syndrome n1=thrombolytique (traitement) | n2=en:doan-wright syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:docetaxel n1=thrombolytique (traitement) | n2=en:docetaxel | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:docetaxel 10mg/ml injection solution 160mg vial n1=thrombolytique (traitement) | n2=en:docetaxel 10mg/ml injection solution 160mg vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:docetaxel 20 mg/ml injectable solution n1=thrombolytique (traitement) | n2=en:docetaxel 20 mg/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:docetaxel 40 mg/ml injectable solution n1=thrombolytique (traitement) | n2=en:docetaxel 40 mg/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dolichyl-p-glc:man(9)glcnac(2)-pp-dolichyl glucosyltransferase deficiency n1=thrombolytique (traitement) | n2=en:dolichyl-p-glc:man(9)glcnac(2)-pp-dolichyl glucosyltransferase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dolichyl-p-man:man(5)glcnac(2)-pp-dolichyl mannosyltransferase deficiency n1=thrombolytique (traitement) | n2=en:dolichyl-p-man:man(5)glcnac(2)-pp-dolichyl mannosyltransferase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:doxorubicin n1=thrombolytique (traitement) | n2=en:doxorubicin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:doxorubicin hydrochloride n1=thrombolytique (traitement) | n2=en:doxorubicin hydrochloride | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:doxorubicin hydrochloride 2 mg/ml injectable solution n1=thrombolytique (traitement) | n2=en:doxorubicin hydrochloride 2 mg/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:doxorubicin hydrochloride liposome 2 mg/ml injectable solution n1=thrombolytique (traitement) | n2=en:doxorubicin hydrochloride liposome 2 mg/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:drug induced thrombocytopenia n1=thrombolytique (traitement) | n2=en:drug induced thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:drug induced thrombotic thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:drug induced thrombotic thrombocytopenic purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:drug-induced immune thrombocytopenia n1=thrombolytique (traitement) | n2=en:drug-induced immune thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:duplication or deletion at 11p15.5 n1=thrombolytique (traitement) | n2=en:duplication or deletion at 11p15.5 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dyserythropoiesis in bone marrow (1 patient) n1=thrombolytique (traitement) | n2=en:dyserythropoiesis in bone marrow (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dyserythropoietic anemia n1=thrombolytique (traitement) | n2=en:dyserythropoietic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dyserythropoietic anemia with thrombocytopenia n1=thrombolytique (traitement) | n2=en:dyserythropoietic anemia with thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dyskeratosis congenita, autosomal dominant n1=thrombolytique (traitement) | n2=en:dyskeratosis congenita, autosomal dominant | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dyskeratosis congenita, autosomal dominant, 2 n1=thrombolytique (traitement) | n2=en:dyskeratosis congenita, autosomal dominant, 2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dyskeratosis congenita, autosomal dominant, 3 n1=thrombolytique (traitement) | n2=en:dyskeratosis congenita, autosomal dominant, 3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dyskeratosis congenita, autosomal recessive n1=thrombolytique (traitement) | n2=en:dyskeratosis congenita, autosomal recessive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dyskeratosis congenita, autosomal recessive, 2 n1=thrombolytique (traitement) | n2=en:dyskeratosis congenita, autosomal recessive, 2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dyskinetic ciliary motility n1=thrombolytique (traitement) | n2=en:dyskinetic ciliary motility | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dyslipidemia n1=thrombolytique (traitement) | n2=en:dyslipidemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dysplastic changes in all cell lineages in the bone marrow n1=thrombolytique (traitement) | n2=en:dysplastic changes in all cell lineages in the bone marrow | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:dysplastic erythroblasts with internuclear chromatin strands n1=thrombolytique (traitement) | n2=en:dysplastic erythroblasts with internuclear chromatin strands | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:easy bruising n1=thrombolytique (traitement) | n2=en:easy bruising | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:eccentrocytes (in some patients) n1=thrombolytique (traitement) | n2=en:eccentrocytes (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:echinocytosis n1=thrombolytique (traitement) | n2=en:echinocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:echocardiogram abnormal n1=thrombolytique (traitement) | n2=en:echocardiogram abnormal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ektacytometric osmotic gradient curve shifted to the left n1=thrombolytique (traitement) | n2=en:ektacytometric osmotic gradient curve shifted to the left | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electrocardiogram abnormal n1=thrombolytique (traitement) | n2=en:electrocardiogram abnormal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electrolyte disturbances from intractable diarrhea n1=thrombolytique (traitement) | n2=en:electrolyte disturbances from intractable diarrhea | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electrolyturia (1 patient) n1=thrombolytique (traitement) | n2=en:electrolyturia (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electron microscopy of foam cells shows lamellar inclusions n1=thrombolytique (traitement) | n2=en:electron microscopy of foam cells shows lamellar inclusions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electron microscopy of patient respiratory cells shows absent inner and outer dynein arms n1=thrombolytique (traitement) | n2=en:electron microscopy of patient respiratory cells shows absent inner and outer dynein arms | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electron microscopy of patient respiratory cells shows absent outer dynein arms n1=thrombolytique (traitement) | n2=en:electron microscopy of patient respiratory cells shows absent outer dynein arms | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electron microscopy of patient respiratory cells shows absent outer dynein arms in the axoneme n1=thrombolytique (traitement) | n2=en:electron microscopy of patient respiratory cells shows absent outer dynein arms in the axoneme | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electron microscopy of patient respiratory cells shows defects in inner and outer dynein arms n1=thrombolytique (traitement) | n2=en:electron microscopy of patient respiratory cells shows defects in inner and outer dynein arms | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electron microscopy of patient respiratory cells shows defects of outer dynein arms n1=thrombolytique (traitement) | n2=en:electron microscopy of patient respiratory cells shows defects of outer dynein arms | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electron microscopy of patient respiratory cells shows loss of ciliary outer dynein arms n1=thrombolytique (traitement) | n2=en:electron microscopy of patient respiratory cells shows loss of ciliary outer dynein arms | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electron microscopy of patient respiratory cells shows reduced inner dynein arms and nexin links n1=thrombolytique (traitement) | n2=en:electron microscopy of patient respiratory cells shows reduced inner dynein arms and nexin links | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electron microscopy shows iron-loaded mitochondria n1=thrombolytique (traitement) | n2=en:electron microscopy shows iron-loaded mitochondria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:electroretinogram is abnormal--rod responses are mildly abnormal and cone responses are markedly diminished n1=thrombolytique (traitement) | n2=en:electroretinogram is abnormal--rod responses are mildly abnormal and cone responses are markedly diminished | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated 1,25(oh)2 d3 n1=thrombolytique (traitement) | n2=en:elevated 1,25(oh)2 d3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated 17-hydroxyprogesterone n1=thrombolytique (traitement) | n2=en:elevated 17-hydroxyprogesterone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated 2-ketoglutarate (urine) n1=thrombolytique (traitement) | n2=en:elevated 2-ketoglutarate (urine) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated 3-hydroxypropionic acid n1=thrombolytique (traitement) | n2=en:elevated 3-hydroxypropionic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated 3-methylcitric acid n1=thrombolytique (traitement) | n2=en:elevated 3-methylcitric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated 7-dehydrocholesterol n1=thrombolytique (traitement) | n2=en:elevated 7-dehydrocholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated 8-dehydrocholesterol n1=thrombolytique (traitement) | n2=en:elevated 8-dehydrocholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated 8(9)-cholestenol n1=thrombolytique (traitement) | n2=en:elevated 8(9)-cholestenol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated acth n1=thrombolytique (traitement) | n2=en:elevated acth | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated afp (endodermal sinus tumor) n1=thrombolytique (traitement) | n2=en:elevated afp (endodermal sinus tumor) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated alkaline phosphatase n1=thrombolytique (traitement) | n2=en:elevated alkaline phosphatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated alkaline phosphatase (if more than one affected site) n1=thrombolytique (traitement) | n2=en:elevated alkaline phosphatase (if more than one affected site) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated alkaline phosphatase (in one patient) n1=thrombolytique (traitement) | n2=en:elevated alkaline phosphatase (in one patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated alkaline phosphatase (varies from 1.3-20 times age-adjusted upper limit of normal) n1=thrombolytique (traitement) | n2=en:elevated alkaline phosphatase (varies from 1.3-20 times age-adjusted upper limit of normal) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated alkaline phosphatase of bone origin n1=thrombolytique (traitement) | n2=en:elevated alkaline phosphatase of bone origin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated alpha-ketoglutarate (in most patients) n1=thrombolytique (traitement) | n2=en:elevated alpha-ketoglutarate (in most patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated ammonia n1=thrombolytique (traitement) | n2=en:elevated ammonia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated androstenedione n1=thrombolytique (traitement) | n2=en:elevated androstenedione | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated androstenedione and testosterone n1=thrombolytique (traitement) | n2=en:elevated androstenedione and testosterone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated antinuclear antibody (ana) (speckled pattern) n1=thrombolytique (traitement) | n2=en:elevated antinuclear antibody (ana) (speckled pattern) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated apoa-i (1.8x normal) in homozygotes n1=thrombolytique (traitement) | n2=en:elevated apoa-i (1.8x normal) in homozygotes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated ast (aspartate aminotransferase) and cpk (creatine phosphokinase) n1=thrombolytique (traitement) | n2=en:elevated ast (aspartate aminotransferase) and cpk (creatine phosphokinase) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated ast and ldh, especially infantile-onset n1=thrombolytique (traitement) | n2=en:elevated ast and ldh, especially infantile-onset | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated bilirubin (bilirubinemia) n1=thrombolytique (traitement) | n2=en:elevated bilirubin (bilirubinemia) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated biopterin in csf n1=thrombolytique (traitement) | n2=en:elevated biopterin in csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated blood spot hydroxybutyryl carnitine n1=thrombolytique (traitement) | n2=en:elevated blood spot hydroxybutyryl carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated branched-chain amino acids (in most patients) n1=thrombolytique (traitement) | n2=en:elevated branched-chain amino acids (in most patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated calcitonin n1=thrombolytique (traitement) | n2=en:elevated calcitonin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated catecholamines (in patients with pheochromocytoma) n1=thrombolytique (traitement) | n2=en:elevated catecholamines (in patients with pheochromocytoma) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated cerebrospinal fluid (csf) protein n1=thrombolytique (traitement) | n2=en:elevated cerebrospinal fluid (csf) protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated cholesta-8,14-dien-3-beta-ol in cultured fibroblasts n1=thrombolytique (traitement) | n2=en:elevated cholesta-8,14-dien-3-beta-ol in cultured fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated circulating parathyroid hormone (pth) level n1=thrombolytique (traitement) | n2=en:elevated circulating parathyroid hormone (pth) level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated creatine kinase (in some patients) n1=thrombolytique (traitement) | n2=en:elevated creatine kinase (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated crp n1=thrombolytique (traitement) | n2=en:elevated crp | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated csf amino acids (arginine, ornithine, aspartate, threonine, glycine, and methionine) n1=thrombolytique (traitement) | n2=en:elevated csf amino acids (arginine, ornithine, aspartate, threonine, glycine, and methionine) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated csf glycine n1=thrombolytique (traitement) | n2=en:elevated csf glycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated csf/plasma glycine ratio n1=thrombolytique (traitement) | n2=en:elevated csf/plasma glycine ratio | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated d-2-hydroxyglutaric acid (urine, plasma, csf) n1=thrombolytique (traitement) | n2=en:elevated d-2-hydroxyglutaric acid (urine, plasma, csf) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated dihydrobiopterin in csf n1=thrombolytique (traitement) | n2=en:elevated dihydrobiopterin in csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated erythrocyte adenosine deaminase n1=thrombolytique (traitement) | n2=en:elevated erythrocyte adenosine deaminase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated erythrocyte adenosine deaminase (eada) n1=thrombolytique (traitement) | n2=en:elevated erythrocyte adenosine deaminase (eada) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated erythrocyte adenosine deaminase activity n1=thrombolytique (traitement) | n2=en:elevated erythrocyte adenosine deaminase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated erythrocyte aicar (zmp) n1=thrombolytique (traitement) | n2=en:elevated erythrocyte aicar (zmp) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated erythrocyte sedimentation rate (esr) n1=thrombolytique (traitement) | n2=en:elevated erythrocyte sedimentation rate (esr) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated erythrocyte sedimentation rate (mean 90mm/h) n1=thrombolytique (traitement) | n2=en:elevated erythrocyte sedimentation rate (mean 90mm/h) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated fasting glucose n1=thrombolytique (traitement) | n2=en:elevated fasting glucose | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated fasting triglycerides n1=thrombolytique (traitement) | n2=en:elevated fasting triglycerides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated fasting triglycerides (seen in heterozygotes as well) n1=thrombolytique (traitement) | n2=en:elevated fasting triglycerides (seen in heterozygotes as well) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated fecal levels of protoporphyrin and coproporphyrin at all times n1=thrombolytique (traitement) | n2=en:elevated fecal levels of protoporphyrin and coproporphyrin at all times | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated ferritin l subunit n1=thrombolytique (traitement) | n2=en:elevated ferritin l subunit | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated fetal hemoglobin (hbf) n1=thrombolytique (traitement) | n2=en:elevated fetal hemoglobin (hbf) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated fibroblast free sialic acid n1=thrombolytique (traitement) | n2=en:elevated fibroblast free sialic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated free carnitine n1=thrombolytique (traitement) | n2=en:elevated free carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated gamma-glutamyltransferase n1=thrombolytique (traitement) | n2=en:elevated gamma-glutamyltransferase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated gamma-glutamyltransferase (ggt) n1=thrombolytique (traitement) | n2=en:elevated gamma-glutamyltransferase (ggt) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated gastrin concentration n1=thrombolytique (traitement) | n2=en:elevated gastrin concentration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated hba(2) n1=thrombolytique (traitement) | n2=en:elevated hba(2) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated hbf n1=thrombolytique (traitement) | n2=en:elevated hbf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated hcg (choriocarcinoma) n1=thrombolytique (traitement) | n2=en:elevated hcg (choriocarcinoma) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated hcg or afp or both (embryonal carcinoma) n1=thrombolytique (traitement) | n2=en:elevated hcg or afp or both (embryonal carcinoma) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated hdl (2-6x normal) in homozygotes n1=thrombolytique (traitement) | n2=en:elevated hdl (2-6x normal) in homozygotes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated hepatic transaminases n1=thrombolytique (traitement) | n2=en:elevated hepatic transaminases | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated il1-beta n1=thrombolytique (traitement) | n2=en:elevated il1-beta | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated il6 n1=thrombolytique (traitement) | n2=en:elevated il6 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated inflammatory markers n1=thrombolytique (traitement) | n2=en:elevated inflammatory markers | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated l-2-hydroxyglutaric acid (urine) n1=thrombolytique (traitement) | n2=en:elevated l-2-hydroxyglutaric acid (urine) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated lathosterol n1=thrombolytique (traitement) | n2=en:elevated lathosterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated leukotriene e(4) n1=thrombolytique (traitement) | n2=en:elevated leukotriene e(4) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated levels of vitamin b12 n1=thrombolytique (traitement) | n2=en:elevated levels of vitamin b12 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated liver enzymes n1=thrombolytique (traitement) | n2=en:elevated liver enzymes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated liver function tests n1=thrombolytique (traitement) | n2=en:elevated liver function tests | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated liver transaminases n1=thrombolytique (traitement) | n2=en:elevated liver transaminases | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated long chain fatty acids n1=thrombolytique (traitement) | n2=en:elevated long chain fatty acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated long-chain acylcarnitine species (in some patients) n1=thrombolytique (traitement) | n2=en:elevated long-chain acylcarnitine species (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated mchc n1=thrombolytique (traitement) | n2=en:elevated mchc | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma acth n1=thrombolytique (traitement) | n2=en:elevated plasma acth | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma adrenocorticotropic hormone (acth) n1=thrombolytique (traitement) | n2=en:elevated plasma adrenocorticotropic hormone (acth) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma alloisoleucine n1=thrombolytique (traitement) | n2=en:elevated plasma alloisoleucine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma ammonia n1=thrombolytique (traitement) | n2=en:elevated plasma ammonia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma and urine inorganic pyrophosphate (ppi) n1=thrombolytique (traitement) | n2=en:elevated plasma and urine inorganic pyrophosphate (ppi) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma and urine succinylacetone n1=thrombolytique (traitement) | n2=en:elevated plasma and urine succinylacetone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma beta-sitosterol (sitosterolemia or phytosterolemia) n1=thrombolytique (traitement) | n2=en:elevated plasma beta-sitosterol (sitosterolemia or phytosterolemia) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma branched chain amino acids (leucine, isoleucine, valine) n1=thrombolytique (traitement) | n2=en:elevated plasma branched chain amino acids (leucine, isoleucine, valine) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma campesterol n1=thrombolytique (traitement) | n2=en:elevated plasma campesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma cholestanol n1=thrombolytique (traitement) | n2=en:elevated plasma cholestanol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma citrulline (citrullinemia) n1=thrombolytique (traitement) | n2=en:elevated plasma citrulline (citrullinemia) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma desmosterol n1=thrombolytique (traitement) | n2=en:elevated plasma desmosterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma estrogen n1=thrombolytique (traitement) | n2=en:elevated plasma estrogen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma follicle stimulating hormone (fsh) n1=thrombolytique (traitement) | n2=en:elevated plasma follicle stimulating hormone (fsh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma galactose (galactosemia) n1=thrombolytique (traitement) | n2=en:elevated plasma galactose (galactosemia) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma insulin n1=thrombolytique (traitement) | n2=en:elevated plasma insulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma levels of lp(a) n1=thrombolytique (traitement) | n2=en:elevated plasma levels of lp(a) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma luteinizing hormone (lh) n1=thrombolytique (traitement) | n2=en:elevated plasma luteinizing hormone (lh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma methionine (methioninemia) n1=thrombolytique (traitement) | n2=en:elevated plasma methionine (methioninemia) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma ornithine (~10-fold) n1=thrombolytique (traitement) | n2=en:elevated plasma ornithine (~10-fold) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma phytanic acid n1=thrombolytique (traitement) | n2=en:elevated plasma phytanic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma propionylcarnitine n1=thrombolytique (traitement) | n2=en:elevated plasma propionylcarnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated plasma stigmasterol n1=thrombolytique (traitement) | n2=en:elevated plasma stigmasterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated pregnenolone n1=thrombolytique (traitement) | n2=en:elevated pregnenolone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated progesterone n1=thrombolytique (traitement) | n2=en:elevated progesterone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated propionate n1=thrombolytique (traitement) | n2=en:elevated propionate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated prothrombin time n1=thrombolytique (traitement) | n2=en:elevated prothrombin time | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated pth (parathyroid hormone) n1=thrombolytique (traitement) | n2=en:elevated pth (parathyroid hormone) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated pyruvate (in most patients) n1=thrombolytique (traitement) | n2=en:elevated pyruvate (in most patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated resting serum lactate, increased with exercise n1=thrombolytique (traitement) | n2=en:elevated resting serum lactate, increased with exercise | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated sed rate n1=thrombolytique (traitement) | n2=en:elevated sed rate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated sepiapterin in csf n1=thrombolytique (traitement) | n2=en:elevated sepiapterin in csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum acid phosphatase n1=thrombolytique (traitement) | n2=en:elevated serum acid phosphatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum alkaline phosphatase during hyperplastic callus formation n1=thrombolytique (traitement) | n2=en:elevated serum alkaline phosphatase during hyperplastic callus formation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum alpha-fetoprotein n1=thrombolytique (traitement) | n2=en:elevated serum alpha-fetoprotein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum alpha-fetoprotein (dominant) n1=thrombolytique (traitement) | n2=en:elevated serum alpha-fetoprotein (dominant) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum angiotensin-converting enzyme (ace) n1=thrombolytique (traitement) | n2=en:elevated serum angiotensin-converting enzyme (ace) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum bile acids n1=thrombolytique (traitement) | n2=en:elevated serum bile acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum glutamic oxaloacetic transaminase (sgot) n1=thrombolytique (traitement) | n2=en:elevated serum glutamic oxaloacetic transaminase (sgot) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum glutamic pyruvic transaminase (sgpt) n1=thrombolytique (traitement) | n2=en:elevated serum glutamic pyruvic transaminase (sgpt) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum insulin-to-c-peptide ratio n1=thrombolytique (traitement) | n2=en:elevated serum insulin-to-c-peptide ratio | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum iron n1=thrombolytique (traitement) | n2=en:elevated serum iron | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum iron and iron binding capacity n1=thrombolytique (traitement) | n2=en:elevated serum iron and iron binding capacity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum lactate n1=thrombolytique (traitement) | n2=en:elevated serum lactate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum levels of 2-prime deoxyadenosine n1=thrombolytique (traitement) | n2=en:elevated serum levels of 2-prime deoxyadenosine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum levels of adenosine n1=thrombolytique (traitement) | n2=en:elevated serum levels of adenosine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum levels of follicle stimulating hormone (fsh) n1=thrombolytique (traitement) | n2=en:elevated serum levels of follicle stimulating hormone (fsh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum levels of luteinizing hormone (lh) n1=thrombolytique (traitement) | n2=en:elevated serum levels of luteinizing hormone (lh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum long-chain fatty acids n1=thrombolytique (traitement) | n2=en:elevated serum long-chain fatty acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum n,n-dimethylglycine (dmg) n1=thrombolytique (traitement) | n2=en:elevated serum n,n-dimethylglycine (dmg) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum parathyroid hormone (pth) n1=thrombolytique (traitement) | n2=en:elevated serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum parathyroid hormone (pth) level n1=thrombolytique (traitement) | n2=en:elevated serum parathyroid hormone (pth) level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum phosphate in heterozygotes n1=thrombolytique (traitement) | n2=en:elevated serum phosphate in heterozygotes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum phosphorus n1=thrombolytique (traitement) | n2=en:elevated serum phosphorus | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum protein n1=thrombolytique (traitement) | n2=en:elevated serum protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum thrombopoietin (tpo) n1=thrombolytique (traitement) | n2=en:elevated serum thrombopoietin (tpo) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum transaminase levels n1=thrombolytique (traitement) | n2=en:elevated serum transaminase levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum transaminases during infections n1=thrombolytique (traitement) | n2=en:elevated serum transaminases during infections | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum transferrin saturation n1=thrombolytique (traitement) | n2=en:elevated serum transferrin saturation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated serum uric acid concentrations n1=thrombolytique (traitement) | n2=en:elevated serum uric acid concentrations | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated sweat chloride n1=thrombolytique (traitement) | n2=en:elevated sweat chloride | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated sweat chloride (some) n1=thrombolytique (traitement) | n2=en:elevated sweat chloride (some) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated testosterone n1=thrombolytique (traitement) | n2=en:elevated testosterone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated thrombopoietin (tpo) n1=thrombolytique (traitement) | n2=en:elevated thrombopoietin (tpo) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated total bilirubin n1=thrombolytique (traitement) | n2=en:elevated total bilirubin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated total cholesterol (seen in heterozygotes as well) n1=thrombolytique (traitement) | n2=en:elevated total cholesterol (seen in heterozygotes as well) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated total iron-binding capacity n1=thrombolytique (traitement) | n2=en:elevated total iron-binding capacity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated uric acid on urinalysis (in some patients) n1=thrombolytique (traitement) | n2=en:elevated uric acid on urinalysis (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary 2-ethylhydracrylate n1=thrombolytique (traitement) | n2=en:elevated urinary 2-ethylhydracrylate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary 3-methylglutaconate n1=thrombolytique (traitement) | n2=en:elevated urinary 3-methylglutaconate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary 3-methylglutarate n1=thrombolytique (traitement) | n2=en:elevated urinary 3-methylglutarate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary 7 alpha-hydroxylated bile alcohols n1=thrombolytique (traitement) | n2=en:elevated urinary 7 alpha-hydroxylated bile alcohols | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary and csf 5-amino-4-imidazolecarboxyamide (aica-riboside) n1=thrombolytique (traitement) | n2=en:elevated urinary and csf 5-amino-4-imidazolecarboxyamide (aica-riboside) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary and csf ribitol and d-arabitol n1=thrombolytique (traitement) | n2=en:elevated urinary and csf ribitol and d-arabitol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary delta-aminolevulinic acid n1=thrombolytique (traitement) | n2=en:elevated urinary delta-aminolevulinic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary delta-aminolevulinic acid and porphyrins n1=thrombolytique (traitement) | n2=en:elevated urinary delta-aminolevulinic acid and porphyrins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary epinephrine n1=thrombolytique (traitement) | n2=en:elevated urinary epinephrine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary free sialic acid (n-acetylneuraminic acid) n1=thrombolytique (traitement) | n2=en:elevated urinary free sialic acid (n-acetylneuraminic acid) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary hyaluronic acid levels n1=thrombolytique (traitement) | n2=en:elevated urinary hyaluronic acid levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary mevalonic acid n1=thrombolytique (traitement) | n2=en:elevated urinary mevalonic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary n,n-dimethylglycine (dmg) n1=thrombolytique (traitement) | n2=en:elevated urinary n,n-dimethylglycine (dmg) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary ornithine, lysine, arginine n1=thrombolytique (traitement) | n2=en:elevated urinary ornithine, lysine, arginine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary pge(2) levels n1=thrombolytique (traitement) | n2=en:elevated urinary pge(2) levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary phosphoethanolamine n1=thrombolytique (traitement) | n2=en:elevated urinary phosphoethanolamine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urinary pyridinoline and deoxypyridinoline n1=thrombolytique (traitement) | n2=en:elevated urinary pyridinoline and deoxypyridinoline | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urine ceramide levels n1=thrombolytique (traitement) | n2=en:elevated urine ceramide levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated urine unsulfated chondroitin sulfate n1=thrombolytique (traitement) | n2=en:elevated urine unsulfated chondroitin sulfate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elevated white blood cell cystine n1=thrombolytique (traitement) | n2=en:elevated white blood cell cystine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:elliptocytosis (in some patients, segregated independently) n1=thrombolytique (traitement) | n2=en:elliptocytosis (in some patients, segregated independently) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:embolism of iliac artery n1=thrombolytique (traitement) | n2=en:embolism of iliac artery | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:emperipolesis n1=thrombolytique (traitement) | n2=en:emperipolesis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:encephalomyopathy, mitochondrial, due to voltage-dependent anion channel deficiency n1=thrombolytique (traitement) | n2=en:encephalomyopathy, mitochondrial, due to voltage-dependent anion channel deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:enlarged cytoplasmic vacuoles in bone, muscle, and brain tissue n1=thrombolytique (traitement) | n2=en:enlarged cytoplasmic vacuoles in bone, muscle, and brain tissue | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:enoxaparin n1=thrombolytique (traitement) | n2=en:enoxaparin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:enoxaparin sodium 100 mg/ml injectable solution n1=thrombolytique (traitement) | n2=en:enoxaparin sodium 100 mg/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:enzyme replacement therapy has not been effective n1=thrombolytique (traitement) | n2=en:enzyme replacement therapy has not been effective | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:eosinophilia n1=thrombolytique (traitement) | n2=en:eosinophilia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:eosinophilia, mild n1=thrombolytique (traitement) | n2=en:eosinophilia, mild | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:episodic bleeding n1=thrombolytique (traitement) | n2=en:episodic bleeding | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:episodic hemolytic anemia n1=thrombolytique (traitement) | n2=en:episodic hemolytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:epistaxis n1=thrombolytique (traitement) | n2=en:epistaxis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:epstein syndrome (disorder) n1=thrombolytique (traitement) | n2=en:epstein syndrome (disorder) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:epstein-barr viraemia n1=thrombolytique (traitement) | n2=en:epstein-barr viraemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:eptifibatide n1=thrombolytique (traitement) | n2=en:eptifibatide | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:eptifibatide 2 mg/ml injection n1=thrombolytique (traitement) | n2=en:eptifibatide 2 mg/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:eptifibatide 750micrograms/ml infusion solution 100ml vial n1=thrombolytique (traitement) | n2=en:eptifibatide 750micrograms/ml infusion solution 100ml vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythroblast morphologic abnormalities n1=thrombolytique (traitement) | n2=en:erythroblast morphologic abnormalities | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythroblasts show atypical cytoplasmic inclusions n1=thrombolytique (traitement) | n2=en:erythroblasts show atypical cytoplasmic inclusions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythrocyte delta-aminolevulinate dehydratase (alad) deficiency n1=thrombolytique (traitement) | n2=en:erythrocyte delta-aminolevulinate dehydratase (alad) deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythrocyte macrocytosis n1=thrombolytique (traitement) | n2=en:erythrocyte macrocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythrocyte morphology - elliptocytes (lab test) n1=thrombolytique (traitement) | n2=en:erythrocyte morphology - elliptocytes (lab test) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythrocyte porphobilinogen (pbg) deaminase deficiency (exception: type ii aip) n1=thrombolytique (traitement) | n2=en:erythrocyte porphobilinogen (pbg) deaminase deficiency (exception: type ii aip) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythrocytes have defects in cation permeability n1=thrombolytique (traitement) | n2=en:erythrocytes have defects in cation permeability | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythrocytosis n1=thrombolytique (traitement) | n2=en:erythrocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythroid colony-forming units show spontaneous growth in the absence of epo n1=thrombolytique (traitement) | n2=en:erythroid colony-forming units show spontaneous growth in the absence of epo | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythroid hyperplasia seen on bone marrow biopsy n1=thrombolytique (traitement) | n2=en:erythroid hyperplasia seen on bone marrow biopsy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythropenia n1=thrombolytique (traitement) | n2=en:erythropenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythropoietic hyperplasia of bone marrow n1=thrombolytique (traitement) | n2=en:erythropoietic hyperplasia of bone marrow | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:erythropoietic porphyria n1=thrombolytique (traitement) | n2=en:erythropoietic porphyria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:estren-dameshek anemia n1=thrombolytique (traitement) | n2=en:estren-dameshek anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ethylmalonic aciduria n1=thrombolytique (traitement) | n2=en:ethylmalonic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:euvolemia n1=thrombolytique (traitement) | n2=en:euvolemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:evans syndrome n1=thrombolytique (traitement) | n2=en:evans syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:excess protoporphyrin in bile and feces but not in urine n1=thrombolytique (traitement) | n2=en:excess protoporphyrin in bile and feces but not in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:excessive iodide trapping n1=thrombolytique (traitement) | n2=en:excessive iodide trapping | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:excessive urinary 5-oxo-l-proline n1=thrombolytique (traitement) | n2=en:excessive urinary 5-oxo-l-proline | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:excretion of dermatan sulfate and heparan sulfate in urine n1=thrombolytique (traitement) | n2=en:excretion of dermatan sulfate and heparan sulfate in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:exercise-induced myoglobinuria n1=thrombolytique (traitement) | n2=en:exercise-induced myoglobinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:exercise-induced myoglobinuria in adults n1=thrombolytique (traitement) | n2=en:exercise-induced myoglobinuria in adults | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:experimental hematology n1=thrombolytique (traitement) | n2=en:experimental hematology | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:extramedullary erythropoiesis n1=thrombolytique (traitement) | n2=en:extramedullary erythropoiesis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:extremely low creatine excretion n1=thrombolytique (traitement) | n2=en:extremely low creatine excretion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:factor vii deficiency n1=thrombolytique (traitement) | n2=en:factor vii deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:factor viii deficiency n1=thrombolytique (traitement) | n2=en:factor viii deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:familial hemophagocytic lymphohistiocytosis n1=thrombolytique (traitement) | n2=en:familial hemophagocytic lymphohistiocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fanconi anemia n1=thrombolytique (traitement) | n2=en:fanconi anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:farber lipogranulomatosis n1=thrombolytique (traitement) | n2=en:farber lipogranulomatosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fasting chylomicronemia n1=thrombolytique (traitement) | n2=en:fasting chylomicronemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fasting hyperinsulinemia n1=thrombolytique (traitement) | n2=en:fasting hyperinsulinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fasting hypoglycemia (early in disease course) n1=thrombolytique (traitement) | n2=en:fasting hypoglycemia (early in disease course) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fasting ketosis n1=thrombolytique (traitement) | n2=en:fasting ketosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fatty acid pattern of serum lecithin shows increased arachidonic acid and decreased linoleic acid n1=thrombolytique (traitement) | n2=en:fatty acid pattern of serum lecithin shows increased arachidonic acid and decreased linoleic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fatty alcohol:nad+ oxidoreductase deficiency in leukocytes and fibroblasts n1=thrombolytique (traitement) | n2=en:fatty alcohol:nad+ oxidoreductase deficiency in leukocytes and fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fecal tryptic activity low n1=thrombolytique (traitement) | n2=en:fecal tryptic activity low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fechtner syndrome (disorder) n1=thrombolytique (traitement) | n2=en:fechtner syndrome (disorder) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:female carriers show markedly skewed x inactivation n1=thrombolytique (traitement) | n2=en:female carriers show markedly skewed x inactivation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ferritin decreased n1=thrombolytique (traitement) | n2=en:ferritin decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ferritin level low n1=thrombolytique (traitement) | n2=en:ferritin level low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibrinogen decreased n1=thrombolytique (traitement) | n2=en:fibrinogen decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibrinopenia n1=thrombolytique (traitement) | n2=en:fibrinopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts accumulate dol-pp-glcnac2man5 n1=thrombolytique (traitement) | n2=en:fibroblasts accumulate dol-pp-glcnac2man5 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts are small and rounded with prominent nucleoli n1=thrombolytique (traitement) | n2=en:fibroblasts are small and rounded with prominent nucleoli | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts attach poorly n1=thrombolytique (traitement) | n2=en:fibroblasts attach poorly | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts demonstrate rapid growth with increased dna synthesis n1=thrombolytique (traitement) | n2=en:fibroblasts demonstrate rapid growth with increased dna synthesis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts have decreased levels of ceramide, sphingomyelin, lactosylceramide, ceramide trihexoside, and globoside n1=thrombolytique (traitement) | n2=en:fibroblasts have decreased levels of ceramide, sphingomyelin, lactosylceramide, ceramide trihexoside, and globoside | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts have increased activity of serine palmitoyltransferase (spt, 605712) n1=thrombolytique (traitement) | n2=en:fibroblasts have increased activity of serine palmitoyltransferase (spt, 605712) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts show decreased activity of mitochondrial respiratory complex i, complex iii, complex iv, and complex v n1=thrombolytique (traitement) | n2=en:fibroblasts show decreased activity of mitochondrial respiratory complex i, complex iii, complex iv, and complex v | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts show decreased mitochondrial complex v activity n1=thrombolytique (traitement) | n2=en:fibroblasts show decreased mitochondrial complex v activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts show decreased peroxisomes arranged in rows n1=thrombolytique (traitement) | n2=en:fibroblasts show decreased peroxisomes arranged in rows | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts show elongated, tangled, tubular mitochondria n1=thrombolytique (traitement) | n2=en:fibroblasts show elongated, tangled, tubular mitochondria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts show global defects in multiple mitochondrial respiratory chain activities n1=thrombolytique (traitement) | n2=en:fibroblasts show global defects in multiple mitochondrial respiratory chain activities | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts show hypersensitivity to uv irradiation due to defect in transcription-coupled nucleotide excision repair (tc-ner) n1=thrombolytique (traitement) | n2=en:fibroblasts show hypersensitivity to uv irradiation due to defect in transcription-coupled nucleotide excision repair (tc-ner) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts show increased sensitivity to apoptosis n1=thrombolytique (traitement) | n2=en:fibroblasts show increased sensitivity to apoptosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts show lamellar lysosomal inclusions on electron microscopy n1=thrombolytique (traitement) | n2=en:fibroblasts show lamellar lysosomal inclusions on electron microscopy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibroblasts shows defects in oxidative phosphorylation n1=thrombolytique (traitement) | n2=en:fibroblasts shows defects in oxidative phosphorylation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fibronectin decreased n1=thrombolytique (traitement) | n2=en:fibronectin decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fingerprint intracellular accumulation of autofluorescent lipopigment storage material n1=thrombolytique (traitement) | n2=en:fingerprint intracellular accumulation of autofluorescent lipopigment storage material | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fluorescence in situ hybridization specific probe for mds critical region n1=thrombolytique (traitement) | n2=en:fluorescence in situ hybridization specific probe for mds critical region | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fluorescence of red blood cells by uv microscopy n1=thrombolytique (traitement) | n2=en:fluorescence of red blood cells by uv microscopy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fluorouracil n1=thrombolytique (traitement) | n2=en:fluorouracil | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fluorouracil 1% cream n1=thrombolytique (traitement) | n2=en:fluorouracil 1% cream | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fluorouracil 10 mg/ml topical solution n1=thrombolytique (traitement) | n2=en:fluorouracil 10 mg/ml topical solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fluorouracil 1g/20ml injection n1=thrombolytique (traitement) | n2=en:fluorouracil 1g/20ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fluorouracil 2% solution n1=thrombolytique (traitement) | n2=en:fluorouracil 2% solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fluorouracil 40 mg/ml topical cream n1=thrombolytique (traitement) | n2=en:fluorouracil 40 mg/ml topical cream | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fluorouracil 5 mg/ml topical cream n1=thrombolytique (traitement) | n2=en:fluorouracil 5 mg/ml topical cream | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fluorouracil 50 mg/ml topical cream n1=thrombolytique (traitement) | n2=en:fluorouracil 50 mg/ml topical cream | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fluorouracil 50 mg/ml topical solution n1=thrombolytique (traitement) | n2=en:fluorouracil 50 mg/ml topical solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:foam cells contain polymorphic cytoplasmic inclusions consisting of lamellar osmiophilic membranes on electron microscopy n1=thrombolytique (traitement) | n2=en:foam cells contain polymorphic cytoplasmic inclusions consisting of lamellar osmiophilic membranes on electron microscopy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:foam cells in bone marrow and renal glomeruli n1=thrombolytique (traitement) | n2=en:foam cells in bone marrow and renal glomeruli | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:foam cells in visceral organs and cns n1=thrombolytique (traitement) | n2=en:foam cells in visceral organs and cns | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:foam cells on bone marrow biopsy n1=thrombolytique (traitement) | n2=en:foam cells on bone marrow biopsy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:folate malabsorption, hereditary n1=thrombolytique (traitement) | n2=en:folate malabsorption, hereditary | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:folate-dependent fragile site at xq28 n1=thrombolytique (traitement) | n2=en:folate-dependent fragile site at xq28 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:folate-responsive megaloblastic anemia n1=thrombolytique (traitement) | n2=en:folate-responsive megaloblastic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:folic acid deficiency n1=thrombolytique (traitement) | n2=en:folic acid deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fondaparinux n1=thrombolytique (traitement) | n2=en:fondaparinux | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fondaparinux sodium 12.5mg/ml injection solution 0.8ml prefilled syringe n1=thrombolytique (traitement) | n2=en:fondaparinux sodium 12.5mg/ml injection solution 0.8ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fondaparinux sodium 2.5mg/0.5ml prefilled syringe n1=thrombolytique (traitement) | n2=en:fondaparinux sodium 2.5mg/0.5ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:forsythe-wakeling syndrome n1=thrombolytique (traitement) | n2=en:forsythe-wakeling syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fragmentation of the mitochondrial network n1=thrombolytique (traitement) | n2=en:fragmentation of the mitochondrial network | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fragmented erythrocytes n1=thrombolytique (traitement) | n2=en:fragmented erythrocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fragmented red cells n1=thrombolytique (traitement) | n2=en:fragmented red cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:frequent deletions of chromosome 9 in melanoma n1=thrombolytique (traitement) | n2=en:frequent deletions of chromosome 9 in melanoma | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:frequent inv(10)(q11.2q21) producing chimeric transforming sequence ret/ptc n1=thrombolytique (traitement) | n2=en:frequent inv(10)(q11.2q21) producing chimeric transforming sequence ret/ptc | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fucosidosis n1=thrombolytique (traitement) | n2=en:fucosidosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fulvestrant n1=thrombolytique (traitement) | n2=en:fulvestrant | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fulvestrant 50mg/ml injection solution 2.5ml prefilled syringe n1=thrombolytique (traitement) | n2=en:fulvestrant 50mg/ml injection solution 2.5ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fumarase activity (mitochondrial and cytosolic) is decreased n1=thrombolytique (traitement) | n2=en:fumarase activity (mitochondrial and cytosolic) is decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fumarase deficiency n1=thrombolytique (traitement) | n2=en:fumarase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:fumarylacetoacetate hydrolase (fah) deficiency n1=thrombolytique (traitement) | n2=en:fumarylacetoacetate hydrolase (fah) deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:galactocerebroside beta-galactosidase deficiency in serum, leukocytes, and fibroblasts n1=thrombolytique (traitement) | n2=en:galactocerebroside beta-galactosidase deficiency in serum, leukocytes, and fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:galactosemia n1=thrombolytique (traitement) | n2=en:galactosemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:galactosuria n1=thrombolytique (traitement) | n2=en:galactosuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:galactosuria without galactosemia n1=thrombolytique (traitement) | n2=en:galactosuria without galactosemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:galactosylation defects n1=thrombolytique (traitement) | n2=en:galactosylation defects | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:galactosyltransferase i deficiency in fibroblasts n1=thrombolytique (traitement) | n2=en:galactosyltransferase i deficiency in fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gamma-glutamylcysteine deficiency n1=thrombolytique (traitement) | n2=en:gamma-glutamylcysteine deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gamma-glutamylcysteine synthetase (glutamate-cysteine ligase) deficiency n1=thrombolytique (traitement) | n2=en:gamma-glutamylcysteine synthetase (glutamate-cysteine ligase) deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ganciclovir n1=thrombolytique (traitement) | n2=en:ganciclovir | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ganciclovir 0.15% eye gel n1=thrombolytique (traitement) | n2=en:ganciclovir 0.15% eye gel | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ganciclovir 250mg capsule n1=thrombolytique (traitement) | n2=en:ganciclovir 250mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ganciclovir 4.5mg ocular implant n1=thrombolytique (traitement) | n2=en:ganciclovir 4.5mg ocular implant | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ganciclovir 500mg capsule n1=thrombolytique (traitement) | n2=en:ganciclovir 500mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ganciclovir 500mg powder for infusion solution vial n1=thrombolytique (traitement) | n2=en:ganciclovir 500mg powder for infusion solution vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ganciclovir sodium n1=thrombolytique (traitement) | n2=en:ganciclovir sodium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gardner morrisson abbot syndrome n1=thrombolytique (traitement) | n2=en:gardner morrisson abbot syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gaucher cells in bone marrow n1=thrombolytique (traitement) | n2=en:gaucher cells in bone marrow | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gaucher cells, diffuse, in spleen, liver, lymph nodes, bone marrow, central nervous system n1=thrombolytique (traitement) | n2=en:gaucher cells, diffuse, in spleen, liver, lymph nodes, bone marrow, central nervous system | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gaucher disease, perinatal lethal n1=thrombolytique (traitement) | n2=en:gaucher disease, perinatal lethal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gaucher disease, type 1 n1=thrombolytique (traitement) | n2=en:gaucher disease, type 1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gaucher disease, type 2 (disorder) n1=thrombolytique (traitement) | n2=en:gaucher disease, type 2 (disorder) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gaucher disease, type 3 (disorder) n1=thrombolytique (traitement) | n2=en:gaucher disease, type 3 (disorder) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:generalized aminoaciduria n1=thrombolytique (traitement) | n2=en:generalized aminoaciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:generalized amyloid deposition n1=thrombolytique (traitement) | n2=en:generalized amyloid deposition | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:generalized bone marrow fibrosis n1=thrombolytique (traitement) | n2=en:generalized bone marrow fibrosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ghosal hematodiaphyseal dysplasia n1=thrombolytique (traitement) | n2=en:ghosal hematodiaphyseal dysplasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:giant cells (degenerating chondrocytes) in resting zone of epiphyseal cartilage n1=thrombolytique (traitement) | n2=en:giant cells (degenerating chondrocytes) in resting zone of epiphyseal cartilage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:giant inclusion bodies present in most granulated cells n1=thrombolytique (traitement) | n2=en:giant inclusion bodies present in most granulated cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:giant platelet n1=thrombolytique (traitement) | n2=en:giant platelet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:giant platelet alpha granules (peripheral blood) n1=thrombolytique (traitement) | n2=en:giant platelet alpha granules (peripheral blood) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:giant platelet syndrome with thrombocytopenia n1=thrombolytique (traitement) | n2=en:giant platelet syndrome with thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glanzmann thrombasthenia n1=thrombolytique (traitement) | n2=en:glanzmann thrombasthenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glcnac-transferase ii deficiency in fibroblast and mononuclear cells n1=thrombolytique (traitement) | n2=en:glcnac-transferase ii deficiency in fibroblast and mononuclear cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:globulin gamma serum plasma increased result n1=thrombolytique (traitement) | n2=en:globulin gamma serum plasma increased result | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glomerular filtration rate decreased n1=thrombolytique (traitement) | n2=en:glomerular filtration rate decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glucose breath hydrogen test shows malabsorption of glucose and galactose n1=thrombolytique (traitement) | n2=en:glucose breath hydrogen test shows malabsorption of glucose and galactose | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glucose-6-phosphate deficiency n1=thrombolytique (traitement) | n2=en:glucose-6-phosphate deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glucosidase i deficiency in liver and fibroblasts n1=thrombolytique (traitement) | n2=en:glucosidase i deficiency in liver and fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glucosuria, mild, intermittent n1=thrombolytique (traitement) | n2=en:glucosuria, mild, intermittent | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glutaric acidemia type 1 n1=thrombolytique (traitement) | n2=en:glutaric acidemia type 1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glutaric aciduria n1=thrombolytique (traitement) | n2=en:glutaric aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glutathione deficiency n1=thrombolytique (traitement) | n2=en:glutathione deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glycinuria n1=thrombolytique (traitement) | n2=en:glycinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glycoamino aciduria n1=thrombolytique (traitement) | n2=en:glycoamino aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glycogen accumulation in both liver and muscle n1=thrombolytique (traitement) | n2=en:glycogen accumulation in both liver and muscle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glycogen storage disease type v n1=thrombolytique (traitement) | n2=en:glycogen storage disease type v | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glycogen storage disease type vi n1=thrombolytique (traitement) | n2=en:glycogen storage disease type vi | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glycogen storage disease type vii n1=thrombolytique (traitement) | n2=en:glycogen storage disease type vii | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glycoprotein ia deficiency n1=thrombolytique (traitement) | n2=en:glycoprotein ia deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glycosuria n1=thrombolytique (traitement) | n2=en:glycosuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glycosuria (less common) n1=thrombolytique (traitement) | n2=en:glycosuria (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:glyoxalase deficiency n1=thrombolytique (traitement) | n2=en:glyoxalase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gm2-ganglioside accumulation n1=thrombolytique (traitement) | n2=en:gm2-ganglioside accumulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gonadotrophin increased n1=thrombolytique (traitement) | n2=en:gonadotrophin increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gonadotrophin levels low n1=thrombolytique (traitement) | n2=en:gonadotrophin levels low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:granular osmiophilic cytoplasmic deposits (grod) ultrastructurally in cells n1=thrombolytique (traitement) | n2=en:granular osmiophilic cytoplasmic deposits (grod) ultrastructurally in cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:granular osmiophilic cytoplasmic deposits ultrastructurally in cells n1=thrombolytique (traitement) | n2=en:granular osmiophilic cytoplasmic deposits ultrastructurally in cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:granular osmiophilic deposits (grod) in cells n1=thrombolytique (traitement) | n2=en:granular osmiophilic deposits (grod) in cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:granular osmiophilic deposits (grod) in cells resulting in 'curvilinear' profiles ultrastructurally n1=thrombolytique (traitement) | n2=en:granular osmiophilic deposits (grod) in cells resulting in 'curvilinear' profiles ultrastructurally | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:granular osmiophilic deposits (grod) in cells resulting in 'fingerprint' profiles ultrastructurally n1=thrombolytique (traitement) | n2=en:granular osmiophilic deposits (grod) in cells resulting in 'fingerprint' profiles ultrastructurally | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:granular osmiophilic deposits (grod) in cells resulting in 'rectilinear' profiles ultrastructurally n1=thrombolytique (traitement) | n2=en:granular osmiophilic deposits (grod) in cells resulting in 'rectilinear' profiles ultrastructurally | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:granulocyte count below reference range n1=thrombolytique (traitement) | n2=en:granulocyte count below reference range | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:granulocyte hypocellularity (in some patients) n1=thrombolytique (traitement) | n2=en:granulocyte hypocellularity (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gray platelet syndrome n1=thrombolytique (traitement) | n2=en:gray platelet syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gray platelets n1=thrombolytique (traitement) | n2=en:gray platelets | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gray polymorphonuclear neutrophils n1=thrombolytique (traitement) | n2=en:gray polymorphonuclear neutrophils | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:gray-to-gray-blue platelet on wright-giemsa stain n1=thrombolytique (traitement) | n2=en:gray-to-gray-blue platelet on wright-giemsa stain | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:greatly increased dopamine in plasma, urine, csf (approximately 10-fold increase) n1=thrombolytique (traitement) | n2=en:greatly increased dopamine in plasma, urine, csf (approximately 10-fold increase) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:green serum n1=thrombolytique (traitement) | n2=en:green serum | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:green urine n1=thrombolytique (traitement) | n2=en:green urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:growth cartilage disorganized, with islands of cells and abnormal collagen arrangement n1=thrombolytique (traitement) | n2=en:growth cartilage disorganized, with islands of cells and abnormal collagen arrangement | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:guanidinoacetate methyltransferase (gamt) deficiency n1=thrombolytique (traitement) | n2=en:guanidinoacetate methyltransferase (gamt) deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:haematocytopenia n1=thrombolytique (traitement) | n2=en:haematocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hair bulb tyrosinase present n1=thrombolytique (traitement) | n2=en:hair bulb tyrosinase present | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hair bulbs will pigment when incubated with tyrosine n1=thrombolytique (traitement) | n2=en:hair bulbs will pigment when incubated with tyrosine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hawkinsinuria n1=thrombolytique (traitement) | n2=en:hawkinsinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hb h erythrocyte inclusions n1=thrombolytique (traitement) | n2=en:hb h erythrocyte inclusions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hb h inclusions in red blood cells n1=thrombolytique (traitement) | n2=en:hb h inclusions in red blood cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hellp syndrome n1=thrombolytique (traitement) | n2=en:hellp syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemangiomatosis with thrombocytopenia n1=thrombolytique (traitement) | n2=en:hemangiomatosis with thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hematocrit - pcv - low n1=thrombolytique (traitement) | n2=en:hematocrit - pcv - low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hematocrit increased n1=thrombolytique (traitement) | n2=en:hematocrit increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hematology, other n1=thrombolytique (traitement) | n2=en:hematology, other | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hematomas after trauma or injury n1=thrombolytique (traitement) | n2=en:hematomas after trauma or injury | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hematopoietic toxicity develops on standard doses of thiopurine drugs n1=thrombolytique (traitement) | n2=en:hematopoietic toxicity develops on standard doses of thiopurine drugs | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hematuria n1=thrombolytique (traitement) | n2=en:hematuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hematuria (less common) n1=thrombolytique (traitement) | n2=en:hematuria (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hematuria, gross and microscopic n1=thrombolytique (traitement) | n2=en:hematuria, gross and microscopic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hematuria, macroscopic and microscopic n1=thrombolytique (traitement) | n2=en:hematuria, macroscopic and microscopic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemizygous deletion at 4p16.3 n1=thrombolytique (traitement) | n2=en:hemizygous deletion at 4p16.3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemizygous deletion at 7q11.23 n1=thrombolytique (traitement) | n2=en:hemizygous deletion at 7q11.23 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemoglobin decreased n1=thrombolytique (traitement) | n2=en:hemoglobin decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemoglobin f increased n1=thrombolytique (traitement) | n2=en:hemoglobin f increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemoglobin increased n1=thrombolytique (traitement) | n2=en:hemoglobin increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemology n1=thrombolytique (traitement) | n2=en:hemology | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolysis (e.g. hb koelliker 141800.0083) n1=thrombolytique (traitement) | n2=en:hemolysis (e.g. hb koelliker 141800.0083) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolysis biological process n1=thrombolytique (traitement) | n2=en:hemolysis biological process | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolytic anemia n1=thrombolytique (traitement) | n2=en:hemolytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolytic anemia (in some patients) n1=thrombolytique (traitement) | n2=en:hemolytic anemia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolytic anemia (variable) n1=thrombolytique (traitement) | n2=en:hemolytic anemia (variable) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolytic anemia in approximately 60% of patients n1=thrombolytique (traitement) | n2=en:hemolytic anemia in approximately 60% of patients | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolytic uremic syndrome, atypical, susceptibility to, 1 n1=thrombolytique (traitement) | n2=en:hemolytic uremic syndrome, atypical, susceptibility to, 1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolytic uremic syndrome, atypical, susceptibility to, 2 n1=thrombolytique (traitement) | n2=en:hemolytic uremic syndrome, atypical, susceptibility to, 2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolytic uremic syndrome, atypical, susceptibility to, 3 n1=thrombolytique (traitement) | n2=en:hemolytic uremic syndrome, atypical, susceptibility to, 3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolytic uremic syndrome, atypical, susceptibility to, 4 n1=thrombolytique (traitement) | n2=en:hemolytic uremic syndrome, atypical, susceptibility to, 4 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolytic uremic syndrome, atypical, susceptibility to, 5 n1=thrombolytique (traitement) | n2=en:hemolytic uremic syndrome, atypical, susceptibility to, 5 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemolytic uremic syndrome, atypical, susceptibility to, 6 n1=thrombolytique (traitement) | n2=en:hemolytic uremic syndrome, atypical, susceptibility to, 6 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemophagocytic lymphohistiocytosis, familial, 2 n1=thrombolytique (traitement) | n2=en:hemophagocytic lymphohistiocytosis, familial, 2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemophagocytic lymphohistiocytosis, familial, 4 n1=thrombolytique (traitement) | n2=en:hemophagocytic lymphohistiocytosis, familial, 4 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hemorrhagic diathesis, mild n1=thrombolytique (traitement) | n2=en:hemorrhagic diathesis, mild | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:henoch-schönlein purpura n1=thrombolytique (traitement) | n2=en:henoch-schönlein purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparan n-sulfatase deficiency in fibroblasts and amniocytes n1=thrombolytique (traitement) | n2=en:heparan n-sulfatase deficiency in fibroblasts and amniocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparan sulfate excretion in urine n1=thrombolytique (traitement) | n2=en:heparan sulfate excretion in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin n1=thrombolytique (traitement) | n2=en:heparin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin calcium n1=thrombolytique (traitement) | n2=en:heparin calcium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin calcium 25,000iu/ml injection solution 0.2ml ampule n1=thrombolytique (traitement) | n2=en:heparin calcium 25,000iu/ml injection solution 0.2ml ampule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin calcium 25,000iu/ml injection solution 0.2ml prefilled syringe n1=thrombolytique (traitement) | n2=en:heparin calcium 25,000iu/ml injection solution 0.2ml prefilled syringe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin cofactor ii deficiency (disorder) n1=thrombolytique (traitement) | n2=en:heparin cofactor ii deficiency (disorder) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium n1=thrombolytique (traitement) | n2=en:heparin sodium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium (beef lung) n1=thrombolytique (traitement) | n2=en:heparin sodium (beef lung) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium 2500iu/sodium chloride 0.9% infusion solution 1l bag n1=thrombolytique (traitement) | n2=en:heparin sodium 2500iu/sodium chloride 0.9% infusion solution 1l bag | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, bovine n1=thrombolytique (traitement) | n2=en:heparin sodium, bovine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, bovine 1000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, bovine 1000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, bovine 10000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, bovine 10000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, bovine 5000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, bovine 5000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 10 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 10 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 100 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 100 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 1000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 1000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 10000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 10000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 15000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 15000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 20000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 20000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 250 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 250 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 3000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 3000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 4000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 4000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 40000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 40000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 5000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 5000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 6000 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 6000 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 7500 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 7500 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin sodium, porcine 8.3 unt/ml injectable solution n1=thrombolytique (traitement) | n2=en:heparin sodium, porcine 8.3 unt/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin-induced thrombocytopenia (hit) n1=thrombolytique (traitement) | n2=en:heparin-induced thrombocytopenia (hit) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heparin-induced thrombocytopenia with thrombosis n1=thrombolytique (traitement) | n2=en:heparin-induced thrombocytopenia with thrombosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hepatic argininosuccinase deficiency n1=thrombolytique (traitement) | n2=en:hepatic argininosuccinase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hepatic argininosuccinate synthetase deficiency n1=thrombolytique (traitement) | n2=en:hepatic argininosuccinate synthetase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hepatic carbamoylphosphate synthetase i deficiency n1=thrombolytique (traitement) | n2=en:hepatic carbamoylphosphate synthetase i deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hepatic gamma-cystathionase deficiency n1=thrombolytique (traitement) | n2=en:hepatic gamma-cystathionase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hepatic glycine cleavage defect n1=thrombolytique (traitement) | n2=en:hepatic glycine cleavage defect | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hepatic lipase deficiency (disorder) n1=thrombolytique (traitement) | n2=en:hepatic lipase deficiency (disorder) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hepatic ornithine transcarbamylase deficiency n1=thrombolytique (traitement) | n2=en:hepatic ornithine transcarbamylase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hepatosplenic t-cell lymphoma n1=thrombolytique (traitement) | n2=en:hepatosplenic t-cell lymphoma | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hepatosplenomegaly, with extramedullary hematopoiesis (rare) n1=thrombolytique (traitement) | n2=en:hepatosplenomegaly, with extramedullary hematopoiesis (rare) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hereditary angioedema n1=thrombolytique (traitement) | n2=en:hereditary angioedema | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hereditary elliptocytosis n1=thrombolytique (traitement) | n2=en:hereditary elliptocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hereditary factor v deficiency n1=thrombolytique (traitement) | n2=en:hereditary factor v deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hereditary factor x deficiency n1=thrombolytique (traitement) | n2=en:hereditary factor x deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hereditary factor xiii deficiency n1=thrombolytique (traitement) | n2=en:hereditary factor xiii deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hereditary fructose intolerance n1=thrombolytique (traitement) | n2=en:hereditary fructose intolerance | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hereditary thrombocytopenic disorder n1=thrombolytique (traitement) | n2=en:hereditary thrombocytopenic disorder | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hereditary xanthinuria n1=thrombolytique (traitement) | n2=en:hereditary xanthinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hermansky-pudlak syndrome 2 n1=thrombolytique (traitement) | n2=en:hermansky-pudlak syndrome 2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heterochromatin clumps with spongy, 'swiss cheese' appearance n1=thrombolytique (traitement) | n2=en:heterochromatin clumps with spongy, 'swiss cheese' appearance | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:heteroplasmic partial duplication of mtdna n1=thrombolytique (traitement) | n2=en:heteroplasmic partial duplication of mtdna | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high blood oxygen saturation of hemoglobin (10% higher mean than the lowest values of population studied) n1=thrombolytique (traitement) | n2=en:high blood oxygen saturation of hemoglobin (10% higher mean than the lowest values of population studied) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high deoxypyridinoline/creatinine (in some patients) n1=thrombolytique (traitement) | n2=en:high deoxypyridinoline/creatinine (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high ebv viral load n1=thrombolytique (traitement) | n2=en:high ebv viral load | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high ft3/ft4 ratio n1=thrombolytique (traitement) | n2=en:high ft3/ft4 ratio | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high m-component n1=thrombolytique (traitement) | n2=en:high m-component | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high newborn serum levels of immunoreactive trypsinogen n1=thrombolytique (traitement) | n2=en:high newborn serum levels of immunoreactive trypsinogen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high nonceruloplasmin-bound serum copper n1=thrombolytique (traitement) | n2=en:high nonceruloplasmin-bound serum copper | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high ornithine n1=thrombolytique (traitement) | n2=en:high ornithine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high plasma asparagine n1=thrombolytique (traitement) | n2=en:high plasma asparagine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high plasma citrulline (100-300 micromolar) n1=thrombolytique (traitement) | n2=en:high plasma citrulline (100-300 micromolar) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high plasma citrulline (1000-5000 micromolar) n1=thrombolytique (traitement) | n2=en:high plasma citrulline (1000-5000 micromolar) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high plasma triglyceride levels n1=thrombolytique (traitement) | n2=en:high plasma triglyceride levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high resolution g- and t- banding karyotype shows reciprocal translocation of distal 9p-6q n1=thrombolytique (traitement) | n2=en:high resolution g- and t- banding karyotype shows reciprocal translocation of distal 9p-6q | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high serum guanosine levels n1=thrombolytique (traitement) | n2=en:high serum guanosine levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high serum inosine levels n1=thrombolytique (traitement) | n2=en:high serum inosine levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high serum osmolality n1=thrombolytique (traitement) | n2=en:high serum osmolality | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high sister chromatid exchange (sce) rate n1=thrombolytique (traitement) | n2=en:high sister chromatid exchange (sce) rate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high sweat electrolyte n1=thrombolytique (traitement) | n2=en:high sweat electrolyte | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high sweat sodium and chloride n1=thrombolytique (traitement) | n2=en:high sweat sodium and chloride | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high urinary copper n1=thrombolytique (traitement) | n2=en:high urinary copper | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high urinary excretion of inosine, 2'deoxyinosine, guanosine, and 2'deoxyguanosine n1=thrombolytique (traitement) | n2=en:high urinary excretion of inosine, 2'deoxyinosine, guanosine, and 2'deoxyguanosine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high urinary orotic acid n1=thrombolytique (traitement) | n2=en:high urinary orotic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high-normal plasma triglyceride concentration (in heterozygotes) n1=thrombolytique (traitement) | n2=en:high-normal plasma triglyceride concentration (in heterozygotes) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:high-resolution electron microscopy tomography shows absence of projection c2b at the central pair (cp) apparatus of cilia n1=thrombolytique (traitement) | n2=en:high-resolution electron microscopy tomography shows absence of projection c2b at the central pair (cp) apparatus of cilia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:histiocytic infiltration of liver, spleen, and lungs n1=thrombolytique (traitement) | n2=en:histiocytic infiltration of liver, spleen, and lungs | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hla-b27 haplotype association (95% patients) n1=thrombolytique (traitement) | n2=en:hla-b27 haplotype association (95% patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hla-dqw6 association (dqb1*0602) n1=thrombolytique (traitement) | n2=en:hla-dqw6 association (dqb1*0602) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:holocarboxylase synthetase deficiency n1=thrombolytique (traitement) | n2=en:holocarboxylase synthetase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:homocitrullinuria n1=thrombolytique (traitement) | n2=en:homocitrullinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:homocysteinemia n1=thrombolytique (traitement) | n2=en:homocysteinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:homocysteinemia (in some patients) n1=thrombolytique (traitement) | n2=en:homocysteinemia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:homocystinemia n1=thrombolytique (traitement) | n2=en:homocystinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:homocystinuria n1=thrombolytique (traitement) | n2=en:homocystinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:homocystinuria (in some patients) n1=thrombolytique (traitement) | n2=en:homocystinuria (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:homozygous 122kb deletion 11p15-p14 n1=thrombolytique (traitement) | n2=en:homozygous 122kb deletion 11p15-p14 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:howell-jolly bodies n1=thrombolytique (traitement) | n2=en:howell-jolly bodies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:howell-jolly bodies seen in peripheral blood smear n1=thrombolytique (traitement) | n2=en:howell-jolly bodies seen in peripheral blood smear | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:human varicella zoster immune globulin n1=thrombolytique (traitement) | n2=en:human varicella zoster immune globulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hydrocortisone decreased n1=thrombolytique (traitement) | n2=en:hydrocortisone decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hydroxyprolinuria n1=thrombolytique (traitement) | n2=en:hydroxyprolinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hydroxyurea n1=thrombolytique (traitement) | n2=en:hydroxyurea | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hydroxyurea 1g tablet n1=thrombolytique (traitement) | n2=en:hydroxyurea 1g tablet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hydroxyurea 200mg capsule n1=thrombolytique (traitement) | n2=en:hydroxyurea 200mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hydroxyurea 300mg capsule n1=thrombolytique (traitement) | n2=en:hydroxyurea 300mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hydroxyurea 400mg capsule n1=thrombolytique (traitement) | n2=en:hydroxyurea 400mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hydroxyurea 500mg capsule n1=thrombolytique (traitement) | n2=en:hydroxyurea 500mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyper-igm immunodeficiency syndrome, type 1 n1=thrombolytique (traitement) | n2=en:hyper-igm immunodeficiency syndrome, type 1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperalphalipoproteinemia n1=thrombolytique (traitement) | n2=en:hyperalphalipoproteinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperammonemia n1=thrombolytique (traitement) | n2=en:hyperammonemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperammonemia after protein intake n1=thrombolytique (traitement) | n2=en:hyperammonemia after protein intake | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperammonemia, asymptomatic (2-5 times normal) n1=thrombolytique (traitement) | n2=en:hyperammonemia, asymptomatic (2-5 times normal) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperammonemia, episodic n1=thrombolytique (traitement) | n2=en:hyperammonemia, episodic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperarginemia n1=thrombolytique (traitement) | n2=en:hyperarginemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperbilirubinemia n1=thrombolytique (traitement) | n2=en:hyperbilirubinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperbilirubinemia in those with liver failure n1=thrombolytique (traitement) | n2=en:hyperbilirubinemia in those with liver failure | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperbilirubinemia, non-hemolytic unconjugated (may rise with fasting or dehydration) n1=thrombolytique (traitement) | n2=en:hyperbilirubinemia, non-hemolytic unconjugated (may rise with fasting or dehydration) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperbilirubinemia, unconjugated, <20mg/dl n1=thrombolytique (traitement) | n2=en:hyperbilirubinemia, unconjugated, <20mg/dl | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperbilirubinemia, unconjugated, 20-30mg/dl n1=thrombolytique (traitement) | n2=en:hyperbilirubinemia, unconjugated, 20-30mg/dl | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercalcemia n1=thrombolytique (traitement) | n2=en:hypercalcemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercalciuria n1=thrombolytique (traitement) | n2=en:hypercalciuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercalciuria (in childhood) n1=thrombolytique (traitement) | n2=en:hypercalciuria (in childhood) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercalciuria (in some patients) n1=thrombolytique (traitement) | n2=en:hypercalciuria (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercellular bone marrow n1=thrombolytique (traitement) | n2=en:hypercellular bone marrow | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercellular bone marrow with erythroid hyperplasia n1=thrombolytique (traitement) | n2=en:hypercellular bone marrow with erythroid hyperplasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperchloremia (mean >110 mm in both dominant and recessive) n1=thrombolytique (traitement) | n2=en:hyperchloremia (mean >110 mm in both dominant and recessive) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperchloremia (mean 109 mm) n1=thrombolytique (traitement) | n2=en:hyperchloremia (mean 109 mm) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperchloremia (mean 111 mm) n1=thrombolytique (traitement) | n2=en:hyperchloremia (mean 111 mm) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperchloremia (mean 114 mm) n1=thrombolytique (traitement) | n2=en:hyperchloremia (mean 114 mm) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperchloridura n1=thrombolytique (traitement) | n2=en:hyperchloridura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercholesterolemia n1=thrombolytique (traitement) | n2=en:hypercholesterolemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercholesterolemia (10%) n1=thrombolytique (traitement) | n2=en:hypercholesterolemia (10%) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercholesterolemia (disorder) n1=thrombolytique (traitement) | n2=en:hypercholesterolemia (disorder) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercholesterolemia (in 75%) n1=thrombolytique (traitement) | n2=en:hypercholesterolemia (in 75%) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercholesterolemia (reported in 2 patients) n1=thrombolytique (traitement) | n2=en:hypercholesterolemia (reported in 2 patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypercholesterolemia, 350-550 mg/l in heterozygotes, 650-1000 mg/l in homozygotes n1=thrombolytique (traitement) | n2=en:hypercholesterolemia, 350-550 mg/l in heterozygotes, 650-1000 mg/l in homozygotes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperdiploid b acute lymphoblastic leukemia n1=thrombolytique (traitement) | n2=en:hyperdiploid b acute lymphoblastic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypereosinophilia n1=thrombolytique (traitement) | n2=en:hypereosinophilia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperglutaminemia n1=thrombolytique (traitement) | n2=en:hyperglutaminemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperglycemia n1=thrombolytique (traitement) | n2=en:hyperglycemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperglycemias, postprandial n1=thrombolytique (traitement) | n2=en:hyperglycemias, postprandial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperglycinemia n1=thrombolytique (traitement) | n2=en:hyperglycinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperglycinemia (1 patient) n1=thrombolytique (traitement) | n2=en:hyperglycinemia (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperglycinuria (disorder) n1=thrombolytique (traitement) | n2=en:hyperglycinuria (disorder) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperglycolic aciduria n1=thrombolytique (traitement) | n2=en:hyperglycolic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperhomocystinemia n1=thrombolytique (traitement) | n2=en:hyperhomocystinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperinsulinemia n1=thrombolytique (traitement) | n2=en:hyperinsulinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperinsulinemic hypoglycemia, familial, 7 n1=thrombolytique (traitement) | n2=en:hyperinsulinemic hypoglycemia, familial, 7 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperkalemia n1=thrombolytique (traitement) | n2=en:hyperkalemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperkalemia (>6.2 mm in both dominant and recessive) n1=thrombolytique (traitement) | n2=en:hyperkalemia (>6.2 mm in both dominant and recessive) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperkalemia (5.8 +/- 0.8 mm) n1=thrombolytique (traitement) | n2=en:hyperkalemia (5.8 +/- 0.8 mm) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperkalemia (6.4 +/- 0.7 mm) n1=thrombolytique (traitement) | n2=en:hyperkalemia (6.4 +/- 0.7 mm) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperkalemia (7.5 +/- 0.9 mm) n1=thrombolytique (traitement) | n2=en:hyperkalemia (7.5 +/- 0.9 mm) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperkalemia during attacks n1=thrombolytique (traitement) | n2=en:hyperkalemia during attacks | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperlactemia n1=thrombolytique (traitement) | n2=en:hyperlactemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperlipoproteinemia type i n1=thrombolytique (traitement) | n2=en:hyperlipoproteinemia type i | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperlipoproteinemia type iib n1=thrombolytique (traitement) | n2=en:hyperlipoproteinemia type iib | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperlysinemia n1=thrombolytique (traitement) | n2=en:hyperlysinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypermagnesemia n1=thrombolytique (traitement) | n2=en:hypermagnesemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypermagnesiuria n1=thrombolytique (traitement) | n2=en:hypermagnesiuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypermature neutrophils have condensed nuclei connected by long, stringy filaments and vacuolated cytoplasm n1=thrombolytique (traitement) | n2=en:hypermature neutrophils have condensed nuclei connected by long, stringy filaments and vacuolated cytoplasm | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypermethioninemia, progressive n1=thrombolytique (traitement) | n2=en:hypermethioninemia, progressive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypernatremia n1=thrombolytique (traitement) | n2=en:hypernatremia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypernatriuria n1=thrombolytique (traitement) | n2=en:hypernatriuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperornithinemia n1=thrombolytique (traitement) | n2=en:hyperornithinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperoxalaemia n1=thrombolytique (traitement) | n2=en:hyperoxalaemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperoxaluria n1=thrombolytique (traitement) | n2=en:hyperoxaluria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperphenylalaninemia n1=thrombolytique (traitement) | n2=en:hyperphenylalaninemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperphosphatemia n1=thrombolytique (traitement) | n2=en:hyperphosphatemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperphosphatemia, transient n1=thrombolytique (traitement) | n2=en:hyperphosphatemia, transient | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperprolinemia (10-15 times normal) n1=thrombolytique (traitement) | n2=en:hyperprolinemia (10-15 times normal) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperprolinemia (5-10 times normal) n1=thrombolytique (traitement) | n2=en:hyperprolinemia (5-10 times normal) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperprolinemia type 1 n1=thrombolytique (traitement) | n2=en:hyperprolinemia type 1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperprostaglandinuria n1=thrombolytique (traitement) | n2=en:hyperprostaglandinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypersegmented neutrophil n1=thrombolytique (traitement) | n2=en:hypersegmented neutrophil | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypersegmented neutrophils (1 patient) n1=thrombolytique (traitement) | n2=en:hypersegmented neutrophils (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypersensitivity of erythroid colony-forming units to erythropoietin (epo, 133170) n1=thrombolytique (traitement) | n2=en:hypersensitivity of erythroid colony-forming units to erythropoietin (epo, 133170) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypersplenism n1=thrombolytique (traitement) | n2=en:hypersplenism | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperthreoninemia n1=thrombolytique (traitement) | n2=en:hyperthreoninemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperthreoninuria n1=thrombolytique (traitement) | n2=en:hyperthreoninuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypertriglyceridemia n1=thrombolytique (traitement) | n2=en:hypertriglyceridemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypertriglyceridemia (in some patients) n1=thrombolytique (traitement) | n2=en:hypertriglyceridemia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypertriglyceridemia (rare) n1=thrombolytique (traitement) | n2=en:hypertriglyceridemia (rare) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypertriglyceridemia, transient n1=thrombolytique (traitement) | n2=en:hypertriglyceridemia, transient | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypertryptophanemia n1=thrombolytique (traitement) | n2=en:hypertryptophanemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperuricemia n1=thrombolytique (traitement) | n2=en:hyperuricemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome n1=thrombolytique (traitement) | n2=en:hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperuricosuria n1=thrombolytique (traitement) | n2=en:hyperuricosuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyperuricuria n1=thrombolytique (traitement) | n2=en:hyperuricuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoalbuminemia n1=thrombolytique (traitement) | n2=en:hypoalbuminemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoalbuminemia (in 83%) n1=thrombolytique (traitement) | n2=en:hypoalbuminemia (in 83%) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoalphalipoproteinemia n1=thrombolytique (traitement) | n2=en:hypoalphalipoproteinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypobetalipoproteinemias n1=thrombolytique (traitement) | n2=en:hypobetalipoproteinemias | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypocalcemia n1=thrombolytique (traitement) | n2=en:hypocalcemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypocalcemia (64% of adults) n1=thrombolytique (traitement) | n2=en:hypocalcemia (64% of adults) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypocalcemia (male) n1=thrombolytique (traitement) | n2=en:hypocalcemia (male) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypocalcemia, transient n1=thrombolytique (traitement) | n2=en:hypocalcemia, transient | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypocalciuria n1=thrombolytique (traitement) | n2=en:hypocalciuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypocalciuria or normocalciuria n1=thrombolytique (traitement) | n2=en:hypocalciuria or normocalciuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypocholesterolemia n1=thrombolytique (traitement) | n2=en:hypocholesterolemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypochromia n1=thrombolytique (traitement) | n2=en:hypochromia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypochromic anemia n1=thrombolytique (traitement) | n2=en:hypochromic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypocitraturia n1=thrombolytique (traitement) | n2=en:hypocitraturia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypocytosis n1=thrombolytique (traitement) | n2=en:hypocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypodiploid b acute lymphoblastic leukemia n1=thrombolytique (traitement) | n2=en:hypodiploid b acute lymphoblastic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypofibrinogenemia n1=thrombolytique (traitement) | n2=en:hypofibrinogenemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypogammaglobulinemia n1=thrombolytique (traitement) | n2=en:hypogammaglobulinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypogammaglobulinemia (in some patients) n1=thrombolytique (traitement) | n2=en:hypogammaglobulinemia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypogammaglobulinemia, profound n1=thrombolytique (traitement) | n2=en:hypogammaglobulinemia, profound | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoglycemia n1=thrombolytique (traitement) | n2=en:hypoglycemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoglycemia, fasting n1=thrombolytique (traitement) | n2=en:hypoglycemia, fasting | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoglycemia, intermittent n1=thrombolytique (traitement) | n2=en:hypoglycemia, intermittent | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoglycorrhachia (low glucose in csf) n1=thrombolytique (traitement) | n2=en:hypoglycorrhachia (low glucose in csf) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoglycosylated serum transferrin n1=thrombolytique (traitement) | n2=en:hypoglycosylated serum transferrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoglycosylation of plasma glycoproteins n1=thrombolytique (traitement) | n2=en:hypoglycosylation of plasma glycoproteins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoglycosylation of red blood cell membranes n1=thrombolytique (traitement) | n2=en:hypoglycosylation of red blood cell membranes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypokalemia n1=thrombolytique (traitement) | n2=en:hypokalemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypokalemia during attacks n1=thrombolytique (traitement) | n2=en:hypokalemia during attacks | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypokalemia during periodic paralysis (most patients) n1=thrombolytique (traitement) | n2=en:hypokalemia during periodic paralysis (most patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypokalemia occurs during paralytic attacks n1=thrombolytique (traitement) | n2=en:hypokalemia occurs during paralytic attacks | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoketotic dicarboxylic aciduria (in some patients) n1=thrombolytique (traitement) | n2=en:hypoketotic dicarboxylic aciduria (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoketotic hypoglycemia n1=thrombolytique (traitement) | n2=en:hypoketotic hypoglycemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypolobulated (bilobed or rod-like) granulocyte nuclei (heterozygote) n1=thrombolytique (traitement) | n2=en:hypolobulated (bilobed or rod-like) granulocyte nuclei (heterozygote) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypolobulated megakaryocytes in the bone marrow n1=thrombolytique (traitement) | n2=en:hypolobulated megakaryocytes in the bone marrow | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypolobulation of granulocyte nuclei (pelger-huet anomaly) n1=thrombolytique (traitement) | n2=en:hypolobulation of granulocyte nuclei (pelger-huet anomaly) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypomagnesemia n1=thrombolytique (traitement) | n2=en:hypomagnesemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypomethioninemia n1=thrombolytique (traitement) | n2=en:hypomethioninemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypomethylation of alpha-satellite repeats on chromosome 9 n1=thrombolytique (traitement) | n2=en:hypomethylation of alpha-satellite repeats on chromosome 9 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypomethylation of satellite repeats on chromosome 1, 9, and 16 n1=thrombolytique (traitement) | n2=en:hypomethylation of satellite repeats on chromosome 1, 9, and 16 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyponatremia n1=thrombolytique (traitement) | n2=en:hyponatremia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyponatremia in infancy n1=thrombolytique (traitement) | n2=en:hyponatremia in infancy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyponatremic dehydration, rarely n1=thrombolytique (traitement) | n2=en:hyponatremic dehydration, rarely | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypophosphatemia (less common) n1=thrombolytique (traitement) | n2=en:hypophosphatemia (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoplastic anemia n1=thrombolytique (traitement) | n2=en:hypoplastic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoplastic myelodysplasia n1=thrombolytique (traitement) | n2=en:hypoplastic myelodysplasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoprebetalipoproteinemia n1=thrombolytique (traitement) | n2=en:hypoprebetalipoproteinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoproteinemia n1=thrombolytique (traitement) | n2=en:hypoproteinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoproteinemia (in 1 patient) n1=thrombolytique (traitement) | n2=en:hypoproteinemia (in 1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoproteinemia due to hypercatabolism n1=thrombolytique (traitement) | n2=en:hypoproteinemia due to hypercatabolism | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyposialylation of o-linked serum glycans n1=thrombolytique (traitement) | n2=en:hyposialylation of o-linked serum glycans | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hyposthenuria (inability to concentrate urine normally) n1=thrombolytique (traitement) | n2=en:hyposthenuria (inability to concentrate urine normally) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypothenar hammer syndrome n1=thrombolytique (traitement) | n2=en:hypothenar hammer syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypouricemia n1=thrombolytique (traitement) | n2=en:hypouricemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoviscosity n1=thrombolytique (traitement) | n2=en:hypoviscosity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoxemia n1=thrombolytique (traitement) | n2=en:hypoxemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:hypoxia n1=thrombolytique (traitement) | n2=en:hypoxia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:i-cell disease n1=thrombolytique (traitement) | n2=en:i-cell disease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ibritumomab tiuxetan n1=thrombolytique (traitement) | n2=en:ibritumomab tiuxetan | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ibritumomab tiuxetan in-111 inj,kit n1=thrombolytique (traitement) | n2=en:ibritumomab tiuxetan in-111 inj,kit | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ibritumomab tiuxetan y-90 inj,kit n1=thrombolytique (traitement) | n2=en:ibritumomab tiuxetan y-90 inj,kit | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:idiopathic maternal thrombocytopenia n1=thrombolytique (traitement) | n2=en:idiopathic maternal thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:idiopathic thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:idiopathic thrombocytopenic purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iduronate sulfatase deficiency in fibroblasts, amniocytes and white blood cells n1=thrombolytique (traitement) | n2=en:iduronate sulfatase deficiency in fibroblasts, amniocytes and white blood cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ifosfamide n1=thrombolytique (traitement) | n2=en:ifosfamide | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ifosfamide 1g powder for infusion solution vial n1=thrombolytique (traitement) | n2=en:ifosfamide 1g powder for infusion solution vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iga antiendomysial antibodies (ema) n1=thrombolytique (traitement) | n2=en:iga antiendomysial antibodies (ema) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:igg deficiency n1=thrombolytique (traitement) | n2=en:igg deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:igg, decreased n1=thrombolytique (traitement) | n2=en:igg, decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:igg, elevated n1=thrombolytique (traitement) | n2=en:igg, elevated | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:igm deficiency n1=thrombolytique (traitement) | n2=en:igm deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iiga and igg antigliadin antibodies (aga) n1=thrombolytique (traitement) | n2=en:iiga and igg antigliadin antibodies (aga) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:imbalanced hemoglobin chain synthesis n1=thrombolytique (traitement) | n2=en:imbalanced hemoglobin chain synthesis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:immediate (type i) skin test reactivity n1=thrombolytique (traitement) | n2=en:immediate (type i) skin test reactivity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:immotile cilia n1=thrombolytique (traitement) | n2=en:immotile cilia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:immotile or weakly motile cilia n1=thrombolytique (traitement) | n2=en:immotile or weakly motile cilia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:immune dysfunction with t-cell inactivation due to calcium entry defect 2 n1=thrombolytique (traitement) | n2=en:immune dysfunction with t-cell inactivation due to calcium entry defect 2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:immunoglobulin a decreased n1=thrombolytique (traitement) | n2=en:immunoglobulin a decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:immunoglobulin antibodies present n1=thrombolytique (traitement) | n2=en:immunoglobulin antibodies present | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:immunohematology n1=thrombolytique (traitement) | n2=en:immunohematology | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:immunoreactive pc protein n1=thrombolytique (traitement) | n2=en:immunoreactive pc protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired carnitine uptake in muscle, heart, kidney, fibroblasts, and lymphocytes n1=thrombolytique (traitement) | n2=en:impaired carnitine uptake in muscle, heart, kidney, fibroblasts, and lymphocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired coagulation due to malnutrition n1=thrombolytique (traitement) | n2=en:impaired coagulation due to malnutrition | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired creatine uptake in fibroblasts n1=thrombolytique (traitement) | n2=en:impaired creatine uptake in fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired long-chain fatty acid oxidation during prolonged, low-intensity exercise n1=thrombolytique (traitement) | n2=en:impaired long-chain fatty acid oxidation during prolonged, low-intensity exercise | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired mitochondrial translation n1=thrombolytique (traitement) | n2=en:impaired mitochondrial translation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired n-glycosylation n1=thrombolytique (traitement) | n2=en:impaired n-glycosylation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired o-glycosylation n1=thrombolytique (traitement) | n2=en:impaired o-glycosylation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired oxidation of pyruvate n1=thrombolytique (traitement) | n2=en:impaired oxidation of pyruvate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired platelet aggregation n1=thrombolytique (traitement) | n2=en:impaired platelet aggregation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired platelet aggregation (in some patients) n1=thrombolytique (traitement) | n2=en:impaired platelet aggregation (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired platelet aggregation and spreading n1=thrombolytique (traitement) | n2=en:impaired platelet aggregation and spreading | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired platelet function n1=thrombolytique (traitement) | n2=en:impaired platelet function | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired release of platelet adenosine diphosphate (adp) n1=thrombolytique (traitement) | n2=en:impaired release of platelet adenosine diphosphate (adp) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired response to gm-csf n1=thrombolytique (traitement) | n2=en:impaired response to gm-csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impaired synthesis of fibroblast sulfated proteoglycans n1=thrombolytique (traitement) | n2=en:impaired synthesis of fibroblast sulfated proteoglycans | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:impairment of urinary concentration n1=thrombolytique (traitement) | n2=en:impairment of urinary concentration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:in untreated patients - elevated blood galactose urine reducing substances (galactosuria), hyperchloremic metabolic acidosis, aminoaciduria, elevated liver enzymes, albuminuria n1=thrombolytique (traitement) | n2=en:in untreated patients - elevated blood galactose urine reducing substances (galactosuria), hyperchloremic metabolic acidosis, aminoaciduria, elevated liver enzymes, albuminuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:inactive mutant form of red cell carbonic anhydrase b in one sibship n1=thrombolytique (traitement) | n2=en:inactive mutant form of red cell carbonic anhydrase b in one sibship | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:inappropriately increased urine osmolality n1=thrombolytique (traitement) | n2=en:inappropriately increased urine osmolality | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:inappropriately low reticulocyte counts n1=thrombolytique (traitement) | n2=en:inappropriately low reticulocyte counts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:inappropriately low urine osmolality n1=thrombolytique (traitement) | n2=en:inappropriately low urine osmolality | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:inappropriately normal or increased plasma hepcidin n1=thrombolytique (traitement) | n2=en:inappropriately normal or increased plasma hepcidin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:inappropriately normal serum 1,25-dihydroxyvitamin d3 n1=thrombolytique (traitement) | n2=en:inappropriately normal serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:inappropriately normal to low-normal serum 1,25-dihydroxyvitamin d3 n1=thrombolytique (traitement) | n2=en:inappropriately normal to low-normal serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:inclusion bodies (membrane-bound vacuoles) in fibroblasts n1=thrombolytique (traitement) | n2=en:inclusion bodies (membrane-bound vacuoles) in fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:inclusions contain phospholipids, phosphatidylcholine, sphingolipids, gangliosides, mucopolysaccharides n1=thrombolytique (traitement) | n2=en:inclusions contain phospholipids, phosphatidylcholine, sphingolipids, gangliosides, mucopolysaccharides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:incomplete n-glycosylation of cellular proteins n1=thrombolytique (traitement) | n2=en:incomplete n-glycosylation of cellular proteins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increase in blood monocytes (2-3 times normal) n1=thrombolytique (traitement) | n2=en:increase in blood monocytes (2-3 times normal) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increase urinary excretion of lysine, arginine, and ornithine n1=thrombolytique (traitement) | n2=en:increase urinary excretion of lysine, arginine, and ornithine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased 11-deoxycorticosterone n1=thrombolytique (traitement) | n2=en:increased 11-deoxycorticosterone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased 11-deoxycortisol n1=thrombolytique (traitement) | n2=en:increased 11-deoxycortisol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased 18-hydroxycortisol n1=thrombolytique (traitement) | n2=en:increased 18-hydroxycortisol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased 18-ohb to aldosterone ratio n1=thrombolytique (traitement) | n2=en:increased 18-ohb to aldosterone ratio | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased 18-oxocortisol n1=thrombolytique (traitement) | n2=en:increased 18-oxocortisol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased absolute neutrophil count (anc) within 0.0-0.2 x 10(9)/l n1=thrombolytique (traitement) | n2=en:increased absolute neutrophil count (anc) within 0.0-0.2 x 10(9)/l | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased acetoacetate: beta-hydroxybutyrate ratio (group b) n1=thrombolytique (traitement) | n2=en:increased acetoacetate: beta-hydroxybutyrate ratio (group b) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased acetylcholinesterase (ache) in amniotic fluid n1=thrombolytique (traitement) | n2=en:increased acetylcholinesterase (ache) in amniotic fluid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased activity of the prpp synthetase 1 enzyme n1=thrombolytique (traitement) | n2=en:increased activity of the prpp synthetase 1 enzyme | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased alpha-fetoprotein (1 patient) n1=thrombolytique (traitement) | n2=en:increased alpha-fetoprotein (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased alpha-fetoprotein in the mother during early pregnancy while carrying an affected fetus n1=thrombolytique (traitement) | n2=en:increased alpha-fetoprotein in the mother during early pregnancy while carrying an affected fetus | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased alpha/beta globin ratio in reticulocytes n1=thrombolytique (traitement) | n2=en:increased alpha/beta globin ratio in reticulocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased ammonia with exercise n1=thrombolytique (traitement) | n2=en:increased ammonia with exercise | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased beta-alanine (in 1 of 2 patients) n1=thrombolytique (traitement) | n2=en:increased beta-alanine (in 1 of 2 patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased bile acid intermediates (dhca and thca) n1=thrombolytique (traitement) | n2=en:increased bile acid intermediates (dhca and thca) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased biliverdin in bodily fluids n1=thrombolytique (traitement) | n2=en:increased biliverdin in bodily fluids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased biopterin in urine and csf n1=thrombolytique (traitement) | n2=en:increased biopterin in urine and csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased bleeding (menorrhagia, gastrointestinal bleeding, hemarthroses) n1=thrombolytique (traitement) | n2=en:increased bleeding (menorrhagia, gastrointestinal bleeding, hemarthroses) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased bleeding after trauma, surgery, or injury n1=thrombolytique (traitement) | n2=en:increased bleeding after trauma, surgery, or injury | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased bleeding tendency (in 1 patient) n1=thrombolytique (traitement) | n2=en:increased bleeding tendency (in 1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased bleeding tendency due to platelet dysfunction n1=thrombolytique (traitement) | n2=en:increased bleeding tendency due to platelet dysfunction | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased bleeding tendency, moderate to severe n1=thrombolytique (traitement) | n2=en:increased bleeding tendency, moderate to severe | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased blood alanine n1=thrombolytique (traitement) | n2=en:increased blood alanine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased bone serum acid phosphatase n1=thrombolytique (traitement) | n2=en:increased bone serum acid phosphatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased bone-specific alkaline phosphatase n1=thrombolytique (traitement) | n2=en:increased bone-specific alkaline phosphatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased c10:2-carnitine n1=thrombolytique (traitement) | n2=en:increased c10:2-carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased cellular sensitivity to uv light n1=thrombolytique (traitement) | n2=en:increased cellular sensitivity to uv light | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased cerebrospinal fluid (csf) protein (>100mg/dl) n1=thrombolytique (traitement) | n2=en:increased cerebrospinal fluid (csf) protein (>100mg/dl) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased cholesterol n1=thrombolytique (traitement) | n2=en:increased cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased chromosomal breakage n1=thrombolytique (traitement) | n2=en:increased chromosomal breakage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased chromosomal breaks in response to cross-linking agents and ionizing radiation n1=thrombolytique (traitement) | n2=en:increased chromosomal breaks in response to cross-linking agents and ionizing radiation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased chromosomal rearrangements (bone marrow and fibroblast culture) n1=thrombolytique (traitement) | n2=en:increased chromosomal rearrangements (bone marrow and fibroblast culture) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased circulating renin level n1=thrombolytique (traitement) | n2=en:increased circulating renin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased ck-mb n1=thrombolytique (traitement) | n2=en:increased ck-mb | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased coproporphyrin isomer iii:i ratio (hcp, feces) n1=thrombolytique (traitement) | n2=en:increased coproporphyrin isomer iii:i ratio (hcp, feces) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased creatine kinase (ck) n1=thrombolytique (traitement) | n2=en:increased creatine kinase (ck) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased creatine kinase, mild to moderate n1=thrombolytique (traitement) | n2=en:increased creatine kinase, mild to moderate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased creatinine n1=thrombolytique (traitement) | n2=en:increased creatinine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased cross-linked c-terminal telopeptide of type i collagen n1=thrombolytique (traitement) | n2=en:increased cross-linked c-terminal telopeptide of type i collagen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf 3-methoxytyrosine (3-mt) n1=thrombolytique (traitement) | n2=en:increased csf 3-methoxytyrosine (3-mt) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf and plasma gaba n1=thrombolytique (traitement) | n2=en:increased csf and plasma gaba | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf and plasma ghb n1=thrombolytique (traitement) | n2=en:increased csf and plasma ghb | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf glycine n1=thrombolytique (traitement) | n2=en:increased csf glycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf histidine n1=thrombolytique (traitement) | n2=en:increased csf histidine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf homovanillic acid (hva) n1=thrombolytique (traitement) | n2=en:increased csf homovanillic acid (hva) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf immunoglobulin levels n1=thrombolytique (traitement) | n2=en:increased csf immunoglobulin levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf interferon n1=thrombolytique (traitement) | n2=en:increased csf interferon | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf interferon alpha n1=thrombolytique (traitement) | n2=en:increased csf interferon alpha | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf lactate n1=thrombolytique (traitement) | n2=en:increased csf lactate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf lactate during acute episodes n1=thrombolytique (traitement) | n2=en:increased csf lactate during acute episodes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf protein n1=thrombolytique (traitement) | n2=en:increased csf protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf protein during acute illness n1=thrombolytique (traitement) | n2=en:increased csf protein during acute illness | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf pyruvic acid n1=thrombolytique (traitement) | n2=en:increased csf pyruvic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf taurine n1=thrombolytique (traitement) | n2=en:increased csf taurine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf threonine n1=thrombolytique (traitement) | n2=en:increased csf threonine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf transferrin despite normal serum transferrin levels n1=thrombolytique (traitement) | n2=en:increased csf transferrin despite normal serum transferrin levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf, plasma, and urinary 3-methoxytyrosine n1=thrombolytique (traitement) | n2=en:increased csf, plasma, and urinary 3-methoxytyrosine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf, plasma, and urinary 3-ortho-methyldopa (3-omd) n1=thrombolytique (traitement) | n2=en:increased csf, plasma, and urinary 3-ortho-methyldopa (3-omd) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf, plasma, and urinary 5-hydroxytryptophan (5htp) n1=thrombolytique (traitement) | n2=en:increased csf, plasma, and urinary 5-hydroxytryptophan (5htp) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased csf, plasma, and urinary l-dopa n1=thrombolytique (traitement) | n2=en:increased csf, plasma, and urinary l-dopa | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased d-glyceric acid in serum, urine, and csf n1=thrombolytique (traitement) | n2=en:increased d-glyceric acid in serum, urine, and csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased di- and asialo-transferrin n1=thrombolytique (traitement) | n2=en:increased di- and asialo-transferrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased di- and asialo-transferrin characteristic of type 1 pattern n1=thrombolytique (traitement) | n2=en:increased di- and asialo-transferrin characteristic of type 1 pattern | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased disialo- and asialotransferrin n1=thrombolytique (traitement) | n2=en:increased disialo- and asialotransferrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased disialotransferrin and asialotransferrin levels n1=thrombolytique (traitement) | n2=en:increased disialotransferrin and asialotransferrin levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased erythrocyte sedimentation rate, episodic n1=thrombolytique (traitement) | n2=en:increased erythrocyte sedimentation rate, episodic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased erythrocyte zinc- and metal-free protoporphyrin n1=thrombolytique (traitement) | n2=en:increased erythrocyte zinc- and metal-free protoporphyrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased erythrocyte-membrane calcium-magnesium-atpase n1=thrombolytique (traitement) | n2=en:increased erythrocyte-membrane calcium-magnesium-atpase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased erythropoietin n1=thrombolytique (traitement) | n2=en:increased erythropoietin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased excretion of urobilinogen n1=thrombolytique (traitement) | n2=en:increased excretion of urobilinogen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased fas ligand n1=thrombolytique (traitement) | n2=en:increased fas ligand | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased ferritin n1=thrombolytique (traitement) | n2=en:increased ferritin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased fibrinolysis (finding) n1=thrombolytique (traitement) | n2=en:increased fibrinolysis (finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased fibroblast free sialic acid n1=thrombolytique (traitement) | n2=en:increased fibroblast free sialic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased fractional excretion of urate (greater than 50%) n1=thrombolytique (traitement) | n2=en:increased fractional excretion of urate (greater than 50%) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased fractional excretion of uric acid n1=thrombolytique (traitement) | n2=en:increased fractional excretion of uric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased free cyanocobalamin in fibroblasts n1=thrombolytique (traitement) | n2=en:increased free cyanocobalamin in fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased free erythrocyte protoporphyrin n1=thrombolytique (traitement) | n2=en:increased free erythrocyte protoporphyrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased frequency of premature centromere disjunction (pcd) in cultured fibroblasts, esp. chromosome 3 n1=thrombolytique (traitement) | n2=en:increased frequency of premature centromere disjunction (pcd) in cultured fibroblasts, esp. chromosome 3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased gamma-aminobutyric acid in plasma, urine, and cerebrospinal fluid (csf) n1=thrombolytique (traitement) | n2=en:increased gamma-aminobutyric acid in plasma, urine, and cerebrospinal fluid (csf) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased gamma-interferon n1=thrombolytique (traitement) | n2=en:increased gamma-interferon | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased growth hormone (in 1 of 2 patients) n1=thrombolytique (traitement) | n2=en:increased growth hormone (in 1 of 2 patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased harderoporphyrin excretion (feces, harderoporphyria) n1=thrombolytique (traitement) | n2=en:increased harderoporphyrin excretion (feces, harderoporphyria) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased hepatic parenchymal cell stainable iron n1=thrombolytique (traitement) | n2=en:increased hepatic parenchymal cell stainable iron | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased histidine in blood, urine, and csf n1=thrombolytique (traitement) | n2=en:increased histidine in blood, urine, and csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased iga level n1=thrombolytique (traitement) | n2=en:increased iga level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased ige level n1=thrombolytique (traitement) | n2=en:increased ige level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased igg level n1=thrombolytique (traitement) | n2=en:increased igg level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased igm level n1=thrombolytique (traitement) | n2=en:increased igm level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased il-6 n1=thrombolytique (traitement) | n2=en:increased il-6 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased il-8 n1=thrombolytique (traitement) | n2=en:increased il-8 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased il18 n1=thrombolytique (traitement) | n2=en:increased il18 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased il1b increased soluble il2r n1=thrombolytique (traitement) | n2=en:increased il1b increased soluble il2r | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased il6, episodic n1=thrombolytique (traitement) | n2=en:increased il6, episodic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased interferon-alpha signal n1=thrombolytique (traitement) | n2=en:increased interferon-alpha signal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased interleukin 10 n1=thrombolytique (traitement) | n2=en:increased interleukin 10 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased intracellular fmrp mrna n1=thrombolytique (traitement) | n2=en:increased intracellular fmrp mrna | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased ketone body or lactate/pyruvate plasma ratios n1=thrombolytique (traitement) | n2=en:increased ketone body or lactate/pyruvate plasma ratios | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased l-2-hydroxyglutaric acid in urine, serum, and csf n1=thrombolytique (traitement) | n2=en:increased l-2-hydroxyglutaric acid in urine, serum, and csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased lactate in spinal fluid n1=thrombolytique (traitement) | n2=en:increased lactate in spinal fluid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased lactate: pyruvate ratio (group b) n1=thrombolytique (traitement) | n2=en:increased lactate: pyruvate ratio (group b) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased level of globotriaosylceramide (gb3) in plasma and urinary sediment n1=thrombolytique (traitement) | n2=en:increased level of globotriaosylceramide (gb3) in plasma and urinary sediment | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased levels of 3-alpha-7-alpha-12-alpha-trihydroxy-5-beta-cholestanoic acid (thca) in bile, urine, and serum n1=thrombolytique (traitement) | n2=en:increased levels of 3-alpha-7-alpha-12-alpha-trihydroxy-5-beta-cholestanoic acid (thca) in bile, urine, and serum | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased levels of carcinoembryonic antigen n1=thrombolytique (traitement) | n2=en:increased levels of carcinoembryonic antigen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased levels of dihydroxyacetone phosphate (dhap) in tissues and red cells n1=thrombolytique (traitement) | n2=en:increased levels of dihydroxyacetone phosphate (dhap) in tissues and red cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased long-chain acylcarnitine n1=thrombolytique (traitement) | n2=en:increased long-chain acylcarnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased lysine in serum and csf n1=thrombolytique (traitement) | n2=en:increased lysine in serum and csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased mean corpuscular hemoglobin concentration n1=thrombolytique (traitement) | n2=en:increased mean corpuscular hemoglobin concentration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased megakaryocyte colony forming units (cfu-mk) n1=thrombolytique (traitement) | n2=en:increased megakaryocyte colony forming units (cfu-mk) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased megakaryocyte precursor cells n1=thrombolytique (traitement) | n2=en:increased megakaryocyte precursor cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased micromegakaryocytes (bone marrow) n1=thrombolytique (traitement) | n2=en:increased micromegakaryocytes (bone marrow) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased myeloid precursor cells n1=thrombolytique (traitement) | n2=en:increased myeloid precursor cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased myeloid to erythroid ratio (m:e ratio) 10:1-200:1 n1=thrombolytique (traitement) | n2=en:increased myeloid to erythroid ratio (m:e ratio) 10:1-200:1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased n-acetyl-l-aspartic acid (naa) in urine, csf, and blood n1=thrombolytique (traitement) | n2=en:increased n-acetyl-l-aspartic acid (naa) in urine, csf, and blood | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased nasal-potential difference (1 of 3 patients) n1=thrombolytique (traitement) | n2=en:increased nasal-potential difference (1 of 3 patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased nasal-potential difference (some) n1=thrombolytique (traitement) | n2=en:increased nasal-potential difference (some) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased neopterin in urine and csf n1=thrombolytique (traitement) | n2=en:increased neopterin in urine and csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased number of abnormal megakaryocytes seen on bone marrow biopsy n1=thrombolytique (traitement) | n2=en:increased number of abnormal megakaryocytes seen on bone marrow biopsy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased or normal serum growth hormone (gh, 139250) n1=thrombolytique (traitement) | n2=en:increased or normal serum growth hormone (gh, 139250) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased osmotic fragility n1=thrombolytique (traitement) | n2=en:increased osmotic fragility | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased oxygen affinity (e.g. hb nunobiki 141800.0109) n1=thrombolytique (traitement) | n2=en:increased oxygen affinity (e.g. hb nunobiki 141800.0109) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased peripheral blood monocytes n1=thrombolytique (traitement) | n2=en:increased peripheral blood monocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased phytanic acid in body tissues and fluids n1=thrombolytique (traitement) | n2=en:increased phytanic acid in body tissues and fluids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma 2-methylbutyrylcarnitine n1=thrombolytique (traitement) | n2=en:increased plasma 2-methylbutyrylcarnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma and urinary pipecolic acid n1=thrombolytique (traitement) | n2=en:increased plasma and urinary pipecolic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma branched-chain fatty acids n1=thrombolytique (traitement) | n2=en:increased plasma branched-chain fatty acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma creatine n1=thrombolytique (traitement) | n2=en:increased plasma creatine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma dihydroxyphenylacetic acid (dopac) n1=thrombolytique (traitement) | n2=en:increased plasma dihydroxyphenylacetic acid (dopac) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma free cholesterol n1=thrombolytique (traitement) | n2=en:increased plasma free cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma globotriaosylsphingosine (lyso-gb3) n1=thrombolytique (traitement) | n2=en:increased plasma globotriaosylsphingosine (lyso-gb3) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma homogentisic acid (hga) n1=thrombolytique (traitement) | n2=en:increased plasma homogentisic acid (hga) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma lactate n1=thrombolytique (traitement) | n2=en:increased plasma lactate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma levels of bile acid intermediates n1=thrombolytique (traitement) | n2=en:increased plasma levels of bile acid intermediates | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma levels of very long-chain fatty acids (vlcfa) n1=thrombolytique (traitement) | n2=en:increased plasma levels of very long-chain fatty acids (vlcfa) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma long-chain acylcarnitines n1=thrombolytique (traitement) | n2=en:increased plasma long-chain acylcarnitines | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma phospholipids n1=thrombolytique (traitement) | n2=en:increased plasma phospholipids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma phytanic acid n1=thrombolytique (traitement) | n2=en:increased plasma phytanic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma pipecolic acid n1=thrombolytique (traitement) | n2=en:increased plasma pipecolic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma pristanic acid n1=thrombolytique (traitement) | n2=en:increased plasma pristanic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma progastrin n1=thrombolytique (traitement) | n2=en:increased plasma progastrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma proglucagon n1=thrombolytique (traitement) | n2=en:increased plasma proglucagon | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma proinsulin n1=thrombolytique (traitement) | n2=en:increased plasma proinsulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma renin activity n1=thrombolytique (traitement) | n2=en:increased plasma renin activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma thrombopoietin (tpo) n1=thrombolytique (traitement) | n2=en:increased plasma thrombopoietin (tpo) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased plasma vldl, ldl n1=thrombolytique (traitement) | n2=en:increased plasma vldl, ldl | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased platelet aggregation with ristocetin n1=thrombolytique (traitement) | n2=en:increased platelet aggregation with ristocetin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased platelet content of plau n1=thrombolytique (traitement) | n2=en:increased platelet content of plau | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased platelet destruction n1=thrombolytique (traitement) | n2=en:increased platelet destruction | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased prevalence among the native american lumbee indians n1=thrombolytique (traitement) | n2=en:increased prevalence among the native american lumbee indians | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased pristanic acid n1=thrombolytique (traitement) | n2=en:increased pristanic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased promyelocytes n1=thrombolytique (traitement) | n2=en:increased promyelocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased prv-1 (162860) mrna n1=thrombolytique (traitement) | n2=en:increased prv-1 (162860) mrna | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased pyruvate in serum and csf n1=thrombolytique (traitement) | n2=en:increased pyruvate in serum and csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased rai (radioactive iodine) uptake n1=thrombolytique (traitement) | n2=en:increased rai (radioactive iodine) uptake | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased red blood cell mass n1=thrombolytique (traitement) | n2=en:increased red blood cell mass | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased red blood cell membrane permeability to univalent cations n1=thrombolytique (traitement) | n2=en:increased red blood cell membrane permeability to univalent cations | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased red cell hemolysis by shear stress n1=thrombolytique (traitement) | n2=en:increased red cell hemolysis by shear stress | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased red cell osmotic fragility n1=thrombolytique (traitement) | n2=en:increased red cell osmotic fragility | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased red cell osmotic resistance n1=thrombolytique (traitement) | n2=en:increased red cell osmotic resistance | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased renal tubular phosphate reabsorption n1=thrombolytique (traitement) | n2=en:increased renal tubular phosphate reabsorption | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased sensitivity to adrenergic and cholinergic agents n1=thrombolytique (traitement) | n2=en:increased sensitivity to adrenergic and cholinergic agents | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum 1,25-dihydroxyvitamin d n1=thrombolytique (traitement) | n2=en:increased serum 1,25-dihydroxyvitamin d | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum 1,25-dihydroxyvitamin d3 n1=thrombolytique (traitement) | n2=en:increased serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum 18-hydroxycorticosterone (18-ohb) n1=thrombolytique (traitement) | n2=en:increased serum 18-hydroxycorticosterone (18-ohb) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum acyl carnitines n1=thrombolytique (traitement) | n2=en:increased serum acyl carnitines | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum acylcarnitine during febrile crisis n1=thrombolytique (traitement) | n2=en:increased serum acylcarnitine during febrile crisis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum acylcarnitines n1=thrombolytique (traitement) | n2=en:increased serum acylcarnitines | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum alanine n1=thrombolytique (traitement) | n2=en:increased serum alanine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum alanine (1 patient) n1=thrombolytique (traitement) | n2=en:increased serum alanine (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum alkaline phosphatase (in some patients) n1=thrombolytique (traitement) | n2=en:increased serum alkaline phosphatase (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum alkaline phosphatase activity of skeletal origin n1=thrombolytique (traitement) | n2=en:increased serum alkaline phosphatase activity of skeletal origin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum alpha-interferon (ifna1, 147660) n1=thrombolytique (traitement) | n2=en:increased serum alpha-interferon (ifna1, 147660) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum alpha-mannosidase n1=thrombolytique (traitement) | n2=en:increased serum alpha-mannosidase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum ammonia (group b) n1=thrombolytique (traitement) | n2=en:increased serum ammonia (group b) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum and cerebrospinal fluid levels of pipecolic acid n1=thrombolytique (traitement) | n2=en:increased serum and cerebrospinal fluid levels of pipecolic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum and csf glycine n1=thrombolytique (traitement) | n2=en:increased serum and csf glycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum and csf lactate n1=thrombolytique (traitement) | n2=en:increased serum and csf lactate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum and urinary 2-oxoglutarate n1=thrombolytique (traitement) | n2=en:increased serum and urinary 2-oxoglutarate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum and urinary lactate n1=thrombolytique (traitement) | n2=en:increased serum and urinary lactate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum aryl-sulfatase a (10-20x) n1=thrombolytique (traitement) | n2=en:increased serum aryl-sulfatase a (10-20x) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum arylsulfatase a (10-20x) n1=thrombolytique (traitement) | n2=en:increased serum arylsulfatase a (10-20x) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum arylsulfatase a. n1=thrombolytique (traitement) | n2=en:increased serum arylsulfatase a. | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum beta-carotene n1=thrombolytique (traitement) | n2=en:increased serum beta-carotene | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum beta-hexosaminidase n1=thrombolytique (traitement) | n2=en:increased serum beta-hexosaminidase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum beta-hexosaminidase (10-20x) n1=thrombolytique (traitement) | n2=en:increased serum beta-hexosaminidase (10-20x) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum bile acid concentration during pregnancy, resolves postpartum n1=thrombolytique (traitement) | n2=en:increased serum bile acid concentration during pregnancy, resolves postpartum | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum bile acids n1=thrombolytique (traitement) | n2=en:increased serum bile acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum bilirubin (in some patients) n1=thrombolytique (traitement) | n2=en:increased serum bilirubin (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum bilirubin due to hemolysis n1=thrombolytique (traitement) | n2=en:increased serum bilirubin due to hemolysis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum butyryl carnitine n1=thrombolytique (traitement) | n2=en:increased serum butyryl carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum c-reactive protein (crp, 123260) n1=thrombolytique (traitement) | n2=en:increased serum c-reactive protein (crp, 123260) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum c-reactive protein, episodic n1=thrombolytique (traitement) | n2=en:increased serum c-reactive protein, episodic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum c26-bile-acid intermediates n1=thrombolytique (traitement) | n2=en:increased serum c26-bile-acid intermediates | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum c4 and c5 acylcarnitine esters n1=thrombolytique (traitement) | n2=en:increased serum c4 and c5 acylcarnitine esters | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum cholesterol (in 3 of 10 patients) n1=thrombolytique (traitement) | n2=en:increased serum cholesterol (in 3 of 10 patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum citrulline (group b) n1=thrombolytique (traitement) | n2=en:increased serum citrulline (group b) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum creatine kinase (1 family) n1=thrombolytique (traitement) | n2=en:increased serum creatine kinase (1 family) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum creatine kinase (less common) n1=thrombolytique (traitement) | n2=en:increased serum creatine kinase (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum creatine kinase (patient a) n1=thrombolytique (traitement) | n2=en:increased serum creatine kinase (patient a) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum creatine kinase during episodes n1=thrombolytique (traitement) | n2=en:increased serum creatine kinase during episodes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum creatine kinase in acute stage n1=thrombolytique (traitement) | n2=en:increased serum creatine kinase in acute stage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum creatine kinase in patients with muscle involvement n1=thrombolytique (traitement) | n2=en:increased serum creatine kinase in patients with muscle involvement | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum creatine kinase, mild n1=thrombolytique (traitement) | n2=en:increased serum creatine kinase, mild | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum deoxyuridine n1=thrombolytique (traitement) | n2=en:increased serum deoxyuridine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum direct bilirubin n1=thrombolytique (traitement) | n2=en:increased serum direct bilirubin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum erythropoietin (epo, 133170) n1=thrombolytique (traitement) | n2=en:increased serum erythropoietin (epo, 133170) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum ferritin n1=thrombolytique (traitement) | n2=en:increased serum ferritin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum ferritin (in some patients) n1=thrombolytique (traitement) | n2=en:increased serum ferritin (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum fgf23 n1=thrombolytique (traitement) | n2=en:increased serum fgf23 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum gamma-ggt (231950) n1=thrombolytique (traitement) | n2=en:increased serum gamma-ggt (231950) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum glutamine n1=thrombolytique (traitement) | n2=en:increased serum glutamine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum glycerol n1=thrombolytique (traitement) | n2=en:increased serum glycerol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum glycine, leucine, isoleucine, valine n1=thrombolytique (traitement) | n2=en:increased serum glycine, leucine, isoleucine, valine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum gm-csf n1=thrombolytique (traitement) | n2=en:increased serum gm-csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum growth hormone levels n1=thrombolytique (traitement) | n2=en:increased serum growth hormone levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum iduronate sulfatase n1=thrombolytique (traitement) | n2=en:increased serum iduronate sulfatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum iduronate sulfatase (10-20x) n1=thrombolytique (traitement) | n2=en:increased serum iduronate sulfatase (10-20x) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum ige n1=thrombolytique (traitement) | n2=en:increased serum ige | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum insulin-like growth factor-1 (igf1, 147740) n1=thrombolytique (traitement) | n2=en:increased serum insulin-like growth factor-1 (igf1, 147740) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lactate n1=thrombolytique (traitement) | n2=en:increased serum lactate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lactate (in some patients) n1=thrombolytique (traitement) | n2=en:increased serum lactate (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lactate (mild) n1=thrombolytique (traitement) | n2=en:increased serum lactate (mild) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lactate (patient a) n1=thrombolytique (traitement) | n2=en:increased serum lactate (patient a) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lactate dehydrogenase (in 1 family) n1=thrombolytique (traitement) | n2=en:increased serum lactate dehydrogenase (in 1 family) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lactate dehydrogenase (ldh) n1=thrombolytique (traitement) | n2=en:increased serum lactate dehydrogenase (ldh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lactate during metabolic crisis n1=thrombolytique (traitement) | n2=en:increased serum lactate during metabolic crisis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lactate hydrogenase n1=thrombolytique (traitement) | n2=en:increased serum lactate hydrogenase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lactate in acute stage n1=thrombolytique (traitement) | n2=en:increased serum lactate in acute stage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lactate, particularly after exercise n1=thrombolytique (traitement) | n2=en:increased serum lactate, particularly after exercise | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum levels of free plasma thyroid hormones n1=thrombolytique (traitement) | n2=en:increased serum levels of free plasma thyroid hormones | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lipoproteins n1=thrombolytique (traitement) | n2=en:increased serum lipoproteins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum lysine (group b) n1=thrombolytique (traitement) | n2=en:increased serum lysine (group b) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum manganese n1=thrombolytique (traitement) | n2=en:increased serum manganese | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum methionine n1=thrombolytique (traitement) | n2=en:increased serum methionine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum methionine (reported in 2 cases) n1=thrombolytique (traitement) | n2=en:increased serum methionine (reported in 2 cases) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum osteocalcin n1=thrombolytique (traitement) | n2=en:increased serum osteocalcin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum pancreatic secretory trypsin inhibitor (psti) n1=thrombolytique (traitement) | n2=en:increased serum pancreatic secretory trypsin inhibitor (psti) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum parathyroid hormone (pth) n1=thrombolytique (traitement) | n2=en:increased serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum plasminogen activator inhibitor-1 (pai1, 173360) n1=thrombolytique (traitement) | n2=en:increased serum plasminogen activator inhibitor-1 (pai1, 173360) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum prostaglandin e2 n1=thrombolytique (traitement) | n2=en:increased serum prostaglandin e2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum pyruvate n1=thrombolytique (traitement) | n2=en:increased serum pyruvate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum pyruvate in acute stage n1=thrombolytique (traitement) | n2=en:increased serum pyruvate in acute stage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum pyruvate, mild n1=thrombolytique (traitement) | n2=en:increased serum pyruvate, mild | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum ratio of corticosterone to 18-hydroxycorticosterone (18-ohb) n1=thrombolytique (traitement) | n2=en:increased serum ratio of corticosterone to 18-hydroxycorticosterone (18-ohb) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum s-adenosylhomocysteine n1=thrombolytique (traitement) | n2=en:increased serum s-adenosylhomocysteine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum s-adenosylmethionine n1=thrombolytique (traitement) | n2=en:increased serum s-adenosylmethionine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum serotonin in 25% n1=thrombolytique (traitement) | n2=en:increased serum serotonin in 25% | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum thrombopoietin may occur n1=thrombolytique (traitement) | n2=en:increased serum thrombopoietin may occur | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum thymidine n1=thrombolytique (traitement) | n2=en:increased serum thymidine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum thyroid-stimulating hormone (tsh) n1=thrombolytique (traitement) | n2=en:increased serum thyroid-stimulating hormone (tsh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum thyrotropin n1=thrombolytique (traitement) | n2=en:increased serum thyrotropin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum total cholesterol n1=thrombolytique (traitement) | n2=en:increased serum total cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum transaminases (in 1 of 3 patients) n1=thrombolytique (traitement) | n2=en:increased serum transaminases (in 1 of 3 patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum transferrin n1=thrombolytique (traitement) | n2=en:increased serum transferrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum triglycerides (in some patients) n1=thrombolytique (traitement) | n2=en:increased serum triglycerides (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum triiodothyronine (t3) n1=thrombolytique (traitement) | n2=en:increased serum triiodothyronine (t3) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum unconjugated bilirubin n1=thrombolytique (traitement) | n2=en:increased serum unconjugated bilirubin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum uric acid n1=thrombolytique (traitement) | n2=en:increased serum uric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum vascular endothelial growth factor (vegf, 192240) n1=thrombolytique (traitement) | n2=en:increased serum vascular endothelial growth factor (vegf, 192240) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum vitamin b12 n1=thrombolytique (traitement) | n2=en:increased serum vitamin b12 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum, cerebrospinal fluid, and urinary levels of alpha-aminoadipic semialdehyde n1=thrombolytique (traitement) | n2=en:increased serum, cerebrospinal fluid, and urinary levels of alpha-aminoadipic semialdehyde | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum, urinary, and csf lysine n1=thrombolytique (traitement) | n2=en:increased serum, urinary, and csf lysine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased serum, urinary, and csf saccharopine (in some patients) n1=thrombolytique (traitement) | n2=en:increased serum, urinary, and csf saccharopine (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased sister chromatid exchange n1=thrombolytique (traitement) | n2=en:increased sister chromatid exchange | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased sodium-potassium pump activity n1=thrombolytique (traitement) | n2=en:increased sodium-potassium pump activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased soluble il2 receptor n1=thrombolytique (traitement) | n2=en:increased soluble il2 receptor | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased succinyladenosine (s-ado) in serum, urine, and csf n1=thrombolytique (traitement) | n2=en:increased succinyladenosine (s-ado) in serum, urine, and csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased succinylaminoimidazole carboxamide ribotide (saicar) n1=thrombolytique (traitement) | n2=en:increased succinylaminoimidazole carboxamide ribotide (saicar) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased susceptibility to ebv infection n1=thrombolytique (traitement) | n2=en:increased susceptibility to ebv infection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased thymine and dihydrothymine in bodily fluids n1=thrombolytique (traitement) | n2=en:increased thymine and dihydrothymine in bodily fluids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased thyroid-stimulating hormone (tsh) n1=thrombolytique (traitement) | n2=en:increased thyroid-stimulating hormone (tsh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased tissue levels of free fatty acids n1=thrombolytique (traitement) | n2=en:increased tissue levels of free fatty acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased tissue levels of triglycerides n1=thrombolytique (traitement) | n2=en:increased tissue levels of triglycerides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased tissue long-chain acylcarnitines n1=thrombolytique (traitement) | n2=en:increased tissue long-chain acylcarnitines | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased tissue long-chain fatty acids n1=thrombolytique (traitement) | n2=en:increased tissue long-chain fatty acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased total and conjugated bilirubin n1=thrombolytique (traitement) | n2=en:increased total and conjugated bilirubin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased total bilirubin may occur n1=thrombolytique (traitement) | n2=en:increased total bilirubin may occur | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased total white blood count n1=thrombolytique (traitement) | n2=en:increased total white blood count | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased toxic thioguanine nucleotides (tgns) on standard doses of thiopurine drugs n1=thrombolytique (traitement) | n2=en:increased toxic thioguanine nucleotides (tgns) on standard doses of thiopurine drugs | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased transferrin saturation (>60%) n1=thrombolytique (traitement) | n2=en:increased transferrin saturation (>60%) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased triglycerides (less common) n1=thrombolytique (traitement) | n2=en:increased triglycerides (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased uracil and dihydrouracil in bodily fluids n1=thrombolytique (traitement) | n2=en:increased uracil and dihydrouracil in bodily fluids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased uric acid level n1=thrombolytique (traitement) | n2=en:increased uric acid level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased uric acid with exercise n1=thrombolytique (traitement) | n2=en:increased uric acid with exercise | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 2-alpha-ketoglutaric acid n1=thrombolytique (traitement) | n2=en:increased urinary 2-alpha-ketoglutaric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 2-butanone n1=thrombolytique (traitement) | n2=en:increased urinary 2-butanone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 2-hydroxybutyrate n1=thrombolytique (traitement) | n2=en:increased urinary 2-hydroxybutyrate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 2-ketoglutarate (variable) n1=thrombolytique (traitement) | n2=en:increased urinary 2-ketoglutarate (variable) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 2-methyl-3 hydroxybutyrate n1=thrombolytique (traitement) | n2=en:increased urinary 2-methyl-3 hydroxybutyrate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 2-methyl-3-hydroxybutyric acid n1=thrombolytique (traitement) | n2=en:increased urinary 2-methyl-3-hydroxybutyric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 2-methylacetoacetic acid n1=thrombolytique (traitement) | n2=en:increased urinary 2-methylacetoacetic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 2-methylbutyryl glycine n1=thrombolytique (traitement) | n2=en:increased urinary 2-methylbutyryl glycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 2-methylbutyrylglycine n1=thrombolytique (traitement) | n2=en:increased urinary 2-methylbutyrylglycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 2-oxoglutaric acid n1=thrombolytique (traitement) | n2=en:increased urinary 2-oxoglutaric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 3-methylcrotonylglycine n1=thrombolytique (traitement) | n2=en:increased urinary 3-methylcrotonylglycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 3-methylglutaconic acid n1=thrombolytique (traitement) | n2=en:increased urinary 3-methylglutaconic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 3-oh-butyric acid n1=thrombolytique (traitement) | n2=en:increased urinary 3-oh-butyric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 3-oh-isovaleric acid ketonuria n1=thrombolytique (traitement) | n2=en:increased urinary 3-oh-isovaleric acid ketonuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 3-oh-propionic acid n1=thrombolytique (traitement) | n2=en:increased urinary 3-oh-propionic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary 7-biopterin (primapterin) n1=thrombolytique (traitement) | n2=en:increased urinary 7-biopterin (primapterin) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary acetoacetic acid n1=thrombolytique (traitement) | n2=en:increased urinary acetoacetic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary adenosine n1=thrombolytique (traitement) | n2=en:increased urinary adenosine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary alpha-ketoglutaric acid, intermittent n1=thrombolytique (traitement) | n2=en:increased urinary alpha-ketoglutaric acid, intermittent | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary and serum glycine n1=thrombolytique (traitement) | n2=en:increased urinary and serum glycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary carnitine n1=thrombolytique (traitement) | n2=en:increased urinary carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary carnitine esters n1=thrombolytique (traitement) | n2=en:increased urinary carnitine esters | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary catecholamines n1=thrombolytique (traitement) | n2=en:increased urinary catecholamines | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary catecholamines (with pheochromocytoma) n1=thrombolytique (traitement) | n2=en:increased urinary catecholamines (with pheochromocytoma) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary citric acid cycle intermediates n1=thrombolytique (traitement) | n2=en:increased urinary citric acid cycle intermediates | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary collagen type i n-telopeptide excretion (ntx) during hyperplastic callus formation n1=thrombolytique (traitement) | n2=en:increased urinary collagen type i n-telopeptide excretion (ntx) during hyperplastic callus formation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary cortisol/cortisone ratio n1=thrombolytique (traitement) | n2=en:increased urinary cortisol/cortisone ratio | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary creatine n1=thrombolytique (traitement) | n2=en:increased urinary creatine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary creatine-to-creatinine ratio n1=thrombolytique (traitement) | n2=en:increased urinary creatine-to-creatinine ratio | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary cross-linked n-telopetide of type i collagen n1=thrombolytique (traitement) | n2=en:increased urinary cross-linked n-telopetide of type i collagen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary cyclic amp (camp) in response to ddavp administration n1=thrombolytique (traitement) | n2=en:increased urinary cyclic amp (camp) in response to ddavp administration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary cystine, arginine, lysine, and ornithine (hcs and 2p21del) n1=thrombolytique (traitement) | n2=en:increased urinary cystine, arginine, lysine, and ornithine (hcs and 2p21del) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary delta-aminolevulinic acid (ala) and porphobilinogen (pbg) during acute attacks n1=thrombolytique (traitement) | n2=en:increased urinary delta-aminolevulinic acid (ala) and porphobilinogen (pbg) during acute attacks | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary dicarboxylic acid, transient n1=thrombolytique (traitement) | n2=en:increased urinary dicarboxylic acid, transient | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary dihydropyrimidines n1=thrombolytique (traitement) | n2=en:increased urinary dihydropyrimidines | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary disaccharides (mannosyl-n-acetylglucosamine) n1=thrombolytique (traitement) | n2=en:increased urinary disaccharides (mannosyl-n-acetylglucosamine) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary dopamine n1=thrombolytique (traitement) | n2=en:increased urinary dopamine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary dopamine and dopamine metabolites (paradoxical) n1=thrombolytique (traitement) | n2=en:increased urinary dopamine and dopamine metabolites (paradoxical) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary excretion of 4-hydroxybutyric acid (ghb) n1=thrombolytique (traitement) | n2=en:increased urinary excretion of 4-hydroxybutyric acid (ghb) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary excretion of camp n1=thrombolytique (traitement) | n2=en:increased urinary excretion of camp | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary excretion of coproporphyrin i n1=thrombolytique (traitement) | n2=en:increased urinary excretion of coproporphyrin i | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary excretion of cystine n1=thrombolytique (traitement) | n2=en:increased urinary excretion of cystine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary excretion of gamma-aminobutyric acid (gaba) n1=thrombolytique (traitement) | n2=en:increased urinary excretion of gamma-aminobutyric acid (gaba) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary excretion of l-xylulose n1=thrombolytique (traitement) | n2=en:increased urinary excretion of l-xylulose | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary formiminoglutamic acid (figlu) n1=thrombolytique (traitement) | n2=en:increased urinary formiminoglutamic acid (figlu) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary free sialic acid (n-acetylneuraminic acid, 20-200x normal) n1=thrombolytique (traitement) | n2=en:increased urinary free sialic acid (n-acetylneuraminic acid, 20-200x normal) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary free sialic acid excretion (n-acetylneuraminic acid, 5-20x normal) enlarged lysosomal vacuoles in lymphocytes and fibroblasts n1=thrombolytique (traitement) | n2=en:increased urinary free sialic acid excretion (n-acetylneuraminic acid, 5-20x normal) enlarged lysosomal vacuoles in lymphocytes and fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary fumaric acid n1=thrombolytique (traitement) | n2=en:increased urinary fumaric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary glutaric acid n1=thrombolytique (traitement) | n2=en:increased urinary glutaric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary glycerol n1=thrombolytique (traitement) | n2=en:increased urinary glycerol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary glycosphingolipids, particularly globotriaosylceramide n1=thrombolytique (traitement) | n2=en:increased urinary glycosphingolipids, particularly globotriaosylceramide | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary hga n1=thrombolytique (traitement) | n2=en:increased urinary hga | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary homovanillic acid (hva) n1=thrombolytique (traitement) | n2=en:increased urinary homovanillic acid (hva) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary hydroxyisovaleric acid n1=thrombolytique (traitement) | n2=en:increased urinary hydroxyisovaleric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary hypoxanthine n1=thrombolytique (traitement) | n2=en:increased urinary hypoxanthine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary isobutyryl glycine n1=thrombolytique (traitement) | n2=en:increased urinary isobutyryl glycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary ketones n1=thrombolytique (traitement) | n2=en:increased urinary ketones | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary l-glycerate n1=thrombolytique (traitement) | n2=en:increased urinary l-glycerate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary lactate n1=thrombolytique (traitement) | n2=en:increased urinary lactate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary levels of maoa substrates (endogenous bioamines) n1=thrombolytique (traitement) | n2=en:increased urinary levels of maoa substrates (endogenous bioamines) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary magnesium n1=thrombolytique (traitement) | n2=en:increased urinary magnesium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary malic acid n1=thrombolytique (traitement) | n2=en:increased urinary malic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary mannose-containing oligosaccharides n1=thrombolytique (traitement) | n2=en:increased urinary mannose-containing oligosaccharides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary methylcitrate n1=thrombolytique (traitement) | n2=en:increased urinary methylcitrate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary n-acetylated amino acids n1=thrombolytique (traitement) | n2=en:increased urinary n-acetylated amino acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary neopterin n1=thrombolytique (traitement) | n2=en:increased urinary neopterin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary o-hydroxyphenylacetic acid, phenylpyruvic acid, phenylacetic acid and phenylacetylglutamine n1=thrombolytique (traitement) | n2=en:increased urinary o-hydroxyphenylacetic acid, phenylpyruvic acid, phenylacetic acid and phenylacetylglutamine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary o-linked sialopeptides n1=thrombolytique (traitement) | n2=en:increased urinary o-linked sialopeptides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary oligosaccharides n1=thrombolytique (traitement) | n2=en:increased urinary oligosaccharides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary organic acids (in some patients) n1=thrombolytique (traitement) | n2=en:increased urinary organic acids (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary orotic acid (in some patients) n1=thrombolytique (traitement) | n2=en:increased urinary orotic acid (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary oxylate n1=thrombolytique (traitement) | n2=en:increased urinary oxylate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary phospholipids n1=thrombolytique (traitement) | n2=en:increased urinary phospholipids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary porphyrin precursors porphobilinogen (pbg) and delta-aminolevulinic acid (ala) during acute attacks n1=thrombolytique (traitement) | n2=en:increased urinary porphyrin precursors porphobilinogen (pbg) and delta-aminolevulinic acid (ala) during acute attacks | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary potassium n1=thrombolytique (traitement) | n2=en:increased urinary potassium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary propionyl glycine n1=thrombolytique (traitement) | n2=en:increased urinary propionyl glycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary prostaglandin e2 n1=thrombolytique (traitement) | n2=en:increased urinary prostaglandin e2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary s-sulfocysteine n1=thrombolytique (traitement) | n2=en:increased urinary s-sulfocysteine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary sialylglycopeptides n1=thrombolytique (traitement) | n2=en:increased urinary sialylglycopeptides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary succinic acid n1=thrombolytique (traitement) | n2=en:increased urinary succinic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary sulfatide excretion n1=thrombolytique (traitement) | n2=en:increased urinary sulfatide excretion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary sulfatides n1=thrombolytique (traitement) | n2=en:increased urinary sulfatides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary sulfite n1=thrombolytique (traitement) | n2=en:increased urinary sulfite | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary taurine n1=thrombolytique (traitement) | n2=en:increased urinary taurine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary thiosulfate n1=thrombolytique (traitement) | n2=en:increased urinary thiosulfate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary thymine n1=thrombolytique (traitement) | n2=en:increased urinary thymine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary tiglylglycine n1=thrombolytique (traitement) | n2=en:increased urinary tiglylglycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary tricarboxylic acid intermediates n1=thrombolytique (traitement) | n2=en:increased urinary tricarboxylic acid intermediates | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary uracil n1=thrombolytique (traitement) | n2=en:increased urinary uracil | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary urate n1=thrombolytique (traitement) | n2=en:increased urinary urate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary vanillylmandelic acid (vma) n1=thrombolytique (traitement) | n2=en:increased urinary vanillylmandelic acid (vma) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary, plasma, and csf d-2-hydroxyglutaric acid n1=thrombolytique (traitement) | n2=en:increased urinary, plasma, and csf d-2-hydroxyglutaric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary, plasma, and csf dihydrothymine n1=thrombolytique (traitement) | n2=en:increased urinary, plasma, and csf dihydrothymine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary, plasma, and csf dihydrouracil n1=thrombolytique (traitement) | n2=en:increased urinary, plasma, and csf dihydrouracil | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary, plasma, and csf l-2-hydroxyglutaric acid n1=thrombolytique (traitement) | n2=en:increased urinary, plasma, and csf l-2-hydroxyglutaric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary, plasma, and csf n-carbamyl-beta-alanine n1=thrombolytique (traitement) | n2=en:increased urinary, plasma, and csf n-carbamyl-beta-alanine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urinary, plasma, and csf n-carbamyl-beta-aminoisobutyric acid n1=thrombolytique (traitement) | n2=en:increased urinary, plasma, and csf n-carbamyl-beta-aminoisobutyric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urine oligosaccharides n1=thrombolytique (traitement) | n2=en:increased urine oligosaccharides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urine porphyrins at times n1=thrombolytique (traitement) | n2=en:increased urine porphyrins at times | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased urine vanillactic acid (vla) n1=thrombolytique (traitement) | n2=en:increased urine vanillactic acid (vla) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased venous pressure n1=thrombolytique (traitement) | n2=en:increased venous pressure | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased very-long chain fatty acids n1=thrombolytique (traitement) | n2=en:increased very-long chain fatty acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:increased vitamin e (alpha-tocopherol) levels n1=thrombolytique (traitement) | n2=en:increased vitamin e (alpha-tocopherol) levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:incresased urinary pyruvate n1=thrombolytique (traitement) | n2=en:incresased urinary pyruvate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indirect bilirubin increased n1=thrombolytique (traitement) | n2=en:indirect bilirubin increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indirect hyperbilirubinemia n1=thrombolytique (traitement) | n2=en:indirect hyperbilirubinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin n1=thrombolytique (traitement) | n2=en:indomethacin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin 100 mg oral capsule n1=thrombolytique (traitement) | n2=en:indomethacin 100 mg oral capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin 1mg injection (pdr for recon) n1=thrombolytique (traitement) | n2=en:indomethacin 1mg injection (pdr for recon) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin 20 mg oral capsule n1=thrombolytique (traitement) | n2=en:indomethacin 20 mg oral capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin 25mg capsule n1=thrombolytique (traitement) | n2=en:indomethacin 25mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin 25mg/5ml suspension n1=thrombolytique (traitement) | n2=en:indomethacin 25mg/5ml suspension | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin 40 mg oral capsule n1=thrombolytique (traitement) | n2=en:indomethacin 40 mg oral capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin 50mg capsule n1=thrombolytique (traitement) | n2=en:indomethacin 50mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin 50mg suppository n1=thrombolytique (traitement) | n2=en:indomethacin 50mg suppository | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin 75 mg extended release oral capsule n1=thrombolytique (traitement) | n2=en:indomethacin 75 mg extended release oral capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin 75 mg oral capsule n1=thrombolytique (traitement) | n2=en:indomethacin 75 mg oral capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin pwdr n1=thrombolytique (traitement) | n2=en:indomethacin pwdr | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:indomethacin sodium n1=thrombolytique (traitement) | n2=en:indomethacin sodium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ineffective erythropoiesis n1=thrombolytique (traitement) | n2=en:ineffective erythropoiesis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:infant acute biphenotypic leukemia n1=thrombolytique (traitement) | n2=en:infant acute biphenotypic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:infant acute undifferentiated leukemia n1=thrombolytique (traitement) | n2=en:infant acute undifferentiated leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:infantile hypophosphatasia n1=thrombolytique (traitement) | n2=en:infantile hypophosphatasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:inherited platelet disorder n1=thrombolytique (traitement) | n2=en:inherited platelet disorder | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:inner and outer dynein arm defects, variable n1=thrombolytique (traitement) | n2=en:inner and outer dynein arm defects, variable | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:insulin-dependent diabetes mellitus secretory diarrhea syndrome n1=thrombolytique (traitement) | n2=en:insulin-dependent diabetes mellitus secretory diarrhea syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intermediate level of cellular sensitivity to uv light n1=thrombolytique (traitement) | n2=en:intermediate level of cellular sensitivity to uv light | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intermittent 3-methylglutaconic aciduria n1=thrombolytique (traitement) | n2=en:intermittent 3-methylglutaconic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intermittent dicarbonic aciduria n1=thrombolytique (traitement) | n2=en:intermittent dicarbonic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intermittent ethylmalonic aciduria n1=thrombolytique (traitement) | n2=en:intermittent ethylmalonic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intermittent increase of urinary ethylmalonic acid n1=thrombolytique (traitement) | n2=en:intermittent increase of urinary ethylmalonic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intermittent severe hypoglycemia (in some patients) n1=thrombolytique (traitement) | n2=en:intermittent severe hypoglycemia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intermittent thrombocytopenia n1=thrombolytique (traitement) | n2=en:intermittent thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:internuclear chromatin bridges n1=thrombolytique (traitement) | n2=en:internuclear chromatin bridges | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:interstitial deletion of 17p11.2 (most common is 3.7mb) n1=thrombolytique (traitement) | n2=en:interstitial deletion of 17p11.2 (most common is 3.7mb) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:interstitial or terminal deletion of 18q n1=thrombolytique (traitement) | n2=en:interstitial or terminal deletion of 18q | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intracellular accumulation of unesterified cholesterol n1=thrombolytique (traitement) | n2=en:intracellular accumulation of unesterified cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intracellular fingerprint profiles on ultrastructural analysis n1=thrombolytique (traitement) | n2=en:intracellular fingerprint profiles on ultrastructural analysis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intracellular glycosphingolipid deposition in all tissues of the body n1=thrombolytique (traitement) | n2=en:intracellular glycosphingolipid deposition in all tissues of the body | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intracellular granular material on ultrastructural analysis n1=thrombolytique (traitement) | n2=en:intracellular granular material on ultrastructural analysis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intracellular pas-positive polyglucosan inclusion bodies ('lafora' bodies) can be found in various tissues (brain, liver, muscle, heart, skin) n1=thrombolytique (traitement) | n2=en:intracellular pas-positive polyglucosan inclusion bodies ('lafora' bodies) can be found in various tissues (brain, liver, muscle, heart, skin) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intracellular redox disturbance (reduced cytoplasm and oxidized mitochondria (group b)) n1=thrombolytique (traitement) | n2=en:intracellular redox disturbance (reduced cytoplasm and oxidized mitochondria (group b)) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:intracytoplasmic vacuoles in eosinophils, neutrophils and lymphocytes n1=thrombolytique (traitement) | n2=en:intracytoplasmic vacuoles in eosinophils, neutrophils and lymphocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iodide organification defect n1=thrombolytique (traitement) | n2=en:iodide organification defect | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iodine depletion n1=thrombolytique (traitement) | n2=en:iodine depletion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iron binding capacity total increased n1=thrombolytique (traitement) | n2=en:iron binding capacity total increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iron deficiency n1=thrombolytique (traitement) | n2=en:iron deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iron deficiency (in some patients) n1=thrombolytique (traitement) | n2=en:iron deficiency (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iron deficiency anemia (adults) n1=thrombolytique (traitement) | n2=en:iron deficiency anemia (adults) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iron deposition in basal ganglia, liver, pancreas, visceral organs detectable by ct and mri n1=thrombolytique (traitement) | n2=en:iron deposition in basal ganglia, liver, pancreas, visceral organs detectable by ct and mri | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iron low n1=thrombolytique (traitement) | n2=en:iron low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iron overload (in some patients) n1=thrombolytique (traitement) | n2=en:iron overload (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:iron-deficiency anemia (in some patients) n1=thrombolytique (traitement) | n2=en:iron-deficiency anemia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:irregular distribution of chondrocytes, enlarged chondrocyte lacunae, excessive fibrous matrix, perilacunar loss of glycosaminoglycan, excessive collagen aggregation n1=thrombolytique (traitement) | n2=en:irregular distribution of chondrocytes, enlarged chondrocyte lacunae, excessive fibrous matrix, perilacunar loss of glycosaminoglycan, excessive collagen aggregation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:irregularly shaped sperm heads n1=thrombolytique (traitement) | n2=en:irregularly shaped sperm heads | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:isochromosome 12p (i(12p)) n1=thrombolytique (traitement) | n2=en:isochromosome 12p (i(12p)) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:isochromosome often missing in lymphocyte n1=thrombolytique (traitement) | n2=en:isochromosome often missing in lymphocyte | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:isovaleric acidemia n1=thrombolytique (traitement) | n2=en:isovaleric acidemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:isovalericaciduria n1=thrombolytique (traitement) | n2=en:isovalericaciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:isovalerylglycinuria n1=thrombolytique (traitement) | n2=en:isovalerylglycinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:itgb3 gene n1=thrombolytique (traitement) | n2=en:itgb3 gene | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:itgb3 wt allele n1=thrombolytique (traitement) | n2=en:itgb3 wt allele | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:itk deficiency n1=thrombolytique (traitement) | n2=en:itk deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:jacobsen syndrome n1=thrombolytique (traitement) | n2=en:jacobsen syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:juvenile myelomonocytic leukemia n1=thrombolytique (traitement) | n2=en:juvenile myelomonocytic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:karyomegaly may be found in other visceral organs n1=thrombolytique (traitement) | n2=en:karyomegaly may be found in other visceral organs | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:karyotype analysis normal finding n1=thrombolytique (traitement) | n2=en:karyotype analysis normal finding | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:keratan sulfate excretion in urine that decreases with age n1=thrombolytique (traitement) | n2=en:keratan sulfate excretion in urine that decreases with age | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:keratan sulfaturia in some patients n1=thrombolytique (traitement) | n2=en:keratan sulfaturia in some patients | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ketoacidosis n1=thrombolytique (traitement) | n2=en:ketoacidosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ketonemia n1=thrombolytique (traitement) | n2=en:ketonemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ketonuria n1=thrombolytique (traitement) | n2=en:ketonuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ketonuria (1 patient) n1=thrombolytique (traitement) | n2=en:ketonuria (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ketonuria, acute n1=thrombolytique (traitement) | n2=en:ketonuria, acute | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ketoses, metabolic n1=thrombolytique (traitement) | n2=en:ketoses, metabolic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ketosis n1=thrombolytique (traitement) | n2=en:ketosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:kypokalemia n1=thrombolytique (traitement) | n2=en:kypokalemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:l'abdomen n1=thrombolytique (traitement) | n2=en:l'abdomen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:laboratory abnormalities n1=thrombolytique (traitement) | n2=en:laboratory abnormalities | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lack of ciliary motility n1=thrombolytique (traitement) | n2=en:lack of ciliary motility | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lack of dense granules in platelets n1=thrombolytique (traitement) | n2=en:lack of dense granules in platelets | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lack of excessive parenchymal iron storage n1=thrombolytique (traitement) | n2=en:lack of excessive parenchymal iron storage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lack of lysosomal inclusions in visceral organs n1=thrombolytique (traitement) | n2=en:lack of lysosomal inclusions in visceral organs | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lactate dehydrogenase increased n1=thrombolytique (traitement) | n2=en:lactate dehydrogenase increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lactate high n1=thrombolytique (traitement) | n2=en:lactate high | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lactate pyruvate ratio normal n1=thrombolytique (traitement) | n2=en:lactate pyruvate ratio normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lactic acidemia n1=thrombolytique (traitement) | n2=en:lactic acidemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lactic acidemia (2p21del) n1=thrombolytique (traitement) | n2=en:lactic acidemia (2p21del) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lactic acidosis n1=thrombolytique (traitement) | n2=en:lactic acidosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lacunar halos around chondrocytes in skeletal cartilage n1=thrombolytique (traitement) | n2=en:lacunar halos around chondrocytes in skeletal cartilage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:large agranular platelets n1=thrombolytique (traitement) | n2=en:large agranular platelets | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:large platelets (in some patients) n1=thrombolytique (traitement) | n2=en:large platelets (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:large spermatozoa n1=thrombolytique (traitement) | n2=en:large spermatozoa | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:large, spherical platelets n1=thrombolytique (traitement) | n2=en:large, spherical platelets | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lemierre syndrome n1=thrombolytique (traitement) | n2=en:lemierre syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:leukemoid reaction n1=thrombolytique (traitement) | n2=en:leukemoid reaction | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:leukocyte inclusion bodies (dohle-like bodies) n1=thrombolytique (traitement) | n2=en:leukocyte inclusion bodies (dohle-like bodies) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:leukocyte inclusion bodies (em) - intermediate filaments and ribosome clusters irregularly dispersed in cytoplasm n1=thrombolytique (traitement) | n2=en:leukocyte inclusion bodies (em) - intermediate filaments and ribosome clusters irregularly dispersed in cytoplasm | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:leukocytosis n1=thrombolytique (traitement) | n2=en:leukocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:leukocytosis (before age 50) n1=thrombolytique (traitement) | n2=en:leukocytosis (before age 50) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:leukocytosis (mean leukocyte count 18.7 x 10(9)/l) n1=thrombolytique (traitement) | n2=en:leukocytosis (mean leukocyte count 18.7 x 10(9)/l) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:leukocytosis with eosinophilia during stage 1 n1=thrombolytique (traitement) | n2=en:leukocytosis with eosinophilia during stage 1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:leukocytosis with predominant granulocytosis (20,000-100,000 /mm3) common n1=thrombolytique (traitement) | n2=en:leukocytosis with predominant granulocytosis (20,000-100,000 /mm3) common | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:leukoerythroblastosis n1=thrombolytique (traitement) | n2=en:leukoerythroblastosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:leukopenia (less common) n1=thrombolytique (traitement) | n2=en:leukopenia (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:leukotriene c4 synthetase deficiency n1=thrombolytique (traitement) | n2=en:leukotriene c4 synthetase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lewis a- and b- negative cells n1=thrombolytique (traitement) | n2=en:lewis a- and b- negative cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lipid droplets in granulocytes n1=thrombolytique (traitement) | n2=en:lipid droplets in granulocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lipid vacuoles in leukocytes (jordan bodies) n1=thrombolytique (traitement) | n2=en:lipid vacuoles in leukocytes (jordan bodies) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lipopigment in extraneuronal cells n1=thrombolytique (traitement) | n2=en:lipopigment in extraneuronal cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:liposomal daunorubicin citrate n1=thrombolytique (traitement) | n2=en:liposomal daunorubicin citrate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lithium level low n1=thrombolytique (traitement) | n2=en:lithium level low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:little to absent aspartylglucosaminuria activity n1=thrombolytique (traitement) | n2=en:little to absent aspartylglucosaminuria activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:liver enzymes abnormal n1=thrombolytique (traitement) | n2=en:liver enzymes abnormal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:liver function tests normal n1=thrombolytique (traitement) | n2=en:liver function tests normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:liver phosphorylase kinase (phk) deficiency n1=thrombolytique (traitement) | n2=en:liver phosphorylase kinase (phk) deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:liver transaminases normal to slightly increased n1=thrombolytique (traitement) | n2=en:liver transaminases normal to slightly increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:long-chain dicarboxylic aciduria n1=thrombolytique (traitement) | n2=en:long-chain dicarboxylic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:long-chain ketonuria n1=thrombolytique (traitement) | n2=en:long-chain ketonuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:loss of ciliary beat coordination n1=thrombolytique (traitement) | n2=en:loss of ciliary beat coordination | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:loss of galactose and sialic acid from multiple branches of complex type n-glycans (in some patients) n1=thrombolytique (traitement) | n2=en:loss of galactose and sialic acid from multiple branches of complex type n-glycans (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:loss of heterozygosity in giant cell astrocytomas, angiomyolipomas, rhabdomyomas n1=thrombolytique (traitement) | n2=en:loss of heterozygosity in giant cell astrocytomas, angiomyolipomas, rhabdomyomas | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low 25-oh-vitamin d level n1=thrombolytique (traitement) | n2=en:low 25-oh-vitamin d level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low absolute lymphocyte count n1=thrombolytique (traitement) | n2=en:low absolute lymphocyte count | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low acth level n1=thrombolytique (traitement) | n2=en:low acth level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low alkaline phosphatase n1=thrombolytique (traitement) | n2=en:low alkaline phosphatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low apolipoprotein n1=thrombolytique (traitement) | n2=en:low apolipoprotein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low blood oxygen saturation n1=thrombolytique (traitement) | n2=en:low blood oxygen saturation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low cd4+ count n1=thrombolytique (traitement) | n2=en:low cd4+ count | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low cholesterol esterification rates n1=thrombolytique (traitement) | n2=en:low cholesterol esterification rates | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low copper and ceruloplasmin n1=thrombolytique (traitement) | n2=en:low copper and ceruloplasmin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low csf creatine n1=thrombolytique (traitement) | n2=en:low csf creatine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low csf creatinine n1=thrombolytique (traitement) | n2=en:low csf creatinine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low density lipoprotein increased n1=thrombolytique (traitement) | n2=en:low density lipoprotein increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low erythrocyte sedimentation rate n1=thrombolytique (traitement) | n2=en:low erythrocyte sedimentation rate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low fasting glucose (in some patients) n1=thrombolytique (traitement) | n2=en:low fasting glucose (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low free carnitine n1=thrombolytique (traitement) | n2=en:low free carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low growth hormone levels n1=thrombolytique (traitement) | n2=en:low growth hormone levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low ldl cholesterol n1=thrombolytique (traitement) | n2=en:low ldl cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low leukocyte alkaline phosphatase activity n1=thrombolytique (traitement) | n2=en:low leukocyte alkaline phosphatase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low level of c4 and c2 n1=thrombolytique (traitement) | n2=en:low level of c4 and c2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low levels of cd11/cd18 (lfa-1 or leukocyte function antigen-1) glycoprotein n1=thrombolytique (traitement) | n2=en:low levels of cd11/cd18 (lfa-1 or leukocyte function antigen-1) glycoprotein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low levels of serum mg(2+) in the absence of other electrolyte disturbances n1=thrombolytique (traitement) | n2=en:low levels of serum mg(2+) in the absence of other electrolyte disturbances | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low maximal oxygen uptake on exercise testing n1=thrombolytique (traitement) | n2=en:low maximal oxygen uptake on exercise testing | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or absent adrenocorticotropic hormone (acth) n1=thrombolytique (traitement) | n2=en:low or absent adrenocorticotropic hormone (acth) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or absent adrenocorticotropic hormone (acth) in some patients n1=thrombolytique (traitement) | n2=en:low or absent adrenocorticotropic hormone (acth) in some patients | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or absent follicle stimulating hormone (fsh) n1=thrombolytique (traitement) | n2=en:low or absent follicle stimulating hormone (fsh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or absent growth hormone (gh) n1=thrombolytique (traitement) | n2=en:low or absent growth hormone (gh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or absent iga levels n1=thrombolytique (traitement) | n2=en:low or absent iga levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or absent igm levels n1=thrombolytique (traitement) | n2=en:low or absent igm levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or absent luteinizing hormone (lh) n1=thrombolytique (traitement) | n2=en:low or absent luteinizing hormone (lh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or absent prolactin (pl) n1=thrombolytique (traitement) | n2=en:low or absent prolactin (pl) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or absent thyroid-stimulating hormone (tsh) n1=thrombolytique (traitement) | n2=en:low or absent thyroid-stimulating hormone (tsh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or absent thyrotropin (tsh) n1=thrombolytique (traitement) | n2=en:low or absent thyrotropin (tsh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or low-normal serum t4 n1=thrombolytique (traitement) | n2=en:low or low-normal serum t4 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or normal serum calcium n1=thrombolytique (traitement) | n2=en:low or normal serum calcium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or normal serum erythropoietin n1=thrombolytique (traitement) | n2=en:low or normal serum erythropoietin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or normal serum igm n1=thrombolytique (traitement) | n2=en:low or normal serum igm | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or undetectable c-peptide n1=thrombolytique (traitement) | n2=en:low or undetectable c-peptide | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low or undetectable insulin n1=thrombolytique (traitement) | n2=en:low or undetectable insulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low peripheral neutrophil counts (absolute neutrophil count less than 500/microliter) n1=thrombolytique (traitement) | n2=en:low peripheral neutrophil counts (absolute neutrophil count less than 500/microliter) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low plasma arginine n1=thrombolytique (traitement) | n2=en:low plasma arginine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low plasma citrulline n1=thrombolytique (traitement) | n2=en:low plasma citrulline | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low plasma free and total carnitine n1=thrombolytique (traitement) | n2=en:low plasma free and total carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low plasma hdl n1=thrombolytique (traitement) | n2=en:low plasma hdl | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low plasma methionine n1=thrombolytique (traitement) | n2=en:low plasma methionine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low plasma triglyceride level n1=thrombolytique (traitement) | n2=en:low plasma triglyceride level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low plasma tryptophan (inflammatory type b) n1=thrombolytique (traitement) | n2=en:low plasma tryptophan (inflammatory type b) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low procollagen 1 c-peptide (in some patients) n1=thrombolytique (traitement) | n2=en:low procollagen 1 c-peptide (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low pyruvate carboxylase activity in liver and cultured fibroblasts n1=thrombolytique (traitement) | n2=en:low pyruvate carboxylase activity in liver and cultured fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low rai (radioactive iodine) uptake n1=thrombolytique (traitement) | n2=en:low rai (radioactive iodine) uptake | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum acth n1=thrombolytique (traitement) | n2=en:low serum acth | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum alkaline phosphatase in heterozygotes n1=thrombolytique (traitement) | n2=en:low serum alkaline phosphatase in heterozygotes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum alpha-fetoprotein (recessive) n1=thrombolytique (traitement) | n2=en:low serum alpha-fetoprotein (recessive) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum anti-mullerian hormone (amh) levels n1=thrombolytique (traitement) | n2=en:low serum anti-mullerian hormone (amh) levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum calcium n1=thrombolytique (traitement) | n2=en:low serum calcium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum ceruloplasmin n1=thrombolytique (traitement) | n2=en:low serum ceruloplasmin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum concentration of intercellular adhesion molecule 1 (icam1) n1=thrombolytique (traitement) | n2=en:low serum concentration of intercellular adhesion molecule 1 (icam1) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum cortisol n1=thrombolytique (traitement) | n2=en:low serum cortisol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum igg and iga n1=thrombolytique (traitement) | n2=en:low serum igg and iga | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum levels of branched-chain amino acids n1=thrombolytique (traitement) | n2=en:low serum levels of branched-chain amino acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum levels of ketone bodies n1=thrombolytique (traitement) | n2=en:low serum levels of ketone bodies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum magnesium n1=thrombolytique (traitement) | n2=en:low serum magnesium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum transferrin n1=thrombolytique (traitement) | n2=en:low serum transferrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low serum uric acid n1=thrombolytique (traitement) | n2=en:low serum uric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low to absent apo a-i (detroit 107680.0011) n1=thrombolytique (traitement) | n2=en:low to absent apo a-i (detroit 107680.0011) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low to absent high density lipoprotein (hdl) (detroit 107680.0011) n1=thrombolytique (traitement) | n2=en:low to absent high density lipoprotein (hdl) (detroit 107680.0011) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low to low-normal magnesium n1=thrombolytique (traitement) | n2=en:low to low-normal magnesium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low to low-normal platelet count n1=thrombolytique (traitement) | n2=en:low to low-normal platelet count | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low to normal plasma methionine n1=thrombolytique (traitement) | n2=en:low to normal plasma methionine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low to normal reticulocyte count n1=thrombolytique (traitement) | n2=en:low to normal reticulocyte count | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low to normal serum calcium n1=thrombolytique (traitement) | n2=en:low to normal serum calcium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low to normal tsh (values may vary depending on the measurement methods used) n1=thrombolytique (traitement) | n2=en:low to normal tsh (values may vary depending on the measurement methods used) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low to very low hdl cholesterol n1=thrombolytique (traitement) | n2=en:low to very low hdl cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low total serum protein n1=thrombolytique (traitement) | n2=en:low total serum protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low urinary cyclic amp response to pth administration n1=thrombolytique (traitement) | n2=en:low urinary cyclic amp response to pth administration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low urinary excretion of neutral 17-ketosteroids n1=thrombolytique (traitement) | n2=en:low urinary excretion of neutral 17-ketosteroids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low urinary orotic acid n1=thrombolytique (traitement) | n2=en:low urinary orotic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low-molecular-weight proteinuria n1=thrombolytique (traitement) | n2=en:low-molecular-weight proteinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low-normal igm n1=thrombolytique (traitement) | n2=en:low-normal igm | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low-normal platelet count (89-290 x 10(9)/l) n1=thrombolytique (traitement) | n2=en:low-normal platelet count (89-290 x 10(9)/l) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low-normal platelet count in carrier females n1=thrombolytique (traitement) | n2=en:low-normal platelet count in carrier females | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low-to-normal csf lactate n1=thrombolytique (traitement) | n2=en:low-to-normal csf lactate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low-to-normal platelet count n1=thrombolytique (traitement) | n2=en:low-to-normal platelet count | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:low-to-normal platelet count (45 x 10(9)/l) n1=thrombolytique (traitement) | n2=en:low-to-normal platelet count (45 x 10(9)/l) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lower total cholesterol n1=thrombolytique (traitement) | n2=en:lower total cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lupus anticoagulant (in some patients) n1=thrombolytique (traitement) | n2=en:lupus anticoagulant (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lutheran negative phenotype n1=thrombolytique (traitement) | n2=en:lutheran negative phenotype | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lymphopenia n1=thrombolytique (traitement) | n2=en:lymphopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lysine-ketoglutarate reductase deficiency n1=thrombolytique (traitement) | n2=en:lysine-ketoglutarate reductase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lysinuric protein intolerance n1=thrombolytique (traitement) | n2=en:lysinuric protein intolerance | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lysosomal-like storage vacuoles in various tissues n1=thrombolytique (traitement) | n2=en:lysosomal-like storage vacuoles in various tissues | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lysyl hydroxylase deficiency n1=thrombolytique (traitement) | n2=en:lysyl hydroxylase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:lysyl pyridinoline/hydroxylysyl pyridinoline (lp/hp) ratio approximately 1 n1=thrombolytique (traitement) | n2=en:lysyl pyridinoline/hydroxylysyl pyridinoline (lp/hp) ratio approximately 1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrocytic anemia n1=thrombolytique (traitement) | n2=en:macrocytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrocytic anemia (1 patient) n1=thrombolytique (traitement) | n2=en:macrocytic anemia (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrocytic anemia (folate or rarely b12 deficiency) n1=thrombolytique (traitement) | n2=en:macrocytic anemia (folate or rarely b12 deficiency) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrocytic anemia in manifesting females n1=thrombolytique (traitement) | n2=en:macrocytic anemia in manifesting females | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrocytic hemolytic anemia, appears in infancy (in 1 family) n1=thrombolytique (traitement) | n2=en:macrocytic hemolytic anemia, appears in infancy (in 1 family) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrocytosis n1=thrombolytique (traitement) | n2=en:macrocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrocytosis (in some patients) n1=thrombolytique (traitement) | n2=en:macrocytosis (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrothrombocyte n1=thrombolytique (traitement) | n2=en:macrothrombocyte | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrothrombocytes occasionally noted in carrier female peripheral blood smear n1=thrombolytique (traitement) | n2=en:macrothrombocytes occasionally noted in carrier female peripheral blood smear | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrothrombocytopenia n1=thrombolytique (traitement) | n2=en:macrothrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrothrombocytopenia and progressive sensorineural deafness n1=thrombolytique (traitement) | n2=en:macrothrombocytopenia and progressive sensorineural deafness | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:macrothrombocytopenia, autosomal dominant, tubb1-related n1=thrombolytique (traitement) | n2=en:macrothrombocytopenia, autosomal dominant, tubb1-related | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:male sex hormones low n1=thrombolytique (traitement) | n2=en:male sex hormones low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:march myoglobinuria n1=thrombolytique (traitement) | n2=en:march myoglobinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:marked elevation of erythrocyte sedimentation rate n1=thrombolytique (traitement) | n2=en:marked elevation of erythrocyte sedimentation rate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:marked elevation of serum c-reactive protein level (crp 123260) n1=thrombolytique (traitement) | n2=en:marked elevation of serum c-reactive protein level (crp 123260) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:marked hypoalphalipoproteinemia (in some patients) n1=thrombolytique (traitement) | n2=en:marked hypoalphalipoproteinemia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:marked hypobetalipoproteinemia n1=thrombolytique (traitement) | n2=en:marked hypobetalipoproteinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:markedly decreased coproporphyrinogen oxidase activity (harderoporphyria, lymphocytes) n1=thrombolytique (traitement) | n2=en:markedly decreased coproporphyrinogen oxidase activity (harderoporphyria, lymphocytes) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:markedly decreased or absent serum 1,25-dihydroxyvitamin d3 n1=thrombolytique (traitement) | n2=en:markedly decreased or absent serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:markedly elevated sodium in urine, sweat, saliva, and stool n1=thrombolytique (traitement) | n2=en:markedly elevated sodium in urine, sweat, saliva, and stool | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:markedly increased serum creatine kinase n1=thrombolytique (traitement) | n2=en:markedly increased serum creatine kinase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:markedly reduced iga levels n1=thrombolytique (traitement) | n2=en:markedly reduced iga levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:markedly reduced igg levels n1=thrombolytique (traitement) | n2=en:markedly reduced igg levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:maturation arrest of neutrophil precursors seen on bone marrow biopsy n1=thrombolytique (traitement) | n2=en:maturation arrest of neutrophil precursors seen on bone marrow biopsy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:maturation arrest platelet n1=thrombolytique (traitement) | n2=en:maturation arrest platelet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:maximal voluntary ventilation capacity below reference range n1=thrombolytique (traitement) | n2=en:maximal voluntary ventilation capacity below reference range | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:may have increased serum parathyroid hormone (pth) n1=thrombolytique (traitement) | n2=en:may have increased serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:may-hegglin anomaly n1=thrombolytique (traitement) | n2=en:may-hegglin anomaly | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mcv - raised n1=thrombolytique (traitement) | n2=en:mcv - raised | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mean corpuscular volume may mildly increased or normal n1=thrombolytique (traitement) | n2=en:mean corpuscular volume may mildly increased or normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mean platelet volume (mpv) 12.6fl n1=thrombolytique (traitement) | n2=en:mean platelet volume (mpv) 12.6fl | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mechanical phlebitis n1=thrombolytique (traitement) | n2=en:mechanical phlebitis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mechlorethamine n1=thrombolytique (traitement) | n2=en:mechlorethamine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mechlorethamine 0.00016 mg/mg topical gel n1=thrombolytique (traitement) | n2=en:mechlorethamine 0.00016 mg/mg topical gel | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mechlorethamine hydrochloride n1=thrombolytique (traitement) | n2=en:mechlorethamine hydrochloride | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mechlorethamine hydrochloride 10mg injection n1=thrombolytique (traitement) | n2=en:mechlorethamine hydrochloride 10mg injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:median mean platelet volume (mpv) 12.5fl n1=thrombolytique (traitement) | n2=en:median mean platelet volume (mpv) 12.5fl | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:median mean platelet volume (mpv) 18fl n1=thrombolytique (traitement) | n2=en:median mean platelet volume (mpv) 18fl | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:median mean platelet volume (mpv) 20fl n1=thrombolytique (traitement) | n2=en:median mean platelet volume (mpv) 20fl | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:median mean platelet volume 13fl n1=thrombolytique (traitement) | n2=en:median mean platelet volume 13fl | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:median platelet volume 15.5fl n1=thrombolytique (traitement) | n2=en:median platelet volume 15.5fl | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mediterranean macrothrombocytopenia n1=thrombolytique (traitement) | n2=en:mediterranean macrothrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mediterranean thrombocytopenia n1=thrombolytique (traitement) | n2=en:mediterranean thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:medium chain dicarboxylic aciduria n1=thrombolytique (traitement) | n2=en:medium chain dicarboxylic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:medium-chain acyl-coa dehydrogenase deficiency n1=thrombolytique (traitement) | n2=en:medium-chain acyl-coa dehydrogenase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:medullary blast count of less than 5% n1=thrombolytique (traitement) | n2=en:medullary blast count of less than 5% | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megakaryocytes are abnormally stretched along bone marrow sinuses n1=thrombolytique (traitement) | n2=en:megakaryocytes are abnormally stretched along bone marrow sinuses | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megakaryocytes decreased n1=thrombolytique (traitement) | n2=en:megakaryocytes decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megakaryocytes have dysplastic features n1=thrombolytique (traitement) | n2=en:megakaryocytes have dysplastic features | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megakaryocytes increased in bone marrow n1=thrombolytique (traitement) | n2=en:megakaryocytes increased in bone marrow | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megakaryocytes show large and irregular bleb protrusions n1=thrombolytique (traitement) | n2=en:megakaryocytes show large and irregular bleb protrusions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megakaryocytes show ultrastructural defects with abnormal membranes n1=thrombolytique (traitement) | n2=en:megakaryocytes show ultrastructural defects with abnormal membranes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megakaryocytes with hypolobulated nuclei or separated nuclei n1=thrombolytique (traitement) | n2=en:megakaryocytes with hypolobulated nuclei or separated nuclei | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megakaryocytic aplasia n1=thrombolytique (traitement) | n2=en:megakaryocytic aplasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megakaryocytic thrombocytopenia n1=thrombolytique (traitement) | n2=en:megakaryocytic thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megakaryocytopenia n1=thrombolytique (traitement) | n2=en:megakaryocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megaloblastic anemia n1=thrombolytique (traitement) | n2=en:megaloblastic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megaloblastic anemia due to dihydrofolate reductase deficiency n1=thrombolytique (traitement) | n2=en:megaloblastic anemia due to dihydrofolate reductase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megaloblastic anemia, chronic, relapsing n1=thrombolytique (traitement) | n2=en:megaloblastic anemia, chronic, relapsing | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:megaloblastic erythropoiesis n1=thrombolytique (traitement) | n2=en:megaloblastic erythropoiesis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:melphalan n1=thrombolytique (traitement) | n2=en:melphalan | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:melphalan 2mg tablet n1=thrombolytique (traitement) | n2=en:melphalan 2mg tablet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:melphalan 5 mg/ml injectable solution n1=thrombolytique (traitement) | n2=en:melphalan 5 mg/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:melphalan hydrochloride n1=thrombolytique (traitement) | n2=en:melphalan hydrochloride | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:menorrhagia n1=thrombolytique (traitement) | n2=en:menorrhagia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mercaptopurine n1=thrombolytique (traitement) | n2=en:mercaptopurine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mercaptopurine 20 mg/ml oral suspension n1=thrombolytique (traitement) | n2=en:mercaptopurine 20 mg/ml oral suspension | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mercaptopurine 50mg tablet n1=thrombolytique (traitement) | n2=en:mercaptopurine 50mg tablet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:metabolic acidosis n1=thrombolytique (traitement) | n2=en:metabolic acidosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:metabolic thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:metabolic thrombocytopenic purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:metachromasia of white blood cells and fibroblasts n1=thrombolytique (traitement) | n2=en:metachromasia of white blood cells and fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:metachromatic deposits (sulfatide-containing) in central and peripheral nervous systems and visceral organs n1=thrombolytique (traitement) | n2=en:metachromatic deposits (sulfatide-containing) in central and peripheral nervous systems and visceral organs | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:metachromatic leukodystrophy due to saposin b deficiency n1=thrombolytique (traitement) | n2=en:metachromatic leukodystrophy due to saposin b deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methemoglobin concentration 12 to 19% n1=thrombolytique (traitement) | n2=en:methemoglobin concentration 12 to 19% | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methemoglobinemia (e.g. hb m boston 141800.0092) n1=thrombolytique (traitement) | n2=en:methemoglobinemia (e.g. hb m boston 141800.0092) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methionine adenosyltransferase deficiency n1=thrombolytique (traitement) | n2=en:methionine adenosyltransferase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methioninuria n1=thrombolytique (traitement) | n2=en:methioninuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methotrexate n1=thrombolytique (traitement) | n2=en:methotrexate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methotrexate 1000 mg injection n1=thrombolytique (traitement) | n2=en:methotrexate 1000 mg injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methotrexate 10mg tablet n1=thrombolytique (traitement) | n2=en:methotrexate 10mg tablet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methotrexate 12.5mg/ml infusion solution 30ml vial n1=thrombolytique (traitement) | n2=en:methotrexate 12.5mg/ml infusion solution 30ml vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methotrexate 15 mg oral tablet n1=thrombolytique (traitement) | n2=en:methotrexate 15 mg oral tablet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methotrexate 2.5mg tablet n1=thrombolytique (traitement) | n2=en:methotrexate 2.5mg tablet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methotrexate 2.5mg/ml injection solution 2ml vial n1=thrombolytique (traitement) | n2=en:methotrexate 2.5mg/ml injection solution 2ml vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methotrexate 25 mg/ml injection n1=thrombolytique (traitement) | n2=en:methotrexate 25 mg/ml injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methotrexate na 2.5mg tab dose pack,8 n1=thrombolytique (traitement) | n2=en:methotrexate na 2.5mg tab dose pack,8 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methotrexate na 20mg/vil inj n1=thrombolytique (traitement) | n2=en:methotrexate na 20mg/vil inj | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methotrexate sodium n1=thrombolytique (traitement) | n2=en:methotrexate sodium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylglutaconic aciduria, mild n1=thrombolytique (traitement) | n2=en:methylglutaconic aciduria, mild | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylmalonic acidemia n1=thrombolytique (traitement) | n2=en:methylmalonic acidemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylmalonic acidemia with homocystinuria n1=thrombolytique (traitement) | n2=en:methylmalonic acidemia with homocystinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylmalonic aciduria n1=thrombolytique (traitement) | n2=en:methylmalonic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylmalonic aciduria and homocystinuria, cblf type (disorder) n1=thrombolytique (traitement) | n2=en:methylmalonic aciduria and homocystinuria, cblf type (disorder) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylmalonic aciduria and homocystinuria, cblj type n1=thrombolytique (traitement) | n2=en:methylmalonic aciduria and homocystinuria, cblj type | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylmalonic aciduria cbla type n1=thrombolytique (traitement) | n2=en:methylmalonic aciduria cbla type | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylmalonic aciduria cblb type n1=thrombolytique (traitement) | n2=en:methylmalonic aciduria cblb type | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylmalonic aciduria due to methylmalonyl-coa mutase deficiency n1=thrombolytique (traitement) | n2=en:methylmalonic aciduria due to methylmalonyl-coa mutase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylmalonic aciduria, mild n1=thrombolytique (traitement) | n2=en:methylmalonic aciduria, mild | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylmalonyl-coenzyme a mutase deficiency n1=thrombolytique (traitement) | n2=en:methylmalonyl-coenzyme a mutase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:methylsuccinic aciduria n1=thrombolytique (traitement) | n2=en:methylsuccinic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:microangiopathic hemolytic anemia n1=thrombolytique (traitement) | n2=en:microangiopathic hemolytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:microangiopathic hemolytic anemia (coomb negative) n1=thrombolytique (traitement) | n2=en:microangiopathic hemolytic anemia (coomb negative) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:microcytic anemia n1=thrombolytique (traitement) | n2=en:microcytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:microcytic hypochromic anemia (disorder) n1=thrombolytique (traitement) | n2=en:microcytic hypochromic anemia (disorder) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:microcytosis n1=thrombolytique (traitement) | n2=en:microcytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:microdeletion 22q11.2 n1=thrombolytique (traitement) | n2=en:microdeletion 22q11.2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:microdeletion of chromosome 11q13 (43-490kb) n1=thrombolytique (traitement) | n2=en:microdeletion of chromosome 11q13 (43-490kb) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:microduplication of chromosome 5p13 n1=thrombolytique (traitement) | n2=en:microduplication of chromosome 5p13 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:micromegakaryocytes (in some patients) n1=thrombolytique (traitement) | n2=en:micromegakaryocytes (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:microscopic hematuria n1=thrombolytique (traitement) | n2=en:microscopic hematuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:microsomal hmg-coa reductase decreased n1=thrombolytique (traitement) | n2=en:microsomal hmg-coa reductase decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:microtubule disorganization in some cilia n1=thrombolytique (traitement) | n2=en:microtubule disorganization in some cilia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild alpha-granule deficiency n1=thrombolytique (traitement) | n2=en:mild alpha-granule deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild anemia n1=thrombolytique (traitement) | n2=en:mild anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild bleeding episodes (epistaxis, gi bleeding, menorrhagia) n1=thrombolytique (traitement) | n2=en:mild bleeding episodes (epistaxis, gi bleeding, menorrhagia) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild cytopenia n1=thrombolytique (traitement) | n2=en:mild cytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild elevation of cholesterol n1=thrombolytique (traitement) | n2=en:mild elevation of cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild elevation of transaminases n1=thrombolytique (traitement) | n2=en:mild elevation of transaminases | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild elevation of triglycerides n1=thrombolytique (traitement) | n2=en:mild elevation of triglycerides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild eosinophilia may occur n1=thrombolytique (traitement) | n2=en:mild eosinophilia may occur | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild form of hemoglobin h (hb h) disease n1=thrombolytique (traitement) | n2=en:mild form of hemoglobin h (hb h) disease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild hyperammonemia n1=thrombolytique (traitement) | n2=en:mild hyperammonemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild hypertriglyceridemia n1=thrombolytique (traitement) | n2=en:mild hypertriglyceridemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild hypochromic microcytic anemia n1=thrombolytique (traitement) | n2=en:mild hypochromic microcytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild reticulocytosis in carrier females n1=thrombolytique (traitement) | n2=en:mild reticulocytosis in carrier females | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild thrombocytopenia n1=thrombolytique (traitement) | n2=en:mild thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild thrombocytopenia (before age 50) n1=thrombolytique (traitement) | n2=en:mild thrombocytopenia (before age 50) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild to moderate hyperammonemia n1=thrombolytique (traitement) | n2=en:mild to moderate hyperammonemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild to moderate thrombocytopenia (40-120 x 10(9)/l) n1=thrombolytique (traitement) | n2=en:mild to moderate thrombocytopenia (40-120 x 10(9)/l) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild-moderate bleeding tendencies n1=thrombolytique (traitement) | n2=en:mild-moderate bleeding tendencies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild-moderate prolonged bleeding time n1=thrombolytique (traitement) | n2=en:mild-moderate prolonged bleeding time | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mild-significant bleeding episodes (epistaxis, easy bruisability, postoperative hemorrhage, menorrhagia) n1=thrombolytique (traitement) | n2=en:mild-significant bleeding episodes (epistaxis, easy bruisability, postoperative hemorrhage, menorrhagia) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly abnormal glycosylation of serum transferrin, type 1 pattern n1=thrombolytique (traitement) | n2=en:mildly abnormal glycosylation of serum transferrin, type 1 pattern | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly decreased phosphaturic response to pth administration has been reported in some cases n1=thrombolytique (traitement) | n2=en:mildly decreased phosphaturic response to pth administration has been reported in some cases | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly decreased serum creatinine n1=thrombolytique (traitement) | n2=en:mildly decreased serum creatinine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly decreased to low-normal platelet count (80-150 x 10(9)/l) n1=thrombolytique (traitement) | n2=en:mildly decreased to low-normal platelet count (80-150 x 10(9)/l) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly elevated acth n1=thrombolytique (traitement) | n2=en:mildly elevated acth | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly elevated blood ammonia n1=thrombolytique (traitement) | n2=en:mildly elevated blood ammonia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly elevated creatine phosphokinase n1=thrombolytique (traitement) | n2=en:mildly elevated creatine phosphokinase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly elevated creatine phosphokinase (cpk) (120270.0002) n1=thrombolytique (traitement) | n2=en:mildly elevated creatine phosphokinase (cpk) (120270.0002) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly elevated hdl in heterozygotes n1=thrombolytique (traitement) | n2=en:mildly elevated hdl in heterozygotes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly elevated hepatic enzymes n1=thrombolytique (traitement) | n2=en:mildly elevated hepatic enzymes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly elevated phosphoethanolamine urinary excretion in heterozygotes n1=thrombolytique (traitement) | n2=en:mildly elevated phosphoethanolamine urinary excretion in heterozygotes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly elevated transaminases n1=thrombolytique (traitement) | n2=en:mildly elevated transaminases | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly elevated urinary mevalonic acid n1=thrombolytique (traitement) | n2=en:mildly elevated urinary mevalonic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly increased serum creatine kinase (in some patients) n1=thrombolytique (traitement) | n2=en:mildly increased serum creatine kinase (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly increased serum lactate n1=thrombolytique (traitement) | n2=en:mildly increased serum lactate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mildly prolonged bleeding time 10-12 minutes n1=thrombolytique (traitement) | n2=en:mildly prolonged bleeding time 10-12 minutes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitochondria dna deletion n1=thrombolytique (traitement) | n2=en:mitochondria dna deletion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitochondrial complex i deficiency in muscle n1=thrombolytique (traitement) | n2=en:mitochondrial complex i deficiency in muscle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitochondrial deletions n1=thrombolytique (traitement) | n2=en:mitochondrial deletions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitochondrial dna depletion syndrome 3 (hepatocerebral type) n1=thrombolytique (traitement) | n2=en:mitochondrial dna depletion syndrome 3 (hepatocerebral type) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitochondrial malic enzyme reduced n1=thrombolytique (traitement) | n2=en:mitochondrial malic enzyme reduced | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitochondrial malonyl-coa decarboxylase activity in fibroblasts is very low (as low as 4%) n1=thrombolytique (traitement) | n2=en:mitochondrial malonyl-coa decarboxylase activity in fibroblasts is very low (as low as 4%) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitochondrial respiratory chain defects (skeletal muscle, fibroblasts) n1=thrombolytique (traitement) | n2=en:mitochondrial respiratory chain defects (skeletal muscle, fibroblasts) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitomycin n1=thrombolytique (traitement) | n2=en:mitomycin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitomycin 0.2 mg/ml ophthalmic solution n1=thrombolytique (traitement) | n2=en:mitomycin 0.2 mg/ml ophthalmic solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitomycin 10mg powder for injection solution vial n1=thrombolytique (traitement) | n2=en:mitomycin 10mg powder for injection solution vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitotic lymphocyte and fibroblast cultures show mosaic variegated aneuploidy n1=thrombolytique (traitement) | n2=en:mitotic lymphocyte and fibroblast cultures show mosaic variegated aneuploidy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mitotic lymphocyte and fibroblast cultures show mosaic variegated aneuploidy (50%) affecting all chromosomes n1=thrombolytique (traitement) | n2=en:mitotic lymphocyte and fibroblast cultures show mosaic variegated aneuploidy (50%) affecting all chromosomes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mixed phenotype acute leukemia n1=thrombolytique (traitement) | n2=en:mixed phenotype acute leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mixed phenotype acute leukemia with t(9;22)(q34;q11.2); bcr-abl1 n1=thrombolytique (traitement) | n2=en:mixed phenotype acute leukemia with t(9;22)(q34;q11.2); bcr-abl1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mixed phenotype acute leukemia with t(v;11q23); mll rearranged n1=thrombolytique (traitement) | n2=en:mixed phenotype acute leukemia with t(v;11q23); mll rearranged | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mixed phenotype acute leukemia, b/myeloid, not otherwise specified n1=thrombolytique (traitement) | n2=en:mixed phenotype acute leukemia, b/myeloid, not otherwise specified | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mixed phenotype acute leukemia, t/myeloid, not otherwise specified n1=thrombolytique (traitement) | n2=en:mixed phenotype acute leukemia, t/myeloid, not otherwise specified | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:moderate cytopenia n1=thrombolytique (traitement) | n2=en:moderate cytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:moderate to severe thrombocytopenia (30-90 x 10(9)/l) n1=thrombolytique (traitement) | n2=en:moderate to severe thrombocytopenia (30-90 x 10(9)/l) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:moderate-severe bleeding tendencies (epistaxis, menorrhagia, hemarthrosis, easy bruisability) n1=thrombolytique (traitement) | n2=en:moderate-severe bleeding tendencies (epistaxis, menorrhagia, hemarthrosis, easy bruisability) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:moderately decreased to normal phk activity in skeletal muscle n1=thrombolytique (traitement) | n2=en:moderately decreased to normal phk activity in skeletal muscle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:molybdenum cofactor deficiency n1=thrombolytique (traitement) | n2=en:molybdenum cofactor deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:monoclonal gammopathy n1=thrombolytique (traitement) | n2=en:monoclonal gammopathy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:monocytopenia n1=thrombolytique (traitement) | n2=en:monocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:monocytosis n1=thrombolytique (traitement) | n2=en:monocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:monomeric igm n1=thrombolytique (traitement) | n2=en:monomeric igm | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mononuclear cell noncaseating granulomatous inflammation on biopsy (lung, skin, lip) n1=thrombolytique (traitement) | n2=en:mononuclear cell noncaseating granulomatous inflammation on biopsy (lung, skin, lip) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:monosomy 7 of bone marrow n1=thrombolytique (traitement) | n2=en:monosomy 7 of bone marrow | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:montreal platelet syndrome n1=thrombolytique (traitement) | n2=en:montreal platelet syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:more than 50% of mitotic cells show premature chromatid separation (pcs) affecting all chromosomes n1=thrombolytique (traitement) | n2=en:more than 50% of mitotic cells show premature chromatid separation (pcs) affecting all chromosomes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mosaic tetrasomy 12p in skin fibroblasts n1=thrombolytique (traitement) | n2=en:mosaic tetrasomy 12p in skin fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mucocutaneous bleeding n1=thrombolytique (traitement) | n2=en:mucocutaneous bleeding | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mucocutaneous bleeding due to platelet dysfunction n1=thrombolytique (traitement) | n2=en:mucocutaneous bleeding due to platelet dysfunction | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mucopolysaccharidosis type iiid n1=thrombolytique (traitement) | n2=en:mucopolysaccharidosis type iiid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:multi-tailed spermatozoa n1=thrombolytique (traitement) | n2=en:multi-tailed spermatozoa | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:multicentric angiofollicular lymphoid hyperplasia n1=thrombolytique (traitement) | n2=en:multicentric angiofollicular lymphoid hyperplasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:multinuclear erythroblasts n1=thrombolytique (traitement) | n2=en:multinuclear erythroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:multinucleated erythroblasts n1=thrombolytique (traitement) | n2=en:multinucleated erythroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:multiple autoantibodies n1=thrombolytique (traitement) | n2=en:multiple autoantibodies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:multiple organs (lung, liver, spleen, kidney, brain) contain foamy resident cells and histiocytes n1=thrombolytique (traitement) | n2=en:multiple organs (lung, liver, spleen, kidney, brain) contain foamy resident cells and histiocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:multiple tissue biopsies show lysosomal storage disease n1=thrombolytique (traitement) | n2=en:multiple tissue biopsies show lysosomal storage disease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:multiple visceral organs (lung, liver, spleen, kidney) contain foamy resident cells and histiocytes n1=thrombolytique (traitement) | n2=en:multiple visceral organs (lung, liver, spleen, kidney) contain foamy resident cells and histiocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:muscle and liver tissue show decreased activities of mitochondrial complexes i, ii, and iii n1=thrombolytique (traitement) | n2=en:muscle and liver tissue show decreased activities of mitochondrial complexes i, ii, and iii | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:mutant mtdna threonine transfer rna gene (mttt, 590090) of questionable etiology n1=thrombolytique (traitement) | n2=en:mutant mtdna threonine transfer rna gene (mttt, 590090) of questionable etiology | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myelin basic protein measurement, spinal fluid n1=thrombolytique (traitement) | n2=en:myelin basic protein measurement, spinal fluid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myelodysplastic syndrome, unclassifiable n1=thrombolytique (traitement) | n2=en:myelodysplastic syndrome, unclassifiable | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myelofibrosis n1=thrombolytique (traitement) | n2=en:myelofibrosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myeloid leukemia associated with down syndrome n1=thrombolytique (traitement) | n2=en:myeloid leukemia associated with down syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myelokathexis (retention of neutrophils in the bone marrow) n1=thrombolytique (traitement) | n2=en:myelokathexis (retention of neutrophils in the bone marrow) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myeloproliferative disease n1=thrombolytique (traitement) | n2=en:myeloproliferative disease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myelosuppression develops on standard doses of thiopurine drugs n1=thrombolytique (traitement) | n2=en:myelosuppression develops on standard doses of thiopurine drugs | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myh9-positive inclusions on immunohistochemical staining n1=thrombolytique (traitement) | n2=en:myh9-positive inclusions on immunohistochemical staining | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myoglobinuria n1=thrombolytique (traitement) | n2=en:myoglobinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myoglobinuria (reported in 1 patient) n1=thrombolytique (traitement) | n2=en:myoglobinuria (reported in 1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myoglobinuria after exertion n1=thrombolytique (traitement) | n2=en:myoglobinuria after exertion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myoglobinuria after exertion (in some patients) n1=thrombolytique (traitement) | n2=en:myoglobinuria after exertion (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myoglobinuria with extreme exertion n1=thrombolytique (traitement) | n2=en:myoglobinuria with extreme exertion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myoglobinuria, particularly after physical exertion (25% of patients) n1=thrombolytique (traitement) | n2=en:myoglobinuria, particularly after physical exertion (25% of patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:myopathy with type i fiber atrophy on muscle biopsy n1=thrombolytique (traitement) | n2=en:myopathy with type i fiber atrophy on muscle biopsy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:n-acetyl-alpha-d-glucosaminidase deficiency in fibroblasts n1=thrombolytique (traitement) | n2=en:n-acetyl-alpha-d-glucosaminidase deficiency in fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:n-acetylgalactosamine-6-sulfatase deficiency in fibroblasts and leukocytes n1=thrombolytique (traitement) | n2=en:n-acetylgalactosamine-6-sulfatase deficiency in fibroblasts and leukocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:n-glycosylation defect n1=thrombolytique (traitement) | n2=en:n-glycosylation defect | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:nadh-cytochrome b(5) reductase deficiency n1=thrombolytique (traitement) | n2=en:nadh-cytochrome b(5) reductase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:natural killer cell lymphoblastic leukemia/lymphoma n1=thrombolytique (traitement) | n2=en:natural killer cell lymphoblastic leukemia/lymphoma | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:near-complete absence of vldl peak on density gradient ultracentrifugation (in some patients) n1=thrombolytique (traitement) | n2=en:near-complete absence of vldl peak on density gradient ultracentrifugation (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:negative nitroblue tetrazolium (nbt) reduction test n1=thrombolytique (traitement) | n2=en:negative nitroblue tetrazolium (nbt) reduction test | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neonatal alloimmune thrombocytopenia n1=thrombolytique (traitement) | n2=en:neonatal alloimmune thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neonatal alloimmune thrombocytopenia (nait) n1=thrombolytique (traitement) | n2=en:neonatal alloimmune thrombocytopenia (nait) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neonatal hemolytic anemia (harderoporphyria) n1=thrombolytique (traitement) | n2=en:neonatal hemolytic anemia (harderoporphyria) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neonatal hyperbilirubinemia n1=thrombolytique (traitement) | n2=en:neonatal hyperbilirubinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neonatal hypocalcemia n1=thrombolytique (traitement) | n2=en:neonatal hypocalcemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neonatal thrombocytopenia n1=thrombolytique (traitement) | n2=en:neonatal thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neonatal thrombocytopenia associated with maternal idiopathic thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:neonatal thrombocytopenia associated with maternal idiopathic thrombocytopenic purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neonatal thrombocytopenia due to exchange transfusion n1=thrombolytique (traitement) | n2=en:neonatal thrombocytopenia due to exchange transfusion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neonatal thrombocytopenia due to idiopathic maternal thrombocytopenia n1=thrombolytique (traitement) | n2=en:neonatal thrombocytopenia due to idiopathic maternal thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:nephrotic syndrome n1=thrombolytique (traitement) | n2=en:nephrotic syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neuraminidase deficiency (white blood cells, fibroblasts, cultured amniotic cells) n1=thrombolytique (traitement) | n2=en:neuraminidase deficiency (white blood cells, fibroblasts, cultured amniotic cells) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neurofibrillary tangles and neuritic senile plaques rare n1=thrombolytique (traitement) | n2=en:neurofibrillary tangles and neuritic senile plaques rare | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutral hyperaminoaciduria n1=thrombolytique (traitement) | n2=en:neutral hyperaminoaciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutropenia n1=thrombolytique (traitement) | n2=en:neutropenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutropenia (in 1 patient) n1=thrombolytique (traitement) | n2=en:neutropenia (in 1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutropenia (in some patients) n1=thrombolytique (traitement) | n2=en:neutropenia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutropenia, chronic or cyclic n1=thrombolytique (traitement) | n2=en:neutropenia, chronic or cyclic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutropenia, mild n1=thrombolytique (traitement) | n2=en:neutropenia, mild | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutropenia, severe congenital, 5, autosomal recessive n1=thrombolytique (traitement) | n2=en:neutropenia, severe congenital, 5, autosomal recessive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutropenia, severe congenital, autosomal recessive 4 n1=thrombolytique (traitement) | n2=en:neutropenia, severe congenital, autosomal recessive 4 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutropenia, variable n1=thrombolytique (traitement) | n2=en:neutropenia, variable | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutrophil maturation in bone marrow intact n1=thrombolytique (traitement) | n2=en:neutrophil maturation in bone marrow intact | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutrophil membranes show absence of sialyl-lewis-x n1=thrombolytique (traitement) | n2=en:neutrophil membranes show absence of sialyl-lewis-x | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutrophilia n1=thrombolytique (traitement) | n2=en:neutrophilia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:neutrophilia, both basal and during infections n1=thrombolytique (traitement) | n2=en:neutrophilia, both basal and during infections | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no 'swiss cheese' abnormality n1=thrombolytique (traitement) | n2=en:no 'swiss cheese' abnormality | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no abnormality n1=thrombolytique (traitement) | n2=en:no abnormality | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no bone marrow abnormalities n1=thrombolytique (traitement) | n2=en:no bone marrow abnormalities | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no c8 antigen detected n1=thrombolytique (traitement) | n2=en:no c8 antigen detected | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no cartilage staining with toluidine blue n1=thrombolytique (traitement) | n2=en:no cartilage staining with toluidine blue | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no chromosomal breakage n1=thrombolytique (traitement) | n2=en:no chromosomal breakage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no chromosome breakage n1=thrombolytique (traitement) | n2=en:no chromosome breakage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no dicarboxylic aciduria n1=thrombolytique (traitement) | n2=en:no dicarboxylic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no elevation of free fatty acids n1=thrombolytique (traitement) | n2=en:no elevation of free fatty acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no evidence of common prenatal infections n1=thrombolytique (traitement) | n2=en:no evidence of common prenatal infections | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no evidence of intrauterine infection in mother or newborn n1=thrombolytique (traitement) | n2=en:no evidence of intrauterine infection in mother or newborn | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no evidence of perinatal infection n1=thrombolytique (traitement) | n2=en:no evidence of perinatal infection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no hematuria n1=thrombolytique (traitement) | n2=en:no hematuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no hemolysis n1=thrombolytique (traitement) | n2=en:no hemolysis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no hemophagocytosis n1=thrombolytique (traitement) | n2=en:no hemophagocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no histochemical evidence of mitochondrial myopathy. n1=thrombolytique (traitement) | n2=en:no histochemical evidence of mitochondrial myopathy. | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no hyperphenylalaninemia n1=thrombolytique (traitement) | n2=en:no hyperphenylalaninemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no hyperuricemia n1=thrombolytique (traitement) | n2=en:no hyperuricemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no increase in urinary cyclic amp (camp) in response to vasopressin or ddavp n1=thrombolytique (traitement) | n2=en:no increase in urinary cyclic amp (camp) in response to vasopressin or ddavp | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no increase of muscle lactate with ischemic exercise testing n1=thrombolytique (traitement) | n2=en:no increase of muscle lactate with ischemic exercise testing | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no increased bleeding tendency n1=thrombolytique (traitement) | n2=en:no increased bleeding tendency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no increased sensitivity to oxidative species n1=thrombolytique (traitement) | n2=en:no increased sensitivity to oxidative species | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no ketonuria n1=thrombolytique (traitement) | n2=en:no ketonuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no ketosis n1=thrombolytique (traitement) | n2=en:no ketosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no lactic acidosis n1=thrombolytique (traitement) | n2=en:no lactic acidosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no leukocyte inclusion bodies on giemsa staining n1=thrombolytique (traitement) | n2=en:no leukocyte inclusion bodies on giemsa staining | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no leukocyte inclusions on giemsa staining n1=thrombolytique (traitement) | n2=en:no leukocyte inclusions on giemsa staining | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no metabolic abnormalities n1=thrombolytique (traitement) | n2=en:no metabolic abnormalities | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no mucopolysacchariduria n1=thrombolytique (traitement) | n2=en:no mucopolysacchariduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:no neutrophil inclusions n1=thrombolytique (traitement) | n2=en:no neutrophil inclusions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:non-immune heparin associated thrombocytopenia n1=thrombolytique (traitement) | n2=en:non-immune heparin associated thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:nonclonal myeloproliferation n1=thrombolytique (traitement) | n2=en:nonclonal myeloproliferation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:nonketotic hypoglycemia n1=thrombolytique (traitement) | n2=en:nonketotic hypoglycemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:noonan syndrome 1 n1=thrombolytique (traitement) | n2=en:noonan syndrome 1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal 46,xy karyotype n1=thrombolytique (traitement) | n2=en:normal 46,xy karyotype | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal activity of von willebrand factor-cleaving protease n1=thrombolytique (traitement) | n2=en:normal activity of von willebrand factor-cleaving protease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal aldosterone n1=thrombolytique (traitement) | n2=en:normal aldosterone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal apoa-ii levels in homozygotes n1=thrombolytique (traitement) | n2=en:normal apoa-ii levels in homozygotes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal arterial oxygen saturation n1=thrombolytique (traitement) | n2=en:normal arterial oxygen saturation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal axonal flare response after intradermal histamine injection n1=thrombolytique (traitement) | n2=en:normal axonal flare response after intradermal histamine injection | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal b12 n1=thrombolytique (traitement) | n2=en:normal b12 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal baseline cortisol n1=thrombolytique (traitement) | n2=en:normal baseline cortisol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal beta-thromboglobulin n1=thrombolytique (traitement) | n2=en:normal beta-thromboglobulin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal blood lactate n1=thrombolytique (traitement) | n2=en:normal blood lactate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal calcium (female) n1=thrombolytique (traitement) | n2=en:normal calcium (female) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal cd8+/cd4+ ratio n1=thrombolytique (traitement) | n2=en:normal cd8+/cd4+ ratio | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal cerebrospinal fluid n1=thrombolytique (traitement) | n2=en:normal cerebrospinal fluid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal ciliary structure and function n1=thrombolytique (traitement) | n2=en:normal ciliary structure and function | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal collagen type i studies n1=thrombolytique (traitement) | n2=en:normal collagen type i studies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal complex ii activity n1=thrombolytique (traitement) | n2=en:normal complex ii activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal concentration of parathyroid hormone n1=thrombolytique (traitement) | n2=en:normal concentration of parathyroid hormone | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal constitutional karyotype n1=thrombolytique (traitement) | n2=en:normal constitutional karyotype | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal csf 5-hiaa n1=thrombolytique (traitement) | n2=en:normal csf 5-hiaa | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal csf 5-hydroxyindoleacetic acid (5-hiaa) n1=thrombolytique (traitement) | n2=en:normal csf 5-hydroxyindoleacetic acid (5-hiaa) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal csf neurotransmitters n1=thrombolytique (traitement) | n2=en:normal csf neurotransmitters | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal dermal hydroxylysine content n1=thrombolytique (traitement) | n2=en:normal dermal hydroxylysine content | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal ellsworth-howard test, normal urinary camp response to parathyroid hormone (pth) administration n1=thrombolytique (traitement) | n2=en:normal ellsworth-howard test, normal urinary camp response to parathyroid hormone (pth) administration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal endocrinologic studies (growth hormone, somatomedin c, thyroid function) n1=thrombolytique (traitement) | n2=en:normal endocrinologic studies (growth hormone, somatomedin c, thyroid function) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal eosinophil peroxidase activity n1=thrombolytique (traitement) | n2=en:normal eosinophil peroxidase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal erythrocyte gs activity n1=thrombolytique (traitement) | n2=en:normal erythrocyte gs activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal exocrine pancreatic function n1=thrombolytique (traitement) | n2=en:normal exocrine pancreatic function | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal extrarenal responses to ddavp administration n1=thrombolytique (traitement) | n2=en:normal extrarenal responses to ddavp administration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal free urinary cortisol n1=thrombolytique (traitement) | n2=en:normal free urinary cortisol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal g(s)-alpha levels (139320) n1=thrombolytique (traitement) | n2=en:normal g(s)-alpha levels (139320) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal growth hormone responses to arginine, l-dopa, and propranolol stimulation n1=thrombolytique (traitement) | n2=en:normal growth hormone responses to arginine, l-dopa, and propranolol stimulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal hematologic parameters (both patients) n1=thrombolytique (traitement) | n2=en:normal hematologic parameters (both patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal heterochromatin in erythroblasts n1=thrombolytique (traitement) | n2=en:normal heterochromatin in erythroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal iga levels n1=thrombolytique (traitement) | n2=en:normal iga levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal igg levels n1=thrombolytique (traitement) | n2=en:normal igg levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal igm levels n1=thrombolytique (traitement) | n2=en:normal igm levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal isoelectric focusing of apolipoprotein ciii n1=thrombolytique (traitement) | n2=en:normal isoelectric focusing of apolipoprotein ciii | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal isoelectric focusing of serum transferrin n1=thrombolytique (traitement) | n2=en:normal isoelectric focusing of serum transferrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal lactate (hcs) n1=thrombolytique (traitement) | n2=en:normal lactate (hcs) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal leukocyte and platelet counts n1=thrombolytique (traitement) | n2=en:normal leukocyte and platelet counts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal levels of complement factor h, but impaired function n1=thrombolytique (traitement) | n2=en:normal levels of complement factor h, but impaired function | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal levels of known coagulation factors n1=thrombolytique (traitement) | n2=en:normal levels of known coagulation factors | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal liver histology n1=thrombolytique (traitement) | n2=en:normal liver histology | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal lysl hydroxylase activity n1=thrombolytique (traitement) | n2=en:normal lysl hydroxylase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal lysosomal hydrolases n1=thrombolytique (traitement) | n2=en:normal lysosomal hydrolases | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal lysyl hydroxylase activity n1=thrombolytique (traitement) | n2=en:normal lysyl hydroxylase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal lysyl oxidase activity n1=thrombolytique (traitement) | n2=en:normal lysyl oxidase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal male karyotype (46,xy) n1=thrombolytique (traitement) | n2=en:normal male karyotype (46,xy) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal maltase, isomaltase, and sucrase activity n1=thrombolytique (traitement) | n2=en:normal maltase, isomaltase, and sucrase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal mean platelet volume (mpv) n1=thrombolytique (traitement) | n2=en:normal mean platelet volume (mpv) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal mitochondrial respiratory chain complex i-v (hcs) n1=thrombolytique (traitement) | n2=en:normal mitochondrial respiratory chain complex i-v (hcs) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal number of t and b lymphocytes n1=thrombolytique (traitement) | n2=en:normal number of t and b lymphocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or decreased serum erythropoietin (epo, 133170) n1=thrombolytique (traitement) | n2=en:normal or decreased serum erythropoietin (epo, 133170) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or decreased serum potassium n1=thrombolytique (traitement) | n2=en:normal or decreased serum potassium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or increased levels of serum arginine vasopressin (antidiuretic hormone, 192340) n1=thrombolytique (traitement) | n2=en:normal or increased levels of serum arginine vasopressin (antidiuretic hormone, 192340) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or increased platelet count n1=thrombolytique (traitement) | n2=en:normal or increased platelet count | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or increased serum creatine kinase n1=thrombolytique (traitement) | n2=en:normal or increased serum creatine kinase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or increased serum phosphate n1=thrombolytique (traitement) | n2=en:normal or increased serum phosphate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or increased serum phytanic acid n1=thrombolytique (traitement) | n2=en:normal or increased serum phytanic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or increased urinary cyclic amp response to pth administration n1=thrombolytique (traitement) | n2=en:normal or increased urinary cyclic amp response to pth administration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or mildly decreased arylsulfatase a activity n1=thrombolytique (traitement) | n2=en:normal or mildly decreased arylsulfatase a activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or mildly decreased serum levels of free thyroid hormones n1=thrombolytique (traitement) | n2=en:normal or mildly decreased serum levels of free thyroid hormones | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or mildly increased serum creatine kinase n1=thrombolytique (traitement) | n2=en:normal or mildly increased serum creatine kinase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or mildly increased serum gamma-ggt (231950) n1=thrombolytique (traitement) | n2=en:normal or mildly increased serum gamma-ggt (231950) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or mildly increased serum gamma-glutamyltransferase (ggt) n1=thrombolytique (traitement) | n2=en:normal or mildly increased serum gamma-glutamyltransferase (ggt) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or mildly increased thyroid-stimulating hormone (tsh) n1=thrombolytique (traitement) | n2=en:normal or mildly increased thyroid-stimulating hormone (tsh) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or mildly reduced serum cobalamin n1=thrombolytique (traitement) | n2=en:normal or mildly reduced serum cobalamin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal or mildly reduced sphingomyelinase activity n1=thrombolytique (traitement) | n2=en:normal or mildly reduced sphingomyelinase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal oxygen affinity of hemoglobin n1=thrombolytique (traitement) | n2=en:normal oxygen affinity of hemoglobin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal parathyroid hormone (female) n1=thrombolytique (traitement) | n2=en:normal parathyroid hormone (female) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal peripheral red blood cell survival time n1=thrombolytique (traitement) | n2=en:normal peripheral red blood cell survival time | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal phytanic acid n1=thrombolytique (traitement) | n2=en:normal phytanic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal plasma and tissue carnitine n1=thrombolytique (traitement) | n2=en:normal plasma and tissue carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal plasma phytanic acid n1=thrombolytique (traitement) | n2=en:normal plasma phytanic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal plasma renin n1=thrombolytique (traitement) | n2=en:normal plasma renin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal plasma total homocysteine n1=thrombolytique (traitement) | n2=en:normal plasma total homocysteine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet aggregation response to arachidonic acid (aa) n1=thrombolytique (traitement) | n2=en:normal platelet aggregation response to arachidonic acid (aa) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet aggregation response to arachidonic acid (aa), adenosine 5'-diphosphate (adp), collagen, and ristocetin n1=thrombolytique (traitement) | n2=en:normal platelet aggregation response to arachidonic acid (aa), adenosine 5'-diphosphate (adp), collagen, and ristocetin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet aggregation response to epinephrine, adp, collagen, and ristocetin n1=thrombolytique (traitement) | n2=en:normal platelet aggregation response to epinephrine, adp, collagen, and ristocetin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet aggregation response to epinephrine, arachidonic acid (aa), adenosine 5'-diphosphate (adp), collagen, and ristocetin n1=thrombolytique (traitement) | n2=en:normal platelet aggregation response to epinephrine, arachidonic acid (aa), adenosine 5'-diphosphate (adp), collagen, and ristocetin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet aggregation response to ristocetin and arachidonic acid (aa) n1=thrombolytique (traitement) | n2=en:normal platelet aggregation response to ristocetin and arachidonic acid (aa) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet aggregation studies n1=thrombolytique (traitement) | n2=en:normal platelet aggregation studies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet aggregation studies with adp, collagen, and ristocetin n1=thrombolytique (traitement) | n2=en:normal platelet aggregation studies with adp, collagen, and ristocetin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet aggregation with adp, collagen, epinephrine n1=thrombolytique (traitement) | n2=en:normal platelet aggregation with adp, collagen, epinephrine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet fibrinogen n1=thrombolytique (traitement) | n2=en:normal platelet fibrinogen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet size n1=thrombolytique (traitement) | n2=en:normal platelet size | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet size (normal mpv) n1=thrombolytique (traitement) | n2=en:normal platelet size (normal mpv) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal platelet size and morphology n1=thrombolytique (traitement) | n2=en:normal platelet size and morphology | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal prolyl 4-hydroxylase activity n1=thrombolytique (traitement) | n2=en:normal prolyl 4-hydroxylase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal prothrombin and partial chromoplastin times n1=thrombolytique (traitement) | n2=en:normal prothrombin and partial chromoplastin times | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal pyridinoline excretion in urine n1=thrombolytique (traitement) | n2=en:normal pyridinoline excretion in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal red cell counts n1=thrombolytique (traitement) | n2=en:normal red cell counts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal red cell osmotic fragility n1=thrombolytique (traitement) | n2=en:normal red cell osmotic fragility | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal renin level n1=thrombolytique (traitement) | n2=en:normal renin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal sedimentation rate n1=thrombolytique (traitement) | n2=en:normal sedimentation rate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum 1,25-dihydroxyvitamin d3 n1=thrombolytique (traitement) | n2=en:normal serum 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum 25-hydroxyvitamin d3 n1=thrombolytique (traitement) | n2=en:normal serum 25-hydroxyvitamin d3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum and mucosal iga n1=thrombolytique (traitement) | n2=en:normal serum and mucosal iga | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum bile acids n1=thrombolytique (traitement) | n2=en:normal serum bile acids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum biotin concentration n1=thrombolytique (traitement) | n2=en:normal serum biotin concentration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum cobalamin n1=thrombolytique (traitement) | n2=en:normal serum cobalamin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum cobalamin (vitamin b12) n1=thrombolytique (traitement) | n2=en:normal serum cobalamin (vitamin b12) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum complement levels n1=thrombolytique (traitement) | n2=en:normal serum complement levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum creatine kinase n1=thrombolytique (traitement) | n2=en:normal serum creatine kinase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum erythropoietin (epo, 133170) n1=thrombolytique (traitement) | n2=en:normal serum erythropoietin (epo, 133170) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum folate levels n1=thrombolytique (traitement) | n2=en:normal serum folate levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum levels of gamma-ggt (231950) n1=thrombolytique (traitement) | n2=en:normal serum levels of gamma-ggt (231950) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum lipoprotein levels n1=thrombolytique (traitement) | n2=en:normal serum lipoprotein levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum liver enzymes n1=thrombolytique (traitement) | n2=en:normal serum liver enzymes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum parathyroid hormone (pth) n1=thrombolytique (traitement) | n2=en:normal serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum phosphorus n1=thrombolytique (traitement) | n2=en:normal serum phosphorus | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum phytanic and pristanic acid n1=thrombolytique (traitement) | n2=en:normal serum phytanic and pristanic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum plasmalogen n1=thrombolytique (traitement) | n2=en:normal serum plasmalogen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum thromboxane b2 n1=thrombolytique (traitement) | n2=en:normal serum thromboxane b2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal serum transferrin profiles n1=thrombolytique (traitement) | n2=en:normal serum transferrin profiles | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal sweat chloride (3 of 3 patients) n1=thrombolytique (traitement) | n2=en:normal sweat chloride (3 of 3 patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal sweat electrolytes n1=thrombolytique (traitement) | n2=en:normal sweat electrolytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal thrombospondin n1=thrombolytique (traitement) | n2=en:normal thrombospondin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal to elevated serum 1,25-dihydroxycholecalciferol (calcitriol) n1=thrombolytique (traitement) | n2=en:normal to elevated serum 1,25-dihydroxycholecalciferol (calcitriol) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal to elevated total plasma carnitine n1=thrombolytique (traitement) | n2=en:normal to elevated total plasma carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal to increased plasma glycine n1=thrombolytique (traitement) | n2=en:normal to increased plasma glycine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal to increased plasma threonine n1=thrombolytique (traitement) | n2=en:normal to increased plasma threonine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal to mildly increased mucopolysacchariduria n1=thrombolytique (traitement) | n2=en:normal to mildly increased mucopolysacchariduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal to mildly increased serum creatine kinase n1=thrombolytique (traitement) | n2=en:normal to mildly increased serum creatine kinase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal to mildly increased serum parathyroid hormone (pth) n1=thrombolytique (traitement) | n2=en:normal to mildly increased serum parathyroid hormone (pth) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal to prolonged bleeding time n1=thrombolytique (traitement) | n2=en:normal to prolonged bleeding time | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal to slightly elevated plasma cholesterol n1=thrombolytique (traitement) | n2=en:normal to slightly elevated plasma cholesterol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal to slightly high alkaline phosphatase n1=thrombolytique (traitement) | n2=en:normal to slightly high alkaline phosphatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal total urinary coproporphyrin n1=thrombolytique (traitement) | n2=en:normal total urinary coproporphyrin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal transferrin isoelectric profile n1=thrombolytique (traitement) | n2=en:normal transferrin isoelectric profile | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal transferrin saturation n1=thrombolytique (traitement) | n2=en:normal transferrin saturation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal tyrosinase n1=thrombolytique (traitement) | n2=en:normal tyrosinase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal urinary 17-ketosteroids n1=thrombolytique (traitement) | n2=en:normal urinary 17-ketosteroids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal urinary cyclic amp response to pth administration n1=thrombolytique (traitement) | n2=en:normal urinary cyclic amp response to pth administration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal urinary orotic acid n1=thrombolytique (traitement) | n2=en:normal urinary orotic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal urinary pterins n1=thrombolytique (traitement) | n2=en:normal urinary pterins | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal von willebrand factor n1=thrombolytique (traitement) | n2=en:normal von willebrand factor | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal-elevated plasma testosterone (male range) n1=thrombolytique (traitement) | n2=en:normal-elevated plasma testosterone (male range) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal-to-decreased plasma glycine (fasting) n1=thrombolytique (traitement) | n2=en:normal-to-decreased plasma glycine (fasting) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normal-to-slightly decreased glcnac phosphotransferase using artificial substrate (e.g., alpha-methylmannoside) n1=thrombolytique (traitement) | n2=en:normal-to-slightly decreased glcnac phosphotransferase using artificial substrate (e.g., alpha-methylmannoside) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normocalcemia n1=thrombolytique (traitement) | n2=en:normocalcemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normochromic anemia n1=thrombolytique (traitement) | n2=en:normochromic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normocytic anemia n1=thrombolytique (traitement) | n2=en:normocytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normocytic hypoplastic anemia n1=thrombolytique (traitement) | n2=en:normocytic hypoplastic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:normocytic pancytopenia following sulfa use n1=thrombolytique (traitement) | n2=en:normocytic pancytopenia following sulfa use | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:nucleated peripheral red cells n1=thrombolytique (traitement) | n2=en:nucleated peripheral red cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:nucleated red cells in peripheral blood n1=thrombolytique (traitement) | n2=en:nucleated red cells in peripheral blood | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:occasional hypomagnesemia n1=thrombolytique (traitement) | n2=en:occasional hypomagnesemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:occasionally mild elevation of csf protein n1=thrombolytique (traitement) | n2=en:occasionally mild elevation of csf protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:oculootoradial syndrome n1=thrombolytique (traitement) | n2=en:oculootoradial syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:oestradiol decreased n1=thrombolytique (traitement) | n2=en:oestradiol decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:often integrated hbv sequences in hepatocellular carcinomas n1=thrombolytique (traitement) | n2=en:often integrated hbv sequences in hepatocellular carcinomas | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:oligospermia or azoospermia n1=thrombolytique (traitement) | n2=en:oligospermia or azoospermia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:organic aciduria n1=thrombolytique (traitement) | n2=en:organic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:organic aciduria (elevated beta-hydroxyisovalerate, beta-methylcrotonylglycine, beta-hydroxypropionate, methylcitrate, lactate, tiglylglycine) n1=thrombolytique (traitement) | n2=en:organic aciduria (elevated beta-hydroxyisovalerate, beta-methylcrotonylglycine, beta-hydroxypropionate, methylcitrate, lactate, tiglylglycine) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:organic aciduria (elevated beta-hydroxyisovalerate, lactate, beta-methylcrotonylglycine, beta-hydroxypropionate, methylcitrate) n1=thrombolytique (traitement) | n2=en:organic aciduria (elevated beta-hydroxyisovalerate, lactate, beta-methylcrotonylglycine, beta-hydroxypropionate, methylcitrate) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:organic aciduria, mild (in some patients) n1=thrombolytique (traitement) | n2=en:organic aciduria, mild (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ornithine-delta-aminotransferase (oat) deficiency n1=thrombolytique (traitement) | n2=en:ornithine-delta-aminotransferase (oat) deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:orotic acid crystalluria n1=thrombolytique (traitement) | n2=en:orotic acid crystalluria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:orotic aciduria n1=thrombolytique (traitement) | n2=en:orotic aciduria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:osmotic fragility (finding) n1=thrombolytique (traitement) | n2=en:osmotic fragility (finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:osteocalcin increased n1=thrombolytique (traitement) | n2=en:osteocalcin increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:osteochondrodysplasia, rhizomelic, with callosal agenesis, thrombocytopenia, hydrocephalus, and hypertension n1=thrombolytique (traitement) | n2=en:osteochondrodysplasia, rhizomelic, with callosal agenesis, thrombocytopenia, hydrocephalus, and hypertension | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:osteopetrosis, autosomal recessive 8 n1=thrombolytique (traitement) | n2=en:osteopetrosis, autosomal recessive 8 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:other cytogenic abnormalities have been associated with dgs phenotype including monosomy 10p13, 11p13, and 4q21 n1=thrombolytique (traitement) | n2=en:other cytogenic abnormalities have been associated with dgs phenotype including monosomy 10p13, 11p13, and 4q21 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:other non-thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:other non-thrombocytopenic purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:other phlebitis and thrombosis complicating pregnancy and the puerperium, delivered, with mention of postpartum complication n1=thrombolytique (traitement) | n2=en:other phlebitis and thrombosis complicating pregnancy and the puerperium, delivered, with mention of postpartum complication | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:other phlebitis and thrombosis complicating pregnancy and the puerperium, unspecified as to episode of care or not applicable n1=thrombolytique (traitement) | n2=en:other phlebitis and thrombosis complicating pregnancy and the puerperium, unspecified as to episode of care or not applicable | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:other primary thrombocytopenia n1=thrombolytique (traitement) | n2=en:other primary thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:other specified haemorrhagic conditions n1=thrombolytique (traitement) | n2=en:other specified haemorrhagic conditions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:oval macrocyte n1=thrombolytique (traitement) | n2=en:oval macrocyte | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ovoid granulocyte nuclei (homozygote) n1=thrombolytique (traitement) | n2=en:ovoid granulocyte nuclei (homozygote) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:p5c levels increased in urine n1=thrombolytique (traitement) | n2=en:p5c levels increased in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pancreatic trypsinogen deficiency n1=thrombolytique (traitement) | n2=en:pancreatic trypsinogen deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pancytopenia (4 patients) n1=thrombolytique (traitement) | n2=en:pancytopenia (4 patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pancytopenia (childhood) n1=thrombolytique (traitement) | n2=en:pancytopenia (childhood) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pancytopenia (in 2 of 3 siblings) n1=thrombolytique (traitement) | n2=en:pancytopenia (in 2 of 3 siblings) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pancytopenia (in 50% of patients) n1=thrombolytique (traitement) | n2=en:pancytopenia (in 50% of patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pancytopenia (in some patients) n1=thrombolytique (traitement) | n2=en:pancytopenia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pancytopenia with pancreatitis n1=thrombolytique (traitement) | n2=en:pancytopenia with pancreatitis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pancytopenia-dysmelia n1=thrombolytique (traitement) | n2=en:pancytopenia-dysmelia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pancytopenia, episodic n1=thrombolytique (traitement) | n2=en:pancytopenia, episodic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:panhypogammaglobulinemia n1=thrombolytique (traitement) | n2=en:panhypogammaglobulinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pappenheimer body (morphologic abnormality) n1=thrombolytique (traitement) | n2=en:pappenheimer body (morphologic abnormality) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:paradoxical increase or no change in serum aldosterone and blood pressure after dexamethasone administration n1=thrombolytique (traitement) | n2=en:paradoxical increase or no change in serum aldosterone and blood pressure after dexamethasone administration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:paradoxical increased cortisol secretion on dexamethasone suppression test n1=thrombolytique (traitement) | n2=en:paradoxical increased cortisol secretion on dexamethasone suppression test | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:paraproteinemia n1=thrombolytique (traitement) | n2=en:paraproteinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:parathyroid hormone (pth) absent to low n1=thrombolytique (traitement) | n2=en:parathyroid hormone (pth) absent to low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:parathyroid hormone level increased n1=thrombolytique (traitement) | n2=en:parathyroid hormone level increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:parathyroid hormone normal n1=thrombolytique (traitement) | n2=en:parathyroid hormone normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:parathyroid hormone-related peptide (pthrp) absent to low n1=thrombolytique (traitement) | n2=en:parathyroid hormone-related peptide (pthrp) absent to low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:paris trousseau thrombocytopenia n1=thrombolytique (traitement) | n2=en:paris trousseau thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:paroxysmal nocturnal hemoglobinuria n1=thrombolytique (traitement) | n2=en:paroxysmal nocturnal hemoglobinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:partial deficiency of factor xi (less common) n1=thrombolytique (traitement) | n2=en:partial deficiency of factor xi (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:partial deficiency of factor xi(c) n1=thrombolytique (traitement) | n2=en:partial deficiency of factor xi(c) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:partial deficiency of factor xii(c) n1=thrombolytique (traitement) | n2=en:partial deficiency of factor xii(c) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:partial deficiency of factor xiii (less common) n1=thrombolytique (traitement) | n2=en:partial deficiency of factor xiii (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:partial deficiency of factor xiii(c) n1=thrombolytique (traitement) | n2=en:partial deficiency of factor xiii(c) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:partial deletion of long arm of chromosome 11 (11q23-qter) n1=thrombolytique (traitement) | n2=en:partial deletion of long arm of chromosome 11 (11q23-qter) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:partial terminal deletion of short arm of chromosome 1 (1p36) n1=thrombolytique (traitement) | n2=en:partial terminal deletion of short arm of chromosome 1 (1p36) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pathologic perinuclear mitochondrial iron deposits in erythrocyte precursors n1=thrombolytique (traitement) | n2=en:pathologic perinuclear mitochondrial iron deposits in erythrocyte precursors | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:patient cells have increased levels of lmnb1 mrna and protein n1=thrombolytique (traitement) | n2=en:patient cells have increased levels of lmnb1 mrna and protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:patient cells show a defect in transcription-coupled and global genome nucleotide excision repair n1=thrombolytique (traitement) | n2=en:patient cells show a defect in transcription-coupled and global genome nucleotide excision repair | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:patient cells show abnormal mitochondrial morphology n1=thrombolytique (traitement) | n2=en:patient cells show abnormal mitochondrial morphology | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:patient cells show defective dna repair in response to irradiation and free radical damage n1=thrombolytique (traitement) | n2=en:patient cells show defective dna repair in response to irradiation and free radical damage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:patient cells show defective transcription-coupled and global genome nucleotide excision repair (ner) n1=thrombolytique (traitement) | n2=en:patient cells show defective transcription-coupled and global genome nucleotide excision repair (ner) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:patient cells show increased chromosome breakage n1=thrombolytique (traitement) | n2=en:patient cells show increased chromosome breakage | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:patient fibroblasts and muscle show decreased activities of mitochondrial complexes i, iii, and iv n1=thrombolytique (traitement) | n2=en:patient fibroblasts and muscle show decreased activities of mitochondrial complexes i, iii, and iv | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:patients have supernumerary chromosome - 47,xx(or xy), +der(22), +(11:22)(q23:q11) n1=thrombolytique (traitement) | n2=en:patients have supernumerary chromosome - 47,xx(or xy), +der(22), +(11:22)(q23:q11) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:patients with factor xiii alpha subunit deficiency usually also have decreased levels of plasma factor xiii beta subunit n1=thrombolytique (traitement) | n2=en:patients with factor xiii alpha subunit deficiency usually also have decreased levels of plasma factor xiii beta subunit | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:patients with factor xiii beta subunit deficiency usually also have decreased levels of plasma factor xiii alpha subunit n1=thrombolytique (traitement) | n2=en:patients with factor xiii beta subunit deficiency usually also have decreased levels of plasma factor xiii alpha subunit | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:patients with type 2b develop thrombocytopenia n1=thrombolytique (traitement) | n2=en:patients with type 2b develop thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pcd shows separate and rod-shaped x chromosomes without discernible centromeres n1=thrombolytique (traitement) | n2=en:pcd shows separate and rod-shaped x chromosomes without discernible centromeres | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pcs involves most of all chromosomes of a metaphase n1=thrombolytique (traitement) | n2=en:pcs involves most of all chromosomes of a metaphase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pcs shows separate and splayed chromatids with discernible centromeres n1=thrombolytique (traitement) | n2=en:pcs shows separate and splayed chromatids with discernible centromeres | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pegylated liposomal doxorubicin hydrochloride n1=thrombolytique (traitement) | n2=en:pegylated liposomal doxorubicin hydrochloride | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pelvic venous thrombosis n1=thrombolytique (traitement) | n2=en:pelvic venous thrombosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pentagastrin stimulation test n1=thrombolytique (traitement) | n2=en:pentagastrin stimulation test | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:percentage of bone-derived alkaline phosphatase is >60% in patients versus 40% in healthy adult subjects n1=thrombolytique (traitement) | n2=en:percentage of bone-derived alkaline phosphatase is >60% in patients versus 40% in healthy adult subjects | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:perinatal thrombocytopenia n1=thrombolytique (traitement) | n2=en:perinatal thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:peripheral blood smear shows abnormal red cells n1=thrombolytique (traitement) | n2=en:peripheral blood smear shows abnormal red cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:peripheral blood smear shows polychromasia n1=thrombolytique (traitement) | n2=en:peripheral blood smear shows polychromasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:peripheral embolism n1=thrombolytique (traitement) | n2=en:peripheral embolism | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pernicious anemia n1=thrombolytique (traitement) | n2=en:pernicious anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pernicious anemia, not influenced by intrinsic factor n1=thrombolytique (traitement) | n2=en:pernicious anemia, not influenced by intrinsic factor | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:peroxisome deficiency n1=thrombolytique (traitement) | n2=en:peroxisome deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:persistence of fetal hemoglobin n1=thrombolytique (traitement) | n2=en:persistence of fetal hemoglobin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:persistence of fetal hemoglobin (5-30% hbf) n1=thrombolytique (traitement) | n2=en:persistence of fetal hemoglobin (5-30% hbf) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:persistent ebv viremia n1=thrombolytique (traitement) | n2=en:persistent ebv viremia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:persistent or intermittent neutropenia n1=thrombolytique (traitement) | n2=en:persistent or intermittent neutropenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:persisting thrombocytopenia n1=thrombolytique (traitement) | n2=en:persisting thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:petechia n1=thrombolytique (traitement) | n2=en:petechia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phenobarbitone level low n1=thrombolytique (traitement) | n2=en:phenobarbitone level low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phenytoin level low n1=thrombolytique (traitement) | n2=en:phenytoin level low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:philadelphia chromosome-positive acute lymphoblastic leukemia n1=thrombolytique (traitement) | n2=en:philadelphia chromosome-positive acute lymphoblastic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phlebitis n1=thrombolytique (traitement) | n2=en:phlebitis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phlebitis and thrombophlebitis n1=thrombolytique (traitement) | n2=en:phlebitis and thrombophlebitis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phlebitis and thrombophlebitis of iliac vein n1=thrombolytique (traitement) | n2=en:phlebitis and thrombophlebitis of iliac vein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phlebitis and thrombophlebitis of other deep vessels of lower extremities n1=thrombolytique (traitement) | n2=en:phlebitis and thrombophlebitis of other deep vessels of lower extremities | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phlegmasia alba dolens n1=thrombolytique (traitement) | n2=en:phlegmasia alba dolens | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phosphate normal n1=thrombolytique (traitement) | n2=en:phosphate normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phosphaturia n1=thrombolytique (traitement) | n2=en:phosphaturia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phosphaturia (in some) n1=thrombolytique (traitement) | n2=en:phosphaturia (in some) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phosphaturia may disappear after a long period of time n1=thrombolytique (traitement) | n2=en:phosphaturia may disappear after a long period of time | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phosphoglycerate dehydrogenase deficiency n1=thrombolytique (traitement) | n2=en:phosphoglycerate dehydrogenase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phospholipid antibody positive n1=thrombolytique (traitement) | n2=en:phospholipid antibody positive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phosphomannomutase deficiency in leukocytes, fibroblasts, or liver n1=thrombolytique (traitement) | n2=en:phosphomannomutase deficiency in leukocytes, fibroblasts, or liver | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phosphomannose isomerase deficiency in leukocytes, fibroblasts, or liver n1=thrombolytique (traitement) | n2=en:phosphomannose isomerase deficiency in leukocytes, fibroblasts, or liver | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phosphorylase kinase deficiency in liver and muscle n1=thrombolytique (traitement) | n2=en:phosphorylase kinase deficiency in liver and muscle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phosphorylase kinase normal in muscle n1=thrombolytique (traitement) | n2=en:phosphorylase kinase normal in muscle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phytanic acid accumulation n1=thrombolytique (traitement) | n2=en:phytanic acid accumulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:phytanic acid increased n1=thrombolytique (traitement) | n2=en:phytanic acid increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pigmented reticuloendothelial cells n1=thrombolytique (traitement) | n2=en:pigmented reticuloendothelial cells | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pink urine n1=thrombolytique (traitement) | n2=en:pink urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pipecolic acid accumulation. n1=thrombolytique (traitement) | n2=en:pipecolic acid accumulation. | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pipecolic acidemia n1=thrombolytique (traitement) | n2=en:pipecolic acidemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pipobroman n1=thrombolytique (traitement) | n2=en:pipobroman | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pipobroman 25 mg oral tablet n1=thrombolytique (traitement) | n2=en:pipobroman 25 mg oral tablet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:plasma aldosterone increased n1=thrombolytique (traitement) | n2=en:plasma aldosterone increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:plasma aldosterone normal n1=thrombolytique (traitement) | n2=en:plasma aldosterone normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:plasma ammonia not elevated n1=thrombolytique (traitement) | n2=en:plasma ammonia not elevated | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:plasma catecholamines decreased n1=thrombolytique (traitement) | n2=en:plasma catecholamines decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:plasma protein c deficiency n1=thrombolytique (traitement) | n2=en:plasma protein c deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:plasma proteins low n1=thrombolytique (traitement) | n2=en:plasma proteins low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:plasma triglycerides increased n1=thrombolytique (traitement) | n2=en:plasma triglycerides increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:plasmalogen deficiency n1=thrombolytique (traitement) | n2=en:plasmalogen deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet n1=thrombolytique (traitement) | n2=en:platelet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet adhesiveness decreased n1=thrombolytique (traitement) | n2=en:platelet adhesiveness decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet aggregation abnormal n1=thrombolytique (traitement) | n2=en:platelet aggregation abnormal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet aggregation decreased n1=thrombolytique (traitement) | n2=en:platelet aggregation decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet aggregation normal n1=thrombolytique (traitement) | n2=en:platelet aggregation normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet anisocytosis n1=thrombolytique (traitement) | n2=en:platelet anisocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet antibody positive n1=thrombolytique (traitement) | n2=en:platelet antibody positive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet changes n1=thrombolytique (traitement) | n2=en:platelet changes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet count n1=thrombolytique (traitement) | n2=en:platelet count | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet count normal n1=thrombolytique (traitement) | n2=en:platelet count normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet disorders nec n1=thrombolytique (traitement) | n2=en:platelet disorders nec | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet factor 4 decreased n1=thrombolytique (traitement) | n2=en:platelet factor 4 decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet function test normal n1=thrombolytique (traitement) | n2=en:platelet function test normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet functional disorder n1=thrombolytique (traitement) | n2=en:platelet functional disorder | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet glycoprotein iiia deficiency n1=thrombolytique (traitement) | n2=en:platelet glycoprotein iiia deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet glycoprotein iv deficiency n1=thrombolytique (traitement) | n2=en:platelet glycoprotein iv deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet morphology normal n1=thrombolytique (traitement) | n2=en:platelet morphology normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelet sequestration n1=thrombolytique (traitement) | n2=en:platelet sequestration | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets cannot synthesize thromboxane a2 from arachidonic acid n1=thrombolytique (traitement) | n2=en:platelets cannot synthesize thromboxane a2 from arachidonic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets fail to inhibit the rise of camp levels in response to adp n1=thrombolytique (traitement) | n2=en:platelets fail to inhibit the rise of camp levels in response to adp | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets had abnormal membrane complexes n1=thrombolytique (traitement) | n2=en:platelets had abnormal membrane complexes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets have decreased alpha-granules n1=thrombolytique (traitement) | n2=en:platelets have decreased alpha-granules | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets have decreased expression of glycoprotein ib-alpha (cd42b) n1=thrombolytique (traitement) | n2=en:platelets have decreased expression of glycoprotein ib-alpha (cd42b) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets have decreased number of alpha-granules, large vacuoles, normal number of dense bodies on electron microscopy n1=thrombolytique (traitement) | n2=en:platelets have decreased number of alpha-granules, large vacuoles, normal number of dense bodies on electron microscopy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets have decreased or absent alpha-granules n1=thrombolytique (traitement) | n2=en:platelets have decreased or absent alpha-granules | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets have increased expression of cd34 n1=thrombolytique (traitement) | n2=en:platelets have increased expression of cd34 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets have increased smooth endoplasmic reticulum n1=thrombolytique (traitement) | n2=en:platelets have increased smooth endoplasmic reticulum | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets have paucity of granules n1=thrombolytique (traitement) | n2=en:platelets have paucity of granules | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets may show reduced adp binding activity n1=thrombolytique (traitement) | n2=en:platelets may show reduced adp binding activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets show decreased gpia/gpiia surface complex n1=thrombolytique (traitement) | n2=en:platelets show decreased gpia/gpiia surface complex | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets show decreased gpib n1=thrombolytique (traitement) | n2=en:platelets show decreased gpib | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets show defective activation n1=thrombolytique (traitement) | n2=en:platelets show defective activation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets show defective adhesion to collagen and subendothelium n1=thrombolytique (traitement) | n2=en:platelets show defective adhesion to collagen and subendothelium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets show impaired aggregation in response to adp n1=thrombolytique (traitement) | n2=en:platelets show impaired aggregation in response to adp | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets show normal adp-induced shape change n1=thrombolytique (traitement) | n2=en:platelets show normal adp-induced shape change | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:platelets.large n1=thrombolytique (traitement) | n2=en:platelets.large | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:plicamycin n1=thrombolytique (traitement) | n2=en:plicamycin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:plicamycin 2.5g powder for injection solution vial n1=thrombolytique (traitement) | n2=en:plicamycin 2.5g powder for injection solution vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pms excrete 10 to 200 times less metabolite in urine than wildtype (em) n1=thrombolytique (traitement) | n2=en:pms excrete 10 to 200 times less metabolite in urine than wildtype (em) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pms have increased metabolic ratio of unchanged drug-to-metabolite in urine n1=thrombolytique (traitement) | n2=en:pms have increased metabolic ratio of unchanged drug-to-metabolite in urine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pms show decreased levels of hepatic cyp2d6 enzyme n1=thrombolytique (traitement) | n2=en:pms show decreased levels of hepatic cyp2d6 enzyme | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pms show deficient oxidation of debrisoquine n1=thrombolytique (traitement) | n2=en:pms show deficient oxidation of debrisoquine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pneumococcal 7-valent conjugate n1=thrombolytique (traitement) | n2=en:pneumococcal 7-valent conjugate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pneumococcal 7-valent conjugate vaccine n1=thrombolytique (traitement) | n2=en:pneumococcal 7-valent conjugate vaccine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:poikilocytosis n1=thrombolytique (traitement) | n2=en:poikilocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:polycythemia (e.g. hb chesapeake 141800.0018) n1=thrombolytique (traitement) | n2=en:polycythemia (e.g. hb chesapeake 141800.0018) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:polycythemia neonatorum n1=thrombolytique (traitement) | n2=en:polycythemia neonatorum | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:polycythemia vera n1=thrombolytique (traitement) | n2=en:polycythemia vera | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:polymorphonuclear leukocytosis, episodic n1=thrombolytique (traitement) | n2=en:polymorphonuclear leukocytosis, episodic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:polyploid sperm heads n1=thrombolytique (traitement) | n2=en:polyploid sperm heads | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:poor anticoagulant response to exogenous activated protein c as measured by the activated partial thromboplastin time (aptt) n1=thrombolytique (traitement) | n2=en:poor anticoagulant response to exogenous activated protein c as measured by the activated partial thromboplastin time (aptt) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:poor mitogenic response to growth factors n1=thrombolytique (traitement) | n2=en:poor mitogenic response to growth factors | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:porphyria n1=thrombolytique (traitement) | n2=en:porphyria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:positive antinuclear antibody test n1=thrombolytique (traitement) | n2=en:positive antinuclear antibody test | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:positive kveim-siltzbach skin test n1=thrombolytique (traitement) | n2=en:positive kveim-siltzbach skin test | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:positive urinary bratton-marshall test n1=thrombolytique (traitement) | n2=en:positive urinary bratton-marshall test | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:positive urine dnph screening test n1=thrombolytique (traitement) | n2=en:positive urine dnph screening test | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:post infectious thrombocytopenic purpura n1=thrombolytique (traitement) | n2=en:post infectious thrombocytopenic purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:post-surgical bleeding n1=thrombolytique (traitement) | n2=en:post-surgical bleeding | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:post-transfusion thrombocytopenia n1=thrombolytique (traitement) | n2=en:post-transfusion thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:postprandial hyperglycemia (early in disease course) n1=thrombolytique (traitement) | n2=en:postprandial hyperglycemia (early in disease course) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:postsurgical bleeding n1=thrombolytique (traitement) | n2=en:postsurgical bleeding | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:posttransfusion purpura n1=thrombolytique (traitement) | n2=en:posttransfusion purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:predominance of the d-stereoisomer n1=thrombolytique (traitement) | n2=en:predominance of the d-stereoisomer | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pregnant mothers of affected children have decreased plasma and urinary estrogen n1=thrombolytique (traitement) | n2=en:pregnant mothers of affected children have decreased plasma and urinary estrogen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:premature centromere division (pcd) of the x chromosome observed in cultured lymphocytes during metaphase n1=thrombolytique (traitement) | n2=en:premature centromere division (pcd) of the x chromosome observed in cultured lymphocytes during metaphase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:premature chromatid separation (pcs) observed in 5% to 50% cultured lymphocytes during metaphase n1=thrombolytique (traitement) | n2=en:premature chromatid separation (pcs) observed in 5% to 50% cultured lymphocytes during metaphase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:premature chromosome condensation n1=thrombolytique (traitement) | n2=en:premature chromosome condensation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:premature separation of centromeric heterochromatin n1=thrombolytique (traitement) | n2=en:premature separation of centromeric heterochromatin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:presence of cytochrome b(-245) n1=thrombolytique (traitement) | n2=en:presence of cytochrome b(-245) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:presence of glial fibrillary acidic proteins (gfap) in astrocytes n1=thrombolytique (traitement) | n2=en:presence of glial fibrillary acidic proteins (gfap) in astrocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:presence of i erythrocyte antigen n1=thrombolytique (traitement) | n2=en:presence of i erythrocyte antigen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:presence of pc mrna n1=thrombolytique (traitement) | n2=en:presence of pc mrna | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:presence of rosenthal fibers (cytoplasmic inclusions) in astrocytes n1=thrombolytique (traitement) | n2=en:presence of rosenthal fibers (cytoplasmic inclusions) in astrocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:presence of serum anti-lu3 antibodies n1=thrombolytique (traitement) | n2=en:presence of serum anti-lu3 antibodies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:presence of the philadelphia chromosome (translocation of 9q34 and 22q11) in greater than 95% of patients n1=thrombolytique (traitement) | n2=en:presence of the philadelphia chromosome (translocation of 9q34 and 22q11) in greater than 95% of patients | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:presence of vacuoles on muscle biopsy n1=thrombolytique (traitement) | n2=en:presence of vacuoles on muscle biopsy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:primary cytopenia n1=thrombolytique (traitement) | n2=en:primary cytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:primary immunoglobulin-related amyloidosis (al) n1=thrombolytique (traitement) | n2=en:primary immunoglobulin-related amyloidosis (al) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:primary thrombocytopenia n1=thrombolytique (traitement) | n2=en:primary thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:procarbazine n1=thrombolytique (traitement) | n2=en:procarbazine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:procarbazine 50mg capsule n1=thrombolytique (traitement) | n2=en:procarbazine 50mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:procarbazine hydrochloride n1=thrombolytique (traitement) | n2=en:procarbazine hydrochloride | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolidase deficiency n1=thrombolytique (traitement) | n2=en:prolidase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolinuria n1=thrombolytique (traitement) | n2=en:prolinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged activated partial prothrombin time (appt) n1=thrombolytique (traitement) | n2=en:prolonged activated partial prothrombin time (appt) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged activated partial thromboplastin time (aptt) n1=thrombolytique (traitement) | n2=en:prolonged activated partial thromboplastin time (aptt) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged appt (in 1 patient) n1=thrombolytique (traitement) | n2=en:prolonged appt (in 1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged bleeding n1=thrombolytique (traitement) | n2=en:prolonged bleeding | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged bleeding after surgery or trauma n1=thrombolytique (traitement) | n2=en:prolonged bleeding after surgery or trauma | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged bleeding due to a qualitative defect in the vwf protein n1=thrombolytique (traitement) | n2=en:prolonged bleeding due to a qualitative defect in the vwf protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged bleeding time n1=thrombolytique (traitement) | n2=en:prolonged bleeding time | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged bleeding time (10 - >30 minutes) n1=thrombolytique (traitement) | n2=en:prolonged bleeding time (10 - >30 minutes) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged bleeding time (less common) n1=thrombolytique (traitement) | n2=en:prolonged bleeding time (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged bleeding time 15-to->30 minutes n1=thrombolytique (traitement) | n2=en:prolonged bleeding time 15-to->30 minutes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged bleeding time due to quantitative decrease of vwf protein n1=thrombolytique (traitement) | n2=en:prolonged bleeding time due to quantitative decrease of vwf protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged partial thromboplastin time (ptt) n1=thrombolytique (traitement) | n2=en:prolonged partial thromboplastin time (ptt) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged prothrombin and partial thromboplastin times n1=thrombolytique (traitement) | n2=en:prolonged prothrombin and partial thromboplastin times | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolonged prothrombin time (pt) n1=thrombolytique (traitement) | n2=en:prolonged prothrombin time (pt) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prolymphocytic leukemia n1=thrombolytique (traitement) | n2=en:prolymphocytic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prominent leukocytosis (30,000/ml) n1=thrombolytique (traitement) | n2=en:prominent leukocytosis (30,000/ml) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:promyelocytes have atypical nuclei and vacuolization of the cytoplasm n1=thrombolytique (traitement) | n2=en:promyelocytes have atypical nuclei and vacuolization of the cytoplasm | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:proper antibody response to protein vaccinations n1=thrombolytique (traitement) | n2=en:proper antibody response to protein vaccinations | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:propionic acidemia n1=thrombolytique (traitement) | n2=en:propionic acidemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prostaglandin-endoperoxide synthase 1 (ptgs1, 176805) deficiency in platelets n1=thrombolytique (traitement) | n2=en:prostaglandin-endoperoxide synthase 1 (ptgs1, 176805) deficiency in platelets | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:protein c decreased n1=thrombolytique (traitement) | n2=en:protein c decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:protein s decreased n1=thrombolytique (traitement) | n2=en:protein s decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:protein total decreased n1=thrombolytique (traitement) | n2=en:protein total decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:protein urine absent n1=thrombolytique (traitement) | n2=en:protein urine absent | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:proteinuria n1=thrombolytique (traitement) | n2=en:proteinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:proteinuria (type ii, congenital) n1=thrombolytique (traitement) | n2=en:proteinuria (type ii, congenital) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:proteinuria in those with cystic kidneys n1=thrombolytique (traitement) | n2=en:proteinuria in those with cystic kidneys | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prothrombin level decreased n1=thrombolytique (traitement) | n2=en:prothrombin level decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prothrombin time increased n1=thrombolytique (traitement) | n2=en:prothrombin time increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:prothrombin time low n1=thrombolytique (traitement) | n2=en:prothrombin time low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pseudohyperkalemia, due to ex vivo efflux of potassium from red cells (in some patients) n1=thrombolytique (traitement) | n2=en:pseudohyperkalemia, due to ex vivo efflux of potassium from red cells (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pseudohypertriglyceridemia in adult form n1=thrombolytique (traitement) | n2=en:pseudohypertriglyceridemia in adult form | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pt normal n1=thrombolytique (traitement) | n2=en:pt normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pulmonary embolism n1=thrombolytique (traitement) | n2=en:pulmonary embolism | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pulmonary thrombosis n1=thrombolytique (traitement) | n2=en:pulmonary thrombosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pyrimidinuria n1=thrombolytique (traitement) | n2=en:pyrimidinuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pyruvate-induced insulin secretion n1=thrombolytique (traitement) | n2=en:pyruvate-induced insulin secretion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:pyruvic acidemia n1=thrombolytique (traitement) | n2=en:pyruvic acidemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:qualitative platelet defects n1=thrombolytique (traitement) | n2=en:qualitative platelet defects | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:qualitative platelet deficiency n1=thrombolytique (traitement) | n2=en:qualitative platelet deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:quinine n1=thrombolytique (traitement) | n2=en:quinine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:quinine 130 mg oral tablet n1=thrombolytique (traitement) | n2=en:quinine 130 mg oral tablet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:quinine 163 mg oral tablet n1=thrombolytique (traitement) | n2=en:quinine 163 mg oral tablet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:quinine 300 mg oral capsule n1=thrombolytique (traitement) | n2=en:quinine 300 mg oral capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:quinine 325 mg oral capsule n1=thrombolytique (traitement) | n2=en:quinine 325 mg oral capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:quinine liquid,oral n1=thrombolytique (traitement) | n2=en:quinine liquid,oral | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:quinine so4 pwdr n1=thrombolytique (traitement) | n2=en:quinine so4 pwdr | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:quinine sulfate n1=thrombolytique (traitement) | n2=en:quinine sulfate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:quinine sulfate 200mg capsule n1=thrombolytique (traitement) | n2=en:quinine sulfate 200mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:quinine sulfate 260mg tablet n1=thrombolytique (traitement) | n2=en:quinine sulfate 260mg tablet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:quinine sulfate 324mg capsule n1=thrombolytique (traitement) | n2=en:quinine sulfate 324mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:radial aplasia-thrombocytopenia syndrome n1=thrombolytique (traitement) | n2=en:radial aplasia-thrombocytopenia syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:radiation thrombocytopenia n1=thrombolytique (traitement) | n2=en:radiation thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:radioulnar synostosis with amegakaryocytic thrombocytopenia n1=thrombolytique (traitement) | n2=en:radioulnar synostosis with amegakaryocytic thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:raeb with fibrosis n1=thrombolytique (traitement) | n2=en:raeb with fibrosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:raeb-1 n1=thrombolytique (traitement) | n2=en:raeb-1 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:raeb-2 n1=thrombolytique (traitement) | n2=en:raeb-2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:raised c-reactive protein n1=thrombolytique (traitement) | n2=en:raised c-reactive protein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:raised tsh level n1=thrombolytique (traitement) | n2=en:raised tsh level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:rapid high rai (radioactive iodine) uptake and turnover n1=thrombolytique (traitement) | n2=en:rapid high rai (radioactive iodine) uptake and turnover | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:rapid radioactive iodide (rai) discharge after thiocyanate or perchlorate n1=thrombolytique (traitement) | n2=en:rapid radioactive iodide (rai) discharge after thiocyanate or perchlorate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:rare occurrences of 9+0 or 8+1 cilia n1=thrombolytique (traitement) | n2=en:rare occurrences of 9+0 or 8+1 cilia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reactive hypoglycemia n1=thrombolytique (traitement) | n2=en:reactive hypoglycemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:rectilinear intracellular accumulation of autofluorescent lipopigment storage material n1=thrombolytique (traitement) | n2=en:rectilinear intracellular accumulation of autofluorescent lipopigment storage material | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:recurrent acute myeloid leukemia with myelodysplasia-related changes n1=thrombolytique (traitement) | n2=en:recurrent acute myeloid leukemia with myelodysplasia-related changes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:recurrent hemorrhagic events n1=thrombolytique (traitement) | n2=en:recurrent hemorrhagic events | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:recurring t(11,14) and t(14,19)(q32,q13.1) translocations n1=thrombolytique (traitement) | n2=en:recurring t(11,14) and t(14,19)(q32,q13.1) translocations | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:red blood cells lack h- antigen n1=thrombolytique (traitement) | n2=en:red blood cells lack h- antigen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:red cell adenylate kinase deficiency n1=thrombolytique (traitement) | n2=en:red cell adenylate kinase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:red cell anisopoikilocytosis (in some patients) n1=thrombolytique (traitement) | n2=en:red cell anisopoikilocytosis (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced (50%) activity of protoporphyrinogen oxidase (proto oxidase) n1=thrombolytique (traitement) | n2=en:reduced (50%) activity of protoporphyrinogen oxidase (proto oxidase) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced aspartoacylase activity in cultured skin fibroblasts n1=thrombolytique (traitement) | n2=en:reduced aspartoacylase activity in cultured skin fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced beating amplitudes in cilia n1=thrombolytique (traitement) | n2=en:reduced beating amplitudes in cilia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced bending capacity of cilia n1=thrombolytique (traitement) | n2=en:reduced bending capacity of cilia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced cd4+ count and proportionally increased cd8+ count n1=thrombolytique (traitement) | n2=en:reduced cd4+ count and proportionally increased cd8+ count | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced cytosolic superoxide dismutase-1 (sod1) n1=thrombolytique (traitement) | n2=en:reduced cytosolic superoxide dismutase-1 (sod1) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced electroretinogram (scotopic > photopic) becoming extinguished in older patients n1=thrombolytique (traitement) | n2=en:reduced electroretinogram (scotopic > photopic) becoming extinguished in older patients | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced erythrocyte adenosine deaminase activity n1=thrombolytique (traitement) | n2=en:reduced erythrocyte adenosine deaminase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced erythrocyte glucose/hexose transport n1=thrombolytique (traitement) | n2=en:reduced erythrocyte glucose/hexose transport | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced erythrocyte gs activity n1=thrombolytique (traitement) | n2=en:reduced erythrocyte gs activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced erythrocyte purine nucleoside phosphorylase activity n1=thrombolytique (traitement) | n2=en:reduced erythrocyte purine nucleoside phosphorylase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced ferrochelatase activity n1=thrombolytique (traitement) | n2=en:reduced ferrochelatase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced hemopoiesis n1=thrombolytique (traitement) | n2=en:reduced hemopoiesis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced iga n1=thrombolytique (traitement) | n2=en:reduced iga | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced ige levels n1=thrombolytique (traitement) | n2=en:reduced ige levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced igg levels, particularly igg2 subclass n1=thrombolytique (traitement) | n2=en:reduced igg levels, particularly igg2 subclass | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced leukocyte alkaline phosphatase n1=thrombolytique (traitement) | n2=en:reduced leukocyte alkaline phosphatase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced liver and red cell uroporphyrinogen decarboxylase (uro decarboxylase) n1=thrombolytique (traitement) | n2=en:reduced liver and red cell uroporphyrinogen decarboxylase (uro decarboxylase) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced or absent erythroid precursors in bone marrow n1=thrombolytique (traitement) | n2=en:reduced or absent erythroid precursors in bone marrow | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced oxygen affinity (e.g. hb thionville 141800.0168) n1=thrombolytique (traitement) | n2=en:reduced oxygen affinity (e.g. hb thionville 141800.0168) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced platelet aggregation response to adenosine 5'-diphosphate (adp) n1=thrombolytique (traitement) | n2=en:reduced platelet aggregation response to adenosine 5'-diphosphate (adp) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced platelet aggregation response to adp, collagen, epinephrine n1=thrombolytique (traitement) | n2=en:reduced platelet aggregation response to adp, collagen, epinephrine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced platelet aggregation response to collagen and thrombin n1=thrombolytique (traitement) | n2=en:reduced platelet aggregation response to collagen and thrombin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced platelet glycoprotein ib complex n1=thrombolytique (traitement) | n2=en:reduced platelet glycoprotein ib complex | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced serum uric acid n1=thrombolytique (traitement) | n2=en:reduced serum uric acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced total and free carnitine in plasma and tissue n1=thrombolytique (traitement) | n2=en:reduced total and free carnitine in plasma and tissue | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reduced unsaturated serum cobalamin binding capacity n1=thrombolytique (traitement) | n2=en:reduced unsaturated serum cobalamin binding capacity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:refractory anemia with excess blasts n1=thrombolytique (traitement) | n2=en:refractory anemia with excess blasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:refractory macrocytic anemia n1=thrombolytique (traitement) | n2=en:refractory macrocytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:relatively low urinary pge-m levels n1=thrombolytique (traitement) | n2=en:relatively low urinary pge-m levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:renin decreased n1=thrombolytique (traitement) | n2=en:renin decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:resistance to 1,25-dihydroxyvitamin d3 n1=thrombolytique (traitement) | n2=en:resistance to 1,25-dihydroxyvitamin d3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:respiratory cilia and sperm flagella show reduced coordination of beating activity n1=thrombolytique (traitement) | n2=en:respiratory cilia and sperm flagella show reduced coordination of beating activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:respiratory epithelial show lack of ciliary movement or abnormal movement n1=thrombolytique (traitement) | n2=en:respiratory epithelial show lack of ciliary movement or abnormal movement | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reticulocyte count increased n1=thrombolytique (traitement) | n2=en:reticulocyte count increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reticulocytopenia n1=thrombolytique (traitement) | n2=en:reticulocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reticulocytosis n1=thrombolytique (traitement) | n2=en:reticulocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:reticulocytosis (in some) n1=thrombolytique (traitement) | n2=en:reticulocytosis (in some) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:retraction clot retard n1=thrombolytique (traitement) | n2=en:retraction clot retard | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:rhabdomyolysis in response to alcohol n1=thrombolytique (traitement) | n2=en:rhabdomyolysis in response to alcohol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:rheumatoid factor negative n1=thrombolytique (traitement) | n2=en:rheumatoid factor negative | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:rheumatoid factor positive (finding) n1=thrombolytique (traitement) | n2=en:rheumatoid factor positive (finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:rifabutin n1=thrombolytique (traitement) | n2=en:rifabutin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:rifabutin 150mg capsule n1=thrombolytique (traitement) | n2=en:rifabutin 150mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ringed sideroblasts on bone marrow aspirate n1=thrombolytique (traitement) | n2=en:ringed sideroblasts on bone marrow aspirate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ringed sideroblasts on bone marrow examination n1=thrombolytique (traitement) | n2=en:ringed sideroblasts on bone marrow examination | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ringed sideroblasts on peripheral smear and bone marrow n1=thrombolytique (traitement) | n2=en:ringed sideroblasts on peripheral smear and bone marrow | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:round, yellow-brown dha urine crystals n1=thrombolytique (traitement) | n2=en:round, yellow-brown dha urine crystals | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:routine liver function tests normal n1=thrombolytique (traitement) | n2=en:routine liver function tests normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:russell's viper venom assay may be prolonged or normal, depending on the genetic defect n1=thrombolytique (traitement) | n2=en:russell's viper venom assay may be prolonged or normal, depending on the genetic defect | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:saccharopine dehydrogenase deficiency n1=thrombolytique (traitement) | n2=en:saccharopine dehydrogenase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:saposin a deficiency (finding) n1=thrombolytique (traitement) | n2=en:saposin a deficiency (finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sce normal in heterozygotes n1=thrombolytique (traitement) | n2=en:sce normal in heterozygotes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:schimke immunoosseous dysplasia n1=thrombolytique (traitement) | n2=en:schimke immunoosseous dysplasia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:schirmer test shows alacrima n1=thrombolytique (traitement) | n2=en:schirmer test shows alacrima | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:schistocyte n1=thrombolytique (traitement) | n2=en:schistocyte | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:schulman upshaw syndrome n1=thrombolytique (traitement) | n2=en:schulman upshaw syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sea-blue histiocyte n1=thrombolytique (traitement) | n2=en:sea-blue histiocyte | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sea-blue histiocyte (bone marrow) n1=thrombolytique (traitement) | n2=en:sea-blue histiocyte (bone marrow) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sebastian syndrome n1=thrombolytique (traitement) | n2=en:sebastian syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:secondary autoimmune thrombocytopenia n1=thrombolytique (traitement) | n2=en:secondary autoimmune thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:secondary cytopenia n1=thrombolytique (traitement) | n2=en:secondary cytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:secondary decrease of plasma free carnitine n1=thrombolytique (traitement) | n2=en:secondary decrease of plasma free carnitine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:secondary decreased activity of argininosuccinate synthetase (ass1) n1=thrombolytique (traitement) | n2=en:secondary decreased activity of argininosuccinate synthetase (ass1) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:secondary decreases in complex i and iv activity n1=thrombolytique (traitement) | n2=en:secondary decreases in complex i and iv activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:segmented neutrophils or band cells greater than 70% n1=thrombolytique (traitement) | n2=en:segmented neutrophils or band cells greater than 70% | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sepiapterin reductase deficiency (fibroblasts) n1=thrombolytique (traitement) | n2=en:sepiapterin reductase deficiency (fibroblasts) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum 5-nucleotidase level low n1=thrombolytique (traitement) | n2=en:serum 5-nucleotidase level low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum acid phosphatase normal n1=thrombolytique (traitement) | n2=en:serum acid phosphatase normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum acylcarnitine returns to borderline high or normal after resolution of fever n1=thrombolytique (traitement) | n2=en:serum acylcarnitine returns to borderline high or normal after resolution of fever | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum albumin low result n1=thrombolytique (traitement) | n2=en:serum albumin low result | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum aldosterone elevated n1=thrombolytique (traitement) | n2=en:serum aldosterone elevated | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum alkaline phosphatase normal or mildly increased n1=thrombolytique (traitement) | n2=en:serum alkaline phosphatase normal or mildly increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum alpha-1-antitrypsin (pi) deficiency n1=thrombolytique (traitement) | n2=en:serum alpha-1-antitrypsin (pi) deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum ammonia increased n1=thrombolytique (traitement) | n2=en:serum ammonia increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum and csf lactate may be increased n1=thrombolytique (traitement) | n2=en:serum and csf lactate may be increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum bicarbonate increased n1=thrombolytique (traitement) | n2=en:serum bicarbonate increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum bilirubin increased n1=thrombolytique (traitement) | n2=en:serum bilirubin increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum c-peptide and glucagon levels measurable n1=thrombolytique (traitement) | n2=en:serum c-peptide and glucagon levels measurable | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum c-reactive protein may be increased n1=thrombolytique (traitement) | n2=en:serum c-reactive protein may be increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum calcitonin, increased n1=thrombolytique (traitement) | n2=en:serum calcitonin, increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum calcium elevated n1=thrombolytique (traitement) | n2=en:serum calcium elevated | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum calcium normal n1=thrombolytique (traitement) | n2=en:serum calcium normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum carnitine deficiency n1=thrombolytique (traitement) | n2=en:serum carnitine deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum chloride level decreased (finding) n1=thrombolytique (traitement) | n2=en:serum chloride level decreased (finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum cholesterol low or normal n1=thrombolytique (traitement) | n2=en:serum cholesterol low or normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum cholesterol normal n1=thrombolytique (traitement) | n2=en:serum cholesterol normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum cholesterol raised n1=thrombolytique (traitement) | n2=en:serum cholesterol raised | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum copper decreased n1=thrombolytique (traitement) | n2=en:serum copper decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum corticosterone increased n1=thrombolytique (traitement) | n2=en:serum corticosterone increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum cortisol decreased n1=thrombolytique (traitement) | n2=en:serum cortisol decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum cortisol elevated n1=thrombolytique (traitement) | n2=en:serum cortisol elevated | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum creatine kinase 20-70 times normal n1=thrombolytique (traitement) | n2=en:serum creatine kinase 20-70 times normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum creatine kinase may be increased n1=thrombolytique (traitement) | n2=en:serum creatine kinase may be increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum creatine kinase may be normal n1=thrombolytique (traitement) | n2=en:serum creatine kinase may be normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum creatine kinase may be normal or elevated n1=thrombolytique (traitement) | n2=en:serum creatine kinase may be normal or elevated | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum creatine kinase may be normal or increased n1=thrombolytique (traitement) | n2=en:serum creatine kinase may be normal or increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum creatinine low n1=thrombolytique (traitement) | n2=en:serum creatinine low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum creatinine raised n1=thrombolytique (traitement) | n2=en:serum creatinine raised | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum ferritin hyperglycosylation n1=thrombolytique (traitement) | n2=en:serum ferritin hyperglycosylation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum ferritin normal n1=thrombolytique (traitement) | n2=en:serum ferritin normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum folate low n1=thrombolytique (traitement) | n2=en:serum folate low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum folate normal n1=thrombolytique (traitement) | n2=en:serum folate normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum gastrin increased n1=thrombolytique (traitement) | n2=en:serum gastrin increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum growth hormone increased n1=thrombolytique (traitement) | n2=en:serum growth hormone increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum homocysteine normal n1=thrombolytique (traitement) | n2=en:serum homocysteine normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum iron low (finding) n1=thrombolytique (traitement) | n2=en:serum iron low (finding) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum iron normal n1=thrombolytique (traitement) | n2=en:serum iron normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum iron raised n1=thrombolytique (traitement) | n2=en:serum iron raised | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum lactate is usually normal n1=thrombolytique (traitement) | n2=en:serum lactate is usually normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum lactate may be increased during encephalopathic exacerbations n1=thrombolytique (traitement) | n2=en:serum lactate may be increased during encephalopathic exacerbations | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum mitochondrial autoantibodies n1=thrombolytique (traitement) | n2=en:serum mitochondrial autoantibodies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum osmolality decreased n1=thrombolytique (traitement) | n2=en:serum osmolality decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum phosphate concentration below normal n1=thrombolytique (traitement) | n2=en:serum phosphate concentration below normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum phosphate normal n1=thrombolytique (traitement) | n2=en:serum phosphate normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum pristanic acid increased n1=thrombolytique (traitement) | n2=en:serum pristanic acid increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum prolactin decreased n1=thrombolytique (traitement) | n2=en:serum prolactin decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum prolactin increased n1=thrombolytique (traitement) | n2=en:serum prolactin increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum testosterone decreased n1=thrombolytique (traitement) | n2=en:serum testosterone decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum testosterone level normal n1=thrombolytique (traitement) | n2=en:serum testosterone level normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum thiamine is normal n1=thrombolytique (traitement) | n2=en:serum thiamine is normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum thyroxine may be decreased or normal n1=thrombolytique (traitement) | n2=en:serum thyroxine may be decreased or normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum transaminase increased n1=thrombolytique (traitement) | n2=en:serum transaminase increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum transferrin glycosylation is normal n1=thrombolytique (traitement) | n2=en:serum transferrin glycosylation is normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum transferrin isoelectric focusing shows type 2 pattern n1=thrombolytique (traitement) | n2=en:serum transferrin isoelectric focusing shows type 2 pattern | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum transferrin shows normal or mild hypo-glycosylation n1=thrombolytique (traitement) | n2=en:serum transferrin shows normal or mild hypo-glycosylation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum triglycerides increased n1=thrombolytique (traitement) | n2=en:serum triglycerides increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:serum triglycerides normal n1=thrombolytique (traitement) | n2=en:serum triglycerides normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severe amyloid angiopathy n1=thrombolytique (traitement) | n2=en:severe amyloid angiopathy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severe autoimmune cytopenia n1=thrombolytique (traitement) | n2=en:severe autoimmune cytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severe bleeding after biopsies (uncommon) n1=thrombolytique (traitement) | n2=en:severe bleeding after biopsies (uncommon) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severe congenital neutropenia n1=thrombolytique (traitement) | n2=en:severe congenital neutropenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severe cytopenia n1=thrombolytique (traitement) | n2=en:severe cytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severe fever with thrombocytopenia syndrome n1=thrombolytique (traitement) | n2=en:severe fever with thrombocytopenia syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severe hypernatremia in neonatal period n1=thrombolytique (traitement) | n2=en:severe hypernatremia in neonatal period | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severe thrombocytopenia (30-60 x 10(9)/l) n1=thrombolytique (traitement) | n2=en:severe thrombocytopenia (30-60 x 10(9)/l) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severe thrombocytopenia (birth) n1=thrombolytique (traitement) | n2=en:severe thrombocytopenia (birth) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severely decreased activity of beta-1,4-mannosyltransferase (less than 10% of normal) n1=thrombolytique (traitement) | n2=en:severely decreased activity of beta-1,4-mannosyltransferase (less than 10% of normal) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severely decreased antigen levels of vwf and factor viii n1=thrombolytique (traitement) | n2=en:severely decreased antigen levels of vwf and factor viii | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severely decreased carnitine palmitoyltransferase ii (cpt ii) activity (less than 10% of normal) in multiple tissues n1=thrombolytique (traitement) | n2=en:severely decreased carnitine palmitoyltransferase ii (cpt ii) activity (less than 10% of normal) in multiple tissues | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severely decreased palmitate oxidation n1=thrombolytique (traitement) | n2=en:severely decreased palmitate oxidation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severely impaired ciliary motility n1=thrombolytique (traitement) | n2=en:severely impaired ciliary motility | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:severity of anemia can range from mild to life-threatening n1=thrombolytique (traitement) | n2=en:severity of anemia can range from mild to life-threatening | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sex-linked thrombocytopenia n1=thrombolytique (traitement) | n2=en:sex-linked thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:shortened metaphase n1=thrombolytique (traitement) | n2=en:shortened metaphase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:shortened telomeres (1 patient) n1=thrombolytique (traitement) | n2=en:shortened telomeres (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:shortened telomeres (classic feature, nola3 patient) n1=thrombolytique (traitement) | n2=en:shortened telomeres (classic feature, nola3 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:shortened telomeres (in 1 of 2 patients) n1=thrombolytique (traitement) | n2=en:shortened telomeres (in 1 of 2 patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:shwachman-diamond syndrome n1=thrombolytique (traitement) | n2=en:shwachman-diamond syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sialylation defects n1=thrombolytique (traitement) | n2=en:sialylation defects | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sideroblastic anemia n1=thrombolytique (traitement) | n2=en:sideroblastic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:skeletal muscle shows decreased activities of mitochondrial respiratory complexes i, iii, iv, and v n1=thrombolytique (traitement) | n2=en:skeletal muscle shows decreased activities of mitochondrial respiratory complexes i, iii, iv, and v | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:skewed x-inactivation in females n1=thrombolytique (traitement) | n2=en:skewed x-inactivation in females | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:skin fibroblasts contain cytoplasmic membrane-bound granular inclusions n1=thrombolytique (traitement) | n2=en:skin fibroblasts contain cytoplasmic membrane-bound granular inclusions | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sky-blue leukocyte inclusion bodies (dohle-like bodies) that contain clusters of ribosomes oriented along parallel microfilaments n1=thrombolytique (traitement) | n2=en:sky-blue leukocyte inclusion bodies (dohle-like bodies) that contain clusters of ribosomes oriented along parallel microfilaments | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:slightly elevated 24-hour mean plasma cortisol n1=thrombolytique (traitement) | n2=en:slightly elevated 24-hour mean plasma cortisol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:slightly increased serum alkaline phosphatase may occur n1=thrombolytique (traitement) | n2=en:slightly increased serum alkaline phosphatase may occur | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:small and large vessel vasculitis n1=thrombolytique (traitement) | n2=en:small and large vessel vasculitis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:small platelet size n1=thrombolytique (traitement) | n2=en:small platelet size | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:smooth muscle antibodies positive n1=thrombolytique (traitement) | n2=en:smooth muscle antibodies positive | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:some cilia show abnormal beating patterns or immotility n1=thrombolytique (traitement) | n2=en:some cilia show abnormal beating patterns or immotility | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:some cilia show central complex and radial spoke defects n1=thrombolytique (traitement) | n2=en:some cilia show central complex and radial spoke defects | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:some fragmented or disrupted golgi n1=thrombolytique (traitement) | n2=en:some fragmented or disrupted golgi | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:some increase in monosialo- and trisialotransferrin (type 1/2 pattern) n1=thrombolytique (traitement) | n2=en:some increase in monosialo- and trisialotransferrin (type 1/2 pattern) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:some patients carry a deletion of minimum of 8.1 mb on 2q32-q33 n1=thrombolytique (traitement) | n2=en:some patients carry a deletion of minimum of 8.1 mb on 2q32-q33 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:some tissues may have normal levels of 3-hydroxyacyl-coa dehydrogenase activity n1=thrombolytique (traitement) | n2=en:some tissues may have normal levels of 3-hydroxyacyl-coa dehydrogenase activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:spastic paraplegia and evans syndrome n1=thrombolytique (traitement) | n2=en:spastic paraplegia and evans syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:specialized branches of medicine n1=thrombolytique (traitement) | n2=en:specialized branches of medicine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:specific gravity in pleural fluid below reference range n1=thrombolytique (traitement) | n2=en:specific gravity in pleural fluid below reference range | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:spherocytosis n1=thrombolytique (traitement) | n2=en:spherocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:splanchnic vein thrombosis n1=thrombolytique (traitement) | n2=en:splanchnic vein thrombosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:splenic manifestation of b-cell prolymphocytic leukemia n1=thrombolytique (traitement) | n2=en:splenic manifestation of b-cell prolymphocytic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:splenic manifestation of prolymphocytic leukemia n1=thrombolytique (traitement) | n2=en:splenic manifestation of prolymphocytic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:splenic manifestation of t-cell prolymphocytic leukemia n1=thrombolytique (traitement) | n2=en:splenic manifestation of t-cell prolymphocytic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:spongy degeneration of brain on histology n1=thrombolytique (traitement) | n2=en:spongy degeneration of brain on histology | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sterol 27-hydroxylase deficiency n1=thrombolytique (traitement) | n2=en:sterol 27-hydroxylase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:stimulation of sympathetic fibers results in release of dopamine, not norepinephrine n1=thrombolytique (traitement) | n2=en:stimulation of sympathetic fibers results in release of dopamine, not norepinephrine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:stomatocyte (cell) n1=thrombolytique (traitement) | n2=en:stomatocyte (cell) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:stomatocytes (may be few in number) n1=thrombolytique (traitement) | n2=en:stomatocytes (may be few in number) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:stomatocytosis result n1=thrombolytique (traitement) | n2=en:stomatocytosis result | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:stormorken syndrome n1=thrombolytique (traitement) | n2=en:stormorken syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:streptokinase n1=thrombolytique (traitement) | n2=en:streptokinase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:streptokinase 1500000unt intravenous infusion vial n1=thrombolytique (traitement) | n2=en:streptokinase 1500000unt intravenous infusion vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:streptokinase 250,000iu powder for infusion solution vial n1=thrombolytique (traitement) | n2=en:streptokinase 250,000iu powder for infusion solution vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:streptokinase 600000iu/vial powder n1=thrombolytique (traitement) | n2=en:streptokinase 600000iu/vial powder | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:streptokinase 750,000iu powder for infusion solution vial n1=thrombolytique (traitement) | n2=en:streptokinase 750,000iu powder for infusion solution vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:structural abnormalities seen on chromosome analysis n1=thrombolytique (traitement) | n2=en:structural abnormalities seen on chromosome analysis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:stt3a-cdg and stt3b-cdg n1=thrombolytique (traitement) | n2=en:stt3a-cdg and stt3b-cdg | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:subepithelial fibrin deposition with inflammation (pseudomembranous inflammation) of mucosal tissues n1=thrombolytique (traitement) | n2=en:subepithelial fibrin deposition with inflammation (pseudomembranous inflammation) of mucosal tissues | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:submucosal macrophages filled with sphingolipids n1=thrombolytique (traitement) | n2=en:submucosal macrophages filled with sphingolipids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:subsarcolemmal pleomorphic mitochondria on em n1=thrombolytique (traitement) | n2=en:subsarcolemmal pleomorphic mitochondria on em | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:subtelomeric deletion of chromosome 16p n1=thrombolytique (traitement) | n2=en:subtelomeric deletion of chromosome 16p | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:subtelomeric deletion of long arm of chromosome 3 (3q29) n1=thrombolytique (traitement) | n2=en:subtelomeric deletion of long arm of chromosome 3 (3q29) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:superficial thrombophlebitis n1=thrombolytique (traitement) | n2=en:superficial thrombophlebitis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sustained eosinophilia (greater than 1,500/cubic mm) for greater than 6 months n1=thrombolytique (traitement) | n2=en:sustained eosinophilia (greater than 1,500/cubic mm) for greater than 6 months | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:sweat test normal n1=thrombolytique (traitement) | n2=en:sweat test normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:syndrome, omenn's n1=thrombolytique (traitement) | n2=en:syndrome, omenn's | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:systemic accumulation of very long chain fatty acids (vlcfa) n1=thrombolytique (traitement) | n2=en:systemic accumulation of very long chain fatty acids (vlcfa) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:systemic amyloidosis may occur n1=thrombolytique (traitement) | n2=en:systemic amyloidosis may occur | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:systemic lupus erythematosus n1=thrombolytique (traitement) | n2=en:systemic lupus erythematosus | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:t activation syndrome n1=thrombolytique (traitement) | n2=en:t activation syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:t cells may be increased or decreased n1=thrombolytique (traitement) | n2=en:t cells may be increased or decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:t-cell deficit n1=thrombolytique (traitement) | n2=en:t-cell deficit | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:t-cell prolymphocytic leukemia n1=thrombolytique (traitement) | n2=en:t-cell prolymphocytic leukemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:t-cell prolymphocytic leukemia, cerebriform cell variant n1=thrombolytique (traitement) | n2=en:t-cell prolymphocytic leukemia, cerebriform cell variant | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:t-cell prolymphocytic leukemia, small cell variant n1=thrombolytique (traitement) | n2=en:t-cell prolymphocytic leukemia, small cell variant | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:t-lymphocytopenia n1=thrombolytique (traitement) | n2=en:t-lymphocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:t1 transport protein (glucose-6-phosphate translocase) defect n1=thrombolytique (traitement) | n2=en:t1 transport protein (glucose-6-phosphate translocase) defect | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tay-sachs disease n1=thrombolytique (traitement) | n2=en:tay-sachs disease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:telomere shortening n1=thrombolytique (traitement) | n2=en:telomere shortening | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ten percent of cases are secondary to submicroscopic deletions of 16p13.3 detectable by fish n1=thrombolytique (traitement) | n2=en:ten percent of cases are secondary to submicroscopic deletions of 16p13.3 detectable by fish | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tenascin x deficiency (serum and fibroblasts) n1=thrombolytique (traitement) | n2=en:tenascin x deficiency (serum and fibroblasts) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tenecteplase n1=thrombolytique (traitement) | n2=en:tenecteplase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tenecteplase 10,000unit powder and solvent for solution for injection vial n1=thrombolytique (traitement) | n2=en:tenecteplase 10,000unit powder and solvent for solution for injection vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tetraphocomelia-thrombocytopenia syndrome n1=thrombolytique (traitement) | n2=en:tetraphocomelia-thrombocytopenia syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:theophylline level low n1=thrombolytique (traitement) | n2=en:theophylline level low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thiamine responsive megaloblastic anemia syndrome n1=thrombolytique (traitement) | n2=en:thiamine responsive megaloblastic anemia syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thiotepa n1=thrombolytique (traitement) | n2=en:thiotepa | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thiotepa 10.4 mg/ml injectable solution [thioplex] n1=thrombolytique (traitement) | n2=en:thiotepa 10.4 mg/ml injectable solution [thioplex] | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thiotepa 15mg injection (pdr for recon) n1=thrombolytique (traitement) | n2=en:thiotepa 15mg injection (pdr for recon) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombasthenia-thrombocytopenia, hereditary n1=thrombolytique (traitement) | n2=en:thrombasthenia-thrombocytopenia, hereditary | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombin decreased n1=thrombolytique (traitement) | n2=en:thrombin decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thromboasthenia (hemorrhagic) (hereditary) n1=thrombolytique (traitement) | n2=en:thromboasthenia (hemorrhagic) (hereditary) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia (33-120 x 10(9)/l) n1=thrombolytique (traitement) | n2=en:thrombocytopenia (33-120 x 10(9)/l) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia (birth) n1=thrombolytique (traitement) | n2=en:thrombocytopenia (birth) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia (hellp syndrome) n1=thrombolytique (traitement) | n2=en:thrombocytopenia (hellp syndrome) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia (in some patients) n1=thrombolytique (traitement) | n2=en:thrombocytopenia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia (less common) n1=thrombolytique (traitement) | n2=en:thrombocytopenia (less common) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia (mean 42.7 x 10(9)/l) n1=thrombolytique (traitement) | n2=en:thrombocytopenia (mean 42.7 x 10(9)/l) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia (onset birth-neonate, may be precipitated by cow's milk allergy) n1=thrombolytique (traitement) | n2=en:thrombocytopenia (onset birth-neonate, may be precipitated by cow's milk allergy) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia (rare) n1=thrombolytique (traitement) | n2=en:thrombocytopenia (rare) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia (reported in 1 patient) n1=thrombolytique (traitement) | n2=en:thrombocytopenia (reported in 1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia 1 (disorder) n1=thrombolytique (traitement) | n2=en:thrombocytopenia 1 (disorder) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia 2 n1=thrombolytique (traitement) | n2=en:thrombocytopenia 2 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia 3 n1=thrombolytique (traitement) | n2=en:thrombocytopenia 3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia 4 n1=thrombolytique (traitement) | n2=en:thrombocytopenia 4 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia 5 n1=thrombolytique (traitement) | n2=en:thrombocytopenia 5 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia absent ulnar syndrome n1=thrombolytique (traitement) | n2=en:thrombocytopenia absent ulnar syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia aggravated n1=thrombolytique (traitement) | n2=en:thrombocytopenia aggravated | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia associated with aids n1=thrombolytique (traitement) | n2=en:thrombocytopenia associated with aids | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia co-occurrent and due to alcoholism n1=thrombolytique (traitement) | n2=en:thrombocytopenia co-occurrent and due to alcoholism | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to alcohol n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to alcohol | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to blood loss n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to blood loss | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to defective platelet production n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to defective platelet production | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to diminished platelet production n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to diminished platelet production | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to drugs n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to drugs | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to extracorporeal circulation n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to extracorporeal circulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to extracorporeal circulation of blood n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to extracorporeal circulation of blood | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to hypersplenism n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to hypersplenism | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to hypothermia n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to hypothermia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to immune destruction n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to immune destruction | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to massive blood transfusion n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to massive blood transfusion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia due to non-immune destruction n1=thrombolytique (traitement) | n2=en:thrombocytopenia due to non-immune destruction | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia post hemolytic anemia n1=thrombolytique (traitement) | n2=en:thrombocytopenia post hemolytic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia purpura (in some patients) n1=thrombolytique (traitement) | n2=en:thrombocytopenia purpura (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia robin sequence n1=thrombolytique (traitement) | n2=en:thrombocytopenia robin sequence | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia toxic n1=thrombolytique (traitement) | n2=en:thrombocytopenia toxic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia with elevated serum iga and renal disease n1=thrombolytique (traitement) | n2=en:thrombocytopenia with elevated serum iga and renal disease | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia, cyclic n1=thrombolytique (traitement) | n2=en:thrombocytopenia, cyclic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia, isolated (1 patient) n1=thrombolytique (traitement) | n2=en:thrombocytopenia, isolated (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia, late-onset (1 patient) n1=thrombolytique (traitement) | n2=en:thrombocytopenia, late-onset (1 patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia, mild-moderate (60-100 x 10(9)/l) n1=thrombolytique (traitement) | n2=en:thrombocytopenia, mild-moderate (60-100 x 10(9)/l) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia, platelet dysfunction, hemolysis, and imbalanced globin synthesis n1=thrombolytique (traitement) | n2=en:thrombocytopenia, platelet dysfunction, hemolysis, and imbalanced globin synthesis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia, x-linked, intermittent n1=thrombolytique (traitement) | n2=en:thrombocytopenia, x-linked, intermittent | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenia, x-linked, with or without dyserythropoietic anemia n1=thrombolytique (traitement) | n2=en:thrombocytopenia, x-linked, with or without dyserythropoietic anemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenic purpura associated with metabolic disorder n1=thrombolytique (traitement) | n2=en:thrombocytopenic purpura associated with metabolic disorder | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenic purpura due to defective platelet production n1=thrombolytique (traitement) | n2=en:thrombocytopenic purpura due to defective platelet production | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytopenic purpura due to platelet consumption n1=thrombolytique (traitement) | n2=en:thrombocytopenic purpura due to platelet consumption | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytosis n1=thrombolytique (traitement) | n2=en:thrombocytosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombocytosis (in some patients) n1=thrombolytique (traitement) | n2=en:thrombocytosis (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thromboembolism n1=thrombolytique (traitement) | n2=en:thromboembolism | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thromboembolism (25%) n1=thrombolytique (traitement) | n2=en:thromboembolism (25%) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombomodulin, human n1=thrombolytique (traitement) | n2=en:thrombomodulin, human | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombopathy n1=thrombolytique (traitement) | n2=en:thrombopathy | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombopeny n1=thrombolytique (traitement) | n2=en:thrombopeny | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombophlebitis multiple n1=thrombolytique (traitement) | n2=en:thrombophlebitis multiple | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombophlebitis of superficial veins of lower extremity n1=thrombolytique (traitement) | n2=en:thrombophlebitis of superficial veins of lower extremity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thromboplastin decreased n1=thrombolytique (traitement) | n2=en:thromboplastin decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombosis of retinal vein n1=thrombolytique (traitement) | n2=en:thrombosis of retinal vein | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombotic microangiopathy (hyaline thrombi of platelets and fibrin in terminal arterioles and capillaries) n1=thrombolytique (traitement) | n2=en:thrombotic microangiopathy (hyaline thrombi of platelets and fibrin in terminal arterioles and capillaries) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thrombotic thrombocytopenic purpura, acquired n1=thrombolytique (traitement) | n2=en:thrombotic thrombocytopenic purpura, acquired | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thymic hormone decreased n1=thrombolytique (traitement) | n2=en:thymic hormone decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thyroid dyshormonogenesis 3 n1=thrombolytique (traitement) | n2=en:thyroid dyshormonogenesis 3 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thyroid dyshormonogenesis 4 n1=thrombolytique (traitement) | n2=en:thyroid dyshormonogenesis 4 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thyroid dyshormonogenesis 5 n1=thrombolytique (traitement) | n2=en:thyroid dyshormonogenesis 5 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thyroid hormone organification defect n1=thrombolytique (traitement) | n2=en:thyroid hormone organification defect | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thyroid hormones increased n1=thrombolytique (traitement) | n2=en:thyroid hormones increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:thyroid peroxidase defect n1=thrombolytique (traitement) | n2=en:thyroid peroxidase defect | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tibc - total iron binding capacity low n1=thrombolytique (traitement) | n2=en:tibc - total iron binding capacity low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tinzaparin n1=thrombolytique (traitement) | n2=en:tinzaparin | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tinzaparin sodium n1=thrombolytique (traitement) | n2=en:tinzaparin sodium | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tinzaparin sodium 20,000iu/ml injection solution 2ml vial n1=thrombolytique (traitement) | n2=en:tinzaparin sodium 20,000iu/ml injection solution 2ml vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tmem165-cdg (cdg-iik) n1=thrombolytique (traitement) | n2=en:tmem165-cdg (cdg-iik) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tonofibril defect (cross-beta-protein structure) n1=thrombolytique (traitement) | n2=en:tonofibril defect (cross-beta-protein structure) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:topotecan n1=thrombolytique (traitement) | n2=en:topotecan | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:topotecan 0.25mg capsule n1=thrombolytique (traitement) | n2=en:topotecan 0.25mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:topotecan 1mg capsule n1=thrombolytique (traitement) | n2=en:topotecan 1mg capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:topotecan 4mg powder for infusion solution vial n1=thrombolytique (traitement) | n2=en:topotecan 4mg powder for infusion solution vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:topotecan hydrochloride n1=thrombolytique (traitement) | n2=en:topotecan hydrochloride | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:total white blood cell count less than 25,000/cubic mm with 30-70% eosinophils n1=thrombolytique (traitement) | n2=en:total white blood cell count less than 25,000/cubic mm with 30-70% eosinophils | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:toxic cytopenia n1=thrombolytique (traitement) | n2=en:toxic cytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transaminitis n1=thrombolytique (traitement) | n2=en:transaminitis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transcobalamin ii deficiency n1=thrombolytique (traitement) | n2=en:transcobalamin ii deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transferase deficiency galactosemia n1=thrombolytique (traitement) | n2=en:transferase deficiency galactosemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transferrin saturation increased n1=thrombolytique (traitement) | n2=en:transferrin saturation increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transfusion medicine n1=thrombolytique (traitement) | n2=en:transfusion medicine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transient abnormal myelopoiesis n1=thrombolytique (traitement) | n2=en:transient abnormal myelopoiesis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transient eosinophilia in first decade n1=thrombolytique (traitement) | n2=en:transient eosinophilia in first decade | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transient hyperlipidemia n1=thrombolytique (traitement) | n2=en:transient hyperlipidemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transient hyperphenylalaninemia occurs on oral loading test with phenylalanine n1=thrombolytique (traitement) | n2=en:transient hyperphenylalaninemia occurs on oral loading test with phenylalanine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transient neonatal hypocalcemia (2p21del) n1=thrombolytique (traitement) | n2=en:transient neonatal hypocalcemia (2p21del) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transient neonatal hypoglycemia (2p21del) n1=thrombolytique (traitement) | n2=en:transient neonatal hypoglycemia (2p21del) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transient neonatal thrombocytopenia n1=thrombolytique (traitement) | n2=en:transient neonatal thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transient neonatal thrombocytopenia due to exchange transfusion n1=thrombolytique (traitement) | n2=en:transient neonatal thrombocytopenia due to exchange transfusion | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transient neonatal thrombocytopenia due to idiopathic maternal thrombocytopenia n1=thrombolytique (traitement) | n2=en:transient neonatal thrombocytopenia due to idiopathic maternal thrombocytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transient neonatal thrombocytopenia due to isoimmunization n1=thrombolytique (traitement) | n2=en:transient neonatal thrombocytopenia due to isoimmunization | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transitory cytopenia n1=thrombolytique (traitement) | n2=en:transitory cytopenia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:translocation (x,7)(p11.3,q11.21) - in some patients n1=thrombolytique (traitement) | n2=en:translocation (x,7)(p11.3,q11.21) - in some patients | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:translocation between 18q21 and 14q32 n1=thrombolytique (traitement) | n2=en:translocation between 18q21 and 14q32 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:translocation of chromosomes 9 and 13 n1=thrombolytique (traitement) | n2=en:translocation of chromosomes 9 and 13 | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:translocation or deletions involving 7p13 (severe case reports) n1=thrombolytique (traitement) | n2=en:translocation or deletions involving 7p13 (severe case reports) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:transmission electron microscopy (tem) of patient respiratory cilia shows normal 9+2 axonemal composition n1=thrombolytique (traitement) | n2=en:transmission electron microscopy (tem) of patient respiratory cilia shows normal 9+2 axonemal composition | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:triglyceride decreased n1=thrombolytique (traitement) | n2=en:triglyceride decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:trilineage dysplasia (in some patients) n1=thrombolytique (traitement) | n2=en:trilineage dysplasia (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tryptophanuria n1=thrombolytique (traitement) | n2=en:tryptophanuria | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tsh decreased n1=thrombolytique (traitement) | n2=en:tsh decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tumor may secrete vasoactive intestinal peptide (vip) n1=thrombolytique (traitement) | n2=en:tumor may secrete vasoactive intestinal peptide (vip) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:two alternative chimeric oncogene products called p210(bcr-abl) and p185(bcr-abl) n1=thrombolytique (traitement) | n2=en:two alternative chimeric oncogene products called p210(bcr-abl) and p185(bcr-abl) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:type 1 collagen overmodification n1=thrombolytique (traitement) | n2=en:type 1 collagen overmodification | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:type 1a autoimmune lymphoproliferative syndrome n1=thrombolytique (traitement) | n2=en:type 1a autoimmune lymphoproliferative syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:type 1b autoimmune lymphoproliferative syndrome n1=thrombolytique (traitement) | n2=en:type 1b autoimmune lymphoproliferative syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:type 2 autoimmune lymphoproliferative syndrome n1=thrombolytique (traitement) | n2=en:type 2 autoimmune lymphoproliferative syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:type 3 autoimmune lymphoproliferative syndrome n1=thrombolytique (traitement) | n2=en:type 3 autoimmune lymphoproliferative syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:type i - methemoglobin concentration 10-35% n1=thrombolytique (traitement) | n2=en:type i - methemoglobin concentration 10-35% | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:type i, classic, decreased antithrombin iii levels n1=thrombolytique (traitement) | n2=en:type i, classic, decreased antithrombin iii levels | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:type ii, normal antithrombin iii level but decreased activity n1=thrombolytique (traitement) | n2=en:type ii, normal antithrombin iii level but decreased activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:type iii collagen defect n1=thrombolytique (traitement) | n2=en:type iii collagen defect | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tyrosine iodination defect n1=thrombolytique (traitement) | n2=en:tyrosine iodination defect | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tyrosine loss n1=thrombolytique (traitement) | n2=en:tyrosine loss | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tyrosinemia n1=thrombolytique (traitement) | n2=en:tyrosinemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:tyrosinemia (transient, resolves in infancy) n1=thrombolytique (traitement) | n2=en:tyrosinemia (transient, resolves in infancy) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:udp-galactose-4-epimerase deficiency in all cells ('generalized' or 'severe' form) n1=thrombolytique (traitement) | n2=en:udp-galactose-4-epimerase deficiency in all cells ('generalized' or 'severe' form) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:ultra large von willebrand factor (ul-vwf) in plasma n1=thrombolytique (traitement) | n2=en:ultra large von willebrand factor (ul-vwf) in plasma | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:undetectable dopamine beta-hydroxylase (dbh) protein in plasma, csf, or sympathetic fibers n1=thrombolytique (traitement) | n2=en:undetectable dopamine beta-hydroxylase (dbh) protein in plasma, csf, or sympathetic fibers | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:undetectable epinephrine (adrenaline) in plasma, urine, csf n1=thrombolytique (traitement) | n2=en:undetectable epinephrine (adrenaline) in plasma, urine, csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:undetectable norepinephrine (noradrenaline) in plasma, urine, csf n1=thrombolytique (traitement) | n2=en:undetectable norepinephrine (noradrenaline) in plasma, urine, csf | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:undetectable plasma dbh activity n1=thrombolytique (traitement) | n2=en:undetectable plasma dbh activity | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:undetectable serum arginine vasopressin, or antidiuretic hormone (adh, avp, 192340) n1=thrombolytique (traitement) | n2=en:undetectable serum arginine vasopressin, or antidiuretic hormone (adh, avp, 192340) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:undetectable serum l-transferrin (homozygous patient) n1=thrombolytique (traitement) | n2=en:undetectable serum l-transferrin (homozygous patient) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:undetectable urinary hypoxanthine n1=thrombolytique (traitement) | n2=en:undetectable urinary hypoxanthine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:unprocessed 3-oxoacyl coa thiolase n1=thrombolytique (traitement) | n2=en:unprocessed 3-oxoacyl coa thiolase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:unresponsive to acth stimulation n1=thrombolytique (traitement) | n2=en:unresponsive to acth stimulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:unstable hemoglobin (e.g. hb contaldo 141800.0022) n1=thrombolytique (traitement) | n2=en:unstable hemoglobin (e.g. hb contaldo 141800.0022) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:upregulation of alpha-interferon-stimulated genes n1=thrombolytique (traitement) | n2=en:upregulation of alpha-interferon-stimulated genes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:uracil mustard n1=thrombolytique (traitement) | n2=en:uracil mustard | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:uracil mustard 1 mg oral capsule n1=thrombolytique (traitement) | n2=en:uracil mustard 1 mg oral capsule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:uremia n1=thrombolytique (traitement) | n2=en:uremia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:uric acid normal n1=thrombolytique (traitement) | n2=en:uric acid normal | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary calcium-creatinine ratio < 0.01:1 supports diagnosis n1=thrombolytique (traitement) | n2=en:urinary calcium-creatinine ratio < 0.01:1 supports diagnosis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary excretion of 2-ethyl-3-hydroxy-hexanoic acid n1=thrombolytique (traitement) | n2=en:urinary excretion of 2-ethyl-3-hydroxy-hexanoic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary excretion of 2-ethyl-3-keto-hexanoic acid n1=thrombolytique (traitement) | n2=en:urinary excretion of 2-ethyl-3-keto-hexanoic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary excretion of 2-ethyl-hexanedioic acid n1=thrombolytique (traitement) | n2=en:urinary excretion of 2-ethyl-hexanedioic acid | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary excretion of 3-hydroxyisovaleric acid, chronic n1=thrombolytique (traitement) | n2=en:urinary excretion of 3-hydroxyisovaleric acid, chronic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary excretion of 3-methylcrotonylglycine, chronic n1=thrombolytique (traitement) | n2=en:urinary excretion of 3-methylcrotonylglycine, chronic | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary excretion of cationic amino acids (lysine, arginine, ornithine) n1=thrombolytique (traitement) | n2=en:urinary excretion of cationic amino acids (lysine, arginine, ornithine) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary excretion of low-molecular-weight proteins, mild n1=thrombolytique (traitement) | n2=en:urinary excretion of low-molecular-weight proteins, mild | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary excretion of mucopolysaccharides n1=thrombolytique (traitement) | n2=en:urinary excretion of mucopolysaccharides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary excretion of retinol-binding proteins (rbp) and vitamin d-binding proteins (dbp) n1=thrombolytique (traitement) | n2=en:urinary excretion of retinol-binding proteins (rbp) and vitamin d-binding proteins (dbp) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary excretion of sialylated oligosaccharides n1=thrombolytique (traitement) | n2=en:urinary excretion of sialylated oligosaccharides | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary loss of potassium, sodium, calcium, and chloride n1=thrombolytique (traitement) | n2=en:urinary loss of potassium, sodium, calcium, and chloride | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urinary prostaglandin e n1=thrombolytique (traitement) | n2=en:urinary prostaglandin e | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urine cortisol, increased n1=thrombolytique (traitement) | n2=en:urine cortisol, increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urine occasionally port-wine in color secondary to porphobilinogen n1=thrombolytique (traitement) | n2=en:urine occasionally port-wine in color secondary to porphobilinogen | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urine odor, maple syrup n1=thrombolytique (traitement) | n2=en:urine odor, maple syrup | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urine osmolarity decreased n1=thrombolytique (traitement) | n2=en:urine osmolarity decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urine uric acid decreased n1=thrombolytique (traitement) | n2=en:urine uric acid decreased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urocanase deficiency n1=thrombolytique (traitement) | n2=en:urocanase deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urokinase 50000units/ml injection solution vial n1=thrombolytique (traitement) | n2=en:urokinase 50000units/ml injection solution vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urokinase 5000units/ml injection solution n1=thrombolytique (traitement) | n2=en:urokinase 5000units/ml injection solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:urokinase-type plasminogen activator n1=thrombolytique (traitement) | n2=en:urokinase-type plasminogen activator | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:uroporphyrin i and coproporphyrin i are found in plasma, red blood cells, urine, and feces n1=thrombolytique (traitement) | n2=en:uroporphyrin i and coproporphyrin i are found in plasma, red blood cells, urine, and feces | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:uroporphyrinogen iii cosynthase (uro cosynthase) deficiency in blood and fibroblasts n1=thrombolytique (traitement) | n2=en:uroporphyrinogen iii cosynthase (uro cosynthase) deficiency in blood and fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vacuolated lymphocytes n1=thrombolytique (traitement) | n2=en:vacuolated lymphocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vacuolated lymphocytes (type ii) n1=thrombolytique (traitement) | n2=en:vacuolated lymphocytes (type ii) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vacuolated macrophages n1=thrombolytique (traitement) | n2=en:vacuolated macrophages | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vacuolated monocytes n1=thrombolytique (traitement) | n2=en:vacuolated monocytes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vacuolization in myeloid cell lines in the bone marrow n1=thrombolytique (traitement) | n2=en:vacuolization in myeloid cell lines in the bone marrow | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vacuolization of marrow precursors n1=thrombolytique (traitement) | n2=en:vacuolization of marrow precursors | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:valganciclovir n1=thrombolytique (traitement) | n2=en:valganciclovir | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:valganciclovir 450mg tablet n1=thrombolytique (traitement) | n2=en:valganciclovir 450mg tablet | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:valganciclovir 50mg/ml powder for oral solution n1=thrombolytique (traitement) | n2=en:valganciclovir 50mg/ml powder for oral solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:valganciclovir hydrochloride n1=thrombolytique (traitement) | n2=en:valganciclovir hydrochloride | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:valproate level low n1=thrombolytique (traitement) | n2=en:valproate level low | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variable bleeding episodes n1=thrombolytique (traitement) | n2=en:variable bleeding episodes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variable bleeding episodes (menorrhagia, easy bruisability, postoperative hemorrhage) n1=thrombolytique (traitement) | n2=en:variable bleeding episodes (menorrhagia, easy bruisability, postoperative hemorrhage) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variable bleeding tendencies n1=thrombolytique (traitement) | n2=en:variable bleeding tendencies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variable defects of inner dynein arms n1=thrombolytique (traitement) | n2=en:variable defects of inner dynein arms | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variable hyperlipidemia n1=thrombolytique (traitement) | n2=en:variable hyperlipidemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variable hypoglycemia n1=thrombolytique (traitement) | n2=en:variable hypoglycemia | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variable platelet functional defects n1=thrombolytique (traitement) | n2=en:variable platelet functional defects | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variable red blood cell size n1=thrombolytique (traitement) | n2=en:variable red blood cell size | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variable reductions in platelet aggregation n1=thrombolytique (traitement) | n2=en:variable reductions in platelet aggregation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variable respiratory chain enzyme deficiency n1=thrombolytique (traitement) | n2=en:variable respiratory chain enzyme deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variably decreased activity of mitochondrial respiratory complexes i, iii, iv, and v in fibroblasts and muscle n1=thrombolytique (traitement) | n2=en:variably decreased activity of mitochondrial respiratory complexes i, iii, iv, and v in fibroblasts and muscle | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variably increased serum creatine kinase n1=thrombolytique (traitement) | n2=en:variably increased serum creatine kinase | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:varicella-zoster immune globulin 125 iu powder for injection solution vial n1=thrombolytique (traitement) | n2=en:varicella-zoster immune globulin 125 iu powder for injection solution vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:varicella-zoster immunoglobulin 250mg powder for injection solution vial n1=thrombolytique (traitement) | n2=en:varicella-zoster immunoglobulin 250mg powder for injection solution vial | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:variegated translocation mosaicism in cultured fibroblasts n1=thrombolytique (traitement) | n2=en:variegated translocation mosaicism in cultured fibroblasts | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vascular disorder n1=thrombolytique (traitement) | n2=en:vascular disorder | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:venospasm n1=thrombolytique (traitement) | n2=en:venospasm | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:venous and venular disorders n1=thrombolytique (traitement) | n2=en:venous and venular disorders | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:venous thrombophlebitis (limb) n1=thrombolytique (traitement) | n2=en:venous thrombophlebitis (limb) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:very long chain fatty acid accumulation n1=thrombolytique (traitement) | n2=en:very long chain fatty acid accumulation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:very long-chain fatty acids may be normal or increased n1=thrombolytique (traitement) | n2=en:very long-chain fatty acids may be normal or increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:very low density lipoprotein increased n1=thrombolytique (traitement) | n2=en:very low density lipoprotein increased | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:very low iga n1=thrombolytique (traitement) | n2=en:very low iga | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:very low igg n1=thrombolytique (traitement) | n2=en:very low igg | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:very low igm n1=thrombolytique (traitement) | n2=en:very low igm | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:very low leptin level n1=thrombolytique (traitement) | n2=en:very low leptin level | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vinblastine n1=thrombolytique (traitement) | n2=en:vinblastine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vinblastine 1 mg/ml injectable solution n1=thrombolytique (traitement) | n2=en:vinblastine 1 mg/ml injectable solution | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vinblastine sulfate n1=thrombolytique (traitement) | n2=en:vinblastine sulfate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vinorelbine n1=thrombolytique (traitement) | n2=en:vinorelbine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vinorelbine tartrate n1=thrombolytique (traitement) | n2=en:vinorelbine tartrate | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vitamin b12 deficiency (in some patients) n1=thrombolytique (traitement) | n2=en:vitamin b12 deficiency (in some patients) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vitamin b12 deficiency (uncommon) n1=thrombolytique (traitement) | n2=en:vitamin b12 deficiency (uncommon) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:vitamin d deficiency n1=thrombolytique (traitement) | n2=en:vitamin d deficiency | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:widespread interstitial fibrosis (visceral organs) n1=thrombolytique (traitement) | n2=en:widespread interstitial fibrosis (visceral organs) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:wiskott-aldrich autosomal dominant variant syndrome n1=thrombolytique (traitement) | n2=en:wiskott-aldrich autosomal dominant variant syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:wiskott-aldrich syndrome n1=thrombolytique (traitement) | n2=en:wiskott-aldrich syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:wiskott-aldrich syndrome, autosomal dominant form n1=thrombolytique (traitement) | n2=en:wiskott-aldrich syndrome, autosomal dominant form | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:wt limb blood syndrome n1=thrombolytique (traitement) | n2=en:wt limb blood syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:x-linked dyskeratosis congenita n1=thrombolytique (traitement) | n2=en:x-linked dyskeratosis congenita | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:x-linked lymphoproliferative syndrome n1=thrombolytique (traitement) | n2=en:x-linked lymphoproliferative syndrome | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> en:xanthine nephrolithiasis n1=thrombolytique (traitement) | n2=en:xanthine nephrolithiasis | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> facteur V Leiden n1=thrombolytique (traitement) | n2=facteur V Leiden | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> glycoprotéine n1=thrombolytique (traitement) | n2=glycoprotéine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> grossesse n1=thrombolytique (traitement) | n2=grossesse | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> hémogramme n1=thrombolytique (traitement) | n2=hémogramme | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> hypoplaquettose n1=thrombolytique (traitement) | n2=hypoplaquettose | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> IGPDs n1=thrombolytique (traitement) | n2=IGPDs | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> immune n1=thrombolytique (traitement) | n2=immune | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> infectieuse n1=thrombolytique (traitement) | n2=infectieuse | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> inflammation n1=thrombolytique (traitement) | n2=inflammation | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> inflammation (médecine) n1=thrombolytique (traitement) | n2=inflammation (médecine) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> insuffisance n1=thrombolytique (traitement) | n2=insuffisance | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> Jacobsen (syndrome de) n1=thrombolytique (traitement) | n2=Jacobsen (syndrome de) | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> leucémie aigüe promyélocytaire n1=thrombolytique (traitement) | n2=leucémie aigüe promyélocytaire | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> liée n1=thrombolytique (traitement) | n2=liée | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> maladie de Glanzmann n1=thrombolytique (traitement) | n2=maladie de Glanzmann | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> maladie de von Willebrand n1=thrombolytique (traitement) | n2=maladie de von Willebrand | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> migrante n1=thrombolytique (traitement) | n2=migrante | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> migratrice n1=thrombolytique (traitement) | n2=migratrice | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> modifications qualitatives des plaquettes n1=thrombolytique (traitement) | n2=modifications qualitatives des plaquettes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> nodulaire n1=thrombolytique (traitement) | n2=nodulaire | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> pancytopénie n1=thrombolytique (traitement) | n2=pancytopénie | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> Paris n1=thrombolytique (traitement) | n2=Paris | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> Paris-Trousseau n1=thrombolytique (traitement) | n2=Paris-Trousseau | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> phlébite de la grossesse n1=thrombolytique (traitement) | n2=phlébite de la grossesse | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> phlébite profonde n1=thrombolytique (traitement) | n2=phlébite profonde | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> phlébothrombose n1=thrombolytique (traitement) | n2=phlébothrombose | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> phlegmatia alba dolens n1=thrombolytique (traitement) | n2=phlegmatia alba dolens | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> plaquette sanguine n1=thrombolytique (traitement) | n2=plaquette sanguine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> plaquettes anormales n1=thrombolytique (traitement) | n2=plaquettes anormales | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> plaquettes sanguines n1=thrombolytique (traitement) | n2=plaquettes sanguines | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> protéine C n1=thrombolytique (traitement) | n2=protéine C | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> protéine S n1=thrombolytique (traitement) | n2=protéine S | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> puerpérale n1=thrombolytique (traitement) | n2=puerpérale | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> purpura n1=thrombolytique (traitement) | n2=purpura | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> purpura thrombopénique n1=thrombolytique (traitement) | n2=purpura thrombopénique | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> score des 4 T n1=thrombolytique (traitement) | n2=score des 4 T | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> se manifestant sur un segment de veine n1=thrombolytique (traitement) | n2=se manifestant sur un segment de veine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> signe clinique n1=thrombolytique (traitement) | n2=signe clinique | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> Spécialités médicales n1=thrombolytique (traitement) | n2=Spécialités médicales | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> spontanée n1=thrombolytique (traitement) | n2=spontanée | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> syndrome des plaquettes grises n1=thrombolytique (traitement) | n2=syndrome des plaquettes grises | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombasthénie n1=thrombolytique (traitement) | n2=thrombasthénie | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombo n1=thrombolytique (traitement) | n2=thrombo | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombocytes anormaux n1=thrombolytique (traitement) | n2=thrombocytes anormaux | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombocytopathie n1=thrombolytique (traitement) | n2=thrombocytopathie | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombocytopathies n1=thrombolytique (traitement) | n2=thrombocytopathies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombocytopénie n1=thrombolytique (traitement) | n2=thrombocytopénie | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombocytopénie immune n1=thrombolytique (traitement) | n2=thrombocytopénie immune | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombocytopénie non précisée n1=thrombolytique (traitement) | n2=thrombocytopénie non précisée | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombocytopénies n1=thrombolytique (traitement) | n2=thrombocytopénies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombopathies n1=thrombolytique (traitement) | n2=thrombopathies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombopénie héparino-induite n1=thrombolytique (traitement) | n2=thrombopénie héparino-induite | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombopénie induite à l'héparine n1=thrombolytique (traitement) | n2=thrombopénie induite à l'héparine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombopénie induite par héparine n1=thrombolytique (traitement) | n2=thrombopénie induite par héparine | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombopénies n1=thrombolytique (traitement) | n2=thrombopénies | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombopénique n1=thrombolytique (traitement) | n2=thrombopénique | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombophlébite migratrice n1=thrombolytique (traitement) | n2=thrombophlébite migratrice | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombophlébite pelvienne du postpartum n1=thrombolytique (traitement) | n2=thrombophlébite pelvienne du postpartum | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombophlébite pelvienne suppurée du postpartum n1=thrombolytique (traitement) | n2=thrombophlébite pelvienne suppurée du postpartum | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombophlébite puerpérale n1=thrombolytique (traitement) | n2=thrombophlébite puerpérale | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombophlébite puerpérale à bascule n1=thrombolytique (traitement) | n2=thrombophlébite puerpérale à bascule | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombophlébite veineuse n1=thrombolytique (traitement) | n2=thrombophlébite veineuse | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombophlébites n1=thrombolytique (traitement) | n2=thrombophlébites | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombose des sinus veineux cérébraux n1=thrombolytique (traitement) | n2=thrombose des sinus veineux cérébraux | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombose veineuse cérébrale n1=thrombolytique (traitement) | n2=thrombose veineuse cérébrale | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> thrombose veineuse profonde n1=thrombolytique (traitement) | n2=thrombose veineuse profonde | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> TM n1=thrombolytique (traitement) | n2=TM | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> trouble des plaquettes n1=thrombolytique (traitement) | n2=trouble des plaquettes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> trouble plaquettaire n1=thrombolytique (traitement) | n2=trouble plaquettaire | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> troubles des plaquettes n1=thrombolytique (traitement) | n2=troubles des plaquettes | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> troubles plaquettaires n1=thrombolytique (traitement) | n2=troubles plaquettaires | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> Trousseau n1=thrombolytique (traitement) | n2=Trousseau | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> TVP n1=thrombolytique (traitement) | n2=TVP | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 10 / 0.123 -> varice n1=thrombolytique (traitement) | n2=varice | rel=r_associated | relid=0 | w=10 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> affection de la peau n1=thrombolytique (traitement) | n2=affection de la peau | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> aptitude n1=thrombolytique (traitement) | n2=aptitude | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> caillot sanguin n1=thrombolytique (traitement) | n2=caillot sanguin | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> coaguler n1=thrombolytique (traitement) | n2=coaguler | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> défaillance multi-viscérale n1=thrombolytique (traitement) | n2=défaillance multi-viscérale | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> déficit en antithrombine III n1=thrombolytique (traitement) | n2=déficit en antithrombine III | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> déficit en antithrombine type 2 n1=thrombolytique (traitement) | n2=déficit en antithrombine type 2 | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> déficit en protéine C n1=thrombolytique (traitement) | n2=déficit en protéine C | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> déficit en protéine S n1=thrombolytique (traitement) | n2=déficit en protéine S | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:abnormality of red blood cells n1=thrombolytique (traitement) | n2=en:abnormality of red blood cells | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:acquired complement deficiency disease n1=thrombolytique (traitement) | n2=en:acquired complement deficiency disease | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:acquired hemolytic anemia n1=thrombolytique (traitement) | n2=en:acquired hemolytic anemia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:adrenal gland myelolipoma n1=thrombolytique (traitement) | n2=en:adrenal gland myelolipoma | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:anticoagulant effect n1=thrombolytique (traitement) | n2=en:anticoagulant effect | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:antithrombin deficiency type 2 n1=thrombolytique (traitement) | n2=en:antithrombin deficiency type 2 | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:aplastic anemia and other bone marrow failure syndromes n1=thrombolytique (traitement) | n2=en:aplastic anemia and other bone marrow failure syndromes | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:blood clot n1=thrombolytique (traitement) | n2=en:blood clot | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:blood coagulation pathway observation n1=thrombolytique (traitement) | n2=en:blood coagulation pathway observation | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:blood group incompatibility n1=thrombolytique (traitement) | n2=en:blood group incompatibility | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:blood protein disorders n1=thrombolytique (traitement) | n2=en:blood protein disorders | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:blood/lymphatic neoplasm n1=thrombolytique (traitement) | n2=en:blood/lymphatic neoplasm | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:bone marrow disorder n1=thrombolytique (traitement) | n2=en:bone marrow disorder | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:bone marrow granulomas n1=thrombolytique (traitement) | n2=en:bone marrow granulomas | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:bone marrow haemorrhage n1=thrombolytique (traitement) | n2=en:bone marrow haemorrhage | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:bone marrow infiltration n1=thrombolytique (traitement) | n2=en:bone marrow infiltration | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:bone marrow ischemia n1=thrombolytique (traitement) | n2=en:bone marrow ischemia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:bone marrow necrosis n1=thrombolytique (traitement) | n2=en:bone marrow necrosis | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:bone marrow oedema n1=thrombolytique (traitement) | n2=en:bone marrow oedema | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:bone marrow oedema syndrome n1=thrombolytique (traitement) | n2=en:bone marrow oedema syndrome | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:bone marrow transplant rejection n1=thrombolytique (traitement) | n2=en:bone marrow transplant rejection | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:carboxyhemoglobinemia n1=thrombolytique (traitement) | n2=en:carboxyhemoglobinemia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:clotting increased n1=thrombolytique (traitement) | n2=en:clotting increased | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:coagulation and hemorrhagic disorders n1=thrombolytique (traitement) | n2=en:coagulation and hemorrhagic disorders | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:complement deficiency n1=thrombolytique (traitement) | n2=en:complement deficiency | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:congenital blood disorder n1=thrombolytique (traitement) | n2=en:congenital blood disorder | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:congenital hematological disorder n1=thrombolytique (traitement) | n2=en:congenital hematological disorder | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:congenital methemoglobinemia n1=thrombolytique (traitement) | n2=en:congenital methemoglobinemia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:cutaneous extramedullary haemopoiesis n1=thrombolytique (traitement) | n2=en:cutaneous extramedullary haemopoiesis | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:cutaneous t-cell dyscrasia n1=thrombolytique (traitement) | n2=en:cutaneous t-cell dyscrasia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:dysglobulinemia n1=thrombolytique (traitement) | n2=en:dysglobulinemia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:engraftment syndrome n1=thrombolytique (traitement) | n2=en:engraftment syndrome | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:erythrosis n1=thrombolytique (traitement) | n2=en:erythrosis | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:factor v excess with spontaneous thrombosis n1=thrombolytique (traitement) | n2=en:factor v excess with spontaneous thrombosis | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:family history of hypercoagulable state n1=thrombolytique (traitement) | n2=en:family history of hypercoagulable state | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:fibrinogen screening finding n1=thrombolytique (traitement) | n2=en:fibrinogen screening finding | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:fibrinolytic system finding n1=thrombolytique (traitement) | n2=en:fibrinolytic system finding | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:finding of anticoagulant control n1=thrombolytique (traitement) | n2=en:finding of anticoagulant control | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:haematotoxicity n1=thrombolytique (traitement) | n2=en:haematotoxicity | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hematologic tests n1=thrombolytique (traitement) | n2=en:hematologic tests | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hematological disorders of fetus and newborn n1=thrombolytique (traitement) | n2=en:hematological disorders of fetus and newborn | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hematopoietic and lymphatic system n1=thrombolytique (traitement) | n2=en:hematopoietic and lymphatic system | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hematopoietic and lymphoid cell n1=thrombolytique (traitement) | n2=en:hematopoietic and lymphoid cell | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hematopoietic and lymphoid cell neoplasm n1=thrombolytique (traitement) | n2=en:hematopoietic and lymphoid cell neoplasm | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hematopoietic and lymphoid tissue n1=thrombolytique (traitement) | n2=en:hematopoietic and lymphoid tissue | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hemoconcentration n1=thrombolytique (traitement) | n2=en:hemoconcentration | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hemodilution n1=thrombolytique (traitement) | n2=en:hemodilution | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hemoglobinopathy n1=thrombolytique (traitement) | n2=en:hemoglobinopathy | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hemolytic disease of the newborn n1=thrombolytique (traitement) | n2=en:hemolytic disease of the newborn | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hemophagocytosis n1=thrombolytique (traitement) | n2=en:hemophagocytosis | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hereditary hemolytic anemia n1=thrombolytique (traitement) | n2=en:hereditary hemolytic anemia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:history of hypercoagulable state n1=thrombolytique (traitement) | n2=en:history of hypercoagulable state | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:history of thrombophilia n1=thrombolytique (traitement) | n2=en:history of thrombophilia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hyperglobulinemia n1=thrombolytique (traitement) | n2=en:hyperglobulinemia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hyperviscosity syndrome n1=thrombolytique (traitement) | n2=en:hyperviscosity syndrome | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hypoglobulinemia n1=thrombolytique (traitement) | n2=en:hypoglobulinemia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:hypolipidemia n1=thrombolytique (traitement) | n2=en:hypolipidemia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:increased number of platelets n1=thrombolytique (traitement) | n2=en:increased number of platelets | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:leukemia in remission n1=thrombolytique (traitement) | n2=en:leukemia in remission | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:leukocyte disorders n1=thrombolytique (traitement) | n2=en:leukocyte disorders | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:lymphoproliferative disorder n1=thrombolytique (traitement) | n2=en:lymphoproliferative disorder | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:mast cell activation syndrome n1=thrombolytique (traitement) | n2=en:mast cell activation syndrome | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:mastocytosis n1=thrombolytique (traitement) | n2=en:mastocytosis | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:medicine n1=thrombolytique (traitement) | n2=en:medicine | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:melanaemia n1=thrombolytique (traitement) | n2=en:melanaemia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:metastatic malignant neoplasm in the bone marrow n1=thrombolytique (traitement) | n2=en:metastatic malignant neoplasm in the bone marrow | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:methemoglobinuria n1=thrombolytique (traitement) | n2=en:methemoglobinuria | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:non-neoplastic hematologic and lymphocytic disorder n1=thrombolytique (traitement) | n2=en:non-neoplastic hematologic and lymphocytic disorder | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:normal hemostatic function n1=thrombolytique (traitement) | n2=en:normal hemostatic function | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:other anaemias n1=thrombolytique (traitement) | n2=en:other anaemias | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:other deficiency anemias n1=thrombolytique (traitement) | n2=en:other deficiency anemias | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:other diseases of blood and blood-forming organs n1=thrombolytique (traitement) | n2=en:other diseases of blood and blood-forming organs | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:other hematologic conditions n1=thrombolytique (traitement) | n2=en:other hematologic conditions | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:other primary thrombophilia n1=thrombolytique (traitement) | n2=en:other primary thrombophilia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:other specified diseases of blood and blood-forming organs n1=thrombolytique (traitement) | n2=en:other specified diseases of blood and blood-forming organs | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:other specified transient hematological disorders of fetus or newborn n1=thrombolytique (traitement) | n2=en:other specified transient hematological disorders of fetus or newborn | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:pathologic hemolysis n1=thrombolytique (traitement) | n2=en:pathologic hemolysis | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:phlebotomy n1=thrombolytique (traitement) | n2=en:phlebotomy | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:placental transfusion syndromes n1=thrombolytique (traitement) | n2=en:placental transfusion syndromes | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:platelet finding n1=thrombolytique (traitement) | n2=en:platelet finding | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:post transplant distal limb syndrome n1=thrombolytique (traitement) | n2=en:post transplant distal limb syndrome | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:pregnancy complications, hematologic n1=thrombolytique (traitement) | n2=en:pregnancy complications, hematologic | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:premalignant hematologic condition n1=thrombolytique (traitement) | n2=en:premalignant hematologic condition | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:red blood cell count raised n1=thrombolytique (traitement) | n2=en:red blood cell count raised | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:reticulin fibrosis of the bone marrow n1=thrombolytique (traitement) | n2=en:reticulin fibrosis of the bone marrow | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:skin disorder n1=thrombolytique (traitement) | n2=en:skin disorder | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:sulfhemoglobinemia n1=thrombolytique (traitement) | n2=en:sulfhemoglobinemia | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:systemic mastocytosis n1=thrombolytique (traitement) | n2=en:systemic mastocytosis | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:tendency to bleed - finding n1=thrombolytique (traitement) | n2=en:tendency to bleed - finding | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:thrombomodulin anomalies, familial n1=thrombolytique (traitement) | n2=en:thrombomodulin anomalies, familial | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:thrombophilia due to elevated histidine-rich glycoprotein n1=thrombolytique (traitement) | n2=en:thrombophilia due to elevated histidine-rich glycoprotein | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:thrombophilia due to thrombin defect n1=thrombolytique (traitement) | n2=en:thrombophilia due to thrombin defect | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:thrombophilia due to thrombomodulin defect n1=thrombolytique (traitement) | n2=en:thrombophilia due to thrombomodulin defect | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:thrombophilia screening n1=thrombolytique (traitement) | n2=en:thrombophilia screening | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:thrombophilia, familial, due to decreased release of tissue plasminogen activator n1=thrombolytique (traitement) | n2=en:thrombophilia, familial, due to decreased release of tissue plasminogen activator | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:thrombophilia, hereditary n1=thrombolytique (traitement) | n2=en:thrombophilia, hereditary | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:thrombophilia, x-linked, due to factor ix defect n1=thrombolytique (traitement) | n2=en:thrombophilia, x-linked, due to factor ix defect | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:thrombotic tendency observations n1=thrombolytique (traitement) | n2=en:thrombotic tendency observations | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:transfusion reaction n1=thrombolytique (traitement) | n2=en:transfusion reaction | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:unspecified hematological disorder specific to newborn n1=thrombolytique (traitement) | n2=en:unspecified hematological disorder specific to newborn | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> en:upper gastrointestinal hemorrhage associated with hypercoagulability state n1=thrombolytique (traitement) | n2=en:upper gastrointestinal hemorrhage associated with hypercoagulability state | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> épidémiologie n1=thrombolytique (traitement) | n2=épidémiologie | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> état n1=thrombolytique (traitement) | n2=état | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> F2 gene n1=thrombolytique (traitement) | n2=F2 gene | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> hémopathie n1=thrombolytique (traitement) | n2=hémopathie | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> hémopathies n1=thrombolytique (traitement) | n2=hémopathies | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> hypercoagulable n1=thrombolytique (traitement) | n2=hypercoagulable | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> hyperprothrombinémie n1=thrombolytique (traitement) | n2=hyperprothrombinémie | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> hypo-bêtalipoprotéinémie n1=thrombolytique (traitement) | n2=hypo-bêtalipoprotéinémie | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> maladie (médecine) n1=thrombolytique (traitement) | n2=maladie (médecine) | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> mutation de la prothrombine n1=thrombolytique (traitement) | n2=mutation de la prothrombine | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> mutation du facteur V n1=thrombolytique (traitement) | n2=mutation du facteur V | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> saignement nasal n1=thrombolytique (traitement) | n2=saignement nasal | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> sang (hémoglobine) n1=thrombolytique (traitement) | n2=sang (hémoglobine) | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> sanguin n1=thrombolytique (traitement) | n2=sanguin | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> sanguine n1=thrombolytique (traitement) | n2=sanguine | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> solidité n1=thrombolytique (traitement) | n2=solidité | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> syndrome des antiphospholipides n1=thrombolytique (traitement) | n2=syndrome des antiphospholipides | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> thrombasthénie de Glanzmann n1=thrombolytique (traitement) | n2=thrombasthénie de Glanzmann | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> thrombophilie dûe à un déficit en thrombomoduline n1=thrombolytique (traitement) | n2=thrombophilie dûe à un déficit en thrombomoduline | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> thrombophilie héréditaire n1=thrombolytique (traitement) | n2=thrombophilie héréditaire | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> thrombophilie liée à l'X dûe à un déficit en facteur IX n1=thrombolytique (traitement) | n2=thrombophilie liée à l'X dûe à un déficit en facteur IX | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> trouble de la coagulation n1=thrombolytique (traitement) | n2=trouble de la coagulation | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> trouble hémorragique n1=thrombolytique (traitement) | n2=trouble hémorragique | rel=r_associated | relid=0 | w=5 thrombolytique (traitement) -- r_associated #0: 5 / 0.062 -> troubles de la coagulation n1=thrombolytique (traitement) | n2=troubles de la coagulation | rel=r_associated | relid=0 | w=5

≈ 63 relations entrantes thrombophilie --- r_associated #0: 93 --> thrombolytique (traitement) n1=thrombophilie | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=93 en:thrombophilia --- r_associated #0: 88 --> thrombolytique (traitement) n1=en:thrombophilia | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=88 hypercoagulabilité sanguine --- r_associated #0: 83 --> thrombolytique (traitement) n1=hypercoagulabilité sanguine | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=83 état d'hypercoagulabilité --- r_associated #0: 83 --> thrombolytique (traitement) n1=état d'hypercoagulabilité | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=83 état hypercoagulable --- r_associated #0: 79 --> thrombolytique (traitement) n1=état hypercoagulable | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=79 en:thrombophlebitis --- r_associated #0: 72 --> thrombolytique (traitement) n1=en:thrombophlebitis | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=72 thrombo-phlébite --- r_associated #0: 71 --> thrombolytique (traitement) n1=thrombo-phlébite | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=71 chirurgie --- r_associated #0: 70 --> thrombolytique (traitement) n1=chirurgie | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=70 thrombophlébite --- r_associated #0: 70 --> thrombolytique (traitement) n1=thrombophlébite | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=70 hypercoagulabilité --- r_associated #0: 63 --> thrombolytique (traitement) n1=hypercoagulabilité | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=63 thrombopénie induite par l'héparine --- r_associated #0: 48 --> thrombolytique (traitement) n1=thrombopénie induite par l'héparine | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=48 thrombolyse --- r_associated #0: 46 --> thrombolytique (traitement) n1=thrombolyse | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=46 en:heparin-induced thrombocytopenia --- r_associated #0: 44 --> thrombolytique (traitement) n1=en:heparin-induced thrombocytopenia | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=44 en:HIT --- r_associated #0: 43 --> thrombolytique (traitement) n1=en:HIT | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=43 en:thrombolysis --- r_associated #0: 43 --> thrombolytique (traitement) n1=en:thrombolysis | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=43 thrombophlébite infectieuse --- r_associated #0: 41 --> thrombolytique (traitement) n1=thrombophlébite infectieuse | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=41 thrombopénie --- r_associated #0: 41 --> thrombolytique (traitement) n1=thrombopénie | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=41 thrombopénie immune --- r_associated #0: 41 --> thrombolytique (traitement) n1=thrombopénie immune | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=41 en:infectious thrombophlebitis --- r_associated #0: 40 --> thrombolytique (traitement) n1=en:infectious thrombophlebitis | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=40 en:immune thrombocytopenia --- r_associated #0: 37 --> thrombolytique (traitement) n1=en:immune thrombocytopenia | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=37 en:thrombopenia --- r_associated #0: 37 --> thrombolytique (traitement) n1=en:thrombopenia | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=37 thrombophlébite cérébrale puerpérale --- r_associated #0: 36 --> thrombolytique (traitement) n1=thrombophlébite cérébrale puerpérale | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=36 thrombophlébite de la grossesse --- r_associated #0: 36 --> thrombolytique (traitement) n1=thrombophlébite de la grossesse | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=36 thrombophlébite nodulaire migratrice --- r_associated #0: 36 --> thrombolytique (traitement) n1=thrombophlébite nodulaire migratrice | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=36 en:arterial thrombosis of the limbs --- r_associated #0: 35 --> thrombolytique (traitement) n1=en:arterial thrombosis of the limbs | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=35 en:thrombophlebitis of pregnancy --- r_associated #0: 35 --> thrombolytique (traitement) n1=en:thrombophlebitis of pregnancy | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=35 thrombose artérielle des membres --- r_associated #0: 35 --> thrombolytique (traitement) n1=thrombose artérielle des membres | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=35 en:noueuse --- r_associated #0: 34 --> thrombolytique (traitement) n1=en:noueuse | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=34 en:puerpueral cerebral thrombophlebitis --- r_associated #0: 34 --> thrombolytique (traitement) n1=en:puerpueral cerebral thrombophlebitis | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=34 anticoagulant --- r_associated #0: 30 --> thrombolytique (traitement) n1=anticoagulant | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=30 thrombophlébite migrante --- r_associated #0: 29 --> thrombolytique (traitement) n1=thrombophlébite migrante | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=29 en:thrombocytopathy --- r_associated #0: 27 --> thrombolytique (traitement) n1=en:thrombocytopathy | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=27 en:thrombocytopenia --- r_associated #0: 27 --> thrombolytique (traitement) n1=en:thrombocytopenia | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=27 thrombopathie --- r_associated #0: 27 --> thrombolytique (traitement) n1=thrombopathie | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=27 en:hypercoagulable state --- r_associated #0: 26 --> thrombolytique (traitement) n1=en:hypercoagulable state | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=26 en:thrombomodulin --- r_associated #0: 26 --> thrombolytique (traitement) n1=en:thrombomodulin | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=26 thrombomoduline --- r_associated #0: 26 --> thrombolytique (traitement) n1=thrombomoduline | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=26 thrombopénie induite par l'héparine dite spontanée --- r_associated #0: 26 --> thrombolytique (traitement) n1=thrombopénie induite par l'héparine dite spontanée | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=26 phlébite de la grossesse --- r_associated #0: 25 --> thrombolytique (traitement) n1=phlébite de la grossesse | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=25 en:thrombopeny --- r_associated #0: 24 --> thrombolytique (traitement) n1=en:thrombopeny | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=24 thrombopénie de Paris-Trousseau --- r_associated #0: 23 --> thrombolytique (traitement) n1=thrombopénie de Paris-Trousseau | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=23 en:thrombopathy --- r_associated #0: 22 --> thrombolytique (traitement) n1=en:thrombopathy | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=22 thrombasthénie --- r_associated #0: 21 --> thrombolytique (traitement) n1=thrombasthénie | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=21 thrombopénie liée à l'X --- r_associated #0: 21 --> thrombolytique (traitement) n1=thrombopénie liée à l'X | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=21 Thrombophilie --- r_associated #0: 20 --> thrombolytique (traitement) n1=Thrombophilie | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 Thrombopénie --- r_associated #0: 20 --> thrombolytique (traitement) n1=Thrombopénie | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 en:heparin induced thrombocytopenia --- r_associated #0: 20 --> thrombolytique (traitement) n1=en:heparin induced thrombocytopenia | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 héparine --- r_associated #0: 20 --> thrombolytique (traitement) n1=héparine | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 maladie --- r_associated #0: 20 --> thrombolytique (traitement) n1=maladie | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 maladies --- r_associated #0: 20 --> thrombolytique (traitement) n1=maladies | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 médecine --- r_associated #0: 20 --> thrombolytique (traitement) n1=médecine | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 pathologie --- r_associated #0: 20 --> thrombolytique (traitement) n1=pathologie | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 processus pathologique --- r_associated #0: 20 --> thrombolytique (traitement) n1=processus pathologique | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 sang --- r_associated #0: 20 --> thrombolytique (traitement) n1=sang | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 spécialités médicales --- r_associated #0: 20 --> thrombolytique (traitement) n1=spécialités médicales | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 thrombolytique --- r_associated #0: 20 --> thrombolytique (traitement) n1=thrombolytique | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 traitement --- r_associated #0: 20 --> thrombolytique (traitement) n1=traitement | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=20 Thrombolyse --- r_associated #0: 15 --> thrombolytique (traitement) n1=Thrombolyse | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=15 Hypercoagulabilité --- r_associated #0: 10 --> thrombolytique (traitement) n1=Hypercoagulabilité | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=10 Thrombophlébite --- r_associated #0: 10 --> thrombolytique (traitement) n1=Thrombophlébite | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=10 en:heparin --- r_associated #0: 10 --> thrombolytique (traitement) n1=en:heparin | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=10 en:l'abdomen --- r_associated #0: 10 --> thrombolytique (traitement) n1=en:l'abdomen | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=10 Spécialités médicales --- r_associated #0: 5 --> thrombolytique (traitement) n1=Spécialités médicales | n2=thrombolytique (traitement) | rel=r_associated | relid=0 | w=5